Original Timestamp,LLM Timestamp,Post,Image,Link,Prompt,Input
2024-08-29 08:38:00,2024-08-29 23:08:40,"üåü Have you heard about the new advancements in antibiotic design? A recent article highlights an exciting discovery regarding a Velcro-like antibiotic, plectasin, which shows promise for developing more effective treatments against bacterial infections!  

Researchers at Utrecht University have revealed that plectasin binds to lipid II‚Äîa crucial component of bacterial cell walls‚Äîthrough a unique supramolecular mechanism. This process forms dense structures on bacterial membranes, enhancing the antibiotic‚Äôs ability to target and disrupt bacterial cell walls effectively. Unlike conventional antibiotics that may target human cells unintentionally, plectasin specifically focuses on this bacterial target, minimizing toxicity while potentially reducing the risk of resistance.  

The implications of this discovery are profound! With its unique mechanism and specificity, plectasin could pave the way for smarter antibiotic designs that mitigate resistance. It encourages us to rethink how we approach antibiotic formulation, emphasizing both the binding and the structural aspects of the compounds we create.  

What do you think about this innovative approach to antibiotic design? Could it be a game changer in our fight against bacterial infections? Let‚Äôs discuss!  

#AntibioticResistance #DrugDiscovery #InfectiousDiseases #Innovation #PharmaceuticalScience  

Read more about it here: [Velcro-like antibiotic may inform new antibiotic design](https://www.drugdiscoverynews.com/velcro-like-antibiotic-may-inform-new-antibiotic-design-16028)  

![Thumbnail](https://medsii.azureedge.net/images/638605175224954478-66d0324a6157181811bbc82f.jpg)",https://medsii.azureedge.net/images/638605175224954478-66d0324a6157181811bbc82f.jpg,https://www.drugdiscoverynews.com/velcro-like-antibiotic-may-inform-new-antibiotic-design-16028,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Thumbnail image URL: https://medsii.azureedge.net/images/638605175224954478-66d0324a6157181811bbc82f.jpg 

Title: Velcro-like antibiotic may inform new antibiotic design

URL Source: https://www.drugdiscoverynews.com/velcro-like-antibiotic-may-inform-new-antibiotic-design-16028

Markdown Content:
Velcro-like antibiotic may inform new antibiotic design | Drug Discovery News
===============
                       

[Drug Discovery News, Development & Diagnostics Articles | DDN Magazine](https://www.drugdiscoverynews.com/)

[Subscribe Today!](https://www.drugdiscoverynews.com/subscribe)

[](https://www.drugdiscoverynews.com/)

*   Disease Focus
    

*   [Neuroscience](https://www.drugdiscoverynews.com/neuroscience)
*   [Cancer Research](https://www.drugdiscoverynews.com/cancer-research)
*   [Immunology](https://www.drugdiscoverynews.com/immunology)
*   [Infectious Disease & Vaccines](https://www.drugdiscoverynews.com/infectious-disease-vaccines)
*   [Hematology](https://www.drugdiscoverynews.com/hematology)
*   [Ophthalmology](https://www.drugdiscoverynews.com/ophthalmology)
*   [Rare & Genetic Diseases](https://www.drugdiscoverynews.com/rare-genetic-diseases)
*   [Dermatology](https://www.drugdiscoverynews.com/dermatology)
*   [Internal Medicine](https://www.drugdiscoverynews.com/internal-medicine)
*   [All Disease Focus](https://www.drugdiscoverynews.com/disease-focus)

*   [News](https://www.drugdiscoverynews.com/tag/news)

*   Tools & Techniques
    

*   [Tools & Techniques News](https://www.drugdiscoverynews.com/tools-techniques-news)
*   [Research Product Highlights](https://www.drugdiscoverynews.com/research-product-highlights)
*   [Experimental Planning Guides](https://www.drugdiscoverynews.com/tag/experimental-planning-guides)
*   [Expert Advice](https://www.drugdiscoverynews.com/tag/expert-advice)
*   [Here‚Äôs What We Know Articles](https://www.drugdiscoverynews.com/tag/here-s-what-we-know-articles)
*   [Quick Literature Reviews](https://www.drugdiscoverynews.com/tag/quick-literature-reviews)
*   [All Tools & Techniques](https://www.drugdiscoverynews.com/tools-techniques)

*   [Magazine](https://www.drugdiscoverynews.com/magazine)

*   Multimedia
    

*   [Webinars](https://www.drugdiscoverynews.com/webinars)
*   [eBooks](https://www.drugdiscoverynews.com/ebooks)
*   [Podcasts](https://www.drugdiscoverynews.com/podcasts)
*   [Posters](https://www.drugdiscoverynews.com/posters)
*   [Videos](https://www.drugdiscoverynews.com/videos)
*   [Advertorials](https://www.drugdiscoverynews.com/advertorials)
*   [Milestones - Articles](https://www.drugdiscoverynews.com/milestones)
*   [Explainers - Articles](https://www.drugdiscoverynews.com/explainers)
*   [Industry Perspectives](https://www.drugdiscoverynews.com/industry-perspectives)
*   [All Multimedia](https://www.drugdiscoverynews.com/multimedia-resources)

*   [Subscribe Today!](https://www.drugdiscoverynews.com/subscribe)

*   [Disease Focus](https://www.drugdiscoverynews.com/disease-focus)

[Disease Focus](https://www.drugdiscoverynews.com/disease-focus)
----------------------------------------------------------------

*   [Neuroscience](https://www.drugdiscoverynews.com/neuroscience)
*   [Cancer Research](https://www.drugdiscoverynews.com/cancer-research)
*   [Immunology](https://www.drugdiscoverynews.com/immunology)
*   [Infectious Disease & Vaccines](https://www.drugdiscoverynews.com/infectious-disease-vaccines)
*   [Hematology](https://www.drugdiscoverynews.com/hematology)
*   [Ophthalmology](https://www.drugdiscoverynews.com/ophthalmology)
*   [Rare & Genetic Diseases](https://www.drugdiscoverynews.com/rare-genetic-diseases)
*   [Dermatology](https://www.drugdiscoverynews.com/dermatology)
*   [Internal Medicine](https://www.drugdiscoverynews.com/internal-medicine)

*   [News](https://www.drugdiscoverynews.com/tag/news)

*   [Tools & Techniques](https://www.drugdiscoverynews.com/tools-techniques)

[Tools & Techniques](https://www.drugdiscoverynews.com/tools-techniques)
------------------------------------------------------------------------

*   [Tools & Techniques News](https://www.drugdiscoverynews.com/tools-techniques-news)
*   [Research Product Highlights](https://www.drugdiscoverynews.com/research-product-highlights)
*   [Experimental Planning Guides](https://www.drugdiscoverynews.com/tag/experimental-planning-guides)
*   [Expert Advice](https://www.drugdiscoverynews.com/tag/expert-advice)
*   [Here‚Äôs What We Know Articles](https://www.drugdiscoverynews.com/tag/here-s-what-we-know-articles)
*   [Quick Literature Reviews](https://www.drugdiscoverynews.com/tag/quick-literature-reviews)

*   [Magazine](https://www.drugdiscoverynews.com/magazine)

*   [Multimedia](https://www.drugdiscoverynews.com/multimedia-resources)

[Multimedia](https://www.drugdiscoverynews.com/multimedia-resources)
--------------------------------------------------------------------

*   [Webinars](https://www.drugdiscoverynews.com/webinars)
*   [eBooks](https://www.drugdiscoverynews.com/ebooks)
*   [Podcasts](https://www.drugdiscoverynews.com/podcasts)
*   [Posters](https://www.drugdiscoverynews.com/posters)
*   [Videos](https://www.drugdiscoverynews.com/videos)
*   [Advertorials](https://www.drugdiscoverynews.com/advertorials)
*   [Milestones - Articles](https://www.drugdiscoverynews.com/milestones)
*   [Explainers - Articles](https://www.drugdiscoverynews.com/explainers)
*   [Industry Perspectives](https://www.drugdiscoverynews.com/industry-perspectives)

1.  [Home](https://www.drugdiscoverynews.com/)
2.  [Infectious Disease & Vaccines](https://www.drugdiscoverynews.com/infectious-disease-vaccines)

Velcro-like antibiotic may inform new antibiotic design
=======================================================

Plectasin forms dense structures on bacterial membranes by binding to unique lipids in bacterial cell walls.
------------------------------------------------------------------------------------------------------------

![Image 1: A group of four scientists, two men and two women, wearing white lab coats stand on a wooden platform in a laboratory setting.](https://cdn.drugdiscoverynews.com/assets/articleNo/16028/aImg/41782/low-res-utrecht-university-s.jpg)

**Top Image:**

Markus Weingarth‚Äôs research team studies antibiotics that target lipids only found in bacterial membranes. From left to right: Maik Derks, Eefjan Breukink, Shehrazade Miranda Jekhmane, and Markus Weingarth.

credit: Utrecht University

Velcro-like antibiotic may inform new antibiotic design
=======================================================

Plectasin forms dense structures on bacterial membranes by binding to unique lipids in bacterial cell walls.
------------------------------------------------------------------------------------------------------------

* * *

![Image 2: Luisa Torres](https://cdn.drugdiscoverynews.com/assets/authorNo/398/iImg/40021/luisa-300x300-t.png)

Aug 28, 2024|3 min read

Luisa Torres, PhD

![Image 3: Luisa Torres, PhD](https://cdn.drugdiscoverynews.com/assets/authorNo/398/iImg/40021/luisa-300x300-t.png)[Luisa Torres, PhD](https://www.drugdiscoverynews.com/author/luisa-torres-phd)

[](mailto:)

Luisa is an assistant science editor at Drug Discovery News. She is a PhD in Molecular and Cellular Pharmacology from Stony Brook University who has written for NPR‚Äôs science desk.

View[full profile.](https://www.drugdiscoverynews.com/author/luisa-torres-phd)

* * *

Learn about our[editorial policies.](https://www.drugdiscoverynews.com/editorial-policies)

PDF Version

[Facebook](https://www.drugdiscoverynews.com/#facebook)[X](https://www.drugdiscoverynews.com/#x)[LinkedIn](https://www.drugdiscoverynews.com/#linkedin)[Email](https://www.drugdiscoverynews.com/#email)[Share](https://www.addtoany.com/share#url=https%3A%2F%2Fwww.drugdiscoverynews.com%2Fvelcro-like-antibiotic-may-inform-new-antibiotic-design-16028&title=Velcro-like%20antibiotic%20may%20inform%20new%20antibiotic%20design%20%7C%20Drug%20Discovery%20News)

Register for free to listen to this article

Listen with [Speechify](https://speechify.com/)

0:00

5:00

[](https://speechify.com/)

Highlights in this article

*   [How is plectasin‚Äôs mechanism of action different from that of other antibiotics?](https://www.drugdiscoverynews.com/velcro-like-antibiotic-may-inform-new-antibiotic-design-16028#16028-section-1)
*   [What makes lipid II a good antibiotic target?](https://www.drugdiscoverynews.com/velcro-like-antibiotic-may-inform-new-antibiotic-design-16028#16028-section-2)
*   [How effective is plectasin as an antibiotic?](https://www.drugdiscoverynews.com/velcro-like-antibiotic-may-inform-new-antibiotic-design-16028#16028-section-3)

[Markus Weingarth](https://www.weingarth-group.net/), a biochemist at Utrecht University, considers lipid II, a building block of bacteria cell walls, one of the most promising antibiotic targets. Human cells don‚Äôt produce it ‚Äî so targeting it avoids toxicity ‚Äî and bacteria struggle to develop resistance against it.

His research group recently published a [study](https://www.nature.com/articles/s41564-024-01696-9) in _Nature Microbiology_, in which they reported that the antibiotic plectasin binds lipid II by forming dense structures on bacterial membranes (1). The findings improve researchers‚Äô understanding of how lipid II binding disrupts the cell walls of bacteria, which can help them develop better antibiotics.

![Image 4: 3D rendering of plectasin binding lipid II on the bacterial cell surface to disrupt cell wall formation.](https://cdn.drugdiscoverynews.com/assets/articleNo/16028/iImg/41784/low-res-plectasin-gloria-fuentes-l.jpg)

Like Velcro, the antibiotic plectasin binds its target on the bacterial cell surface.

credit: Gloria Fuentes

Novozyme‚Äôs scientists first [described](https://www.science.org/doi/10.1126/science.1185723?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed) plectasin‚Äôs mechanism of action in 2010 (2). However, in their experiments, they used artificial membranes called micelles and showed that each plectasin molecule paired with one lipid II molecule. However, micelles do not accurately mimic the membrane environment. ‚ÄúWe took a gamble, believing that what happened in micelles was not the real deal, and this turned out to be the case,‚Äù said Weingarth. In biological membranes, the team found that plectasin formed massive supramolecular structures upon lipid II binding. ‚ÄúWe saw that the supramolecular mechanism was not the exception, but rather the rule among the lipid II binders.‚Äù

**How is plectasin‚Äôs mechanism of action different from that of other antibiotics?**
------------------------------------------------------------------------------------

Conventional antimicrobial peptides selectively bind bacteria based on electrostatics, as bacterial membranes are negatively charged while human cell membranes are positively charged. This electrostatic interaction is fairly unspecific. However, plectasin targets lipid II specifically based on both structure and charge, making it a highly selective target binder. This specificity marks its first major difference. Most drugs follow a conventional ""one drug, one target"" mechanism, where the drug and the target interact directly. In contrast, plectasin and other lipid II binders form massive supramolecular structures upon target binding. This formation is not just a feature but a critical aspect of the mechanism. Without these superstructures, there would be no stable target binding. These two prominent features of plectasin ‚Äî highly specific interaction with the target and supramolecular recognition ‚Äî distinguish it from conventional antimicrobial peptides.

The other thing that stands out about plectasin‚Äôs mechanism is that it is calcium modulated, which was an unexpected discovery. In hindsight, it seems obvious given the presence of a large ionic pocket that naturally binds calcium. However, this aspect had not been mentioned in any previous publications on plectasin.

**What makes lipid II a good antibiotic target?**
-------------------------------------------------

Lipid II has fatty acid tails and a pyrophosphate head group, which bacteria cannot alter. There are no known cases of bacteria replacing the pyrophosphate group for peptidoglycan synthesis, making it an absolute bottleneck for their cell wall biosynthesis. However, bacteria might be able to develop indirect resistance mechanisms, such as making the target inaccessible. They could make the peptidoglycan layer so dense that the drug never reaches the target. This is energy-intensive and unstable. Additionally, bacteria cannot make more lipid II once it‚Äôs captured, so targeting lipid II at these immutable sites makes it difficult for bacteria to develop stable resistance mechanisms.

> We saw that the supramolecular mechanism was not the exception, but rather the rule among the lipid II binders.¬†  
> ‚Äì Markus Weingarth, Utrecht University

**How effective is plectasin as an antibiotic?**
------------------------------------------------

Plectasin is not effective against gram-negative bacteria because it cannot overcome their outer membrane. However, plectasin is highly efficient against gram-positive bacteria and maintains this effectiveness in animal models of infection. Despite its potential as a relevant therapeutic, I am pessimistic about its future because the clinical development of plectasin was discontinued, and the work was never published. However, plectasin ticks many important boxes: It is stable in serum, non-cytotoxic, and highly efficient against a broad range of superbugs, including in animal models of infection, making it a compelling clinical candidate.

Although plectasin‚Äôs future as a therapeutic is uncertain, the study‚Äôs findings have significant implications for the design of lipid II-binding antibiotics. It‚Äôs crucial to optimize both the part of the drug that binds the target and the part responsible for oligomerization. This aspect has been ignored so far, as the focus has traditionally been on target binding alone. However, target binding and oligomerization are strongly interdependent. Only when both are optimized can ideal target binding occur.

_This interview has been condensed and edited for clarity._

### References

1.  Jekhmane, S. _et al._ [Host defence peptide plectasin targets bacterial cell wall precursor lipid II by a calcium-sensitive supramolecular mechanism](https://www.nature.com/articles/s41564-024-01696-9). _Nat Microbiol_¬† **9,** 1778‚Äì1791 (2024).
2.  Schneider, T. _et al._ [Plectasin, a Fungal Defensin, Targets the Bacterial Cell Wall Precursor Lipid II](https://www.science.org/doi/10.1126/science.1185723?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed). _Science_¬† **328,** 1168‚Äì1172 (2010).

* * *

![Image 5: Luisa Torres](https://cdn.drugdiscoverynews.com/assets/authorNo/398/iImg/40021/luisa-300x300-t.png)

Aug 28, 2024|3 min read

Luisa Torres, PhD

![Image 6: Luisa Torres, PhD](https://cdn.drugdiscoverynews.com/assets/authorNo/398/iImg/40021/luisa-300x300-t.png)[Luisa Torres, PhD](https://www.drugdiscoverynews.com/author/luisa-torres-phd)

[](mailto:)

Luisa is an assistant science editor at Drug Discovery News. She is a PhD in Molecular and Cellular Pharmacology from Stony Brook University who has written for NPR‚Äôs science desk.

View[full profile.](https://www.drugdiscoverynews.com/author/luisa-torres-phd)

* * *

Learn about our[editorial policies.](https://www.drugdiscoverynews.com/editorial-policies)

PDF Version

[Facebook](https://www.drugdiscoverynews.com/#facebook)[X](https://www.drugdiscoverynews.com/#x)[LinkedIn](https://www.drugdiscoverynews.com/#linkedin)[Email](https://www.drugdiscoverynews.com/#email)[Share](https://www.addtoany.com/share#url=https%3A%2F%2Fwww.drugdiscoverynews.com%2Fvelcro-like-antibiotic-may-inform-new-antibiotic-design-16028&title=Velcro-like%20antibiotic%20may%20inform%20new%20antibiotic%20design%20%7C%20Drug%20Discovery%20News)

Topics:[Infectious Disease & Vaccines](https://www.drugdiscoverynews.com/infectious-disease-vaccines),[Disease Focus](https://www.drugdiscoverynews.com/disease-focus)

Tags:[antibiotic resistance](https://www.drugdiscoverynews.com/tag/antibiotic-resistance)[antibiotics](https://www.drugdiscoverynews.com/tag/antibiotics)[bacterial cell wall](https://www.drugdiscoverynews.com/tag/bacterial-cell-wall)[bacterial membranes](https://www.drugdiscoverynews.com/tag/bacterial-membranes)[lipid II](https://www.drugdiscoverynews.com/tag/lipid-ii)[News](https://www.drugdiscoverynews.com/tag/news)[plectasin](https://www.drugdiscoverynews.com/tag/plectasin)[supramolecular structures](https://www.drugdiscoverynews.com/tag/supramolecular-structures)

* * *

### Did you enjoy this article related to

*   News

? Here's a free milestone on the topic.

#### Milestone

Milestone: Pulling down answers to biological mysteries with ChIP
=================================================================

Through many innovations over the past 40 years, ChIP rapidly evolved to become a powerful tool for understanding the epigenome.
--------------------------------------------------------------------------------------------------------------------------------

[](https://www.addtoany.com/share)

Scientists developed chromatin immunoprecipitation (ChIP) as a tool to understand the epigenome. The technique has rapidly evolved to become faster, higher-throughput, and offer real-time epigenetic data for health and disease.

**Explore this milestone article from _Drug Discovery News_ to learn how researchers developed ChIP and have used it to understand the relationships between proteins, DNA, and RNA as they relate to gene expression.**

First name\*

Last name\*

Company name\*

Email\*

Country\*

Postal/ Zip Code\*

Business Type\*

Discipline\*

I would like to subscribe to _DDN_ email communications to receive the latest content relevant to my interests\*

The information you provide will be shared with the sponsors of this content. _Drug Discovery News_ or its sponsors may contact you to offer you content or products based on your interest in this topic. You may unsubscribe from these communications at any time. For information on how to unsubscribe, our privacy practices, and commitment to protecting your privacy, check out our [Privacy Policy](https://www.drugdiscoverynews.com/privacy-policy).

You might also be interested in...
----------------------------------

[![Image 7: A 3D illustration of a molecular structure that uses a ball-and-stick model to show the spatial arrangement of atoms and the bonds connecting them](https://cdn.drugdiscoverynews.com/assets/articleNo/16030/aImg/41789/1800x900-10-t.jpg)](https://www.drugdiscoverynews.com/accelerating-drug-discovery-with-synthetic-chemistry-advances-16030)

Aug 28, 2024|1 min read

[### Accelerating drug discovery with synthetic chemistry advances ### Accelerating drug discovery with synthetic chemistry advances](https://www.drugdiscoverynews.com/accelerating-drug-discovery-with-synthetic-chemistry-advances-16030)

[Webinar](https://www.drugdiscoverynews.com/webinars)[View Webinar](https://www.drugdiscoverynews.com/accelerating-drug-discovery-with-synthetic-chemistry-advances-16030)

[![Image 8: A 3D-rendered illustration of floating human cells](https://cdn.drugdiscoverynews.com/assets/articleNo/16029/aImg/41786/1800x900-10-t.jpg)](https://www.drugdiscoverynews.com/automating-hepatocyte-counting-16029)

Aug 27, 2024|1 min read

[### Automating hepatocyte counting ### Automating hepatocyte counting](https://www.drugdiscoverynews.com/automating-hepatocyte-counting-16029)

[Webinar](https://www.drugdiscoverynews.com/webinars)[View Webinar](https://www.drugdiscoverynews.com/automating-hepatocyte-counting-16029)

[![Image 9: A syringe with a needle drawing the vaccine out of a vial with ampules in the background ](https://cdn.drugdiscoverynews.com/assets/articleNo/16005/aImg/41688/70668-elegen-turbocharging-mrna-vaccine-development-ppl-kr800x560-istock-only-t.jpg)](https://www.drugdiscoverynews.com/turbocharging-mrna-vaccine-development-16005)

Jul 30, 2024|1 min read

[### Turbocharging mRNA vaccine development ### Turbocharging mRNA vaccine development](https://www.drugdiscoverynews.com/turbocharging-mrna-vaccine-development-16005)¬†

[Poster](https://www.drugdiscoverynews.com/posters)[View Poster](https://www.drugdiscoverynews.com/turbocharging-mrna-vaccine-development-16005)

[![Image 10: A compass on a nautical map](https://cdn.drugdiscoverynews.com/assets/articleNo/15991/aImg/41625/800x560-istock-only-17-t.jpg)](https://www.drugdiscoverynews.com/charting-a-cellular-treasure-map-with-spatial-transcriptomics-15991)

Jul 11, 2024|1 min read

[### Charting a cellular treasure map with spatial transcriptomics ### Charting a cellular treasure map with spatial transcriptomics](https://www.drugdiscoverynews.com/charting-a-cellular-treasure-map-with-spatial-transcriptomics-15991)¬†

[Poster](https://www.drugdiscoverynews.com/posters)[View Poster](https://www.drugdiscoverynews.com/charting-a-cellular-treasure-map-with-spatial-transcriptomics-15991)

Mitochondrial transplants recover damaged kidneys
=================================================

Researchers injected healthy mitochondria to acutely injured kidneys to make them viable for donation.
------------------------------------------------------------------------------------------------------

![Image 11: A microscopic blue, black, and white image of mitochondria grouped together.](https://cdn.drugdiscoverynews.com/assets/articleNo/16027/aImg/41778/istock-846236814-1800x900-1-s.jpg)

**Top Image:**

Injecting healthy mitochondria into otherwise non-transplantable kidneys could make them viable for donation.

credit: iStock.com/wir0man

Mitochondrial transplants recover damaged kidneys
=================================================

Researchers injected healthy mitochondria to acutely injured kidneys to make them viable for donation.
------------------------------------------------------------------------------------------------------

* * *

Aug 27, 2024|4 min read

Samantha Borje

![Image 12: Samantha Borje](https://cdn.drugdiscoverynews.com/assets/authorNo/425/iImg/40778/samantha-t.jpg)[Samantha Borje](https://www.drugdiscoverynews.com/author/samantha-borje)

[](mailto:)

Samantha joined Drug Discovery News as an intern in 2023. She is currently pursuing her PhD at the University of Washington, where she studies scaling up DNA nanotechnology for new applications and develops science education and outreach materials.

View[full profile.](https://www.drugdiscoverynews.com/author/samantha-borje)

* * *

Learn about our[editorial policies.](https://www.drugdiscoverynews.com/editorial-policies)

PDF Version

[](https://www.addtoany.com/share)

Every year, thousands of patients die while waiting for a kidney transplant. The overwhelming demand for donated kidneys has pushed medical professionals to expand the donation criteria to injured kidneys and kidneys donated after cardiac death (DCD). Still, up to a quarter of donated kidneys are too damaged for patients to receive.

‚ÄúWe need to render transplantable untransplantable organs,‚Äù said [Giuseppe Orlando](https://school.wakehealth.edu/faculty/o/giuseppe-orlando), a transplant surgeon at Wake Forest University School of Medicine. He and his collaborators recently [demonstrated](https://journals.lww.com/annalsofsurgery/fulltext/2023/12000/mitochondria_transplantation_mitigates_damage_in.55.aspx) a potential new way to do that: injecting donor kidneys with healthy mitochondria (1).

![Image 13: Giuseppe Orlando smiles while wearing glasses, a blue-and-white pin-stripe shirt, a dark blue tie, and a white lab coat. ](https://cdn.drugdiscoverynews.com/assets/articleNo/16027/iImg/41777/wfu-l.jpg)

Giuseppe Orlando studies regenerative therapies and bioengineering transplantable organs at Wake Forest University School of Medicine. He is also a practicing surgeon.

credit: Giuseppe Orlando

The team used a protocol for mitochondrial transplantation (MITO) [developed](https://www.sciencedirect.com/science/article/abs/pii/S1567724917300053)[](https://www.drugdiscoverynews.com/velcro-like-antibiotic-may-inform-new-antibiotic-design-16028#_msocom_4) by [James McCully](https://www.childrenshospital.org/research/researchers/james-mccully), a coauthor of the new study at Boston Children‚Äôs Hospital (2). The method originally came to Orlando‚Äôs attention when he received a call from his long-time collaborator [Benedetta Bussolati](https://bcsd.campusnet.unito.it/do/docenti.pl/Alias?benedetta.bussolati#tab-profilo) at the University of Turin. Bussolati‚Äôs PhD student [Andrea Rossi](https://www.dmbhs.unito.it/do/docenti.pl/Show?_id=anrossi#tab-profilo), the study‚Äôs first author, had been using MITO in kidney cells and wanted Orlando‚Äôs help to develop a more clinically-relevant animal model for improving kidney transplant[](https://www.drugdiscoverynews.com/velcro-like-antibiotic-may-inform-new-antibiotic-design-16028#_msocom_6). ‚ÄúI read the literature and \[thought\] it was pretty cool,‚Äù said Orlando. ‚Äú[](https://www.drugdiscoverynews.com/velcro-like-antibiotic-may-inform-new-antibiotic-design-16028#_msocom_7)I smelled the potential.‚Äù

For their initial _in vitro_ studies, they extracted mitochondria from a model kidney cell line (cIPTECs). To confirm that these isolated mitochondria were functioning properly, the researchers used luminescence and fluorescence assays to show that they were producing ATP and that their membranes were intact. The team then confirmed through fluorescent tagging that the mitochondria could be successfully transplanted into new cIPTECs.

A common issue for donated organs is ischemia reperfusion injury. When organs get cut off from the donor blood stream (ischemia), they can incur even further damage when blood begins to flow through them again (reperfusion). As a model for this phenomenon, Orlando‚Äôs team subjected ciPTECs to antimycin A, an ATP production inhibitor, and 2-deoxyglucose, a glycolysis inhibitor. Predictably, this led to a depletion of ATP production and cell proliferation along with an increase in cell death, but the team found that MITO was largely able to reverse this. MITO also alleviated oxidative damage and recovered Krebs Cycle enzyme activity.

‚ÄúThere's an adage that just says that everything works in mice,‚Äù said Orlando, who instead chose what he described as a more clinically relevant porcine model [](https://www.drugdiscoverynews.com/velcro-like-antibiotic-may-inform-new-antibiotic-design-16028#_msocom_15)for their _ex vivo_ animal studies. To mimic DCD conditions, they extracted the kidneys and subjected them to warm ischemia, storing them in a 37¬∞C bath without blood supply for 30 minutes. ¬†The researchers then treated one kidney from each animal with MITO and left the other untreated before placing both of them in separate reperfusion machinery for 24 hours. MITO kidneys consistently exhibited fewer signs of apoptosis and structural tissue damage than the untreated control kidneys.

Lastly, the team collected the external blood flow[](https://www.drugdiscoverynews.com/velcro-like-antibiotic-may-inform-new-antibiotic-design-16028#_msocom_17) from each kidney‚Äôs reperfusion. As a way of characterizing gene expression, the team used Raman spectroscopy to examine the molecules shed by the control and MITO kidneys during the 24-hour period. [](https://www.drugdiscoverynews.com/velcro-like-antibiotic-may-inform-new-antibiotic-design-16028#_msocom_18)‚ÄúWhat we found was very interesting,‚Äù said Orlando. ‚ÄúThe control and the study groups basically localized to two extremes of the spectrum.‚Äù Whereas MITO kidneys activated the expression of several genes related to regeneration and repair, the control kidneys did not. MITO kidneys also shed fewer molecules overall, which Orlando explained was a sign of less damage. RNA sequencing supported this finding; dozens of transcripts were upregulated in MITO that were not in the controls. The researchers further investigated these upregulated transcripts and found that they were largely involved in key signaling pathways, both within the mitochondria and in the surrounding cell.

> We need to render transplantable untransplantable organs.¬†  
> \- Giuseppe Orlando, Wake Forest University School of Medicine

‚ÄúI don't believe any of this in this field, I'm afraid,‚Äù said [Mike Murphy](https://www.mrc-mbu.cam.ac.uk/research-groups/murphy-group), a mitochondrial redox biologist at the University of Cambridge who was not part of the study. Murphy was not convinced that the mitochondria integrated and were active inside the cell. He argued that the changes in gene expression between MITO and control kidneys could have been the result of cells generally protecting themselves from stress or damage. [](https://www.drugdiscoverynews.com/velcro-like-antibiotic-may-inform-new-antibiotic-design-16028#_msocom_20)‚ÄúThe assumption is that mitochondria go in there, doing stuff inside the cell that is making it a better place,‚Äù he said. ‚ÄúThere are no papers that I'm aware of that show that convincingly.‚Äù

‚ÄúThere are still many questions to be answered,‚Äù Orlando acknowledged. His team is in talks with the Food and Drug Administration and the Wake Forest Institutional Review Board to move forward to clinical trials. He also hopes to optimize the MITO protocol and to identify a source for more durable mitochondria, as isolated mitochondria decay within an hour or two of extraction. ‚ÄúThe holy grail in the field would be the ability to isolate mitochondria that stay viable,‚Äù he said.

However, Murphy recommended going back to the basics: ‚ÄúThis field, they‚Äôve sort of jumped ahead quite a bit,‚Äù he said. ‚ÄúThe positive side is we're getting interesting effects, protective things going on. Adding anything that does these things is really interesting, but how does it do it?‚Äù

Murphy suggested a series of controls to clarify the mechanisms of MITO, for example, injecting individual components of mitochondria such as the DNA or cardiolipin, a uniquely mitochondrial phospholipid. He also suggested testing for the same effect with aged or denatured mitochondria, which do not perform active respiration, and other cellular components altogether. ‚ÄúIf you can show for certain that you really were enhancing the mitochondria, that will be very important,‚Äù said Murphy.

Orlando remained hopeful about the potential of MITO technology, which he believed will have many applications across most if not all fields of health sciences. ‚ÄúWe are still at the dawn of this mitochondrial transplant era,‚Äù said Orlando. ‚ÄúThe next couple of decades will be very interesting.‚Äù

### References

1.  Rossi, A _et al._¬†[Mitochondria Transplantation Mitigates Damage in an In Vitro Model of Renal Tubular Injury and in an Ex Vivo Model of DCD Renal Transplantation.](https://journals.lww.com/annalsofsurgery/fulltext/2023/12000/mitochondria_transplantation_mitigates_damage_in.55.aspx) _Ann Surg_ ¬†**278**, e1313-e1326 (2023).
2.  McCully, J.D. _et al._¬†¬†[Mitochondrial transplantation: From animal models to clinical use in humans](https://www.sciencedirect.com/science/article/abs/pii/S1567724917300053). _Mitochondrion_ ¬†**34**,¬†127-134 (2017).

* * *

Aug 27, 2024|4 min read

Samantha Borje

![Image 14: Samantha Borje](https://cdn.drugdiscoverynews.com/assets/authorNo/425/iImg/40778/samantha-t.jpg)[Samantha Borje](https://www.drugdiscoverynews.com/author/samantha-borje)

[](mailto:)

Samantha joined Drug Discovery News as an intern in 2023. She is currently pursuing her PhD at the University of Washington, where she studies scaling up DNA nanotechnology for new applications and develops science education and outreach materials.

View[full profile.](https://www.drugdiscoverynews.com/author/samantha-borje)

* * *

Learn about our[editorial policies.](https://www.drugdiscoverynews.com/editorial-policies)

PDF Version

[](https://www.addtoany.com/share)

Topics:[Internal Medicine](https://www.drugdiscoverynews.com/internal-medicine),[Disease Focus](https://www.drugdiscoverynews.com/disease-focus),[Tools & Techniques News](https://www.drugdiscoverynews.com/tools-techniques-news),[Tools & Techniques](https://www.drugdiscoverynews.com/tools-techniques)

Tags:[cIPTEC](https://www.drugdiscoverynews.com/tag/ciptec)[collaboration](https://www.drugdiscoverynews.com/tag/collaboration)[ischemia reperfusion injury](https://www.drugdiscoverynews.com/tag/ischemia-reperfusion-injury)[kidney](https://www.drugdiscoverynews.com/tag/kidney)[mitochondria](https://www.drugdiscoverynews.com/tag/mitochondria)[News](https://www.drugdiscoverynews.com/tag/news)[organ donation](https://www.drugdiscoverynews.com/tag/organ-donation)

* * *

[![Image 15: Subscribe to Newsletter](https://cdn.drugdiscoverynews.com/static/12.3.1/assets/img_ddn_enewsletter_weekly_round_2023.png)](https://go.drugdiscoverynews.com/ddn-newsletter-subscription-form)

[Subscribe to our eNewsletters](https://go.drugdiscoverynews.com/ddn-newsletter-subscription-form)Stay connected with all of the latest from Drug Discovery News.

[Subscribe](https://go.drugdiscoverynews.com/ddn-newsletter-subscription-form)

[![Image 16: DDN July 2024 Magazine Issue](https://cdn.drugdiscoverynews.com/assets/magazineIssueNo/2023/iImg/41572/screenshot-2024-06-27-153336-1-s.png)](https://www.drugdiscoverynews.com/magazine/current-issue)

**Latest Issue**

‚Ä¢ Volume 20 ‚Ä¢ Issue 4 ‚Ä¢ July 2024

[July 2024](https://www.drugdiscoverynews.com/magazine/current-issue)July 2024 Issue

[Explore This Issue](https://www.drugdiscoverynews.com/magazine/current-issue)

[](https://www.facebook.com/DrugDiscoveryNewsMagazine/ ""Facebook"")[](https://twitter.com/DrugDiscovNews ""Twitter"")[](https://www.linkedin.com/company/drug-discovery-news/ ""LinkedIn"")

*   [About Us](https://www.drugdiscoverynews.com/about-ddn)
*   [Contact Us](https://www.drugdiscoverynews.com/contact-us)
*   [Advertise with DDN](https://mediakit.drugdiscoverynews.com/access)
*   [Privacy Policy](https://www.drugdiscoverynews.com/privacy-policy)
*   [Cookie Policy](https://www.drugdiscoverynews.com/cookie-policy)
*   [Terms & Conditions](https://www.drugdiscoverynews.com/terms-and-conditions)
*   [Editorial Policies](https://www.drugdiscoverynews.com/editorial-policies)

¬© 2024 Drug Discovery News. All rights reserved.

We‚Äôve updated our [Privacy Policy](https://www.drugdiscoverynews.com/privacy-policy) to make it clearer how we use your personal data.  
Please read our [Cookie Policy](https://www.drugdiscoverynews.com/cookie-policy) to learn how we use cookies to provide you with a better experience.

I UNDERSTAND

  

‚úì

Thanks for sharing!

[AddToAny](https://www.addtoany.com/ ""Share Buttons"")

[More‚Ä¶](https://www.drugdiscoverynews.com/velcro-like-antibiotic-may-inform-new-antibiotic-design-16028#addtoany ""Show all"")

Feedback
"
2024-08-29 08:27:00,2024-08-29 23:08:50,"üåü Exciting news from the ophthalmology world! The European Commission has officially granted marketing authorization for Akantior, a groundbreaking treatment for _Acanthamoeba_ keratitis. This marks a significant milestone for both healthcare providers and patients battling this challenging condition.

üîç **Key Highlights from the Announcement:**  
- The authorization comes after an impressive phase 3 pivotal trial involving 135 patients, where **84.8%** of participants were cured.  
- Notably, **66.7%** of those patients restored their full vision without requiring corneal transplants.
- Akantior (polyhexanide) is poised to be the first and only authorized medicinal treatment for this condition globally, with exclusive marketing rights awarded to Avanzanite Bioscience in 26 European countries.

üí° **What This Means for Us:**  
As professionals in the field, this development is a vital step forward in our fight against _Acanthamoeba_ keratitis. With the positive results from the trial, we can look forward to enhanced patient outcomes and broader access to innovative treatments. It's an opportunity for us to engage with local health authorities to ensure sustainable access for patients in need.  

How do you see this new treatment impacting patient care in your practice? I‚Äôd love to hear your thoughts! üí¨

#Ophthalmology #InnovativeTreatments #AcanthamoebaKeratitis #PatientCare

Read more: [Healio](https://www.healio.com/news/ophthalmology/20240828/european-commission-grants-marketing-authorization-to-akantior-for-acanthamoeba-keratitis)  
![Akantior for Acanthamoeba Keratitis](https://medsii.azureedge.net/images/638605168410416521-66d0300b6157181811bbc82c.jpg)",https://medsii.azureedge.net/images/638605168410416521-66d0300b6157181811bbc82c.jpg,https://www.healio.com/news/ophthalmology/20240828/european-commission-grants-marketing-authorization-to-akantior-for-acanthamoeba-keratitis,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Thumbnail image URL: https://medsii.azureedge.net/images/638605168410416521-66d0300b6157181811bbc82c.jpg 

Title: European Commission grants marketing authorization to Akantior for<i> </i><i>A</i><i>canthamoeba</i> keratiti

URL Source: https://www.healio.com/news/ophthalmology/20240828/european-commission-grants-marketing-authorization-to-akantior-for-acanthamoeba-keratitis

Published Time: 2024-08-28

Markdown Content:
European Commission grants marketing authorization to Akantior for A canthamoeba keratitis
===============

[![Image 1: Healio](https://m1.healio.com/~/media/images/healio/healiologooptimized.svg)](https://www.healio.com/)

*   [News News](https://www.healio.com/news ""News"")
*   [CME CME](https://www.healio.com/cme ""CME"")
*   [Clinical Guidance Clinical Guidance](https://www.healio.com/clinical-guidance ""Clinical Guidance"")

*   [_Account_](https://www.healio.com/footer/account-information/my-account "" "")
*   [_Account Anonymous User_](javascript:void\($j.get\('/loginregistration/modals/loadloginmodal',function\(data\){$j\('body'\).append\(data\);}\)\) "" "")
*   [Log In Log In](javascript:void\($j.get\('/utilityapp/json/na/li/healiotwo/{ACC50322-FB7D-42FC-940E-84BDDAD3B84D}',function\(data\){$j\('body'\).append\(data\);}\)\) ""Log In"")
*   [Log Out Log Out](javascript:; ""Log Out"")

*   [News News](https://www.healio.com/news ""News"")
*   [CME CME](https://www.healio.com/cme ""CME"")
*   [Clinical Guidance Clinical Guidance](https://www.healio.com/clinical-guidance ""Clinical Guidance"")

*   [_Account_](https://www.healio.com/footer/account-information/my-account "" "")
*   [_Account Anonymous User_](javascript:void\($j.get\('/loginregistration/modals/loadloginmodal',function\(data\){$j\('body'\).append\(data\);}\)\) "" "")

*   [Specialties](https://www.healio.com/news/ophthalmology/20240828/european-commission-grants-marketing-authorization-to-akantior-for-acanthamoeba-keratitis#)
    
    Choose a specialty
    
    [All Specialties](https://www.healio.com/) [Allergy/Asthma](https://www.healio.com/allergy-asthma) [Hematology/Oncology](https://www.healio.com/hematology-oncology) [Infectious Disease](https://www.healio.com/infectious-disease) [Orthopedics](https://www.healio.com/orthopedics) [Rheumatology](https://www.healio.com/rheumatology)
    
*   [Home](https://www.healio.com/)
*   [Headline News](https://www.healio.com/news)
*   [Meeting News](https://www.healio.com/news/meeting-news)
*   [Podcasts](https://www.healio.com/news/podcasts)
*   [Blogs & Columns](https://www.healio.com/news/blogs-and-columns)
*   [Resources](https://www.healio.com/news/resources)

Menu Close

[Specialties](https://www.healio.com/news/ophthalmology/20240828/european-commission-grants-marketing-authorization-to-akantior-for-acanthamoeba-keratitis#collapseSpecialty)

*   [All Specialties](https://www.healio.com/news/?showall=1)
*   [Allergy/Asthma](https://www.healio.com/allergy-asthma)
*   [Hematology/Oncology](https://www.healio.com/hematology-oncology)
*   [Infectious Disease](https://www.healio.com/infectious-disease)
*   [Orthopedics](https://www.healio.com/orthopedics)
*   [Rheumatology](https://www.healio.com/rheumatology)

[Home](https://www.healio.com/)

[Headline News](https://www.healio.com/news/ophthalmology)

*   [Ophthalmology Subspecialties](https://www.healio.com/news/ophthalmology)
*   [Cataract Surgery](https://www.healio.com/news/ophthalmology/cataract-surgery)
*   [Contact Lenses](https://www.healio.com/news/ophthalmology/contact-lenses)
*   [Cornea/External Disease](https://www.healio.com/news/ophthalmology/cornea-external-disease)
*   [Glaucoma](https://www.healio.com/news/ophthalmology/glaucoma)
*   [Imaging/Diagnostics](https://www.healio.com/news/ophthalmology/imaging-diagnostics)
*   [Neurosciences](https://www.healio.com/news/ophthalmology/neurosciences)
*   [Ocular Oncology](https://www.healio.com/news/ophthalmology/ocular-oncology)
*   [Oculoplastics](https://www.healio.com/news/ophthalmology/oculoplastics)
*   [Ophthalmic Business](https://www.healio.com/news/ophthalmology/ophthalmic-business)
*   [Optics](https://www.healio.com/news/ophthalmology/optics)
*   [Pediatrics Strabismus](https://www.healio.com/news/ophthalmology/pediatrics-strabismus)
*   [Practice Management](https://www.healio.com/news/ophthalmology/practice-management)
*   [Presbyopia](https://www.healio.com/news/ophthalmology/presbyopia)
*   [Refractive Surgery](https://www.healio.com/news/ophthalmology/refractive-surgery)
*   [Regulatory/Legislative](https://www.healio.com/news/ophthalmology/regulatory-legislative)
*   [Retina/Vitreous](https://www.healio.com/news/ophthalmology/retina-vitreous)
*   [Technology](https://www.healio.com/news/ophthalmology/technology)
*   [Trauma](https://www.healio.com/news/ophthalmology/trauma)

[Meeting News](https://www.healio.com/news/meeting-news)

[Podcasts](https://www.healio.com/news/podcasts)

[Blogs & Columns](https://www.healio.com/news/blogs-and-columns)

[Resources](https://www.healio.com/news/resources)

[Account Account](https://www.healio.com/footer/account-information/my-account ""Account"")

[Log In Log In](javascript:void\($j.get\('/utilityapp/json/na/li/healiotwo/{ACC50322-FB7D-42FC-940E-84BDDAD3B84D}',function\(data\){$j\('body'\).append\(data\);}\)\) ""Log In"")

[Log Out Log Out](javascript:; ""Log Out"")

[![Image 2: Healio](https://m1.healio.com/~/media/images/healio/healiologooptimized.svg)](https://www.healio.com/)

Close Searchbar

1.  [Healio](https://www.healio.com/)
2.  [News](https://www.healio.com/news)
3.  [Ophthalmology](https://www.healio.com/news/ophthalmology)
4.  [Ophthalmic Business](https://www.healio.com/news/ophthalmology/ophthalmic-business)

![Image 3: occular surgery news logo](https://www.healio.com/~/media/h5/feature/news/publogos/osn.svg?la=en&h=32&w=145&hash=C099A5ADC410818ECDF2097A4CD3C51F)

Fact checked by[Gina Brockenbrough, MA](https://www.healio.com/authors/gbrockenbrough)

[](https://www.healio.com/news/ophthalmology/20240828/european-commission-grants-marketing-authorization-to-akantior-for-acanthamoeba-keratitis#)

#### Read more

#### [](https://www.healio.com/news/ophthalmology/20240828/european-commission-grants-marketing-authorization-to-akantior-for-acanthamoeba-keratitis#)

#### [](https://www.healio.com/news/ophthalmology/20240828/european-commission-grants-marketing-authorization-to-akantior-for-acanthamoeba-keratitis#)

#### [](https://www.healio.com/news/ophthalmology/20240828/european-commission-grants-marketing-authorization-to-akantior-for-acanthamoeba-keratitis#)

#### [](https://www.healio.com/news/ophthalmology/20240828/european-commission-grants-marketing-authorization-to-akantior-for-acanthamoeba-keratitis#)

August 28, 2024

1 min read

Save

European Commission grants marketing authorization to Akantior for _A__canthamoeba_ keratitis
=============================================================================================

![Image 4: occular surgery news logo](https://www.healio.com/~/media/h5/feature/news/publogos/osn.svg?la=en&h=32&w=145&hash=C099A5ADC410818ECDF2097A4CD3C51F)

Fact checked by[Gina Brockenbrough, MA](https://www.healio.com/authors/gbrockenbrough)

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

**You've successfully added to your alerts. You will receive an email when new content is published.**  
  
**[Click Here to Manage Email Alerts](javascript:void\(0\))**

**You've successfully added to your alerts. You will receive an email when new content is published.**  
  
**[Click Here to Manage Email Alerts](javascript:void\(0\))**  
  
Back to Healio

**We were unable to process your request. Please try again later. If you continue to have this issue please contact [customerservice@slackinc.com](mailto:customerservice@slackinc.com).**  
  
Back to Healio

Key takeaways:
--------------

*   The authorization is supported by positive data from a phase 3 pivotal trial.
*   Avanzanite Bioscience has exclusive rights to market Akantior in 26 countries in Europe.

The European Commission granted marketing authorization to Akantior for the treatment of _A__canthamoeba_ [keratitis](https://www.healio.com/news/ophthalmology/20240304/video-oxygen-does-not-play-a-role-in-crosslinking-for-infectious-keratitis), according to a press release from Avanzanite Bioscience.

The decision was backed by positive results from the phase 3 pivotal Orphan Drug for _Acanthamoeba_ Keratitis (ODAK) trial, which included 135 patients. Of these patients, 84.8% were cured of _A__canthamoeba_ keratitis (AK) after treatment with Akantior (polyhexanide, Avanzanite Bioscience). In addition, 66.7% of patients achieved full vision restoration without the need for optical [cornea transplants](https://www.healio.com/news/ophthalmology/20240718/blog-choose-the-transplantsaving-path).

     ![Image 5: Generic Breaking News infographic](https://www.healio.com/~/media/slack-news/generic-infographics/2023/generic-breaking-news.jpg?w=800)

The European Commission granted marketing authorization to Akantior for the treatment of _Acanthamoeba_ keratitis.  
  

According to the release, the drug is the first and only authorized medicinal treatment for AK globally. It previously received a positive opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use and a positive recommendation from the EMA Committee for Orphan Medicinal Products.

Akantior is the second rare disease medicine commercialized by Avanzanite, which has secured exclusive rights to commercialize the treatment in 26 countries in Europe.

‚ÄúThis marketing authorization is the beginning of a new chapter for the treatment of _A__canthamoeba_ keratitis and a monumental victory for AK patients in Europe,‚Äù **Adam Plich,** founder and CEO of Avanzanite Bioscience, said in the release. ‚ÄúAt Avanzanite, we are committed to supporting broad access to our innovative therapies and look forward to collaborating with local health authorities in 26 European countries to secure sustainable access agreements so we can save the eyes of as many eligible patients as possible.‚Äù

Published by: ![Image 6: occular surgery news logo](https://www.healio.com/~/media/h5/feature/news/publogos/osn.svg?la=en&h=32&w=145&hash=C099A5ADC410818ECDF2097A4CD3C51F)

Sources/DisclosuresCollapse

**Source:**[Press Release](https://www.businesswire.com/news/home/20240826744342/en/Avanzanite-Bioscience-Reports-European-Commissions-Authorisation-of-Orphan-Medicinal-Product-AKANTIOR%C2%AE)

Read more about

[acanthamoeba keratitis](https://www.healio.com/topics/acanthamoeba-keratitis)

[cornea transplants](https://www.healio.com/topics/cornea-transplants)

[marketing](https://www.healio.com/topics/marketing)

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

**You've successfully added to your alerts. You will receive an email when new content is published.**  
  
**[Click Here to Manage Email Alerts](javascript:void\(0\))**

**You've successfully added to your alerts. You will receive an email when new content is published.**  
  
**[Click Here to Manage Email Alerts](javascript:void\(0\))**  
  
Back to Healio

**We were unable to process your request. Please try again later. If you continue to have this issue please contact [customerservice@slackinc.com](mailto:customerservice@slackinc.com).**  
  
Back to Healio

*   [Facebook](javascript:void\(0\))
*   [Twitter](javascript:void\(0\))
*   [LinkedIn](javascript:void\(0\))
*   [Email](mailto:?subject=IsawthisarticleonHealio.comandthoughtyoumightbeinterestedinit&Body=https%3a%2f%2fwww.healio.com%2fnews%2fophthalmology%2f20240828%2feuropean-commission-grants-marketing-authorization-to-akantior-for-acanthamoeba-keratitis)
*   [Print](javascript:void\(0\))
*   [Comment](https://www.healio.com/footer/healio-dot-com/contact-the-news-desk)

[Continue Reading](javascript:void\(0\))

Related Content
---------------

[Play on Healio ![Image 7: Word Doc](https://m2.healio.com/~/media/images/footer/worddoc_desktop.svg)](https://www.healio.com/worddoc)

Follow Healio

*   [Twitter](https://twitter.com/GoHealio)
*   [Facebook](https://www.facebook.com/HealioNetwork)
*   [Instagram](https://www.instagram.com/gohealio)
*   [Threads](https://www.threads.net/gohealio)
*   [LinkedIn](http://www.linkedin.com/company/healio)

About

*   [About Healio About Healio](https://www.healio.com/about-healio ""About Healio"")
*   [About the Wyanoke Group About the Wyanoke Group](https://www.healio.com/about-the-wyanoke-group ""About the Wyanoke Group"")
*   [Editorial Policy and Philosophy Editorial Policy and Philosophy](https://www.healio.com/editorial-policy-and-philosophy ""Editorial Policy and Philosophy"")
*   [Sitemap Sitemap](https://www.healio.com/sitemap ""Sitemap"")

Account Information

*   [My Account Login](javascript:void\($j.get\('/utilityapp/json/na/li/healiotwo/{ACC50322-FB7D-42FC-940E-84BDDAD3B84D}?returnUrl=https://preview.healio.com/footer/account-information/my-account',function\(data\){$j\('body'\).append\(data\);}\)\) ""My Account"")
*   [My Account My Account](https://www.healio.com/my-account ""My Account"")
*   [Help Help](https://www.healio.com/help ""Help"")
*   [Email Subscriptions Email Subscriptions](https://www.healio.com/my-account/email-subscriptions-and-alerts ""Email Subscriptions"")
*   [Email Subscriptions Email Subscriptions Unknown](javascript:void\($j.get\('/utilityapp/json/na/li/healiotwo/{ACC50322-FB7D-42FC-940E-84BDDAD3B84D}?returnUrl=https://www.healio.com/my-account/email-subscriptions-and-alerts',function\(data\){$j\('body'\).append\(data\);}\)\) ""Email Subscriptions"")
*   [Newspaper and Journal Subscriptions Newspaper and Journal Subscriptions](https://www.healio.com/subscribe ""Newspaper and Journal Subscriptions"")

Contact Us

*   [Email Us Email Us](https://www.healio.com/help#request ""Email Us"")
*   [Contact Newsroom Contact Newsroom](https://www.healio.com/contact-newsroom ""Contact Newsroom"")
*   [Advertising Information Advertising Information](https://www.healio.com/advertising-information ""Advertising Information"")
*   [Permissions and Reprints Permissions and Reprints](https://www.healio.com/reprints-permissions ""Permissions and Reprints"")

Legal

*   [Do Not Sell My Personal Information Do Not Sell My Personal Information](https://www.healio.com/do-not-sell-my-personal-information ""Do Not Sell My Personal Information"")
*   [Terms and Conditions Terms and Conditions](https://www.healio.com/terms-and-conditions ""Terms and Conditions"")
*   [Medical Disclaimer Medical Disclaimer](https://www.healio.com/medical-disclaimer ""Medical Disclaimer"")
*   [Privacy Policy Privacy Policy](https://www.healio.com/privacy-policy ""Privacy Policy"")

Sign Up for Email

Get the latest news and education delivered to your inbox

Email address 

Enter your email

Enter your email

[Update email address](https://www.healio.com/footer/account-information/my-account/edit-profile)

Specialty

Choose your specialty\*

*   All Specialties
*   Allergy & Asthma
*   Cardiology
*   Dermatology
*   Endocrinology
*   Gastroenterology/Hepatology
*   Hematology Oncology
*   Infectious Disease
*   Nephrology
*   Neurology
*   Ophthalmology
*   Optometry
*   Orthopedics
*   Pediatrics
*   Primary Care
*   Psychiatry
*   Pulmonology
*   Rheumatology
*   Women‚Äôs Health & OB/GYN

Choose your specialty

Subscribe

Update email address
--------------------

The email address associated with your Healio account is:

If you would like to edit or change the email address that your subscriptions and alerts are sent to, use the ""Update email address"" link.

[Update email address](https://www.healio.com/footer/account-information/my-account/edit-profile)

¬© 2024 Healio All Rights Reserved.

We‚Äôre sorry, but an unexpected error has occurred.
--------------------------------------------------

**Please refresh your browser and try again. If this error persists, please contact [ITSupport@wyanokegroup.com](mailto:itsupport@wyanokegroup.com) for assistance.**

Close

 

      

Would you like to receive email reminders to complete your saved activities from Healio CME?

 Yes

 No

Activity saved! You'll receive reminders to complete your saved activities from Healio CME.

Unsubscribe

   ![Image 8](https://www.healio.com/medialibrary/pixel.png?tp=hid&uid=undefined&iid=461546b2-2a5a-4ac9-8778-495e0512c85f|1724970426855-web) ![Image 9](https://sync.graph.bluecava.com/ds.png?p=f044c44d-2a0b-11ef-bd99-4201ac100014&segment=healiodefault&event=imp&cb=1724970426856&uid=461546b2-2a5a-4ac9-8778-495e0512c85f)![Image 10](https://thrtle.com/insync?vxii_pid=40005&sessionid=461546b2-2a5a-4ac9-8778-495e0512c85f)![Image 11](https://ad-delivery.net/px.gif?ch=2)![Image 12](https://ad.doubleclick.net/favicon.ico?ad=300x250&ad_box_=1&adnet=1&showad=1&size=250x250)![Image 13](https://ad-delivery.net/px.gif?ch=1&e=0.8500586108547263)![Image 14](https://ads.stickyadstv.com/user-matching?id=3656)
"
2024-08-29 08:17:00,2024-08-29 23:08:59,"‚ú® **Could Diabetes Medications Help Prevent Dementia?** ‚ú®  
Have you ever wondered if the medications meant to manage our health could play an unexpected role in preventing cognitive decline? A recent study published in *The BMJ* has brought to light a fascinating potential of Sodium-glucose cotransporter-2 (SGLT-2) inhibitors, commonly prescribed for type 2 diabetes, in reducing the risk of dementia. 

The findings from this large-scale observational study conducted in South Korea suggest that SGLT-2 inhibitors might actually decrease the risk of dementia by about 35% compared to other diabetes medications, particularly Dipeptidyl peptidase-4 (DPP-4) inhibitors. This is particularly encouraging as the global dementia rate is expected to skyrocket, hitting approximately 78 million by 2030 according to the World Health Organization. 

In simple terms, the study tracked over 110,000 individuals aged 40-69 with type 2 diabetes, and the results showed that those on SGLT-2 inhibitors had much lower rates of dementia incidence‚Äî0.22 cases per 100 person years versus 0.35 for DPP-4 users. Interestingly, the protective effect seemed to increase over time, with prolonged treatment offering even greater benefits. 

While it‚Äôs important to note that more randomized controlled trials are needed to fully understand these results‚Äîparticularly as the study was observational‚Äîthey shine a spotlight on the potential for existing medications to offer secondary benefits in our fight against cognitive decline. 

As professionals in the healthcare community, we always strive to stay ahead of the curve. Imagine the impact if these findings are confirmed! It opens the door for revamping treatment plans and clinical guidelines to not only manage diabetes effectively but also proactively prevent dementia. 

What are your thoughts on this connection between diabetes medications and dementia risk? Could this change how we view treatment strategies? Let‚Äôs delve into this together!  

#DiabetesManagement #DementiaResearch #HealthcareInnovation #SLGT2Inhibitors #Neuroscience

[Read the full article here](https://www.eurekalert.org/news-releases/1055806)",https://medsii.azureedge.net/images/638605162654079998-66d02d1a6157181811bbc82b.jpg,https://www.eurekalert.org/news-releases/1055806,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Thumbnail image URL: https://medsii.azureedge.net/images/638605162654079998-66d02d1a6157181811bbc82b.jpg 

Title: Certain diabetes drugs might prevent dementia

URL Source: https://www.eurekalert.org/news-releases/1055806

Markdown Content:
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors used to treat type 2 diabetes might prevent dementia, providing greater benefits with longer treatment, suggests a large study from Korea published by¬†_The BMJ_¬†today.

As this study was observational, the researchers note that the effect size could have been overestimated and say randomised controlled trials are now needed to confirm these findings.

According to the World Health Organization, the number of people with dementia globally is expected to reach 78 million by 2030 and type 2 diabetes is associated with a greater risk of developing dementia.

A recent study of¬†over 65s with type 2 diabetes¬†suggested a decreased risk of dementia associated with SGLT-2 inhibitors versus another type of diabetes drug, dipeptidyl peptidase-4 (DPP-4)¬†inhibitors. But the effects on younger people and specific types of dementia (eg, Alzheimer‚Äôs disease, vascular dementia) remains unclear.

To address this, researchers used¬†the Korea National Health Insurance Service database to identify 110,885 pairs of adults with type 2 diabetes¬†aged 40-69 years¬†who were free of dementia and started taking either an SGLT-2 inhibitor or a DPP-4 inhibitor between 2013 and 2021.

All participants (average age 62; 56% men) were matched by age, sex, use of the diabetes drug metformin, and baseline cardiovascular risk and were followed up for an average of 670 days to see who developed dementia.

Potentially influential factors including personal characteristics, income level, underlying risk factors for dementia, other conditions and related medicine use, were also taken into account.

Over the follow-up period, a total of 1,172 participants with newly diagnosed dementia were identified.

Dementia rates per 100 person years were 0.22 for those using SGLT-2 inhibitors and 0.35 for those using DPP-4 inhibitors, corresponding to a 35% reduced risk of dementia associated with use of SGLT-2 inhibitors compared with DPP-4 inhibitors.

The researchers also found a 39% reduced risk for Alzheimer‚Äôs disease, and a 52% reduced risk for vascular dementia associated with SGLT-2 inhibitors compared with DPP-4 inhibitors.

What‚Äôs more, the effect of SGLT-2 inhibitors seemed more pronounced with longer treatment duration. A 48% reduced risk of dementia was seen for more than two years of treatment versus a 43% reduced risk for two years or less.

This is an observational study so no firm conclusions can be drawn about cause and effect, and the authors note that details of health behaviours (eg, smoking and alcohol consumption) and duration of type 2 diabetes were not fully available.

However, they point out that this was a large study based on nationally representative data that included relatively younger people with type 2 diabetes, and results were highly consistent across subgroups.

As such, they say SGLT-2 inhibitors might prevent dementia, providing greater benefits with longer treatment, and they call for randomised controlled trials to confirm these findings.

This study reports promising results that have important implications for clinical practice as well as from a public health perspective, say researchers from Taiwan in a linked editorial.

They agree that further trials are needed to confirm these findings, and suggest that studies are also needed ‚Äúto explore the underlying mechanisms of any neuroprotective effects of SGLT-2 inhibitors.‚Äù

As no cure currently exists for dementia and few effective treatment options are available, strategies that can potentially prevent onset are critically important, they write.

Given the substantial socioeconomic and public health burdens associated with both dementia and type 2 diabetes, they also recommend that clinical guidelines and healthcare policies should be updated regularly to incorporate latest best evidence on the potential benefits of SGLT-2 inhibitors, including reduced dementia risk.

* * *

* * *

#### Method of Research

Observational study

#### Subject of Research

People

#### Article Title

Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study

#### Article Publication Date

28-Aug-2024

#### COI Statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: support from the Korea Health Industry Development Institute (KHIDI)AZ Diabetes Research programme; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. EHK receives grants from Celltrion and SK Chemicals to Seoul National University Bundang Hospital for unrelated studies. BKK receives grants from KHIDI to SMGSNU Boramae Medical Centre for unrelated studies.
"
2024-08-28 06:46:00,2024-08-29 23:09:07,"üåü Have you ever wondered how our metabolites shape our health? Recent research has brought surprising insights into how amino acids like glycine and glutamine may lower the risk of hospitalized gout!  

In a compelling study featured in HCPLive, researchers analyzed the metabolomes of almost 250,000 participants and discovered that individuals with higher levels of glycine and glutamine had a significantly lower risk of being hospitalized for gout. Specifically, glycine showed an almost 36% reduced risk, while glutamine offered a 31% reduction!  

The study underscores the potential of using metabolomics in predicting health risks. This could pave the way for metabolic profiling as a routine practice, providing key insights into patient health and perhaps guiding dietary recommendations or supplementation aimed at gout prevention.  

As professionals in the healthcare field, understanding these relationships can enhance patient care strategies. Have you considered how dietary factors could influence metabolic disorders in your practice?  

üí° Let‚Äôs explore this topic further! What are your thoughts on the role of amino acids in managing metabolic diseases?  

#GoutPrevention #Metabolomics #AminoAcids #PatientCare #HealthcareResearch  

üëâ [Read the full article here!](https://www.hcplive.com/view/glycine-glutamine-may-reduce-risk-hospitalized-gout)",https://medsii.azureedge.net/images/638604243910499483-66cec74fac48c5e342a25f19.jpg,https://www.hcplive.com/view/glycine-glutamine-may-reduce-risk-hospitalized-gout,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Thumbnail image URL: https://medsii.azureedge.net/images/638604243910499483-66cec74fac48c5e342a25f19.jpg 

Title: Glycine, Glutamine May Reduce Risk of Hospitalized Gout

URL Source: https://www.hcplive.com/view/glycine-glutamine-may-reduce-risk-hospitalized-gout

Published Time: 2024-08-27T15:00:00.000Z

Markdown Content:
Glycine, Glutamine May Reduce Risk of Hospitalized Gout
===============
     

[![Image 1](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/)

[News](https://www.hcplive.com/news)

Media

[Podcasts](https://www.hcplive.com/podcasts)[Shows](https://www.hcplive.com/shows)[State Of Sciences - Presentations](https://www.hcplive.com/state-of-sciences-presentations)[Videos](https://www.hcplive.com/videos)[Webinars](https://www.hcplive.com/webinars)

Multimedia Series

[CURE Connections¬Æ](https://www.hcplive.com/cure-connections)[Insights](https://www.hcplive.com/insights)[Medcast Podcasts](https://www.hcplive.com/medcast-podcasts)[Medcast Videos](https://www.hcplive.com/medcast-videos)[News Network](https://www.hcplive.com/news-network)[Peer Exchange](https://www.hcplive.com/peer-exchange)[Peers & Perspectives](https://www.hcplive.com/peers-and-perspective)

Conferences

[Conference Coverage](https://www.hcplive.com/latest-conference)[Conference Listing](https://www.hcplive.com/conference)

[Partners](https://www.hcplive.com/sap-partner)[CME/CE](https://www.hcplive.com/continuing-education)

Resources

[Interactive Tools](https://www.hcplive.com/interactive-tools)[Live Events](https://www.hcplive.com/events)[Press Release](https://www.hcplive.com/press-release)[Publications](https://www.hcplive.com/journals)[Sponsored](https://www.hcplive.com/sponsored)

[Advisory Board](https://www.hcplive.com/advisory-board)[Subscribe](https://one.hcplive.com/subscribe/)

Choose Specialty

[Allergy](https://www.hcplive.com/clinical/allergy)[Allergy](https://www.hcplive.com/clinical/allergy)[Allergy](https://www.hcplive.com/clinical/allergy)[Allergy](https://www.hcplive.com/clinical/allergy)

[Biosimilars](https://www.hcplive.com/clinical/biosimilars)

[Cardiology](https://www.hcplive.com/clinical/cardiology)[Cardiology](https://www.hcplive.com/clinical/cardiology)[Cardiology](https://www.hcplive.com/clinical/cardiology)[Cardiology](https://www.hcplive.com/clinical/cardiology)[Cardiology](https://www.hcplive.com/clinical/cardiology)[Cardiology](https://www.hcplive.com/clinical/cardiology)[Cardiology](https://www.hcplive.com/clinical/cardiology)[Cardiology](https://www.hcplive.com/clinical/cardiology)[Cardiology](https://www.hcplive.com/clinical/cardiology)

[Dermatology](https://www.hcplive.com/clinical/dermatology)[Dermatology](https://www.hcplive.com/clinical/dermatology)[Dermatology](https://www.hcplive.com/clinical/dermatology)[Dermatology](https://www.hcplive.com/clinical/dermatology)[Dermatology](https://www.hcplive.com/clinical/dermatology)[Dermatology](https://www.hcplive.com/clinical/dermatology)[Dermatology](https://www.hcplive.com/clinical/dermatology)

[Endocrinology](https://www.hcplive.com/clinical/endocrinology)[Endocrinology](https://www.hcplive.com/clinical/endocrinology)[Endocrinology](https://www.hcplive.com/clinical/endocrinology)[Endocrinology](https://www.hcplive.com/clinical/endocrinology)[Endocrinology](https://www.hcplive.com/clinical/endocrinology)[Endocrinology](https://www.hcplive.com/clinical/endocrinology)

[FDA News](https://www.hcplive.com/clinical/fda-news)

[Family Medicine](https://www.hcplive.com/clinical/family-medicine)[Family Medicine](https://www.hcplive.com/clinical/family-medicine)[Family Medicine](https://www.hcplive.com/clinical/family-medicine)[Family Medicine](https://www.hcplive.com/clinical/family-medicine)

[Gastroenterology](https://www.hcplive.com/clinical/gastroenterology)[Gastroenterology](https://www.hcplive.com/clinical/gastroenterology)[Gastroenterology](https://www.hcplive.com/clinical/gastroenterology)[Gastroenterology](https://www.hcplive.com/clinical/gastroenterology)[Gastroenterology](https://www.hcplive.com/clinical/gastroenterology)[Gastroenterology](https://www.hcplive.com/clinical/gastroenterology)[Gastroenterology](https://www.hcplive.com/clinical/gastroenterology)

[Geriatrics](https://www.hcplive.com/clinical/geriatrics)[Geriatrics](https://www.hcplive.com/clinical/geriatrics)[Geriatrics](https://www.hcplive.com/clinical/geriatrics)

[Hematology](https://www.hcplive.com/clinical/hematology)[Hematology](https://www.hcplive.com/clinical/hematology)[Hematology](https://www.hcplive.com/clinical/hematology)

[Hepatology](https://www.hcplive.com/clinical/hepatology)[Hepatology](https://www.hcplive.com/clinical/hepatology)[Hepatology](https://www.hcplive.com/clinical/hepatology)[Hepatology](https://www.hcplive.com/clinical/hepatology)[Hepatology](https://www.hcplive.com/clinical/hepatology)

[Hospital Medicine](https://www.hcplive.com/clinical/hospital-medicine)

[Infectious Disease](https://www.hcplive.com/clinical/infectious-disease)[Infectious Disease](https://www.hcplive.com/clinical/infectious-disease)

[Internal Medicine](https://www.hcplive.com/clinical/internal-medicine)

[Nephrology](https://www.hcplive.com/clinical/nephrology)[Nephrology](https://www.hcplive.com/clinical/nephrology)[Nephrology](https://www.hcplive.com/clinical/nephrology)

[Neurology](https://www.hcplive.com/clinical/neurology)[Neurology](https://www.hcplive.com/clinical/neurology)[Neurology](https://www.hcplive.com/clinical/neurology)[Neurology](https://www.hcplive.com/clinical/neurology)[Neurology](https://www.hcplive.com/clinical/neurology)

[Obesity Management](https://www.hcplive.com/clinical/obesity-management)

[Ophthalmology](https://www.hcplive.com/clinical/ophthalmology)[Ophthalmology](https://www.hcplive.com/clinical/ophthalmology)[Ophthalmology](https://www.hcplive.com/clinical/ophthalmology)[Ophthalmology](https://www.hcplive.com/clinical/ophthalmology)[Ophthalmology](https://www.hcplive.com/clinical/ophthalmology)

[Pain](https://www.hcplive.com/clinical/pain)[Pain](https://www.hcplive.com/clinical/pain)[Pain](https://www.hcplive.com/clinical/pain)[Pain](https://www.hcplive.com/clinical/pain)[Pain](https://www.hcplive.com/clinical/pain)

[Pediatrics](https://www.hcplive.com/clinical/pediatrics)

[Psychiatry](https://www.hcplive.com/clinical/psychiatry)[Psychiatry](https://www.hcplive.com/clinical/psychiatry)[Psychiatry](https://www.hcplive.com/clinical/psychiatry)[Psychiatry](https://www.hcplive.com/clinical/psychiatry)[Psychiatry](https://www.hcplive.com/clinical/psychiatry)[Psychiatry](https://www.hcplive.com/clinical/psychiatry)[Psychiatry](https://www.hcplive.com/clinical/psychiatry)

[Pulmonology](https://www.hcplive.com/clinical/pulmonology)[Pulmonology](https://www.hcplive.com/clinical/pulmonology)[Pulmonology](https://www.hcplive.com/clinical/pulmonology)[Pulmonology](https://www.hcplive.com/clinical/pulmonology)[Pulmonology](https://www.hcplive.com/clinical/pulmonology)

[Rare Disease Report¬Æ](https://www.hcplive.com/clinical/rare-diseases)[Rare Disease Report¬Æ](https://www.hcplive.com/clinical/rare-diseases)[Rare Disease Report¬Æ](https://www.hcplive.com/clinical/rare-diseases)[Rare Disease Report¬Æ](https://www.hcplive.com/clinical/rare-diseases)[Rare Disease Report¬Æ](https://www.hcplive.com/clinical/rare-diseases)

[Rheumatology](https://www.hcplive.com/clinical/rheumatology)[Rheumatology](https://www.hcplive.com/clinical/rheumatology)[Rheumatology](https://www.hcplive.com/clinical/rheumatology)[Rheumatology](https://www.hcplive.com/clinical/rheumatology)[Rheumatology](https://www.hcplive.com/clinical/rheumatology)[Rheumatology](https://www.hcplive.com/clinical/rheumatology)[Rheumatology](https://www.hcplive.com/clinical/rheumatology)[Rheumatology](https://www.hcplive.com/clinical/rheumatology)[Rheumatology](https://www.hcplive.com/clinical/rheumatology)

[Sleep](https://www.hcplive.com/clinical/sleep)[Sleep](https://www.hcplive.com/clinical/sleep)[Sleep](https://www.hcplive.com/clinical/sleep)

[Surgery](https://www.hcplive.com/clinical/surgery)[Surgery](https://www.hcplive.com/clinical/surgery)

[Women's Health](https://www.hcplive.com/clinical/womens-health)

Spotlight -

*   [FDA News](https://www.hcplive.com/view/clinical/fda-news)
*   [Qazi Corner](https://www.hcplive.com/qazi-corner)
*   [Biosimilars Spotlight](https://www.hcplive.com/clinical/biosimilars)
*   [DME & nAMD On-Demand Presentation](https://www.hcplive.com/interactive-tools/dual-pathway-inhibition/chapter-1)
*   [COVID-19](https://www.hcplive.com/clinical/coronavirus)

![Image 3: HCP Live](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)

*   [![Image 5: Contagion Live](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contagionlive.com/)
*   [![Image 7: CGT Live](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.cgtlive.com/)
*   [![Image 9: Neurology Live](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.neurologylive.com/)
*   [![Image 11: HCP Live](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/)
*   [![Image 13: Oncology Live](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.onclive.com/)
*   [![Image 15: Contemporary Pediatrics](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/)
*   [![Image 17: Contemporary OBGYN](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporaryobgyn.net/)
*   [![Image 19: Urology Times](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.urologytimes.com/)

[![Image 21](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/)

[](https://www.hcplive.com/search)

Choose Specialty

[Allergy](https://www.hcplive.com/clinical/allergy)[Allergy](https://www.hcplive.com/clinical/allergy)[Allergy](https://www.hcplive.com/clinical/allergy)[Allergy](https://www.hcplive.com/clinical/allergy)

[Biosimilars](https://www.hcplive.com/clinical/biosimilars)

[Cardiology](https://www.hcplive.com/clinical/cardiology)[Cardiology](https://www.hcplive.com/clinical/cardiology)[Cardiology](https://www.hcplive.com/clinical/cardiology)[Cardiology](https://www.hcplive.com/clinical/cardiology)[Cardiology](https://www.hcplive.com/clinical/cardiology)[Cardiology](https://www.hcplive.com/clinical/cardiology)[Cardiology](https://www.hcplive.com/clinical/cardiology)[Cardiology](https://www.hcplive.com/clinical/cardiology)[Cardiology](https://www.hcplive.com/clinical/cardiology)

[Dermatology](https://www.hcplive.com/clinical/dermatology)[Dermatology](https://www.hcplive.com/clinical/dermatology)[Dermatology](https://www.hcplive.com/clinical/dermatology)[Dermatology](https://www.hcplive.com/clinical/dermatology)[Dermatology](https://www.hcplive.com/clinical/dermatology)[Dermatology](https://www.hcplive.com/clinical/dermatology)[Dermatology](https://www.hcplive.com/clinical/dermatology)

[Endocrinology](https://www.hcplive.com/clinical/endocrinology)[Endocrinology](https://www.hcplive.com/clinical/endocrinology)[Endocrinology](https://www.hcplive.com/clinical/endocrinology)[Endocrinology](https://www.hcplive.com/clinical/endocrinology)[Endocrinology](https://www.hcplive.com/clinical/endocrinology)[Endocrinology](https://www.hcplive.com/clinical/endocrinology)

[FDA News](https://www.hcplive.com/clinical/fda-news)

[Family Medicine](https://www.hcplive.com/clinical/family-medicine)[Family Medicine](https://www.hcplive.com/clinical/family-medicine)[Family Medicine](https://www.hcplive.com/clinical/family-medicine)[Family Medicine](https://www.hcplive.com/clinical/family-medicine)

[Gastroenterology](https://www.hcplive.com/clinical/gastroenterology)[Gastroenterology](https://www.hcplive.com/clinical/gastroenterology)[Gastroenterology](https://www.hcplive.com/clinical/gastroenterology)[Gastroenterology](https://www.hcplive.com/clinical/gastroenterology)[Gastroenterology](https://www.hcplive.com/clinical/gastroenterology)[Gastroenterology](https://www.hcplive.com/clinical/gastroenterology)[Gastroenterology](https://www.hcplive.com/clinical/gastroenterology)

[Geriatrics](https://www.hcplive.com/clinical/geriatrics)[Geriatrics](https://www.hcplive.com/clinical/geriatrics)[Geriatrics](https://www.hcplive.com/clinical/geriatrics)

[Hematology](https://www.hcplive.com/clinical/hematology)[Hematology](https://www.hcplive.com/clinical/hematology)[Hematology](https://www.hcplive.com/clinical/hematology)

[Hepatology](https://www.hcplive.com/clinical/hepatology)[Hepatology](https://www.hcplive.com/clinical/hepatology)[Hepatology](https://www.hcplive.com/clinical/hepatology)[Hepatology](https://www.hcplive.com/clinical/hepatology)[Hepatology](https://www.hcplive.com/clinical/hepatology)

[Hospital Medicine](https://www.hcplive.com/clinical/hospital-medicine)

[Infectious Disease](https://www.hcplive.com/clinical/infectious-disease)[Infectious Disease](https://www.hcplive.com/clinical/infectious-disease)

[Internal Medicine](https://www.hcplive.com/clinical/internal-medicine)

[Nephrology](https://www.hcplive.com/clinical/nephrology)[Nephrology](https://www.hcplive.com/clinical/nephrology)[Nephrology](https://www.hcplive.com/clinical/nephrology)

[Neurology](https://www.hcplive.com/clinical/neurology)[Neurology](https://www.hcplive.com/clinical/neurology)[Neurology](https://www.hcplive.com/clinical/neurology)[Neurology](https://www.hcplive.com/clinical/neurology)[Neurology](https://www.hcplive.com/clinical/neurology)

[Obesity Management](https://www.hcplive.com/clinical/obesity-management)

[Ophthalmology](https://www.hcplive.com/clinical/ophthalmology)[Ophthalmology](https://www.hcplive.com/clinical/ophthalmology)[Ophthalmology](https://www.hcplive.com/clinical/ophthalmology)[Ophthalmology](https://www.hcplive.com/clinical/ophthalmology)[Ophthalmology](https://www.hcplive.com/clinical/ophthalmology)

[Pain](https://www.hcplive.com/clinical/pain)[Pain](https://www.hcplive.com/clinical/pain)[Pain](https://www.hcplive.com/clinical/pain)[Pain](https://www.hcplive.com/clinical/pain)[Pain](https://www.hcplive.com/clinical/pain)

[Pediatrics](https://www.hcplive.com/clinical/pediatrics)

[Psychiatry](https://www.hcplive.com/clinical/psychiatry)[Psychiatry](https://www.hcplive.com/clinical/psychiatry)[Psychiatry](https://www.hcplive.com/clinical/psychiatry)[Psychiatry](https://www.hcplive.com/clinical/psychiatry)[Psychiatry](https://www.hcplive.com/clinical/psychiatry)[Psychiatry](https://www.hcplive.com/clinical/psychiatry)[Psychiatry](https://www.hcplive.com/clinical/psychiatry)

[Pulmonology](https://www.hcplive.com/clinical/pulmonology)[Pulmonology](https://www.hcplive.com/clinical/pulmonology)[Pulmonology](https://www.hcplive.com/clinical/pulmonology)[Pulmonology](https://www.hcplive.com/clinical/pulmonology)[Pulmonology](https://www.hcplive.com/clinical/pulmonology)

[Rare Disease Report¬Æ](https://www.hcplive.com/clinical/rare-diseases)[Rare Disease Report¬Æ](https://www.hcplive.com/clinical/rare-diseases)[Rare Disease Report¬Æ](https://www.hcplive.com/clinical/rare-diseases)[Rare Disease Report¬Æ](https://www.hcplive.com/clinical/rare-diseases)[Rare Disease Report¬Æ](https://www.hcplive.com/clinical/rare-diseases)

[Rheumatology](https://www.hcplive.com/clinical/rheumatology)[Rheumatology](https://www.hcplive.com/clinical/rheumatology)[Rheumatology](https://www.hcplive.com/clinical/rheumatology)[Rheumatology](https://www.hcplive.com/clinical/rheumatology)[Rheumatology](https://www.hcplive.com/clinical/rheumatology)[Rheumatology](https://www.hcplive.com/clinical/rheumatology)[Rheumatology](https://www.hcplive.com/clinical/rheumatology)[Rheumatology](https://www.hcplive.com/clinical/rheumatology)[Rheumatology](https://www.hcplive.com/clinical/rheumatology)

[Sleep](https://www.hcplive.com/clinical/sleep)[Sleep](https://www.hcplive.com/clinical/sleep)[Sleep](https://www.hcplive.com/clinical/sleep)

[Surgery](https://www.hcplive.com/clinical/surgery)[Surgery](https://www.hcplive.com/clinical/surgery)

[Women's Health](https://www.hcplive.com/clinical/womens-health)

![Image 23: HCP Live](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)

*   [![Image 25: Contagion Live](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contagionlive.com/)
*   [![Image 27: CGT Live](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.cgtlive.com/)
*   [![Image 29: Neurology Live](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.neurologylive.com/)
*   [![Image 31: HCP Live](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/)
*   [![Image 33: Oncology Live](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.onclive.com/)
*   [![Image 35: Contemporary Pediatrics](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporarypediatrics.com/)
*   [![Image 37: Contemporary OBGYN](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.contemporaryobgyn.net/)
*   [![Image 39: Urology Times](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.urologytimes.com/)

![Image 41](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)

*   *   Spotlight
        
    *   [News](https://www.hcplive.com/news)
    *   Media
        
    *   Multimedia Series
        
    *   Conferences
        
    *   [Partners](https://www.hcplive.com/sap-partner)
    *   [CME/CE](https://www.hcplive.com/continuing-education)
    *   Resources
        
    *   [Advisory Board](https://www.hcplive.com/advisory-board)
    *   [Subscribe](https://one.hcplive.com/subscribe/)

[](https://www.facebook.com/HCPLiveNews/)[](https://twitter.com/HCPLiveNews)[](https://www.linkedin.com/company/hcplive)[](https://www.hcplive.com/rss)

Advertisement

* * *

Glycine, Glutamine May Reduce Risk of Hospitalized Gout
=======================================================

August 27, 2024

By [Victoria Johnson](https://www.hcplive.com/authors/victoria-johnson)

_News_

_Article_

Investigators found that 107 metabolites were associated with the incidence of hospitalized gout.

![Image 43](blob:https://www.hcplive.com/c449a78589edbf1a8b5a3047afa18786)![Image 44: Natalie McCormick, PhD, instructor in medicine, Massachusetts General Hospital, Harvard Medical School, and Arthritis Research Canada, Vancouver, Canada](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)

Natalie McCormick, PhD

Credit: Harvard University

![Image 46](https://cdn.sanity.io/images/0vv8moc6/hcplive/4215479595f73990a271a3cc3126f20f36deaf85-300x300.jpg?fit=crop&auto=format)

New research has found associations between a number of metabolites and the risk of incident [hospitalized gout](https://www.hcplive.com/view/new-research-molybdenum-ward-off-hyperuricemia-gout).1

‚ÄúOur objective was to prospectively investigate pre-diagnostic population-based metabolome for risk of hospitalized gout (i.e., most accurate, severe, and costly cases), accounting for serum urate,‚Äù lead investigator Natalie McCormick, PhD, instructor in medicine, Massachusetts General Hospital, Harvard Medical School, and Arthritis Research Canada, Vancouver, Canada, and colleagues wrote.1

McCormick and colleagues analyzed pre-diagnostic metabolomes of 249,677 United Kingdom Biobank participants from baseline blood samples collected from 2006 to 2010 without a history of gout. They conducted NMR metabolomic profiling, looking at 168 metabolites, including 8 amino acids. After multivariable adjustment, they calculated hazard ratios (HRs) for incident hospitalized gout, before and after adjusting for serum urate levels, and also analyzed non-hospitalized incident gout cases in a sensitivity analysis. They used 2-sample Mendelian randomization to evaluate potential causal effects.1

The investigators found that after correcting for multiple testing, 107 metabolites were associated with the incidence of hospitalized gout (N=2735) before urate adjustment. These included glycine (HR, 0.64 \[95% CI, 0.54-0.75\]; _P_ \= 8.3x10-8)¬†and glutamine (HR, 0.69 \[95% CI, 0.61-0.78\]; _P_ \= 3.3x10-9)¬†inversely,between extreme quintiles, and glycoprotein acetyls (GlycA; HR, 2.48 \[95% CI, 2.15-2.87\]; _P_ \= 1.96x10-34). After adjusting for urates, the associations remained significant and directionally consistent, with respective HRs of 0.83 (95% CI, 0.70-0.98), 0.86 (95% CI, 0.76-0.98), and 1.41 (95% CI, 1.21-1.63) between extreme quintiles, with¬†corresponding HRs per standard deviations of 0.91 (95% CI, 0.86-0.97), 0.94 (95% CI, 0.91-0.98), and 1.10 (95% CI, 1.06-1.14).1

Sensitivity analyses including non-hospitalized incident gout cases corroborated the potential causal role of these metabolites on hyperuricemia or gout risk, with Mendelian randomization showing a change in urate levels of -0.05 mg/dL (-0.08, -0.01) per SD of glycine and a change of -0.12 mg/dL (-0.22, -0.03)per SD of glutamine. Accordingly, odds ratios per SD were 0.94 (95% CI, 0.88-1.00) for glycine and 0.81 (95% CI, 0.67-0.97) for gout.1

‚ÄúThese prospective findings with causal implications could lead to biomarker-based risk prediction and potential supplementation-based interventions with glycine or glutamine,‚Äù McCormick and colleagues concluded.1

Other recent research on urates found that circulating¬†uric acid¬†have a potential role in [accelerating biological aging](https://www.hcplive.com/view/uric-acid-levels-pose-potential-harm-in-accelerating-biological-aging) among¬†older adults. Investigators found that uric acid levels increased as frailty severity increased from non-frail to frail (_P_¬†\= .002). Frail adults presented with greater serum uric acid levels than non-frail adults (_P_¬†\= .002).

After adjusting for age, sex, and other comorbidities, investigators found serum uric acid levels were significantly greater in frail participants than in non-frail participants (_P_¬†< .001). The study showed serum uric acid concentrations were positively correlated to the frail index (_P_¬†< .001). Moreover, per 1 mg/dL increase in serum uric acid, the odds for frailty were 1.22 (95% confidence interval \[CI\], 1.12 ‚Äì 1.33;¬†_P_¬†< .001), and the risks were 25% and 22% as shown in the age- and sex-adjusted and multivariable-adjusted models, respectively (_P_¬†< .001).

‚ÄúThese results clinically underscore the potential of circulating \[uric acid\] as a pro-aging factor rather than an anti-aging one in this demographic,‚Äù wrote investigators, led by Min-gu Kang, from Chonnam National University Bitgoeul Hospital in South Korea.2 ‚ÄúMoreover, this research adds to the growing body of evidence that suggests serum UA could serve as a potential blood-based biomarker for detecting frailty in older adults.‚Äù

###### REFERENCES

###### 1\. McCormick N, Joshi AD, Yokose C, et al. Pre-Diagnostic Amino Acid Metabolites and Risk of Gout, Accounting for Serum Urate: Prospective Cohort Study and Mendelian Randomization. Published online August 21, 2024. _Arthritis Care Res_. Doi:10.1002/acr.25420  
2\. Kang MG, Baek JY, Jo Y, et al. Higher serum uric acid as a risk factor for frailty in older adults: A nationwide population-based study.¬†_J Cachexia Sarcopenia Muscle_. Published online August 18, 2024. doi:10.1002/jcsm.13561

Recent Videos

[![Image 47: Discussing Use of Vaping Among Students, Conversations About Vaccines](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/view/discussing-use-vaping-among-students-conversations-vaccines)[![Image 49](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/view/taha-qazi-md-clinical-considerations-for-glp-1-ra-use-before-endoscopy)[![Image 51: Taha Qazi, MD | Credit: Cleveland Clinic](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/view/taha-qazi-md-bleeding-risk-early-versus-late-ercp-following-liver-transplant)[![Image 53: Taha Qazi, MD | Credit: Cleveland Clinic](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/view/taha-qazi-md-assessing-common-causes-seronegative-villous-atrophy)[![Image 55: 3 KOLs are featured in this series.](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/view/moving-beyond-the-joint-unraveling-gout-s-systemic-and-renal-implications-video)[![Image 57](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/view/evaluating-and-adjusting-rheumatoid-arthritis-treatment-adhering-to-acr-guidelines-for-csdmards-and-advanced-therapies)[![Image 59](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/view/exploring-the-discrepancy-between-patient-perception-and-disease-activity-assessments)[![Image 61: Pavel Strnad, MD | Credit: RWTH Aachen](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/view/pavel-strnad-md-considerations-safe-alcohol-consumption-aatd)[![Image 63: 1 KOL is featured in this series.](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/view/sleep-and-cognitive-symptoms-in-fibromyalgia)[![Image 65: Laurence Sperling, MD | Credit: Emory University](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/view/laurence-sperling-md-navigating-the-changing-landscape-of-lipidology)

Related Content

Advertisement

[![Image 67: Cases of Retinal Vasculitis Observed After Aflibercept 8 mg for nAMD | Image Credit: V2osk/Unsplash](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/view/cases-of-retinal-vasculitis-observed-after-aflibercept-8-mg-for-namd?utm_source=www.hcplive.com&utm_medium=relatedContent)

[Cases of Retinal Vasculitis Observed After Aflibercept 8 mg for nAMD](https://www.hcplive.com/view/cases-of-retinal-vasculitis-observed-after-aflibercept-8-mg-for-namd?utm_source=www.hcplive.com&utm_medium=relatedContent)

[Connor Iapoce](https://www.hcplive.com/authors/connor-iapoce)

[August 27th 2024 Article](https://www.hcplive.com/view/cases-of-retinal-vasculitis-observed-after-aflibercept-8-mg-for-namd?utm_source=www.hcplive.com&utm_medium=relatedContent)

[![Image 69: Diabetes Dialogue: Stelo OTC Availability and Omnipod 5 for Type 2 Diabetes](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/view/diabetes-dialogue-stelo-otc-availability-and-omnipod-5-for-type-2-diabetes?utm_source=www.hcplive.com&utm_medium=relatedContent)

[Diabetes Dialogue: Stelo OTC Availability and Omnipod 5 for Type 2 Diabetes](https://www.hcplive.com/view/diabetes-dialogue-stelo-otc-availability-and-omnipod-5-for-type-2-diabetes?utm_source=www.hcplive.com&utm_medium=relatedContent)

[Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES](https://www.hcplive.com/authors/diana-isaacs-pharmd-bcps-bc-adm-cdces);[Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE](https://www.hcplive.com/authors/natalie-bellini-dnp-fnp-bc)

[August 27th 2024 Podcast](https://www.hcplive.com/view/diabetes-dialogue-stelo-otc-availability-and-omnipod-5-for-type-2-diabetes?utm_source=www.hcplive.com&utm_medium=relatedContent)

[![Image 71: David Lasorda, DO | Credit: Allegheny Health Network](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/view/ahn-a-game-changer-for-challenging-restenosis?utm_source=www.hcplive.com&utm_medium=relatedContent)

[A Game-Changer for Challenging Restenosis](https://www.hcplive.com/view/ahn-a-game-changer-for-challenging-restenosis?utm_source=www.hcplive.com&utm_medium=relatedContent)

[Allegheny Health Network](https://www.hcplive.com/authors/allegheny-health-network)

[August 27th 2024 Article](https://www.hcplive.com/view/ahn-a-game-changer-for-challenging-restenosis?utm_source=www.hcplive.com&utm_medium=relatedContent)

[![Image 73: Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/view/diabetes-dialogue-sotagliflozin-for-t1d-and-other-adces-2024-highlights?utm_source=www.hcplive.com&utm_medium=relatedContent)

[Diabetes Dialogue: Sotagliflozin for T1D and Other ADCES 2024 Highlights](https://www.hcplive.com/view/diabetes-dialogue-sotagliflozin-for-t1d-and-other-adces-2024-highlights?utm_source=www.hcplive.com&utm_medium=relatedContent)

[Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES](https://www.hcplive.com/authors/diana-isaacs-pharmd-bcps-bc-adm-cdces);[Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE](https://www.hcplive.com/authors/natalie-bellini-dnp-fnp-bc)

[August 21st 2024 Podcast](https://www.hcplive.com/view/diabetes-dialogue-sotagliflozin-for-t1d-and-other-adces-2024-highlights?utm_source=www.hcplive.com&utm_medium=relatedContent)

[![Image 75: George Shaw, MD | Credit: Allegheny Health Network](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/view/ahn-implants-innovative-device-to-manage-central-sleep-apnea-in-heart-failure-patients?utm_source=www.hcplive.com&utm_medium=relatedContent)

[AHN implants innovative device to manage central sleep apnea in heart failure patients](https://www.hcplive.com/view/ahn-implants-innovative-device-to-manage-central-sleep-apnea-in-heart-failure-patients?utm_source=www.hcplive.com&utm_medium=relatedContent)

[Allegheny Health Network](https://www.hcplive.com/authors/allegheny-health-network)

[August 27th 2024 Article](https://www.hcplive.com/view/ahn-implants-innovative-device-to-manage-central-sleep-apnea-in-heart-failure-patients?utm_source=www.hcplive.com&utm_medium=relatedContent)

[![Image 77: Andrew Waligora, MD Credit: Allegheny Health Network](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/view/ahn-leading-the-way-in-robotic-hip-and-knee-arthroplasty?utm_source=www.hcplive.com&utm_medium=relatedContent)

[Leading the way in robotic hip and knee arthroplasty](https://www.hcplive.com/view/ahn-leading-the-way-in-robotic-hip-and-knee-arthroplasty?utm_source=www.hcplive.com&utm_medium=relatedContent)

[Allegheny Health Network](https://www.hcplive.com/authors/allegheny-health-network)

[August 27th 2024 Article](https://www.hcplive.com/view/ahn-leading-the-way-in-robotic-hip-and-knee-arthroplasty?utm_source=www.hcplive.com&utm_medium=relatedContent)

Related Content

Advertisement

[![Image 79: Cases of Retinal Vasculitis Observed After Aflibercept 8 mg for nAMD | Image Credit: V2osk/Unsplash](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/view/cases-of-retinal-vasculitis-observed-after-aflibercept-8-mg-for-namd?utm_source=www.hcplive.com&utm_medium=relatedContent)

[Cases of Retinal Vasculitis Observed After Aflibercept 8 mg for nAMD](https://www.hcplive.com/view/cases-of-retinal-vasculitis-observed-after-aflibercept-8-mg-for-namd?utm_source=www.hcplive.com&utm_medium=relatedContent)

[Connor Iapoce](https://www.hcplive.com/authors/connor-iapoce)

[August 27th 2024 Article](https://www.hcplive.com/view/cases-of-retinal-vasculitis-observed-after-aflibercept-8-mg-for-namd?utm_source=www.hcplive.com&utm_medium=relatedContent)

[![Image 81: Diabetes Dialogue: Stelo OTC Availability and Omnipod 5 for Type 2 Diabetes](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/view/diabetes-dialogue-stelo-otc-availability-and-omnipod-5-for-type-2-diabetes?utm_source=www.hcplive.com&utm_medium=relatedContent)

[Diabetes Dialogue: Stelo OTC Availability and Omnipod 5 for Type 2 Diabetes](https://www.hcplive.com/view/diabetes-dialogue-stelo-otc-availability-and-omnipod-5-for-type-2-diabetes?utm_source=www.hcplive.com&utm_medium=relatedContent)

[Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES](https://www.hcplive.com/authors/diana-isaacs-pharmd-bcps-bc-adm-cdces);[Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE](https://www.hcplive.com/authors/natalie-bellini-dnp-fnp-bc)

[August 27th 2024 Podcast](https://www.hcplive.com/view/diabetes-dialogue-stelo-otc-availability-and-omnipod-5-for-type-2-diabetes?utm_source=www.hcplive.com&utm_medium=relatedContent)

[![Image 83: David Lasorda, DO | Credit: Allegheny Health Network](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/view/ahn-a-game-changer-for-challenging-restenosis?utm_source=www.hcplive.com&utm_medium=relatedContent)

[A Game-Changer for Challenging Restenosis](https://www.hcplive.com/view/ahn-a-game-changer-for-challenging-restenosis?utm_source=www.hcplive.com&utm_medium=relatedContent)

[Allegheny Health Network](https://www.hcplive.com/authors/allegheny-health-network)

[August 27th 2024 Article](https://www.hcplive.com/view/ahn-a-game-changer-for-challenging-restenosis?utm_source=www.hcplive.com&utm_medium=relatedContent)

[![Image 85: Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/view/diabetes-dialogue-sotagliflozin-for-t1d-and-other-adces-2024-highlights?utm_source=www.hcplive.com&utm_medium=relatedContent)

[Diabetes Dialogue: Sotagliflozin for T1D and Other ADCES 2024 Highlights](https://www.hcplive.com/view/diabetes-dialogue-sotagliflozin-for-t1d-and-other-adces-2024-highlights?utm_source=www.hcplive.com&utm_medium=relatedContent)

[Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES](https://www.hcplive.com/authors/diana-isaacs-pharmd-bcps-bc-adm-cdces);[Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE](https://www.hcplive.com/authors/natalie-bellini-dnp-fnp-bc)

[August 21st 2024 Podcast](https://www.hcplive.com/view/diabetes-dialogue-sotagliflozin-for-t1d-and-other-adces-2024-highlights?utm_source=www.hcplive.com&utm_medium=relatedContent)

[![Image 87: George Shaw, MD | Credit: Allegheny Health Network](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/view/ahn-implants-innovative-device-to-manage-central-sleep-apnea-in-heart-failure-patients?utm_source=www.hcplive.com&utm_medium=relatedContent)

[AHN implants innovative device to manage central sleep apnea in heart failure patients](https://www.hcplive.com/view/ahn-implants-innovative-device-to-manage-central-sleep-apnea-in-heart-failure-patients?utm_source=www.hcplive.com&utm_medium=relatedContent)

[Allegheny Health Network](https://www.hcplive.com/authors/allegheny-health-network)

[August 27th 2024 Article](https://www.hcplive.com/view/ahn-implants-innovative-device-to-manage-central-sleep-apnea-in-heart-failure-patients?utm_source=www.hcplive.com&utm_medium=relatedContent)

[![Image 89: Andrew Waligora, MD Credit: Allegheny Health Network](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.hcplive.com/view/ahn-leading-the-way-in-robotic-hip-and-knee-arthroplasty?utm_source=www.hcplive.com&utm_medium=relatedContent)

[Leading the way in robotic hip and knee arthroplasty](https://www.hcplive.com/view/ahn-leading-the-way-in-robotic-hip-and-knee-arthroplasty?utm_source=www.hcplive.com&utm_medium=relatedContent)

[Allegheny Health Network](https://www.hcplive.com/authors/allegheny-health-network)

[August 27th 2024 Article](https://www.hcplive.com/view/ahn-leading-the-way-in-robotic-hip-and-knee-arthroplasty?utm_source=www.hcplive.com&utm_medium=relatedContent)

[About Us](https://www.hcplive.com/about)

[Advertise](https://www.hcplive.com/advertise)

[Editorial](https://www.hcplive.com/editorial)

[Contact Us](https://www.mjhlifesciences.com/contact)

[Do Not Sell My Information](https://www.mjhlifesciences.com/ccpa?domain=www.hcplive.com)

[Privacy](https://www.hcplive.com/privacy)

[Terms & Conditions](https://www.hcplive.com/terms)

Contact Info

2 Commerce Drive  
Cranbury, NJ 08512

[609-716-7777](tel:609-716-7777)

![Image 91](blob:https://www.hcplive.com/0b56f675ecfd870f746e03cb2a00669b)![Image 92](blob:https://www.hcplive.com/b9a31d3949b1882a09ed2f8508d538f3)

[](https://www.facebook.com/HCPLiveNews/)[](https://twitter.com/HCPLiveNews)[](https://www.linkedin.com/company/hcplive)[](https://www.hcplive.com/rss)

¬© 2024 MJH Life Sciences  
  
All rights reserved.
"
2024-08-28 06:41:00,2024-08-29 23:09:37,"üí° **Did you know that multiple sclerosis (MS) might actually lower the risk of developing Alzheimer‚Äôs disease?** 

A recent study highlights that individuals with MS are about half as likely to show signs of amyloid-beta plaques‚Äîhallmarks of Alzheimer‚Äôs‚Äîcompared to those without the condition. This intriguing finding suggests that some components of MS biology or genetics could offer protective effects against Alzheimer's, although the exact reasons remain to be uncovered.

The study involved 100 MS patients, aged over 60, and it utilized advanced blood tests to measure amyloid-beta and tau proteins, alongside brain imaging to corroborate the findings. Remarkably, only 7.1% of MS patients tested positive for amyloid-beta plaques, compared to 15.3% of those without MS.

**Key Takeaways:**  
- The immune system‚Äôs complexities in MS may somehow shield these patients from developing Alzheimer's traits.  
- Understanding these mechanisms might pave the way towards new therapeutic strategies for combating Alzheimer‚Äôs disease.

This knowledge encourages a broader conversation about the intersection of neurodegenerative diseases and the potential for protective factors inherent in other conditions. 

ü§î *What are your thoughts on the findings of this study? How could these insights change our approach to MS and Alzheimer‚Äôs?*

Let‚Äôs engage in a discussion!

#MultipleSclerosis #Alzheimers #HealthcareResearch #Neurology #PatientCare  

Source: [MS patients less likely to have Alzheimer‚Äôs, study finds](https://multiplesclerosisnewstoday.com/news-posts/2024/08/27/ms-patients-less-likely-alzheimers-study/)",https://medsii.azureedge.net/images/638604240797637089-66cec5ed6157181811bbc788.jpg,https://multiplesclerosisnewstoday.com/news-posts/2024/08/27/ms-patients-less-likely-alzheimers-study/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Thumbnail image URL: https://medsii.azureedge.net/images/638604240797637089-66cec5ed6157181811bbc788.jpg 

Title: MS patients less likely to have Alzheimer‚Äôs, study finds

URL Source: https://multiplesclerosisnewstoday.com/news-posts/2024/08/27/ms-patients-less-likely-alzheimers-study/

Published Time: 2024-08-27T12:00:16+00:00

Markdown Content:
MS patients less likely to have Alzheimer‚Äôs, study finds
===============

![Image 1](https://insight.bionewsservices.com/matomo.php?idsite=21&rec=1)

          [Skip to content](https://multiplesclerosisnewstoday.com/news-posts/2024/08/27/ms-patients-less-likely-alzheimers-study/#content)

 [![Image 2: Multiple Sclerosis News Today logo](https://multiplesclerosisnewstoday.com/wp-content/uploads/2022/09/MSnewstoday.png)](https://multiplesclerosisnewstoday.com/)Toggle navigation

*   [![Image 3](https://multiplesclerosisnewstoday.com/wp-content/uploads/2021/06/color-fb.png)](https://www.facebook.com/multiplesclerosisnewstoday)
*   [![Image 4](https://multiplesclerosisnewstoday.com/wp-content/uploads/2024/07/x-blue-logo-56.png)](https://twitter.com/MSNewsToday)
*   [![Image 5](https://multiplesclerosisnewstoday.com/wp-content/uploads/2021/06/color-ig.png)](https://www.instagram.com/msnewstoday/)
*   [![Image 6](https://multiplesclerosisnewstoday.com/wp-content/uploads/2021/06/color-sc.png)](https://soundcloud.com/msnewstoday)
*   [![Image 7](https://multiplesclerosisnewstoday.com/wp-content/uploads/2023/08/color-pin.png)](https://www.pinterest.pt/msnewstoday/)

*   [Home](https://multiplesclerosisnewstoday.com/)
*   [About MS](https://multiplesclerosisnewstoday.com/news-posts/2024/08/27/ms-patients-less-likely-alzheimers-study/#) Toggle menu
    
    [Multiple sclerosis overview](https://multiplesclerosisnewstoday.com/multiple-sclerosis-overview/)
    
    * * *
    
    *   [Types of MS](https://multiplesclerosisnewstoday.com/4-types-ms/)
    *   [Causes and risk factors](https://multiplesclerosisnewstoday.com/risk-factors-for-multiple-sclerosis/)
    *   [Symptoms](https://multiplesclerosisnewstoday.com/symptoms-of-multiple-sclerosis/)
    *   [Diagnosis](https://multiplesclerosisnewstoday.com/multiple-sclerosis-diagnosis/)
    *   [Living with MS](https://multiplesclerosisnewstoday.com/living-with-multiple-sclerosis/)
    
    [Treatments options for MS](https://multiplesclerosisnewstoday.com/multiple-sclerosis-treatment/)
    
    * * *
    
    *   [Approved treatments](https://multiplesclerosisnewstoday.com/approved-treatments-for-multiple-sclerosis/)
    *   [Experimental treatments](https://multiplesclerosisnewstoday.com/experimental-treatments-for-multiple-sclerosis/)
    
    [Clinical Trials](https://multiplesclerosisnewstoday.com/clinical-trials-101/)
    
    * * *
    
    *   [What are clinical trials?](https://multiplesclerosisnewstoday.com/what-are-clinical-trials/)
    *   [Types of clinical trials](https://multiplesclerosisnewstoday.com/types-of-clinical-trials/)
    *   [How do clinical trials work?](https://multiplesclerosisnewstoday.com/how-do-clinical-trials-work/)
    *   [Traditional vs. remote vs. hybrid clinical trials](https://multiplesclerosisnewstoday.com/traditional-vs-remote-vs-hybrid-clinical-trials-what-you-need-to-know/)
    *   [FAQs about clinical trials](https://multiplesclerosisnewstoday.com/faqs-about-clinical-trials/)
    
*   [Featured Topics](https://multiplesclerosisnewstoday.com/news-posts/2024/08/27/ms-patients-less-likely-alzheimers-study/#) Toggle menu
    
    [Newly diagnosed guide](https://multiplesclerosisnewstoday.com/newly-diagnosed-guide-for-ms/)
    
    * * *
    
    *   [Next steps after an MS diagnosis](https://multiplesclerosisnewstoday.com/next-steps-after-ms-diagnosis/)
    *   [MS caregivers guide](https://multiplesclerosisnewstoday.com/guide-for-multiple-sclerosis-caregivers/)
    *   [MS healthcare team](https://multiplesclerosisnewstoday.com/your-ms-healthcare-team/)
    *   [Perspectives on MS diagnosis](https://multiplesclerosisnewstoday.com/perspectives-ms-diagnosis/)
    *   [MS treatment explainer](https://multiplesclerosisnewstoday.com/ms-treatment-explainer-what-are-my-options/)
    *   [Questions to ask your doctor](https://multiplesclerosisnewstoday.com/newly-diagnosed-ms-12-questions-ask-your-doctor/)
    *   [Guidelines for MS diagnosis](https://multiplesclerosisnewstoday.com/ms-diagnosis-mcdonald-criteria/)
    *   [Physical activity and quality of life](https://multiplesclerosisnewstoday.com/news-posts/2023/06/12/physical-activity-improve-life-quality-newly-diagnosed-patients/)
    *   [Foods to eat and avoid](https://multiplesclerosisnewstoday.com/living-with-ms/ms-diet-nutrition/healthy-eating-ms/)
    *   [Vitamin D and MS](https://multiplesclerosisnewstoday.com/vitamin-d-ms-multiple-sclerosis/)
    *   [Support and resources](https://multiplesclerosisnewstoday.com/support-groups-and-resources/)
    *   [MS and spasticity](https://multiplesclerosisnewstoday.com/what-does-ms-spasticity-feel-like/)
    *   [View all](https://multiplesclerosisnewstoday.com/newly-diagnosed-guide-for-ms/)
    
    [Expert voices](https://multiplesclerosisnewstoday.com/ms-expert-voices/)
    
    * * *
    
    *   [Exercise](https://multiplesclerosisnewstoday.com/expert-voices/2022/07/13/expert-voices-effective-safe-exercise-ms/)
    *   [Pain management](https://multiplesclerosisnewstoday.com/expert-voices/2022/06/15/expert-voices-pain-management-people-with-multiple-sclerosis/)
    *   [Cannabis use](https://multiplesclerosisnewstoday.com/expert-voices/2022/05/11/expert-voices-cannabis-use-multiple-sclerosis/)
    *   [Diet and nutrition](https://multiplesclerosisnewstoday.com/expert-voices/2021/12/15/expert-voices-diet-nutrition-supplements-multiple-sclerosis/)
    *   [Financial planning](https://multiplesclerosisnewstoday.com/news-posts/2021/09/15/expert-voices-financial-planning-with-ms/)
    *   [Managing fatigue](https://multiplesclerosisnewstoday.com/expert-voices/2021/09/30/expert-voices-understanding-managing-ms-fatigue/)
    *   [Sleeping well](https://multiplesclerosisnewstoday.com/expert-voices/2022/10/12/expert-voices-sleep-well-multiple-sclerosis/)
    *   [More](https://multiplesclerosisnewstoday.com/ms-expert-voices/)
    
    [Resources](https://multiplesclerosisnewstoday.com/news-posts/2024/08/27/ms-patients-less-likely-alzheimers-study/#)
    
    * * *
    
    *   [MS hug](https://multiplesclerosisnewstoday.com/multiple-sclerosis-symptoms/the-ms-hug/)
    *   [MS and heat](https://multiplesclerosisnewstoday.com/multiple-sclerosis-symptoms/heat-intolerance/)
    *   [Cannabis and MS](https://multiplesclerosisnewstoday.com/cannabis-and-ms/)
    *   [Lesions and MS](https://multiplesclerosisnewstoday.com/ms-lesions/)
    *   [Myelin's role in MS](https://multiplesclerosisnewstoday.com/myelin-sheath/)
    *   [Epstein-Barr virus and MS](https://multiplesclerosisnewstoday.com/epstein-barr-virus-and-ms/)
    *   [Stem cell therapy for MS](https://multiplesclerosisnewstoday.com/stem-cell-therapy-and-ms/)
    *   [MS prognosis and life expectancy](https://multiplesclerosisnewstoday.com/multiple-sclerosis-prognosis-life-expectancy/)
    *   [MS and mental health](https://multiplesclerosisnewstoday.com/multiple-sclerosis-and-mental-health/)
    
*   [News](https://multiplesclerosisnewstoday.com/category/news-posts/)
*   [Columns](https://multiplesclerosisnewstoday.com/category/columns/) Toggle menu
    
    [Authentically Human ‚Äì Desiree Lama](https://multiplesclerosisnewstoday.com/authentically-human-desiree-lama/)
    
    [Balancing Grit and Grace ‚Äì Ahna Crum](https://multiplesclerosisnewstoday.com/balancing-grit-and-grace-ahna-crum/)
    
    [Chairborne ‚Äî Ben Hofmeister](https://multiplesclerosisnewstoday.com/chairborne-ben-hofmeister/)
    
    [Delicate Balance ‚Äì Leigh Anne Nelson](https://multiplesclerosisnewstoday.com/delicate-balance-leigh-anne-nelson/)
    
    [Rhythms and Routines ‚Äì Susan Payrovi, MD](https://multiplesclerosisnewstoday.com/rhythms-and-routines-susan-payrovi/)
    
    [Archived Columns](https://multiplesclerosisnewstoday.com/category/columns/)
    
    * * *
    
    *   [A Life in Letters ‚Äî Jamie Hughes](https://multiplesclerosisnewstoday.com/a-life-in-letters-jamie-hughes/)
    *   [DISabled to ENabled ‚Äî Jessie Ace](https://multiplesclerosisnewstoday.com/disabled-to-enabled-jessie-ace/)
    *   [Dive to Fight MS ‚Äì Mike Parker](https://multiplesclerosisnewstoday.com/dive-to-fight-ms-mike-parker/)
    *   [Fall Down, Get Up Again ‚Äî John Connor](https://multiplesclerosisnewstoday.com/fall-down-get-up-again-john-connor/)
    *   [Goldilochs ‚Äî Stephen De Marzo](https://multiplesclerosisnewstoday.com/goldilochs-stephen-de-marzo/)
    *   [Patiently Awakened ‚Äî Teresa Wright-Johnson](https://multiplesclerosisnewstoday.com/patiently-awakened-teresa-wright-johnson/)
    *   [The MS Wire ‚Äî Ed Tobias](https://multiplesclerosisnewstoday.com/the-ms-wire-ed-tobias/)
    *   [Silver Linings ‚Äî Jennifer Powell](https://multiplesclerosisnewstoday.com/silver-linings-jennifer-powell/)
    
    [In memoriam](https://multiplesclerosisnewstoday.com/news-posts/2024/08/27/ms-patients-less-likely-alzheimers-study/#)
    
    * * *
    
    *   [Through the Looking Glass ‚Äî Beth Shorthouse-Ullah](https://multiplesclerosisnewstoday.com/through-the-looking-glass-beth-shorthouse-ullah/)
    
*   [Forums](https://multiplesclerosisnewstoday.com/forums/)
*   [Podcast](https://multiplesclerosisnewstoday.com/the-multiple-sclerosis-podcast/)
*   Search
    
    Close drawer
    
    What can we help you find today?
    --------------------------------
    
    Search for:  Search Search
    

*   Search for:  Search
    
*   *   [![Image 8](https://multiplesclerosisnewstoday.com/wp-content/uploads/2021/06/color-fb.png)](https://www.facebook.com/multiplesclerosisnewstoday)
    *   [![Image 9](https://multiplesclerosisnewstoday.com/wp-content/uploads/2024/07/x-blue-logo-56.png)](https://twitter.com/MSNewsToday)
    *   [![Image 10](https://multiplesclerosisnewstoday.com/wp-content/uploads/2021/06/color-ig.png)](https://www.instagram.com/msnewstoday/)
    *   [![Image 11](https://multiplesclerosisnewstoday.com/wp-content/uploads/2021/06/color-sc.png)](https://soundcloud.com/msnewstoday)
    *   [![Image 12](https://multiplesclerosisnewstoday.com/wp-content/uploads/2023/08/color-pin.png)](https://www.pinterest.pt/msnewstoday/)
    

*   [News](https://multiplesclerosisnewstoday.com/category/news-posts/)
*   MS patients less likely to have Alzheimer‚Äôs, study finds

MS patients less likely to have Alzheimer‚Äôs, study finds
========================================================

MS appears protective against Alzheimer‚Äôs damage

![Image 13: Margarida Maia, PhD avatar](https://multiplesclerosisnewstoday.com/wp-content/uploads/2022/05/margarida-48x48.png)

by [Margarida Maia, PhD](https://multiplesclerosisnewstoday.com/author/margarida-maia/) | August 27, 2024

#### Share this article:

[Share article via email](mailto:typeemailaddresshere?subject=IwantedtosharethispostwithyoufromMultipleSclerosisNewsToday&body=MSpatientslesslikelytohaveAlzheimer%E2%80%99s,studyfindshttps://multiplesclerosisnewstoday.com/news-posts/2024/08/27/ms-patients-less-likely-alzheimers-study/ ""Email to a friend/colleague"") Copy article link

![Image 14: A risk illustration shows a pair of dice being thrown.](https://multiplesclerosisnewstoday.com/wp-content/uploads/2023/09/Dice-risk.png)

*   [![Image 15](https://bionews.com/global-code/images/facebook.png)](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fmultiplesclerosisnewstoday.com%2Fnews-posts%2F2024%2F08%2F27%2Fms-patients-less-likely-alzheimers-study%2F)
    
*   [![Image 16](https://bionews.com/global-code/images/twitter.png)](https://twitter.com/intent/tweet?original_referer=https%3A%2F%2Fmultiplesclerosisnewstoday.com%2Fnews-posts%2F2024%2F08%2F27%2Fms-patients-less-likely-alzheimers-study%2F&url=https%3A%2F%2Fmultiplesclerosisnewstoday.com%2Fnews-posts%2F2024%2F08%2F27%2Fms-patients-less-likely-alzheimers-study%2F&text=Multiple%20sclerosis%20patients%20are%20less%20likely%20than%20others%20to%20have%20the%20amyloid-beta%20plaques%20in%20the%20brain%20that%20mark%20Alzheimer%E2%80%99s%2C%20per%20a%20study.)
    
*   [![Image 17](https://bionews.com/global-code/images/reddit-icon.png)](https://www.reddit.com/submit?url=https%3A%2F%2Fmultiplesclerosisnewstoday.com%2Fnews-posts%2F2024%2F08%2F27%2Fms-patients-less-likely-alzheimers-study%2F&title=MS%20patients%20less%20likely%20to%20have%20Alzheimer%E2%80%99s%2C%20study%20finds&text=Multiple%20sclerosis%20patients%20are%20less%20likely%20than%20others%20to%20have%20the%20amyloid-beta%20plaques%20in%20the%20brain%20that%20mark%20Alzheimer%E2%80%99s%2C%20per%20a%20study.)
    
*   [![Image 18](https://bionews.com/global-code/images/mail.png)](mailto:?subject=Share:%20MS%20patients%20less%20likely%20to%20have%20Alzheimer%E2%80%99s%2C%20study%20finds&body=MS%20patients%20less%20likely%20to%20have%20Alzheimer%E2%80%99s%2C%20study%20finds%20%E2%80%93%20Multiple%20sclerosis%20patients%20are%20less%20likely%20than%20others%20to%20have%20the%20amyloid-beta%20plaques%20in%20the%20brain%20that%20mark%20Alzheimer%E2%80%99s%2C%20per%20a%20study.%0D%0A%0D%0ARead%20more%20at%20https%3A%2F%2Fmultiplesclerosisnewstoday.com%2Fnews-posts%2F2024%2F08%2F27%2Fms-patients-less-likely-alzheimers-study%2F%0D%0A)
    

People with [multiple sclerosis](https://multiplesclerosisnewstoday.com/multiple-sclerosis-overview/) (MS) are about half as likely as those without the disease to have signs of the amyloid-beta plaques in the brain that are a hallmark of [Alzheimer‚Äôs disease](https://alzheimersnewstoday.com/what-is-alzheimers-disease/), according to a study in the U.S.

‚ÄúOur findings imply that some component of the biology of multiple sclerosis, or the genetics of MS patients, is protective against Alzheimer‚Äôs disease,‚Äù Matthew Brier, MD, PhD, the study‚Äôs first author and an assistant professor at Washington University School of Medicine in St. Louis, said in a [university news story](https://d.newswise.com/articles/multiple-sclerosis-appears-to-protect-against-alzheimer-s-disease).

The reason behind the link remains unknown.

The study, ‚Äú[Unexpected Low Rate of Amyloid-\[beta\] Pathology in Multiple Sclerosis Patients](https://onlinelibrary.wiley.com/doi/10.1002/ana.27027),‚Äù was published as a brief communication in the _Annals of Neurology_.

In MS, the immune system mistakenly attacks [myelin](http://multiplesclerosisnewstoday.com/myelin-sheath/), the fatty sheath around nerve fibers in the brain and spinal cord, causing [symptoms](https://multiplesclerosisnewstoday.com/symptoms-of-multiple-sclerosis/) such as muscle weakness, poor vision, and numbness. It also can cause cognitive problems, including memory loss. These symptoms could be confused with symptoms of Alzheimer‚Äôs, the most common cause of dementia.

Recommended Reading

![Image 19: banner image for Ben Hofmeister's column ](https://multiplesclerosisnewstoday.com/wp-content/uploads/2022/07/Image-from-iOS-5-150x0-c-default.jpg)

August 8, 2024 [Columns](https://multiplesclerosisnewstoday.com/category/columns/) by [Benjamin Hofmeister](https://multiplesclerosisnewstoday.com/author/benjamin-hofmeister/)

[### Crying at Donald Duck, and other strange emotional reactions](https://multiplesclerosisnewstoday.com/columns/chairborne-a-column-by-ben-hofmeister/2024/08/08/crying-donald-duck-other-strange-emotional-reactions/)

### Seeking a link between MS and Alzheimer‚Äôs risk

Anne Cross, MD, an MS specialist at the university, found it interesting that her patients rarely developed Alzheimer‚Äôs, even though they were old enough to be at risk for it.

‚ÄúI noticed that I couldn‚Äôt find a single MS patient of mine who had typical Alzheimer‚Äôs disease,‚Äù Cross said. ‚ÄúIf they had cognitive problems, I would send them to the memory and aging specialists here at WashU Medicine for an Alzheimer‚Äôs assessment, and those doctors would always come back and tell me, ‚ÄòNo, this is not due to Alzheimer‚Äôs disease.‚Äô‚Äù

Cross teamed up with Brier and other researchers to study whether people with MS have the same risk of developing Alzheimer‚Äôs as those without the condition.

The researchers used PrecivityAD2, a blood test from [C2N Diagnostics](https://c2n.com/) that‚Äôs approved in the U.S. to predict the presence of amyloid-beta plaques in the brain. These toxic protein clumps are a hallmark and a driver of Alzheimer‚Äôs-associated neurodegeneration.

PrecivityAD2 looks for signs of Alzheimer‚Äôs in the blood by measuring three key indicators: the ratio of two forms of a protein called tau, the ratio of two forms of amyloid-beta protein, and a score called the amyloid probability score (APS2), which predicts the likelihood of having Alzheimer‚Äôs.

The team recruited 100 people older than 60 with MS and compared their PrecivityAD2 results with those of 300 sex- and age-matched adults without MS. These controls, who could have either normal or impaired cognitive function, had similar rates of an Alzheimer‚Äôs genetic risk factor, called _APOE_, to MS patients.

Results showed that people with MS were about half as likely to have signs of Alzheimer‚Äôs as controls. For example, the proportion of people with a positive APS2 score was more than twice as high among those without MS (15.3% vs. 7.1%), meaning they were more likely to have amyloid-beta plaques than MS patients. Similar observations were made for the tau ratio (18.3% vs. 9%).

When the researchers performed brain scans on 11 MS patients, they found that the blood test results generally matched the brain imaging findings, especially for the APS2 and tau ratio. This means the PrecivityAD2 test is reliable for predicting amyloid-beta plaques in the brain.

The findings suggest that MS may protect against Alzheimer‚Äôs.

Moreover, MS patients positive for either APS2 or tau ratio were significantly more likely, by up to 23 times, to have two or more atypical MS features at diagnosis, suggesting that a more typical MS profile was even more protective against Alzheimer‚Äôs.

The researchers also studied the effects of a gene called _APOE_, which is linked to Alzheimer‚Äôs.

They found that patients carrying one or two copies of _APOE3_, the most common genetic _APOE_ variant that is linked to an average risk of Alzheimer‚Äôs, had lower APS2 and tau ratio than those without MS. This protective effect wasn‚Äôt seen in MS patients with two copies of _APOE4_, a variant linked to a more than twofold higher risk of Alzheimer‚Äôs.

The results suggest ‚Äúthat MS is associated with a low prevalence of \[amyloid-related damage\] based on \[blood\] biomarkers,‚Äù the researchers wrote.

‚ÄúIf we could identify what aspect is protective and apply it in a controlled way, that could inform therapeutic strategies for Alzheimer‚Äôs disease,‚Äù Brier said.

[Print This Page](https://multiplesclerosisnewstoday.com/news-posts/2024/08/27/ms-patients-less-likely-alzheimers-study/# ""Printer Friendly, PDF & Email"")

About the Author
----------------

![Image 20: Margarida Maia, PhD avatar](https://multiplesclerosisnewstoday.com/wp-content/uploads/2022/05/margarida-96x96.png)

[Margarida Maia, PhD](https://multiplesclerosisnewstoday.com/author/margarida-maia/) Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.

#### Tags

[Alzheimer's disease](https://multiplesclerosisnewstoday.com/tag/alzheimers-disease/), [cognitive impairment](https://multiplesclerosisnewstoday.com/tag/cognitive-impairment/)

[![Image 21](https://multiplesclerosisnewstoday.com/wp-content/uploads/2024/01/MS-Guide-Pop-Up-2024-V1.1-300x370-1.png)](https://multiplesclerosisnewstoday.com/newly-diagnosed-guide-for-ms/)

[![Image 22](https://multiplesclerosisnewstoday.com/wp-content/uploads/2023/05/REEL1-214x380.png)](https://multiplesclerosisnewstoday.com/ms-head-start-damian-washington/)

### Recent Posts

*   [Glial cells implicated in MS disease progression, development](https://multiplesclerosisnewstoday.com/news-posts/2024/08/28/glial-cells-implicated-ms-disease-progression-development/)
*   [MS patients less likely to have Alzheimer‚Äôs, study finds](https://multiplesclerosisnewstoday.com/news-posts/2024/08/27/ms-patients-less-likely-alzheimers-study/)
*   [Struggling with depression after learning my MS has progressed](https://multiplesclerosisnewstoday.com/columns/2024/08/26/struggling-depression-after-learning-ms-progressed/)

  

Recommended reading
-------------------

[![Image 23: An illustration shows the human brain inside a person's head, seen in profile.](https://multiplesclerosisnewstoday.com/wp-content/uploads/2022/08/BrainProfile-380x200-c-default.png)](https://multiplesclerosisnewstoday.com/news-posts/2024/08/06/cognitive-impairments-affect-one-third-rrms-patients-analysis/)

August 6, 2024 [News](https://multiplesclerosisnewstoday.com/category/news-posts/) by [Lindsey Shapiro, PhD](https://multiplesclerosisnewstoday.com/author/lindsey-shapiro/)

[### Cognitive impairments affect about a third of RRMS patients: Analysis](https://multiplesclerosisnewstoday.com/news-posts/2024/08/06/cognitive-impairments-affect-one-third-rrms-patients-analysis/)

[![Image 24: A person grimaces and holds his head while red lines are shown radiating from the forehead.](https://multiplesclerosisnewstoday.com/wp-content/uploads/2024/04/Headache_700x350-380x200-c-default.png)](https://multiplesclerosisnewstoday.com/news-posts/2024/06/24/cognitive-problems-ms-associated-with-worse-mental-physical-quality-life/)

June 24, 2024 [News](https://multiplesclerosisnewstoday.com/category/news-posts/) by [Marisa Wexler, MS](https://multiplesclerosisnewstoday.com/author/marisa-wexler/)

[### MS cognitive problems linked to worse mental, physical life quality](https://multiplesclerosisnewstoday.com/news-posts/2024/06/24/cognitive-problems-ms-associated-with-worse-mental-physical-quality-life/)

[![Image 25: Various foods, including fish and fresh vegetables, are seen clustered together.](https://multiplesclerosisnewstoday.com/wp-content/uploads/2024/04/food_700x350-380x200-c-default.png)](https://multiplesclerosisnewstoday.com/news-posts/2024/05/22/whole-grain-food-diet-may-reduce-risk-pediatric-onset-ms-study/)

May 22, 2024 [News](https://multiplesclerosisnewstoday.com/category/news-posts/) by [Andrea Lobo, PhD](https://multiplesclerosisnewstoday.com/author/andrea-lobo/)

[### Whole grain food diet may reduce risk of pediatric-onset MS: Study](https://multiplesclerosisnewstoday.com/news-posts/2024/05/22/whole-grain-food-diet-may-reduce-risk-pediatric-onset-ms-study/)

Subscribe to our newsletter
---------------------------

Get regular updates to your inbox.

Your Email 

Subscribe

Leave this field empty if you're human: 

![Image 26](https://multiplesclerosisnewstoday.com/wp-content/uploads/2024/06/BionewsLogo_Black.svg) Bionews, Inc.

3 W Garden St  
Suite 700  
Pensacola, FL 32502  
Website: [bionews.com](https://bionews.com/)  
Email: [info@bionews.com](mailto:info@bionews.com)  
Phone: [1-800-936-1363](tel:+18009361363)

*   [About Us](https://multiplesclerosisnewstoday.com/about-multiple-sclerosis-news-today/)
*   [Leadership](https://bionews.com/about/#leadership)
*   [Our Culture](https://bionews.com/our-culture/)
*   [Editorial Policy](https://bionews.com/editorial-policy/)
*   [Advertising Policy](https://bionews.com/advertising-policy/)
*   [Corrections Policy](https://bionews.com/corrections-policy/)
*   [Terms of Service](https://bionews.com/terms-service/)
*   [Privacy Policy](https://bionews.com/privacy-policy/)
*   [Careers](https://bionews.com/careers/)
*   [Contact Us](https://bionews.com/contact-us/)

DisclaimerThis site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

*   [![Image 27](https://multiplesclerosisnewstoday.com/wp-content/uploads/2021/06/color-fb.png)](https://www.facebook.com/multiplesclerosisnewstoday)
*   [![Image 28](https://multiplesclerosisnewstoday.com/wp-content/uploads/2024/07/x-blue-logo-56.png)](https://twitter.com/MSNewsToday)
*   [![Image 29](https://multiplesclerosisnewstoday.com/wp-content/uploads/2021/06/color-ig.png)](https://www.instagram.com/msnewstoday/)
*   [![Image 30](https://multiplesclerosisnewstoday.com/wp-content/uploads/2021/06/color-sc.png)](https://soundcloud.com/msnewstoday)
*   [![Image 31](https://multiplesclerosisnewstoday.com/wp-content/uploads/2023/08/color-pin.png)](https://www.pinterest.pt/msnewstoday/)

Copyright ¬© 2013-2024 All rights reserved.

      

**We use cookies** to enhance your experience on our website. [Privacy Policy](https://multiplesclerosisnewstoday.com/privacypolicy)[Accept](https://multiplesclerosisnewstoday.com/news-posts/2024/08/27/ms-patients-less-likely-alzheimers-study/#)
"
2024-08-28 06:36:00,2024-08-29 23:10:41,"üåü **Did you catch the latest FDA roundup?** It‚Äôs packed with vital updates that could reshape our understanding of regulatory practices and innovations in the healthcare sector!

In the recent article from PR Newswire, the FDA announced several key approvals and ongoing studies that are essential for both professionals and stakeholders in the medical field. Notably, the agency outlined advancements in drug approvals that focus on precision medicine and highlighted important steps toward enhancing patient safety and efficacy standards. 

This roundup emphasizes the FDA's commitment to adapting to new challenges, including the ongoing developments in digital health and telemedicine. These innovations are not just theoretical; they have practical implications for how we interact with patients and deliver care. For instance, integrating these technologies can streamline patient management and improve treatment outcomes. 

As industry professionals, it‚Äôs crucial we stay informed and adapt our strategies accordingly. How do you see these FDA updates impacting your daily practice or organizational goals?  Let‚Äôs share ideas on how we can leverage these insights for better patient experiences!

#FDAUpdates #HealthcareInnovation #PatientSafety #RegulatoryAffairs #Telemedicine

[Read the full article here!](https://www.prnewswire.com/news-releases/fda-roundup-august-27-2024-302232046.html)",https://medsii.azureedge.net/images/638604237763059957-66cec4cf4e2a8b3bb83557f1.jpg,https://www.prnewswire.com/news-releases/fda-roundup-august-27-2024-302232046.html,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Thumbnail image URL: https://medsii.azureedge.net/images/638604237763059957-66cec4cf4e2a8b3bb83557f1.jpg 

Title: FDA Roundup: August 27, 2024

URL Source: https://www.prnewswire.com/news-releases/fda-roundup-august-27-2024-302232046.html

Published Time: 2024-08-27T14:48:00-04:00

Markdown Content:
*   [Resources](https://www.prnewswire.com/resources/)
*   [Blog](https://www.prnewswire.com/resources/articles/)
*   [Journalists](https://prnmedia.prnewswire.com/)

*   [Log In](https://portal.prnewswire.com/Login.aspx)
*   [Sign Up](https://www.prnewswire.com/account/online-membership-form/)
*   [Data Privacy](https://gdpr.cision.com/)
*   [Send a Release](https://www.prnewswire.com/account/online-membership-form/)

[![Image 1: Cision PR Newswire: news distribution, targeting and monitoring home](https://www.prnewswire.com/content/dam/prnewswire/homepage/prn_cision_logo_desktop.png)](https://www.prnewswire.com/)

*   [News](https://www.prnewswire.com/news-releases/)
*   [Products](https://www.prnewswire.com/products/overview/)
*   [Contact](https://www.prnewswire.com/contact-us/)
"
2024-08-27 06:32:00,2024-08-29 23:10:50,"üåü Exciting advances in cancer research! üåü A recent article highlights a groundbreaking approach that combines two protein analysis methods, potentially paving the way for more effective cancer treatments.  

Researchers at Scripps Research have successfully mapped over 300 cancer-related proteins, pinpointing how certain small molecules can disrupt their function and slow cancer cell growth. This innovative strategy connects chemical compounds directly to specific protein interactions, aiming to stop cancer cells from multiplying by targeting crucial points in their life cycle. As Dr. Benjamin Cravatt explains, this dual approach provides a broader and more detailed understanding of how cancer cells survive and interact with potential drugs.  

The implications of this research could be monumental. By identifying new protein pockets and interactions, scientists aim to develop targeted therapies that may improve treatment outcomes. Imagine a future where cancer therapies are not just effective but precise, minimizing side effects and maximizing impact!  

How do you see this new approach influencing future cancer treatments in our field? Let's share insights!  

#CancerResearch #ProteinAnalysis #DrugDiscovery #ScrippsResearch #HealthcareInnovation  

[Source of the article](https://www.eurekalert.org/news-releases/1055729)  
[Learn more about the research](https://www.nature.com/articles/s41557-024-01601-1)  

![Image of the research article](https://medsii.azureedge.net/images/638603371363536957-66cd7157ac48c5e342a25f0f.jpg)",https://medsii.azureedge.net/images/638603371363536957-66cd7157ac48c5e342a25f0f.jpg,https://www.eurekalert.org/news-releases/1055729,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Thumbnail image URL: https://medsii.azureedge.net/images/638603371363536957-66cd7157ac48c5e342a25f0f.jpg 

Title: New way to potentially slow cancer growth

URL Source: https://www.eurekalert.org/news-releases/1055729

Markdown Content:
[![Image 1: New way to potentially slow cancer growth](https://earimediaprodweb.azurewebsites.net/Api/v1/Multimedia/5798974f-20c5-48f4-bebb-53ab6877e0be/Rendition/low-res/Content/Public)](https://www.eurekalert.org/multimedia/1039221)

**image:**

**Chemopproteomic methods (ABPP) identify a stereoprobe that interacts with a cysteine in the cell cycle protein MAD2L1BP and disrupts its interaction with other proteins. Disruption of this protein complex delays cell division in cancer cells.**

[view more](https://www.eurekalert.org/multimedia/1039221)¬†Credit: Scripps Research

**LA JOLLA, CA‚Äî**Fighting cancer effectively often involves stopping cancer cells from multiplying, which requires understanding proteins that the cells rely on to survive. Protein profiling plays a critical role in this process by helping researchers identify proteins‚Äîand their specific parts‚Äîthat future drugs should target. But when used on their own, past approaches haven‚Äôt been detailed enough to spotlight all potential protein targets, leading to some being missed.

Now, by combining two methods of protein analysis, a team of chemists at Scripps Research has mapped more than 300 small molecule-reactive cancer proteins, as well as their small molecule binding sites. Revealing key protein targets that, when disrupted with certain chemical compounds (or small molecules), halt cancer cell growth may eventually enable the development of more effective and precise cancer treatments. The findings were published in [_Nature Chemistry_](https://www.nature.com/articles/s41557-024-01601-1) on August 13, 2024.

‚ÄúOne method gave us a broad view of which proteins were interacting with the chemicals, and the second method showed exactly where those interactions were happening,‚Äù says co-senior author [Benjamin Cravatt, PhD](https://www.scripps.edu/faculty/cravatt/), the Norton B. Gilula Chair in Biology and Chemistry at Scripps Research.

Both methods are forms of activity-based protein profiling (ABPP), a technique that Cravatt pioneered to capture protein activity on a global scale. The research team used their dual approach to flag both the proteins and protein sites that interacted with a library of stereoprobes‚Äîchemical compounds designed to permanently bind to proteins in a selective manner. Stereoprobes are used to study protein functions and identify possible drug targets.

‚ÄúWe made a conscious effort to design our stereoprobes with chemical features that tend to be underrepresented in compounds typically used in drug discovery settings,‚Äù¬†says co-senior author¬†[Bruno Melillo, PhD](https://www.scripps.edu/faculty/melillo/), an institute investigator in the Department of Chemistry at Scripps Research.¬†‚ÄúThis strategy increases our chances of making discoveries that can advance biology, and eventually translate into improvements¬†to human health.‚Äù

The research team‚Äôs stereoprobes were electrophilic, meaning they were designed to irreversibly bind to proteins‚Äîspecifically to cysteine. This amino acid is pervasive in proteins, including those found in cancer cells, and it helps form important structural bonds. When chemicals react with cysteine, they can disrupt these bonds and cause proteins to malfunction, which interferes with cell growth, and many cancer drugs irreversibly bind to cysteines on proteins.

‚ÄúWe also focused on cysteine because it‚Äôs the most nucleophilic amino acid,‚Äù says first author [Evert Njomen, PhD](https://magazine.scripps.edu/awards-and-honors/2021/summer/evert-njomen-howard-hughes-medical-institute-fellowship/), an HHMI Hanna H. Gray Fellow at Scripps Research and a postdoctoral research associate in Cravatt‚Äôs lab.

To find out which specific proteins would bond with the stereoprobes, the team turned to a method known as protein-directed ABPP. Using this approach, the researchers uncovered more than 300 individual proteins that reacted with the stereoprobe compounds. But still, they wanted to dig deeper and identify the reactions‚Äô precise locations.

The second method, called cysteine-directed ABPP, pinpointed exactly where the stereoprobes were binding on the proteins. This allowed the team to ‚Äúzoom in‚Äù on a specific protein pocket and examine whether the cysteine within reacted with the stereoprobes, similar to focusing on a single spot on a puzzle board to see if a particular piece fits.

Each stereoprobe molecule had two main components: the binding part and the electrophilic part. Once the binding component recognizes the cancer cell protein pocket, hopefully, the stereoprobe molecule can enter‚Äîlike how a key needs to fit in a lock. When a stereoprobe remained in a pocket that‚Äôs critical to the cancer cell‚Äôs function, it blocked the protein from binding to other proteins‚Äîultimately preventing cell division.

‚ÄúBy targeting these very specific stages in the cell cycle, there‚Äôs potential to slow down the growth of cancer cells,‚Äù says Njomen. ‚ÄúA cancer cell would stay in what is _almost_ a state of two cells, and your body‚Äôs immune system would detect it as defective and direct it to die.‚Äù

Identifying precise protein regions that are critical to cancer cell survival could help researchers develop more targeted treatments to stop cells from multiplying.

Among the team‚Äôs other key findings was confirming that their double-pronged approach painted a more accurate picture of protein-stereoprobe reactivity than a single method.

‚ÄúWe've always known that both methods had their drawbacks, but we didn‚Äôt know exactly how much information was lost by using just one technique,‚Äù says Njomen. ‚ÄúIt was surprising to see that a substantial number of protein targets were missed when we used one platform over the other.‚Äù

The team hopes that their findings will one day inform new cancer therapies targeting cell division. In the meantime, Njomen wants to design new stereoprobe libraries to uncover protein pockets implicated in illnesses beyond cancer, including inflammatory disorders.

‚ÄúMany proteins have been implicated in diseases, but we don't have stereoprobes to research them,‚Äù she said. ‚ÄúMoving forward, I‚Äôd like to find more protein pockets that we can study for drug discovery purposes.‚Äù

_In addition to Cravatt, Njomen and co-senior author Bruno Melillo, authors of the study, ‚Äú_[_Multi-Tiered Chemical Proteomic Maps of Tryptoline Acrylamide-Protein Interactions in Cancer Cells_](https://www.nature.com/articles/s41557-024-01601-1)_‚Äù are Rachel E. Hayward, Kristen E. DeMeester, Daisuke Ogasawara and Melissa M. Dix of Scripps Research; Tracey Nguyen, Paige Ashby and Gabriel M. Simon of Vividion Therapeutics; and Stuart L. Schreiber of the Broad Institute_.

_This work and the researchers involved were supported by funding from the National Institutes of Health (U19 AI142784 and R35 CA231991); Cancer Research UK (CGCATF-2021/100012 and CGCATF-2021/100021) the National Cancer Institute (OT2CA278688 and OT2CA278692); the Howard Hughes Medical Institute Hanna H. Gray Fellowship (NGT15176), the Jane Coffin Childs Memorial Fellowship, and Vividion Therapeutics._

_//_

**About Scripps Research**

Scripps Research is an independent, nonprofit biomedical institute ranked one of the most influential in the world for its impact on innovation by Nature Index. We are advancing human health through profound discoveries that address pressing medical concerns around the globe. Our drug discovery and development division, Calibr-Skaggs, works hand-in-hand with scientists across disciplines to bring new medicines to patients as quickly and efficiently as possible, while teams at Scripps Research Translational Institute harness genomics, digital medicine and cutting-edge informatics to understand individual health and render more effective healthcare. Scripps Research also trains the next generation of leading scientists at our Skaggs Graduate School, consistently named among the top 10 US programs for chemistry and biological sciences. Learn more at¬†[www.scripps.edu](http://www.scripps.edu/).

* * *

* * *

#### Article Title

Multi-tiered chemical proteomic maps of tryptoline acrylamide‚Äìprotein interactions in cancer cells

#### Article Publication Date

13-Aug-2024

**Disclaimer:** AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
"
2024-08-27 06:23:00,2024-08-29 23:11:01,"üåü Exciting News in Diabetes Management! üåü

Did you know that the FDA recently cleared the first device to enable automated insulin dosing specifically for individuals with type 2 diabetes? This is a significant step towards enhancing the quality of life for many, allowing for improved glucose management and reducing the constant burden of monitoring blood sugar levels.

The Insulet SmartAdjust technology, initially designed for type 1 diabetes, is now available for adults with type 2 diabetes, offering them an innovative way to automate insulin delivery using an interoperable glycemic controller. This means that patients will find it easier to manage their insulin therapy without the repeated manual effort they‚Äôve previously faced.

**Key Takeaways:**  
1. **Improved Diabetes Management:** Automated systems can significantly reduce the manual tasks required in insulin administration, providing more consistent dosing.
2. **Broader Access:** This technology aims to close the gap in diabetes care, expanding its benefits to a broader audience, particularly to the 11% of Americans living with diabetes.
3. **Enhanced Clinical Outcomes:** Data from clinical studies show that this technology has improved blood sugar control among diverse patient populations without serious adverse events.

As we celebrate this advancement, it's critical to think about how integrating technology into healthcare can provide better care pathways for patients. Are you leveraging new technologies in your practice or daily management? Let's share insights on how these innovations are shaping diabetes care! 

#DiabetesManagement #FDAApproval #HealthTech

For more details, check out the full article here: [FDA News Release](https://www.prnewswire.com/news-releases/fda-clears-first-device-to-enable-automated-insulin-dosing-for-individuals-with-type-2-diabetes-302230838.html)  

![FDA Clears First Device to Enable Automated Insulin Dosing](https://medsii.azureedge.net/images/638603365792184149-66cd7043ac48c5e342a25f0e.jpg)",https://medsii.azureedge.net/images/638603365792184149-66cd7043ac48c5e342a25f0e.jpg,https://www.prnewswire.com/news-releases/fda-clears-first-device-to-enable-automated-insulin-dosing-for-individuals-with-type-2-diabetes-302230838.html,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Thumbnail image URL: https://medsii.azureedge.net/images/638603365792184149-66cd7043ac48c5e342a25f0e.jpg 

Title: FDA Clears First Device to Enable Automated Insulin Dosing for Individuals with Type 2 Diabetes

URL Source: https://www.prnewswire.com/news-releases/fda-clears-first-device-to-enable-automated-insulin-dosing-for-individuals-with-type-2-diabetes-302230838.html

Published Time: 2024-08-26T17:20:00-04:00

Markdown Content:
FDA Clears First Device to Enable Automated Insulin Dosing for Individuals with Type 2 Diabetes
===============

*   [Resources](https://www.prnewswire.com/resources/)
*   [Blog](https://www.prnewswire.com/resources/articles/)
*   [Journalists](https://prnmedia.prnewswire.com/)

*   [Log In](https://portal.prnewswire.com/Login.aspx)
*   [Sign Up](https://www.prnewswire.com/account/online-membership-form/)
*   [Data Privacy](https://gdpr.cision.com/)
*   [Send a Release](https://www.prnewswire.com/account/online-membership-form/)

[![Image 1: Cision PR Newswire: news distribution, targeting and monitoring home](https://www.prnewswire.com/content/dam/prnewswire/homepage/prn_cision_logo_desktop.png)](https://www.prnewswire.com/)

*   [News](https://www.prnewswire.com/news-releases/)
*   [Products](https://www.prnewswire.com/products/overview/)
*   [Contact](https://www.prnewswire.com/contact-us/)

Search   

        Search When typing in this field, a list of search results will appear and be automatically updated as you type. 

Searching for your content...

**No results found. Please change your search terms and try again.**

*   [News in Focus](https://www.prnewswire.com/news-releases/fda-clears-first-device-to-enable-automated-insulin-dosing-for-individuals-with-type-2-diabetes-302230838.html# ""News in Focus"")
    *   *   [Browse News Releases](https://www.prnewswire.com/news-releases/)
            -----------------------------------------------------------------
            
        *   [All News Releases](https://www.prnewswire.com/news-releases/news-releases-list/)
        *   [All Public Company](https://www.prnewswire.com/news-releases/all-public-company-news/)
        *   [English-only](https://www.prnewswire.com/news-releases/english-releases/)
        *   [News Releases Overview](https://www.prnewswire.com/news-releases/)
            -------------------------------------------------------------------
            
        
        *   [Multimedia Gallery](https://www.prnewswire.com/news-releases/multimedia/)
            --------------------------------------------------------------------------
            
        *   [All Multimedia](https://www.prnewswire.com/news-releases/multimedia/multimedia-list/)
        *   [All Photos](https://www.prnewswire.com/news-releases/photos/photos-list/)
        *   [All Videos](https://www.prnewswire.com/news-releases/videos/videos-list/)
        *   [Multimedia Gallery Overview](https://www.prnewswire.com/news-releases/multimedia/)
            -----------------------------------------------------------------------------------
            
        
        *   [Trending Topics](https://www.prnewswire.com/news-releases/latest-news-topics/)
            -------------------------------------------------------------------------------
            
        *   [All Trending Topics](https://www.prnewswire.com/news-releases/latest-news-topics/)
        
*   [Business & Money](https://www.prnewswire.com/news-releases/fda-clears-first-device-to-enable-automated-insulin-dosing-for-individuals-with-type-2-diabetes-302230838.html# ""Business & Money"")
    *   *   [Auto & Transportation](https://www.prnewswire.com/news-releases/automotive-transportation-latest-news/)
            --------------------------------------------------------------------------------------------------------
            
        *   [All Automotive & Transportation](https://www.prnewswire.com/news-releases/automotive-transportation-latest-news/automotive-transportation-latest-news-list/)
        *   [Aerospace, Defense](https://www.prnewswire.com/news-releases/automotive-transportation-latest-news/aerospace-defense-list/)
        *   [Air Freight](https://www.prnewswire.com/news-releases/automotive-transportation-latest-news/air-freight-list/)
        *   [Airlines & Aviation](https://www.prnewswire.com/news-releases/automotive-transportation-latest-news/airlines-aviation-list/)
        *   [Automotive](https://www.prnewswire.com/news-releases/automotive-transportation-latest-news/automotive-list/)
        *   [Maritime & Shipbuilding](https://www.prnewswire.com/news-releases/automotive-transportation-latest-news/maritime-shipbuilding-list/)
        *   [Railroads and Intermodal Transportation](https://www.prnewswire.com/news-releases/automotive-transportation-latest-news/railroads-and-intermodal-transportation-list/)
        *   [Supply Chain/Logistics](https://www.prnewswire.com/news-releases/automotive-transportation-latest-news/supply-chain-logistics-list/)
        *   [Transportation, Trucking & Railroad](https://www.prnewswire.com/news-releases/automotive-transportation-latest-news/transportation-trucking-railroad-list/)
        *   [Travel](https://www.prnewswire.com/news-releases/automotive-transportation-latest-news/travel-list/)
        *   [Trucking and Road Transportation](https://www.prnewswire.com/news-releases/automotive-transportation-latest-news/trucking-and-road-transportation-list/)
        *   [Auto & Transportation Overview](https://www.prnewswire.com/news-releases/automotive-transportation-latest-news/)
            -----------------------------------------------------------------------------------------------------------------
            
        *   [View All Auto & Transportation](https://www.prnewswire.com/news-releases/automotive-transportation-latest-news/automotive-transportation-latest-news-list/)
            ------------------------------------------------------------------------------------------------------------------------------------------------------------
            
        
        *   [Business Technology](https://www.prnewswire.com/news-releases/business-technology-latest-news/)
            ------------------------------------------------------------------------------------------------
            
        *   [All Business Technology](https://www.prnewswire.com/news-releases/business-technology-latest-news/business-technology-latest-news-list/)
        *   [Blockchain](https://www.prnewswire.com/news-releases/business-technology-latest-news/blockchain-list/)
        *   [Broadcast Tech](https://www.prnewswire.com/news-releases/business-technology-latest-news/broadcast-tech-list/)
        *   [Computer & Electronics](https://www.prnewswire.com/news-releases/business-technology-latest-news/computer-electronics-list/)
        *   [Computer Hardware](https://www.prnewswire.com/news-releases/business-technology-latest-news/computer-hardware-list/)
        *   [Computer Software](https://www.prnewswire.com/news-releases/business-technology-latest-news/computer-software-list/)
        *   [Data Analytics](https://www.prnewswire.com/news-releases/business-technology-latest-news/data-analytics-list/)
        *   [Electronic Commerce](https://www.prnewswire.com/news-releases/business-technology-latest-news/electronic-commerce-list/)
        *   [Electronic Components](https://www.prnewswire.com/news-releases/business-technology-latest-news/electronic-components-list/)
        *   [Electronic Design Automation](https://www.prnewswire.com/news-releases/business-technology-latest-news/electronic-design-automation-list/)
        *   [Financial Technology](https://www.prnewswire.com/news-releases/business-technology-latest-news/financial-technology-list/)
        *   [High Tech Security](https://www.prnewswire.com/news-releases/business-technology-latest-news/high-tech-security-list/)
        *   [Internet Technology](https://www.prnewswire.com/news-releases/business-technology-latest-news/internet-technology-list/)
        *   [Nanotechnology](https://www.prnewswire.com/news-releases/business-technology-latest-news/nanotechnology-list/)
        *   [Networks](https://www.prnewswire.com/news-releases/business-technology-latest-news/networks-list/)
        *   [Peripherals](https://www.prnewswire.com/news-releases/business-technology-latest-news/peripherals-list/)
        *   [Semiconductors](https://www.prnewswire.com/news-releases/business-technology-latest-news/semiconductors-list/)
        *   [Business Technology Overview](https://www.prnewswire.com/news-releases/business-technology-latest-news/)
            ---------------------------------------------------------------------------------------------------------
            
        *   [View All Business Technology](https://www.prnewswire.com/news-releases/business-technology-latest-news/business-technology-latest-news-list/)
            ----------------------------------------------------------------------------------------------------------------------------------------------
            
        
        *   [Entertain¬≠ment & Media](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/)
            ---------------------------------------------------------------------------------------------------
            
        *   [All Entertain¬≠ment & Media](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/)
        *   [Advertising](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/advertising-list/)
        *   [Art](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/art-list/)
        *   [Books](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/books-list/)
        *   [Entertainment](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/entertainment-list/)
        *   [Film and Motion Picture](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/film-and-motion-picture-list/)
        *   [Magazines](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/magazines-list/)
        *   [Music](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/music-list/)
        *   [Publishing & Information Services](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/publishing-information-services-list/)
        *   [Radio & Podcast](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/radio-list/)
        *   [Television](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/television-list/)
        *   [Entertain¬≠ment & Media Overview](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/)
            ------------------------------------------------------------------------------------------------------------
            
        *   [View All Entertain¬≠ment & Media](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/)
            -------------------------------------------------------------------------------------------------------------------------------------------------
            
        
        *   [Financial Services & Investing](https://www.prnewswire.com/news-releases/financial-services-latest-news/)
            ----------------------------------------------------------------------------------------------------------
            
        *   [All Financial Services & Investing](https://www.prnewswire.com/news-releases/financial-services-latest-news/financial-services-latest-news-list/)
        *   [Accounting News & Issues](https://www.prnewswire.com/news-releases/financial-services-latest-news/accounting-news-issues-list/)
        *   [Acquisitions, Mergers and Takeovers](https://www.prnewswire.com/news-releases/financial-services-latest-news/acquisitions-mergers-and-takeovers-list/)
        *   [Banking & Financial Services](https://www.prnewswire.com/news-releases/financial-services-latest-news/banking-financial-services-list/)
        *   [Bankruptcy](https://www.prnewswire.com/news-releases/financial-services-latest-news/bankruptcy-list/)
        *   [Bond & Stock Ratings](https://www.prnewswire.com/news-releases/financial-services-latest-news/bond-stock-ratings-list/)
        *   [Conference Call Announcements](https://www.prnewswire.com/news-releases/financial-services-latest-news/conference-call-announcements-list/)
        *   [Contracts](https://www.prnewswire.com/news-releases/financial-services-latest-news/contracts-list/)
        *   [Cryptocurrency](https://www.prnewswire.com/news-releases/financial-services-latest-news/cryptocurrency-list/)
        *   [Dividends](https://www.prnewswire.com/news-releases/financial-services-latest-news/dividends-list/)
        *   [Earnings](https://www.prnewswire.com/news-releases/financial-services-latest-news/earnings-list/)
        *   [Earnings Forecasts & Projections](https://www.prnewswire.com/news-releases/financial-services-latest-news/earnings-forecasts-projections-list/)
        *   [Financing Agreements](https://www.prnewswire.com/news-releases/financial-services-latest-news/financing-agreements-list/)
        *   [Insurance](https://www.prnewswire.com/news-releases/financial-services-latest-news/insurance-list/)
        *   [Investments Opinions](https://www.prnewswire.com/news-releases/financial-services-latest-news/investment-opinions-list/)
        *   [Joint Ventures](https://www.prnewswire.com/news-releases/financial-services-latest-news/joint-ventures-list/)
        *   [Mutual Funds](https://www.prnewswire.com/news-releases/financial-services-latest-news/mutual-funds-list/)
        *   [Private Placement](https://www.prnewswire.com/news-releases/financial-services-latest-news/private-placement-list/)
        *   [Real Estate](https://www.prnewswire.com/news-releases/financial-services-latest-news/real-estate-list/)
        *   [Restructuring & Recapitalization](https://www.prnewswire.com/news-releases/financial-services-latest-news/restructuring-recapitalization-list/)
        *   [Sales Reports](https://www.prnewswire.com/news-releases/financial-services-latest-news/sales-reports-list/)
        *   [Shareholder Activism](https://www.prnewswire.com/news-releases/financial-services-latest-news/shareholder-activism-list/)
        *   [Shareholder Meetings](https://www.prnewswire.com/news-releases/financial-services-latest-news/shareholder-meetings-list/)
        *   [Stock Offering](https://www.prnewswire.com/news-releases/financial-services-latest-news/stock-offering-list/)
        *   [Stock Split](https://www.prnewswire.com/news-releases/financial-services-latest-news/stock-split-list/)
        *   [Venture Capital](https://www.prnewswire.com/news-releases/financial-services-latest-news/venture-capital-list/)
        *   [Financial Services & Investing Overview](https://www.prnewswire.com/news-releases/financial-services-latest-news/)
            -------------------------------------------------------------------------------------------------------------------
            
        *   [View All Financial Services & Investing](https://www.prnewswire.com/news-releases/financial-services-latest-news/financial-services-latest-news-list/)
            -------------------------------------------------------------------------------------------------------------------------------------------------------
            
        
        *   [General Business](https://www.prnewswire.com/news-releases/general-business-latest-news/)
            ------------------------------------------------------------------------------------------
            
        *   [All General Business](https://www.prnewswire.com/news-releases/general-business-latest-news/general-business-latest-news-list/)
        *   [Awards](https://www.prnewswire.com/news-releases/general-business-latest-news/awards-list/)
        *   [Commercial Real Estate](https://www.prnewswire.com/news-releases/general-business-latest-news/commercial-real-estate-list/)
        *   [Corporate Expansion](https://www.prnewswire.com/news-releases/general-business-latest-news/corporate-expansion-list/)
        *   [Earnings](https://www.prnewswire.com/news-releases/general-business-latest-news/earnings-list/)
        *   [Environmental, Social and Governance (ESG)](https://www.prnewswire.com/news-releases/general-business-latest-news/environmental-social-governance-list/)
        *   [Human Resource & Workforce Management](https://www.prnewswire.com/news-releases/general-business-latest-news/human-resource-workforce-management-list/)
        *   [Licensing](https://www.prnewswire.com/news-releases/general-business-latest-news/licensing-list/)
        *   [New Products & Services](https://www.prnewswire.com/news-releases/general-business-latest-news/new-products-services-list/)
        *   [Obituaries](https://www.prnewswire.com/news-releases/general-business-latest-news/obituaries-list/)
        *   [Outsourcing Businesses](https://www.prnewswire.com/news-releases/general-business-latest-news/outsourcing-businesses-list/)
        *   [Overseas Real Estate (non-US)](https://www.prnewswire.com/news-releases/general-business-latest-news/overseas-real-estate-list/)
        *   [Personnel Announcements](https://www.prnewswire.com/news-releases/general-business-latest-news/personnel-announcements-list/)
        *   [Real Estate Transactions](https://www.prnewswire.com/news-releases/general-business-latest-news/real-estate-transactions-list/)
        *   [Residential Real Estate](https://www.prnewswire.com/news-releases/general-business-latest-news/residential-real-estate-list/)
        *   [Small Business Services](https://www.prnewswire.com/news-releases/general-business-latest-news/small-business-services-list/)
        *   [Socially Responsible Investing](https://www.prnewswire.com/news-releases/general-business-latest-news/socially-responsible-investing-list/)
        *   [Surveys, Polls and Research](https://www.prnewswire.com/news-releases/general-business-latest-news/surveys-polls-and-research-list/)
        *   [Trade Show News](https://www.prnewswire.com/news-releases/general-business-latest-news/trade-show-news-list/)
        *   [General Business Overview](https://www.prnewswire.com/news-releases/general-business-latest-news/)
            ---------------------------------------------------------------------------------------------------
            
        *   [View All General Business](https://www.prnewswire.com/news-releases/general-business-latest-news/general-business-latest-news-list/)
            -------------------------------------------------------------------------------------------------------------------------------------
            
*   [Science & Tech](https://www.prnewswire.com/news-releases/fda-clears-first-device-to-enable-automated-insulin-dosing-for-individuals-with-type-2-diabetes-302230838.html# ""Science & Tech"")
    *   *   [Consumer Technology](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/)
            ------------------------------------------------------------------------------------------------
            
        *   [All Consumer Technology](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/consumer-technology-latest-news-list/)
        *   [Artificial Intelligence](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/artificial-intelligence-list/)
        *   [Blockchain](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/blockchain-list/)
        *   [Cloud Computing/Internet of Things](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/cloud-computing-internet-of-things-list/)
        *   [Computer Electronics](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/computer-electronics-list/)
        *   [Computer Hardware](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/computer-hardware-list/)
        *   [Computer Software](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/computer-software-list/)
        *   [Consumer Electronics](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/consumer-electronics-list/)
        *   [Cryptocurrency](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/cryptocurrency-list/)
        *   [Data Analytics](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/data-analytics-list/)
        *   [Electronic Commerce](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/electronic-commerce-list/)
        *   [Electronic Gaming](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/electronic-gaming-list/)
        *   [Financial Technology](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/financial-technology-list/)
        *   [Mobile Entertainment](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/mobile-entertainment-list/)
        *   [Multimedia & Internet](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/multimedia-internet-list/)
        *   [Peripherals](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/peripherals-list/)
        *   [Social Media](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/social-media-list/)
        *   [STEM (Science, Tech, Engineering, Math)](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/science-tech-engineering-math-list/)
        *   [Supply Chain/Logistics](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/supply-chain-logistics-list/)
        *   [Wireless Communications](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/wireless-communications-list/)
        *   [Consumer Technology Overview](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/)
            ---------------------------------------------------------------------------------------------------------
            
        *   [View All Consumer Technology](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/consumer-technology-latest-news-list/)
            ----------------------------------------------------------------------------------------------------------------------------------------------
            
        
        *   [Energy & Natural Resources](https://www.prnewswire.com/news-releases/energy-latest-news/)
            ------------------------------------------------------------------------------------------
            
        *   [All Energy](https://www.prnewswire.com/news-releases/energy-latest-news/energy-latest-news-list/)
        *   [Alternative Energies](https://www.prnewswire.com/news-releases/energy-latest-news/alternative-energies-list/)
        *   [Chemical](https://www.prnewswire.com/news-releases/energy-latest-news/chemical-list/)
        *   [Electrical Utilities](https://www.prnewswire.com/news-releases/energy-latest-news/electrical-utilities-list/)
        *   [Gas](https://www.prnewswire.com/news-releases/energy-latest-news/gas-list/)
        *   [General Manufacturing](https://www.prnewswire.com/news-releases/energy-latest-news/general-manufacturing-list/)
        *   [Mining](https://www.prnewswire.com/news-releases/energy-latest-news/mining-list/)
        *   [Mining & Metals](https://www.prnewswire.com/news-releases/energy-latest-news/mining-metals-list/)
        *   [Oil & Energy](https://www.prnewswire.com/news-releases/energy-latest-news/oil-energy-list/)
        *   [Oil and Gas Discoveries](https://www.prnewswire.com/news-releases/energy-latest-news/oil-and-gas-discoveries-list/)
        *   [Utilities](https://www.prnewswire.com/news-releases/energy-latest-news/utilities-list/)
        *   [Water Utilities](https://www.prnewswire.com/news-releases/energy-latest-news/water-utilities-list/)
        *   [Energy & Natural Resources Overview](https://www.prnewswire.com/news-releases/energy-latest-news/)
            ---------------------------------------------------------------------------------------------------
            
        *   [View All Energy & Natural Resources](https://www.prnewswire.com/news-releases/energy-latest-news/energy-latest-news-list/)
            ---------------------------------------------------------------------------------------------------------------------------
            
        
        *   [Environ¬≠ment](https://www.prnewswire.com/news-releases/environment-latest-news/)
            ---------------------------------------------------------------------------------
            
        *   [All Environ¬≠ment](https://www.prnewswire.com/news-releases/environment-latest-news/environment-latest-news-list/)
        *   [Conservation & Recycling](https://www.prnewswire.com/news-releases/environment-latest-news/conservation-recycling-list/)
        *   [Environmental Issues](https://www.prnewswire.com/news-releases/environment-latest-news/environmental-issues-list/)
        *   [Environmental Policy](https://www.prnewswire.com/news-releases/environment-latest-news/environmental-policy-list/)
        *   [Environmental Products & Services](https://www.prnewswire.com/news-releases/environment-latest-news/environmental-products-services-list/)
        *   [Green Technology](https://www.prnewswire.com/news-releases/environment-latest-news/green-technology-list/)
        *   [Natural Disasters](https://www.prnewswire.com/news-releases/environment-latest-news/natural-disasters/)
        *   [Environ¬≠ment Overview](https://www.prnewswire.com/news-releases/environment-latest-news/)
            ------------------------------------------------------------------------------------------
            
        *   [View All Environ¬≠ment](https://www.prnewswire.com/news-releases/environment-latest-news/environment-latest-news-list/)
            -----------------------------------------------------------------------------------------------------------------------
            
        
        *   [Heavy Industry & Manufacturing](https://www.prnewswire.com/news-releases/heavy-industry-manufacturing-latest-news/)
            --------------------------------------------------------------------------------------------------------------------
            
        *   [All Heavy Industry & Manufacturing](https://www.prnewswire.com/news-releases/heavy-industry-manufacturing-latest-news/heavy-industry-manufacturing-latest-news-list/)
        *   [Aerospace & Defense](https://www.prnewswire.com/news-releases/heavy-industry-manufacturing-latest-news/aerospace-defense-list/)
        *   [Agriculture](https://www.prnewswire.com/news-releases/heavy-industry-manufacturing-latest-news/agriculture-list/)
        *   [Chemical](https://www.prnewswire.com/news-releases/heavy-industry-manufacturing-latest-news/chemical-list/)
        *   [Construction & Building](https://www.prnewswire.com/news-releases/heavy-industry-manufacturing-latest-news/construction-building-list/)
        *   [General Manufacturing](https://www.prnewswire.com/news-releases/heavy-industry-manufacturing-latest-news/general-manufacturing-list/)
        *   [HVAC (Heating, Ventilation and Air-Conditioning)](https://www.prnewswire.com/news-releases/heavy-industry-manufacturing-latest-news/hvac-list/)
        *   [Machinery](https://www.prnewswire.com/news-releases/heavy-industry-manufacturing-latest-news/machinery-list/)
        *   [Machine Tools, Metalworking and Metallurgy](https://www.prnewswire.com/news-releases/heavy-industry-manufacturing-latest-news/machine-tools-metalworking-and-metallury-list/)
        *   [Mining](https://www.prnewswire.com/news-releases/heavy-industry-manufacturing-latest-news/mining-list/)
        *   [Mining & Metals](https://www.prnewswire.com/news-releases/heavy-industry-manufacturing-latest-news/mining-metals-list/)
        *   [Paper, Forest Products & Containers](https://www.prnewswire.com/news-releases/heavy-industry-manufacturing-latest-news/paper-forest-products-containers-list/)
        *   [Precious Metals](https://www.prnewswire.com/news-releases/heavy-industry-manufacturing-latest-news/precious-metals-list/)
        *   [Textiles](https://www.prnewswire.com/news-releases/heavy-industry-manufacturing-latest-news/textiles-list/)
        *   [Tobacco](https://www.prnewswire.com/news-releases/heavy-industry-manufacturing-latest-news/tobacco-list/)
        *   [Heavy Industry & Manufacturing Overview](https://www.prnewswire.com/news-releases/heavy-industry-manufacturing-latest-news/)
            -----------------------------------------------------------------------------------------------------------------------------
            
        *   [View All Heavy Industry & Manufacturing](https://www.prnewswire.com/news-releases/heavy-industry-manufacturing-latest-news/heavy-industry-manufacturing-latest-news-list/)
            ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
            
        
        *   [Telecomm¬≠unications](https://www.prnewswire.com/news-releases/telecommunications-latest-news/)
            -----------------------------------------------------------------------------------------------
            
        *   [All Telecomm¬≠unications](https://www.prnewswire.com/news-releases/telecommunications-latest-news/telecommunications-latest-news-list/)
        *   [Carriers and Services](https://www.prnewswire.com/news-releases/telecommunications-latest-news/carriers-and-services-list/)
        *   [Mobile Entertainment](https://www.prnewswire.com/news-releases/telecommunications-latest-news/mobile-entertainment-list/)
        *   [Networks](https://www.prnewswire.com/news-releases/telecommunications-latest-news/networks-list/)
        *   [Peripherals](https://www.prnewswire.com/news-releases/telecommunications-latest-news/peripherals-list/)
        *   [Telecommunications Equipment](https://www.prnewswire.com/news-releases/telecommunications-latest-news/telecommunications-equipment-list/)
        *   [Telecommunications Industry](https://www.prnewswire.com/news-releases/telecommunications-latest-news/telecommunications-industry-list/)
        *   [VoIP (Voice over Internet Protocol)](https://www.prnewswire.com/news-releases/telecommunications-latest-news/voip-list/)
        *   [Wireless Communications](https://www.prnewswire.com/news-releases/telecommunications-latest-news/wireless-communications-list/)
        *   [Telecomm¬≠unications Overview](https://www.prnewswire.com/news-releases/telecommunications-latest-news/)
            --------------------------------------------------------------------------------------------------------
            
        *   [View All Telecomm¬≠unications](https://www.prnewswire.com/news-releases/telecommunications-latest-news/telecommunications-latest-news-list/)
            --------------------------------------------------------------------------------------------------------------------------------------------
            
*   [Lifestyle & Health](https://www.prnewswire.com/news-releases/fda-clears-first-device-to-enable-automated-insulin-dosing-for-individuals-with-type-2-diabetes-302230838.html# ""Lifestyle & Health"")
    *   *   [Consumer Products & Retail](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/)
            ------------------------------------------------------------------------------------------------------------
            
        *   [All Consumer Products & Retail](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/consumer-products-retail-latest-news-list/)
        *   [Animals & Pets](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/animals-pets-list/)
        *   [Beers, Wines and Spirits](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/beers-wines-and-spirits-list/)
        *   [Beverages](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/beverages-list/)
        *   [Bridal Services](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/bridal-services-list/)
        *   [Cannabis](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/cannabis-list/)
        *   [Cosmetics and Personal Care](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/cosmetics-and-personal-care-list/)
        *   [Fashion](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/fashion-list/)
        *   [Food & Beverages](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/food-beverages-list/)
        *   [Furniture and Furnishings](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/furniture-and-furnishings-list/)
        *   [Home Improvement](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/home-improvements-list/)
        *   [Household, Consumer & Cosmetics](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/household-consumer-cosmetics-list/)
        *   [Household Products](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/household-products-list/)
        *   [Jewelry](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/jewelry-list/)
        *   [Non-Alcoholic Beverages](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/non-alcoholic-beverages-list/)
        *   [Office Products](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/office-products-list/)
        *   [Organic Food](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/organic-food-list/)
        *   [Product Recalls](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/product-recalls-list/)
        *   [Restaurants](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/restaurants-list/)
        *   [Retail](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/retail-list/)
        *   [Supermarkets](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/supermarkets-list/)
        *   [Toys](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/toys-list/)
        *   [Consumer Products & Retail Overview](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/)
            ---------------------------------------------------------------------------------------------------------------------
            
        *   [View All Consumer Products & Retail](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/consumer-products-retail-latest-news-list/)
            ---------------------------------------------------------------------------------------------------------------------------------------------------------------
            
        
        *   [Entertain¬≠ment & Media](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/)
            ---------------------------------------------------------------------------------------------------
            
        *   [All Entertain¬≠ment & Media](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/)
        *   [Advertising](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/advertising-list/)
        *   [Art](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/art-list/)
        *   [Books](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/books-list/)
        *   [Entertainment](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/entertainment-list/)
        *   [Film and Motion Picture](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/film-and-motion-picture-list/)
        *   [Magazines](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/magazines-list/)
        *   [Music](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/music-list/)
        *   [Publishing & Information Services](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/publishing-information-services-list/)
        *   [Radio & Podcast](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/radio-list/)
        *   [Television](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/television-list/)
        *   [Entertain¬≠ment & Media Overview](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/)
            ------------------------------------------------------------------------------------------------------------
            
        *   [View All Entertain¬≠ment & Media](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/)
            -------------------------------------------------------------------------------------------------------------------------------------------------
            
        
        *   [Health](https://www.prnewswire.com/news-releases/health-latest-news/)
            ----------------------------------------------------------------------
            
        *   [All Health](https://www.prnewswire.com/news-releases/health-latest-news/health-latest-news-list/)
        *   [Biometrics](https://www.prnewswire.com/news-releases/health-latest-news/biometrics-list/)
        *   [Biotechnology](https://www.prnewswire.com/news-releases/health-latest-news/biotechnology-list/)
        *   [Clinical Trials & Medical Discoveries](https://www.prnewswire.com/news-releases/health-latest-news/clinical-trials-medical-discoveries-list/)
        *   [Dentistry](https://www.prnewswire.com/news-releases/health-latest-news/dentistry-list/)
        *   [FDA Approval](https://www.prnewswire.com/news-releases/health-latest-news/fda-approval-list/)
        *   [Fitness/Wellness](https://www.prnewswire.com/news-releases/health-latest-news/fitness-wellness-list/)
        *   [Health Care & Hospitals](https://www.prnewswire.com/news-releases/health-latest-news/health-care-hospitals-list/)
        *   [Health Insurance](https://www.prnewswire.com/news-releases/health-latest-news/health-insurance-list/)
        *   [Infection Control](https://www.prnewswire.com/news-releases/health-latest-news/infection-control-list/)
        *   [International Medical Approval](https://www.prnewswire.com/news-releases/health-latest-news/international-medical-approval-list/)
        *   [Medical Equipment](https://www.prnewswire.com/news-releases/health-latest-news/medical-equipment-list/)
        *   [Medical Pharmaceuticals](https://www.prnewswire.com/news-releases/health-latest-news/medical-pharmaceuticals-list/)
        *   [Mental Health](https://www.prnewswire.com/news-releases/health-latest-news/mental-health-list/)
        *   [Pharmaceuticals](https://www.prnewswire.com/news-releases/health-latest-news/pharmaceuticals-list/)
        *   [Supplementary Medicine](https://www.prnewswire.com/news-releases/health-latest-news/supplementary-medicine-list/)
        *   [Health Overview](https://www.prnewswire.com/news-releases/health-latest-news/)
            -------------------------------------------------------------------------------
            
        *   [View All Health](https://www.prnewswire.com/news-releases/health-latest-news/health-latest-news-list/)
            -------------------------------------------------------------------------------------------------------
            
        
        *   [Sports](https://www.prnewswire.com/news-releases/sports-latest-news/)
            ----------------------------------------------------------------------
            
        *   [All Sports](https://www.prnewswire.com/news-releases/sports-latest-news/sports-latest-news-list/)
        *   [General Sports](https://www.prnewswire.com/news-releases/sports-latest-news/general-sports-list/)
        *   [Outdoors, Camping & Hiking](https://www.prnewswire.com/news-releases/sports-latest-news/outdoors-camping-hiking-list/)
        *   [Sporting Events](https://www.prnewswire.com/news-releases/sports-latest-news/sporting-events-list/)
        *   [Sports Equipment & Accessories](https://www.prnewswire.com/news-releases/sports-latest-news/sports-equipment-accessories-list/)
        *   [Sports Overview](https://www.prnewswire.com/news-releases/sports-latest-news/)
            -------------------------------------------------------------------------------
            
        *   [View All Sports](https://www.prnewswire.com/news-releases/sports-latest-news/sports-latest-news-list/)
            -------------------------------------------------------------------------------------------------------
            
        
        *   [Travel](https://www.prnewswire.com/news-releases/travel-latest-news/)
            ----------------------------------------------------------------------
            
        *   [All Travel](https://www.prnewswire.com/news-releases/travel-latest-news/travel-latest-news-list/)
        *   [Amusement Parks and Tourist Attractions](https://www.prnewswire.com/news-releases/travel-latest-news/amusement-parks-and-tourist-attractions-list/)
        *   [Gambling & Casinos](https://www.prnewswire.com/news-releases/travel-latest-news/gambling-casinos-list/)
        *   [Hotels and Resorts](https://www.prnewswire.com/news-releases/travel-latest-news/hotels-and-resorts-list/)
        *   [Leisure & Tourism](https://www.prnewswire.com/news-releases/travel-latest-news/leisure-tourism-list/)
        *   [Outdoors, Camping & Hiking](https://www.prnewswire.com/news-releases/travel-latest-news/outdoors-camping-hiking-list/)
        *   [Passenger Aviation](https://www.prnewswire.com/news-releases/travel-latest-news/passenger-aviation-list/)
        *   [Travel Industry](https://www.prnewswire.com/news-releases/travel-latest-news/travel-industry-list/)
        *   [Travel Overview](https://www.prnewswire.com/news-releases/travel-latest-news/)
            -------------------------------------------------------------------------------
            
        *   [View All Travel](https://www.prnewswire.com/news-releases/travel-latest-news/travel-latest-news-list/)
            -------------------------------------------------------------------------------------------------------
            
*   [Policy & Public Interest](https://www.prnewswire.com/news-releases/fda-clears-first-device-to-enable-automated-insulin-dosing-for-individuals-with-type-2-diabetes-302230838.html# ""Policy & Public Interest"")
    *   *   [Policy & Public Interest](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/)
            --------------------------------------------------------------------------------------------------------
            
        *   [All Policy & Public Interest](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/policy-public-interest-latest-news-list/)
        *   [Advocacy Group Opinion](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/advocacy-group-opinion-list/)
        *   [Animal Welfare](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/animal-welfare-list/)
        *   [Congressional & Presidential Campaigns](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/congressional-presidential-campaigns-list/)
        *   [Corporate Social Responsibility](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/corporate-social-responsibility-list/)
        *   [Domestic Policy](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/domestic-policy-list/)
        *   [Economic News, Trends, Analysis](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/economic-news-trends-analysis-list/)
        *   [Education](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/education-list/)
        *   [Environmental](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/environmental-list/)
        *   [European Government](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/european-government-list/)
        *   [FDA Approval](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/fda-approval-list/)
        *   [Federal and State Legislation](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/federal-and-state-legislation-list/)
        *   [Federal Executive Branch & Agency](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/federal-executive-branch-agency-news-list/)
        *   [Foreign Policy & International Affairs](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/foreign-policy-international-affairs-list/)
        *   [Homeland Security](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/homeland-security-list/)
        *   [Labor & Union](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/labor-union-news-list/)
        *   [Legal Issues](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/legal-issues-list/)
        *   [Natural Disasters](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/natural-disasters-list/)
        *   [Not For Profit](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/not-for-profit-list/)
        *   [Patent Law](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/patent-law-list/)
        *   [Public Safety](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/public-safety-list/)
        *   [Trade Policy](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/trade-policy-list/)
        *   [U.S. State Policy](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/us-state-policy-news-list/)
        *   [Policy & Public Interest Overview](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/)
            -----------------------------------------------------------------------------------------------------------------
            
        *   [View All Policy & Public Interest](https://www.prnewswire.com/news-releases/policy-public-interest-latest-news/policy-public-interest-latest-news-list/)
            ---------------------------------------------------------------------------------------------------------------------------------------------------------
            
*   [People & Culture](https://www.prnewswire.com/news-releases/fda-clears-first-device-to-enable-automated-insulin-dosing-for-individuals-with-type-2-diabetes-302230838.html# ""People & Culture"")
    *   *   [People & Culture](https://www.prnewswire.com/news-releases/multicultural-latest-news/)
            ---------------------------------------------------------------------------------------
            
        *   [All People & Culture](https://www.prnewswire.com/news-releases/multicultural-latest-news/multicultural-latest-news-list/)
        *   [Aboriginal, First Nations & Native American](https://www.prnewswire.com/news-releases/multicultural-latest-news/native-american-list/)
        *   [African American](https://www.prnewswire.com/news-releases/multicultural-latest-news/african-american-related-news-list/)
        *   [Asian American](https://www.prnewswire.com/news-releases/multicultural-latest-news/asian-related-news-list/)
        *   [Children](https://www.prnewswire.com/news-releases/multicultural-latest-news/children-related-news-list/)
        *   [Diversity, Equity & Inclusion](https://www.prnewswire.com/news-releases/multicultural-latest-news/diversity-equity-inclusion/)
        *   [Hispanic](https://www.prnewswire.com/news-releases/multicultural-latest-news/hispanic-oriented-news-list/)
        *   [Lesbian, Gay & Bisexual](https://www.prnewswire.com/news-releases/multicultural-latest-news/lesbian-gay-bisexual-list/)
        *   [Men's Interest](https://www.prnewswire.com/news-releases/multicultural-latest-news/mens-interest-list/)
        *   [People with Disabilities](https://www.prnewswire.com/news-releases/multicultural-latest-news/people-with-disabilities-list/)
        *   [Religion](https://www.prnewswire.com/news-releases/multicultural-latest-news/religion-list/)
        *   [Senior Citizens](https://www.prnewswire.com/news-releases/multicultural-latest-news/senior-citizens-list/)
        *   [Veterans](https://www.prnewswire.com/news-releases/multicultural-latest-news/veterans-list/)
        *   [Women](https://www.prnewswire.com/news-releases/multicultural-latest-news/women-related-news-list/)
        *   [People & Culture Overview](https://www.prnewswire.com/news-releases/multicultural-latest-news/)
            ------------------------------------------------------------------------------------------------
            
        *   [View All People & Culture](https://www.prnewswire.com/news-releases/multicultural-latest-news/multicultural-latest-news-list/)
            -------------------------------------------------------------------------------------------------------------------------------
            
        
        *   In-Language News
            
        *   [Arabic](https://www.prnewswire.com/ae/ar/news-releases/)
        *   [espa√±ol](https://www.prnewswire.com/comunicados-de-prensa/)
        *   [portugu√™s](https://www.prnewswire.com/comunicados-para-a-imprensa/)
        *   [ƒåesko](https://www.prnewswire.com/cs/tiskova-zprava/)
        *   [Danmark](https://www.prnewswire.com/da/pressemeddelelser/)
        *   [Deutschland](https://www.prnewswire.com/de/pressemitteilungen/)
        *   [Espa√±a](https://www.prnewswire.com/es/comunicados-de-prensa/)
        *   [France](https://www.prnewswire.com/fr/communiques-de-presse/)
        *   [Italia](https://www.prnewswire.com/it/comunicati-stampa/)
        *   [Nederland](https://www.prnewswire.com/nl/persberichten/)
        *   [Norge](https://www.prnewswire.com/no/pressemeldinger/)
        *   [Polska](https://www.prnewswire.com/pl/komunikat-prasowy/)
        *   [Portugal](https://www.prnewswire.com/pt/comunicados-de-imprensa/)
        *   [–†–æ—Å—Å–∏—è](https://www.prnewswire.com/ru/press-releases/)
        *   [Slovensko](https://www.prnewswire.com/sk/tlacova-sprava/)
        *   [Suomi](https://www.prnewswire.com/fi/lehdistotiedotteet/)
        *   [Sverige](https://www.prnewswire.com/sv/pressmeddelanden/)
        

*   [Overview](https://www.prnewswire.com/products/overview/ ""Overview"")
*   [Distribution by PR Newswire](https://www.prnewswire.com/pr-distribution-and-placement/ ""Distribution by PR Newswire"")
*   [Investor Relations](https://www.prnewswire.com/ir-website/ ""Investor Relations"")
*   [Guaranteed Paid Placement](https://www.prnewswire.com/guaranteed-paid-placement/ ""Guaranteed Paid Placement"")
*   [SocialBoost](https://www.prnewswire.com/socialboost/ ""SocialBoost"")
*   [All Products](https://www.prnewswire.com/products/all-products/ ""All Products"")

*   [General Inquiries](https://www.prnewswire.com/contact-us/general-inquiries/ ""General Inquiries"")
*   [Editorial Bureaus](https://www.prnewswire.com/contact-us/editorial-bureaus/ ""Editorial Bureaus"")
*   [Partnerships](https://www.prnewswire.com/contact-us/partnerships/ ""Partnerships"")
*   [Media Inquiries](https://www.prnewswire.com/contact-us/media-inquiries/ ""Media Inquiries"")
*   [Worldwide Offices](https://www.prnewswire.com/contact-us/worldwide-offices/ ""Worldwide Offices"")

*   [](https://www.prnewswire.com/news-releases/fda-clears-first-device-to-enable-automated-insulin-dosing-for-individuals-with-type-2-diabetes-302230838.html#nav-mobile)
*   [![Image 2: PR Newswire: news distribution, targeting and monitoring](https://www.prnewswire.com/content/dam/prnewswire/homepage/prn_cision_logo_mobile.png)](https://www.prnewswire.com/)

*   [Send a Release](https://portal.prnewswire.com/)
*   [](https://www.prnewswire.com/contact-us/)
*   [](javascript:void\(0\))
    *   [ALL CONTACT INFO](https://www.prnewswire.com/contact-us/)
    *   [Contact Us](https://www.prnewswire.com/contact-us/)
        
        [888-776-0942](tel:+1-888-776-0942)  
        from 8 AM - 10 PM ET
        
*   [](javascript:void\(0\))
*   [](https://www.prnewswire.com/news-releases/fda-clears-first-device-to-enable-automated-insulin-dosing-for-individuals-with-type-2-diabetes-302230838.html#)
    *    

*   [Send a Release](https://www.prnewswire.com/account/online-membership-form/)
*   [Sign Up](https://www.prnewswire.com/account/online-membership-form/)
*   [Log In](https://portal.prnewswire.com/)
*   [Resources](https://www.prnewswire.com/resources/)
*   [Blog](https://www.prnewswire.com/resources/articles)
*   [Journalists](https://prnmedia.prnewswire.com/)
*   [RSS](https://www.prnewswire.com/rss/)
*   [GDPR](https://gdpr.cision.com/)
*   [](https://twitter.com/PRNewswire)[](https://www.facebook.com/pages/PR-Newswire/26247320522)[](https://www.linkedin.com/company/pr-newswire/)

*   News in Focus
    *   [Browse All News](https://www.prnewswire.com/news-releases/)
    *   [Multimedia Gallery](https://www.prnewswire.com/news-releases/multimedia/)
    *   [Trending Topics](https://www.prnewswire.com/news-releases/latest-news-topics/)
*   Business & Money
    *   [Auto & Transportation](https://www.prnewswire.com/news-releases/automotive-transportation-latest-news/)
    *   [Business Technology](https://www.prnewswire.com/news-releases/business-technology-latest-news/)
    *   [Entertain¬≠ment & Media](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/)
    *   [Financial Services & Investing](https://www.prnewswire.com/news-releases/financial-services-latest-news/)
    *   [General Business](https://www.prnewswire.com/news-releases/general-business-latest-news/)
*   Science & Tech
    *   [Consumer Technology](https://www.prnewswire.com/news-releases/consumer-technology-latest-news/)
    *   [Energy & Natural Resources](https://www.prnewswire.com/news-releases/energy-latest-news/)
    *   [Environ¬≠ment](https://www.prnewswire.com/news-releases/environment-latest-news/)
    *   [Heavy Industry & Manufacturing](https://www.prnewswire.com/news-releases/heavy-industry-manufacturing-latest-news/)
    *   [Telecomm¬≠unications](https://www.prnewswire.com/news-releases/telecommunications-latest-news/)
*   Lifestyle & Health
    *   [Consumer Products & Retail](https://www.prnewswire.com/news-releases/consumer-products-retail-latest-news/)
    *   [Entertain¬≠ment & Media](https://www.prnewswire.com/news-releases/entertainment-media-latest-news/)
    *   [Health](https://www.prnewswire.com/news-releases/health-latest-news/)
    *   [Sports](https://www.prnewswire.com/news-releases/sports-latest-news/)
    *   [Travel](https://www.prnewswire.com/news-releases/travel-latest-news/)
*   Policy & Public Interest
    
*   People & Culture
    *   [People & Culture](https://www.prnewswire.com/news-releases/multicultural-latest-news/)
*   [Send a Release](https://www.prnewswire.com/account/online-membership-form/)
*   [Sign Up](https://www.prnewswire.com/account/online-membership-form/)
*   [Log In](https://portal.prnewswire.com/)
*   [Resources](https://www.prnewswire.com/resources/)
*   [Blog](https://www.prnewswire.com/resources/articles)
*   [Journalists](https://prnmedia.prnewswire.com/)
*   [RSS](https://www.prnewswire.com/rss/)
*   [GDPR](https://gdpr.cision.com/)
*   [](https://twitter.com/PRNewswire)[](https://www.facebook.com/pages/PR-Newswire/26247320522)[](https://www.linkedin.com/company/pr-newswire/)

*   [Overview](https://www.prnewswire.com/products/overview/ ""Overview"")
*   [Distribution by PR Newswire](https://www.prnewswire.com/pr-distribution-and-placement/ ""Distribution by PR Newswire"")
*   [Investor Relations](https://www.prnewswire.com/ir-website/ ""Investor Relations"")
*   [SocialBoost](https://www.prnewswire.com/socialboost/ ""SocialBoost"")
*   [All Products](https://www.prnewswire.com/products/all-products/ ""All Products"")
*   [Send a Release](https://www.prnewswire.com/account/online-membership-form/)
*   [Sign Up](https://www.prnewswire.com/account/online-membership-form/)
*   [Log In](https://portal.prnewswire.com/)
*   [Resources](https://www.prnewswire.com/resources/)
*   [Blog](https://www.prnewswire.com/resources/articles)
*   [Journalists](https://prnmedia.prnewswire.com/)
*   [RSS](https://www.prnewswire.com/rss/)
*   [GDPR](https://gdpr.cision.com/)
*   [](https://twitter.com/PRNewswire)[](https://www.facebook.com/pages/PR-Newswire/26247320522)[](https://www.linkedin.com/company/pr-newswire/)

*   [General Inquiries](https://www.prnewswire.com/contact-us/#general ""General Inquiries"")
*   [Editorial Bureaus](https://www.prnewswire.com/contact-us/#editorial ""Editorial Bureaus"")
*   [Partnerships](https://www.prnewswire.com/contact-us/#partnerships ""Partnerships"")
*   [Media Inquiries](https://www.prnewswire.com/contact-us/#media ""Media Inquiries"")
*   [Worldwide Offices](https://www.prnewswire.com/contact-us/worldwide-offices ""Worldwide Offices"")
*   [Send a Release](https://www.prnewswire.com/account/online-membership-form/)
*   [Sign Up](https://www.prnewswire.com/account/online-membership-form/)
*   [Log In](https://portal.prnewswire.com/)
*   [Resources](https://www.prnewswire.com/resources/)
*   [Blog](https://www.prnewswire.com/resources/articles)
*   [Journalists](https://prnmedia.prnewswire.com/)
*   [RSS](https://www.prnewswire.com/rss/)
*   [GDPR](https://gdpr.cision.com/)
*   [](https://twitter.com/PRNewswire)[](https://www.facebook.com/pages/PR-Newswire/26247320522)[](https://www.linkedin.com/company/pr-newswire/)

    

FDA Clears First Device to Enable Automated Insulin Dosing for Individuals with Type 2 Diabetes
===============================================================================================

[![Image 3: U.S. Food and Drug Administration (FDA) logo (PRNewsfoto/FDA)](https://www.prnewswire.com/news-releases/fda-clears-first-device-to-enable-automated-insulin-dosing-for-individuals-with-type-2-diabetes-302230838.html)](https://www.prnewswire.com/news-releases/fda-clears-first-device-to-enable-automated-insulin-dosing-for-individuals-with-type-2-diabetes-302230838.html#)

* * *

News provided by

[**U.S. Food and Drug Administration**](https://www.prnewswire.com/news/u.s.-food-and-drug-administration/)Aug 26, 2024, 17:20 ET

Share this article
------------------

[](javascript:;)[](javascript:;)[](javascript:;)[](javascript:;)[](javascript:;)[](javascript:;)

Share toX

![Image 4](https://www.prnewswire.com/news-releases/fda-clears-first-device-to-enable-automated-insulin-dosing-for-individuals-with-type-2-diabetes-302230838.html)

Share this article

[](javascript:;)[](javascript:;)[](javascript:;)[](javascript:;)

Share toX

![Image 5](https://www.prnewswire.com/news-releases/fda-clears-first-device-to-enable-automated-insulin-dosing-for-individuals-with-type-2-diabetes-302230838.html)

* * *

_Agency Supports Broader Access to Innovative Technology in Diabetes Management_

SILVER SPRING, Md., Aug. 26, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration expanded the indications of the Insulet SmartAdjust technology, an interoperable automated glycemic controller previously indicated for the management of type 1 diabetes in individuals two years and older, to also include management of type 2 diabetes in individuals 18 years and older. An interoperable automated glycemic controller is software that automatically adjusts insulin delivery to a person with diabetes by connecting to an alternate controller-enabled insulin pump (ACE pump) and integrated continuous glucose monitor (iCGM).

**""The FDA has long worked with the diabetes community to ensure access to additional options and flexibilities for diabetes management,"" said Michelle Tarver, M.D., Ph.D., acting director of the FDA's Center for Devices and Radiological Health. ""Automated insulin dosing technology has previously been available only for people with type 1 diabetes. Today's action helps expand access to this important diabetes management tool to millions of adults living in the U.S. with type 2 diabetes. ¬†The FDA is committed to advancing new device innovation that can improve the health and quality of life for people living with chronic diseases that require day-to-day maintenance like diabetes.""**

More than 11% of Americans are diagnosed with diabetes, a condition in which the body does not make enough or properly use the blood glucose-regulating hormone insulin. In people with type 2 diabetes, patients may take medications that can help increase insulin secretion or improve insulin sensitivity, in addition to following a healthy eating plan and physical activity. Many patients also need to use insulin therapy to keep their blood sugar in a safe range.

Previously, insulin therapy options for people with type 2 diabetes were limited to methods such as injection with a syringe, an insulin pen or an insulin pump, all of which require patients to self-administer insulin one or more times a day and check blood glucose frequently to achieve the best results. Today's clearance provides a new option that can automate many of these manual tasks, potentially reducing the burden of living with this chronic disease.

The FDA reviewed data from a clinical study in which 289 individuals 18 years and older with type 2 diabetes on insulin used the Insulet SmartAdjust technology for 13 weeks. This study enrolled a diverse group of subjects from different racial and ethnic backgrounds, with a wide range of ages, education and income levels. Study participants had varying amounts of experience with diabetes and insulin use, and many subjects were also using common non-insulin diabetes medications like GLP1 agonists. Overall, the study showed that subjects' blood sugar control improved compared to before the study and these improvements were seen across all demographic groups. There were no complications or serious adverse events related to the use of the SmartAdjust technology. Adverse events reported during the study were generally mild to moderate, and included hyperglycemia (high blood sugar), hypoglycemia (low blood sugar) and skin irritation.

The FDA reviewed the SmartAdjust technology software through the [510(k) premarket clearance pathway](https://c212.net/c/link/?t=0&l=en&o=4240582-1&h=4035831424&u=https%3A%2F%2Fwww.fda.gov%2Fmedical-devices%2Fdevice-approvals-denials-and-clearances%2F510k-clearances&a=510\(k\)+premarket+clearance+pathway). A 510(k) is a premarket submission made to the FDA to demonstrate that a new device is substantially equivalent to a legally marketed predicate device.

**Media Contact:** [Jim McKinney](mailto:james.mckinney@fda.hhs.gov), 240-328-7305  
**Consumer Inquiries**: [Email](mailto:dice@fda.hhs.gov), 888-INFO-FDA

_The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products._

SOURCE U.S. Food and Drug Administration

![Image 6](https://rt.prnewswire.com/rt.gif?NewsItemId=PH91707&Transmission_Id=202408261720PR_NEWS_USPR_____PH91707&DateId=20240826)

√ó

### Modal title

Also from this source
---------------------

[![Image 7: La FDA aprueba y autoriza vacunas actualizadas de ARNm contra el COVID-19 para mejorar la protecci√≥n contra las variantes que circulan actualmente](https://mma.prnewswire.com/media/317925/FDA_Logo.jpg?w=300)](https://www.prnewswire.com/news-releases/la-fda-aprueba-y-autoriza-vacunas-actualizadas-de-arnm-contra-el-covid-19-para-mejorar-la-proteccion-contra-las-variantes-que-circulan-actualmente-834882401.html)

[### La FDA aprueba y autoriza vacunas actualizadas de ARNm contra el COVID-19 para mejorar la protecci√≥n contra las variantes que circulan actualmente La Administraci√≥n de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en ingl√©s) aprob√≥ y otorg√≥ la autorizaci√≥n de uso de...](https://www.prnewswire.com/news-releases/la-fda-aprueba-y-autoriza-vacunas-actualizadas-de-arnm-contra-el-covid-19-para-mejorar-la-proteccion-contra-las-variantes-que-circulan-actualmente-834882401.html)

[![Image 8: FDA Roundup: August 23, 2024](https://mma.prnewswire.com/media/317925/FDA_Logo.jpg?w=300)](https://www.prnewswire.com/news-releases/fda-roundup-august-23-2024-302229743.html)

[### FDA Roundup: August 23, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a Small Entity ...](https://www.prnewswire.com/news-releases/fda-roundup-august-23-2024-302229743.html)

[More Releases From This Source](https://www.prnewswire.com/news/u.s.-food-and-drug-administration/)

Explore
-------

[![Image 9: Image1](https://www.prnewswire.com/content/dam/prnewswire/subject-and-industry-code-images/HEA.jpg)](https://www.prnewswire.com/news-releases/health-latest-news/health-care-hospitals-list/)[](https://www.prnewswire.com/news-releases/health-latest-news/health-care-hospitals-list/)[Health Care & Hospitals](https://www.prnewswire.com/news-releases/health-latest-news/health-care-hospitals-list/)

[![Image 10: Image1](https://www.prnewswire.com/content/dam/prnewswire/subject-and-industry-code-images/MTC.jpg)](https://www.prnewswire.com/news-releases/health-latest-news/medical-pharmaceuticals-list/)[](https://www.prnewswire.com/news-releases/health-latest-news/medical-pharmaceuticals-list/)[Medical Pharmaceuticals](https://www.prnewswire.com/news-releases/health-latest-news/medical-pharmaceuticals-list/)

[![Image 11: Image1](https://www.prnewswire.com/content/dam/prnewswire/subject-and-industry-code-images/PHA.jpg)](https://www.prnewswire.com/news-releases/health-latest-news/pharmaceuticals-list/)[](https://www.prnewswire.com/news-releases/health-latest-news/pharmaceuticals-list/)[Pharmaceuticals](https://www.prnewswire.com/news-releases/health-latest-news/pharmaceuticals-list/)

[![Image 12: Image1](https://www.prnewswire.com/content/dam/prnewswire/subject-and-industry-code-images/MEQ.jpg)](https://www.prnewswire.com/news-releases/health-latest-news/medical-equipment-list/)[](https://www.prnewswire.com/news-releases/health-latest-news/medical-equipment-list/)[Medical Equipment](https://www.prnewswire.com/news-releases/health-latest-news/medical-equipment-list/)

[News Releases in Similar Topics](https://www.prnewswire.com/news-releases/)

 

                  

Contact PR Newswire
-------------------

*   [Call 888-776-0942](tel:Call%20888-776-0942)  
    from 8 AM - 9 PM ET
    
*   [Chat with an Expert](javascript://Chat)

Contact Us

*   [General Inquiries](https://www.prnewswire.com/contact-us/general-inquiries/ ""General Inquiries"")
*   [Partnerships](https://www.prnewswire.com/contact-us/partnerships/ ""Partnerships"")
*   [Media Inquiries](https://www.prnewswire.com/contact-us/media-inquiries/ ""Media Inquiries"")

[](https://twitter.com/PRNewswire ""Twitter"")[](https://www.facebook.com/PR-Newswire-26247320522/ ""Facebook"")[](https://www.linkedin.com/company/pr-newswire/ ""LinkedIn"")

Products
--------

*   [For Marketers](https://www.prnewswire.com/products/marketing/ ""For Marketers"")
*   [For Public Relations](https://www.prnewswire.com/products/public-relations/ ""For Public Relations"")
*   [For IR & Compliance](https://www.prnewswire.com/products/ir-compliance/ ""For IR & Compliance"")
*   [For Agency](https://www.prnewswire.com/products/agency/ ""For Agency"")
*   [For Small Business](https://www.smallbusinesspr.com/request_information ""For Small Business"")
*   [All Products](https://www.prnewswire.com/products/all-products/ ""All Products"")

About
-----

*   [About PR Newswire](https://www.prnewswire.com/about-pr-newswire/ ""About PR Newswire"")
*   [About Cision](https://www.cision.com/us/?utm_medium=website&utm_source=prnewswire&utm_content=cishomepage&utm_campaign=prnewswire ""About Cision"")
*   [Become a Publishing Partner](https://www.prnewswire.com/contact-us/prnewswire-partners/ ""Become a Publishing Partner"")
*   [Become a Channel Partner](https://www.prnewswire.com/contact-us/become-a-partner/ ""Become a Channel Partner"")
*   [Careers](https://www.cision.com/careers/ ""Careers"")
*   [Accessibility Statement](https://www.cision.com/about/accessibility/ ""Accessibility Statement"")

Global Sites

*   [Asia](https://www.prnasia.com/ ""Asia"")
*   [APAC](https://www.prnewswire.com/apac/ ""APAC"")
*   [APAC - Traditional Chinese](https://www.prnewswire.com/apac/zh/ ""APAC - Traditional Chinese"")
*   [Brazil](https://prnewswire.com.br/ ""Brazil"")
*   [Canada](https://www.newswire.ca/ ""Canada"")
*   [Czech](https://www.prnewswire.com/cs/tiskova-zprava/ ""Czech"")
*   [Denmark](https://www.prnewswire.com/da/pressemeddelelser/ ""Denmark"")
*   [Finland](https://www.prnewswire.com/fi/lehdistotiedotteet/ ""Finland"")
*   [France](https://www.prnewswire.com/fr/communiques-de-presse/ ""France"")
*   [Germany](https://www.prnewswire.com/de/pressemitteilungen/ ""Germany"")
*   [India](https://www.prnewswire.com/in/news-releases/ ""India"")
*   [Indonesia](https://www.prnewswire.com/id/ ""Indonesia"")
*   [Israel](https://www.prnewswire.com/il/news-releases/ ""Israel"")
*   [Korea](https://www.prnewswire.com/kr/ ""Korea"")
*   [Italy](https://www.prnewswire.com/it/comunicati-stampa/ ""Italy"")
*   [Japan](https://www.prnewswire.com/jp/ ""Japan"")
*   [Mexico](https://prnewswire.com.mx/ ""Mexico"")
*   [Middle East](https://www.prnewswire.com/ae/news-releases/ ""Middle East"")
*   [Middle East - Arabic](https://www.prnewswire.com/ae/ar/news-releases/ ""Middle East - Arabic"")
*   [Netherlands](https://www.prnewswire.com/nl/persberichten/ ""Netherlands"")
*   [Norway](https://www.prnewswire.com/no/pressemeldinger/ ""Norway"")
*   [Poland](https://www.prnewswire.com/pl/komunikat-prasowy/ ""Poland"")
*   [Portugal](https://www.prnewswire.com/pt/comunicados-de-imprensa/ ""Portugal"")
*   [Russia](https://www.prnewswire.com/ru/press-releases/ ""Russia"")
*   [Slovakia](https://www.prnewswire.com/sk/tlacova-sprava/ ""Slovakia"")
*   [Spain](https://www.prnewswire.com/es/comunicados-de-prensa/ ""Spain"")
*   [Sweden](https://www.prnewswire.com/sv/pressmeddelanden/ ""Sweden"")
*   [United Kingdom](https://www.prnewswire.co.uk/ ""United Kingdom"")

My Services
-----------

*   [All New Releases](https://www.prnewswire.com/news-releases/ ""All New Releases"")
*   [Online Member Center](https://portal.prnewswire.com/Login.aspx ""Online Member Center"")
*   [ProfNet](https://profnet.prnewswire.com/ProfNetHome/What-is-Profnet.aspx ""ProfNet"")

[Contact PR Newswire](https://www.prnewswire.com/contact-us)
------------------------------------------------------------

[Products](https://www.prnewswire.com/products/overview)
--------------------------------------------------------

[About](https://prnewswire.mediaroom.com/index.php)
---------------------------------------------------

My Services

*   [All News Releases](https://www.prnewswire.com/news-releases/ ""All News Releases"")
*   [Online Member Center](https://portal.prnewswire.com/Login.aspx ""Online Member Center"")
*   [ProfNet](https://profnet.prnewswire.com/ProfNetHome/What-is-Profnet.aspx ""ProfNet"")

[PR Newswire Distribution Helpline 888-776-0942](tel:PR%20Newswire%20Distribution%20Helpline ""Contact Us"")

*   [Terms of Use](https://www.prnewswire.com/terms-of-use/ ""Terms of Use"")
*   [Privacy Policy](https://www.prnewswire.com/privacy-policy/ ""Privacy Policy"")
*   [Information Security Policy](https://www.prnewswire.com/prn-information-security-policy/ ""Information Security Policy"")
*   [Site Map](https://www.prnewswire.com/sitemap/ ""Site Map"")
*   [RSS](https://www.prnewswire.com/rss/ ""RSS"")
*   [Cookie Settings](https://www.prnewswire.com/cookie-settings/ ""Cookie Settings"")

Copyright ¬© 2024¬†[Cision](https://www.cision.com/us/?utm_medium=website&utm_source=prnewswire&utm_content=cishomepage&utm_campaign=prnewswire ""Cision"")¬†US Inc.

  [](javascript://Chat)
"
2024-08-27 06:19:00,2024-08-29 23:11:09,"üåü **Exciting News in Oncology!** üåü

I just came across an insightful article discussing the FDA's recent decision to grant **orphan drug designation** to **Opaganib** for treating **neuroblastoma**‚Äîa significant condition in pediatric oncology. This marks another important milestone for Opaganib, which previously received similar recognition for cholangiocarcinoma. As many of you know, neuroblastoma accounts for approximately 15% of all pediatric cancer-related deaths, and effective treatment options are urgently needed.

**Key Highlights from the Article:**  
- Opaganib is a first-in-class agent that selectively inhibits sphingosine kinase-2, demonstrating promising **anticancer and anti-inflammatory properties**.  
- Receiving orphan drug designation not only provides a **7-year marketing exclusivity** but also allows for potential grants, tax credits, and a faster drug development process.  
- Opaganib's versatility is remarkable‚Äîyou'll be interested to learn that it‚Äôs also in development for various indications beyond oncology, including **viral and inflammatory conditions.**  

This development is a beacon of hope for many, showing the rapid advancements in our field. The potential for Opaganib in treating not just neuroblastoma, but also a variety of other conditions, highlights the need for innovation and research in drug development.

üó£Ô∏è What are your thoughts on how orphan drug designations can facilitate research and innovation in oncology? Let‚Äôs discuss!  

#Oncology #Neuroblastoma #FDAApproval #DrugDevelopment #CancerResearch  

Read more about this significant development [here](https://www.targetedonc.com/view/fda-grants-orphan-drug-designation-to-opaganib-in-neuroblastoma).",https://medsii.azureedge.net/images/638603363484132696-66cd6f454e2a8b3bb83557de.jpg,https://www.targetedonc.com/view/fda-grants-orphan-drug-designation-to-opaganib-in-neuroblastoma,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Thumbnail image URL: https://medsii.azureedge.net/images/638603363484132696-66cd6f454e2a8b3bb83557de.jpg 

Title: FDA Grants Orphan Drug Designation to Opaganib in Neuroblastoma

URL Source: https://www.targetedonc.com/view/fda-grants-orphan-drug-designation-to-opaganib-in-neuroblastoma

Published Time: 2024-08-26T17:00:00.000Z

Markdown Content:
FDA Grants Orphan Drug Designation to Opaganib in Neuroblastoma
===============
     

[![Image 1](blob:https://www.targetedonc.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.targetedonc.com/)

NEWS

[All News](https://www.targetedonc.com/news)[FDA Briefs](https://www.targetedonc.com/fda-briefs)[Oncology Icons](https://www.targetedonc.com/oncology-icons)[Special Reports](https://www.targetedonc.com/news/special-reports)[Voices from the Field](https://www.targetedonc.com/news/voices-from-the-field)

CONFERENCES

[Conference Coverage](https://www.targetedonc.com/latest-conference)[Conference Listing](https://www.targetedonc.com/conference)[Data Dialogue with the Oncology Brothers](https://www.targetedonc.com/data-dialogue-with-the-oncology-brothers)

MEDIA

[All Videos](https://www.targetedonc.com/videos)[Case-Based Peer Perspectives](https://www.targetedonc.com/case-based-peer-perspectives)[Expert Perspective Virtual Tumor Board](https://www.targetedonc.com/expert-perspective-tumor-board)[Interviews](https://www.targetedonc.com/interviews)[Investigator Perspectives](https://www.targetedonc.com/investigator-perspectives)[Medical World News](https://www.medicalworldnews.com/)[Pivotal Practice Views with the Oncology Brothers](https://www.targetedonc.com/pivotal-practice-views-with-the-oncology-brothers)[Podcasts](https://www.targetedonc.com/podcasts)[Precision Medicine](https://www.targetedonc.com/precision-medicine)[Speaking Out](https://www.targetedonc.com/speaking-out)

PUBLICATIONS

[All Publications](https://www.targetedonc.com/publications)[Evolving Paradigms](https://www.targetedonc.com/publications/evolving-paradigms)[Peers & Perspectives in Oncology](https://www.targetedonc.com/publications/peers-perspectives-in-oncology)[Targeted Therapies in Oncology](https://www.targetedonc.com/publications/targeted-therapy-news)

[CASE-BASED ROUNDTABLE](https://www.targetedonc.com/case-based-roundtable-series)[PARTNERS](https://www.targetedonc.com/partners)

RESOURCES

[CME/CE](https://www.targetedonc.com/continuing-education)[Clinical Trials](https://www.targetedonc.com/clinical-trials)[Precision Medicine Perspectives](https://www.targetedonc.com/precision-medicine-perspectives)[Press Releases](https://www.targetedonc.com/press-releases)[Sponsored Content](https://www.targetedonc.com/sponsored)[Treatment Resources](https://www.targetedonc.com/treatment-resources)

[SUBSCRIBE](https://one.targetedonc.com/subscribe)

Choose Specialty

[BRAIN CANCER](https://www.targetedonc.com/clinical/brain)

[BREAST CANCER](https://www.targetedonc.com/clinical/breast)[BREAST CANCER](https://www.targetedonc.com/clinical/breast)

[GENITOURINARY CANCERS](https://www.targetedonc.com/clinical/genitourinary)[GENITOURINARY CANCERS](https://www.targetedonc.com/clinical/genitourinary)[GENITOURINARY CANCERS](https://www.targetedonc.com/clinical/genitourinary)[GENITOURINARY CANCERS](https://www.targetedonc.com/clinical/genitourinary)

[GENOMIC TESTING](https://www.targetedonc.com/clinical/genomic-testing)[GENOMIC TESTING](https://www.targetedonc.com/clinical/genomic-testing)

[GI CANCERS](https://www.targetedonc.com/clinical/gastrointestinal)[GI CANCERS](https://www.targetedonc.com/clinical/gastrointestinal)[GI CANCERS](https://www.targetedonc.com/clinical/gastrointestinal)[GI CANCERS](https://www.targetedonc.com/clinical/gastrointestinal)[GI CANCERS](https://www.targetedonc.com/clinical/gastrointestinal)

[GYNECOLOGIC CANCERS](https://www.targetedonc.com/clinical/gynecologic)[GYNECOLOGIC CANCERS](https://www.targetedonc.com/clinical/gynecologic)[GYNECOLOGIC CANCERS](https://www.targetedonc.com/clinical/gynecologic)[GYNECOLOGIC CANCERS](https://www.targetedonc.com/clinical/gynecologic)

[HEAD & NECK CANCERS](https://www.targetedonc.com/clinical/head-and-neck)

[HEMATOLOGY](https://www.targetedonc.com/clinical/hematology)[HEMATOLOGY](https://www.targetedonc.com/clinical/hematology)

[IMMUNOTHERAPY](https://www.targetedonc.com/clinical/immunotherapy)[IMMUNOTHERAPY](https://www.targetedonc.com/clinical/immunotherapy)

[LEUKEMIAS](https://www.targetedonc.com/clinical/leukemias)[LEUKEMIAS](https://www.targetedonc.com/clinical/leukemias)[LEUKEMIAS](https://www.targetedonc.com/clinical/leukemias)[LEUKEMIAS](https://www.targetedonc.com/clinical/leukemias)

[LUNG CANCER](https://www.targetedonc.com/clinical/lung)[LUNG CANCER](https://www.targetedonc.com/clinical/lung)[LUNG CANCER](https://www.targetedonc.com/clinical/lung)[LUNG CANCER](https://www.targetedonc.com/clinical/lung)[LUNG CANCER](https://www.targetedonc.com/clinical/lung)

[LYMPHOMAS](https://www.targetedonc.com/clinical/lymphoma)[LYMPHOMAS](https://www.targetedonc.com/clinical/lymphoma)[LYMPHOMAS](https://www.targetedonc.com/clinical/lymphoma)[LYMPHOMAS](https://www.targetedonc.com/clinical/lymphoma)

[MPNs](https://www.targetedonc.com/clinical/mpn)

[MULTIPLE MYELOMA](https://www.targetedonc.com/clinical/multiple-myeloma-rc)

[NTRK GENE FUSIONS](https://www.targetedonc.com/clinical/ntrk)

[SARCOMA](https://www.targetedonc.com/clinical/sarcoma)

[SKIN CANCERS](https://www.targetedonc.com/clinical/skin-cancers)[SKIN CANCERS](https://www.targetedonc.com/clinical/skin-cancers)

[THYROID CANCERS](https://www.targetedonc.com/clinical/thyroid)

Spotlight -

*   [Biomarker-Driven Lung Cancer](https://www.targetedonc.com/clinical/biomarker-lung-cancer)
*   [GIST](https://www.targetedonc.com/clinical/gist)
*   [HER2 Breast Cancer](https://www.targetedonc.com/clinical/her2-positive)
*   [Chronic Lymphocytic Leukemia](https://www.targetedonc.com/clinical/cll)
*   [Small Cell Lung Cancer](https://www.targetedonc.com/clinical/small-cell-lung-cancer)
*   [Renal Cell Carcinoma](https://www.targetedonc.com/clinical/rcc)

[![Image 3](blob:https://www.targetedonc.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.targetedonc.com/)

[](https://www.targetedonc.com/search)

Choose Specialty

[BRAIN CANCER](https://www.targetedonc.com/clinical/brain)

[BREAST CANCER](https://www.targetedonc.com/clinical/breast)[BREAST CANCER](https://www.targetedonc.com/clinical/breast)

[GENITOURINARY CANCERS](https://www.targetedonc.com/clinical/genitourinary)[GENITOURINARY CANCERS](https://www.targetedonc.com/clinical/genitourinary)[GENITOURINARY CANCERS](https://www.targetedonc.com/clinical/genitourinary)[GENITOURINARY CANCERS](https://www.targetedonc.com/clinical/genitourinary)

[GENOMIC TESTING](https://www.targetedonc.com/clinical/genomic-testing)[GENOMIC TESTING](https://www.targetedonc.com/clinical/genomic-testing)

[GI CANCERS](https://www.targetedonc.com/clinical/gastrointestinal)[GI CANCERS](https://www.targetedonc.com/clinical/gastrointestinal)[GI CANCERS](https://www.targetedonc.com/clinical/gastrointestinal)[GI CANCERS](https://www.targetedonc.com/clinical/gastrointestinal)[GI CANCERS](https://www.targetedonc.com/clinical/gastrointestinal)

[GYNECOLOGIC CANCERS](https://www.targetedonc.com/clinical/gynecologic)[GYNECOLOGIC CANCERS](https://www.targetedonc.com/clinical/gynecologic)[GYNECOLOGIC CANCERS](https://www.targetedonc.com/clinical/gynecologic)[GYNECOLOGIC CANCERS](https://www.targetedonc.com/clinical/gynecologic)

[HEAD & NECK CANCERS](https://www.targetedonc.com/clinical/head-and-neck)

[HEMATOLOGY](https://www.targetedonc.com/clinical/hematology)[HEMATOLOGY](https://www.targetedonc.com/clinical/hematology)

[IMMUNOTHERAPY](https://www.targetedonc.com/clinical/immunotherapy)[IMMUNOTHERAPY](https://www.targetedonc.com/clinical/immunotherapy)

[LEUKEMIAS](https://www.targetedonc.com/clinical/leukemias)[LEUKEMIAS](https://www.targetedonc.com/clinical/leukemias)[LEUKEMIAS](https://www.targetedonc.com/clinical/leukemias)[LEUKEMIAS](https://www.targetedonc.com/clinical/leukemias)

[LUNG CANCER](https://www.targetedonc.com/clinical/lung)[LUNG CANCER](https://www.targetedonc.com/clinical/lung)[LUNG CANCER](https://www.targetedonc.com/clinical/lung)[LUNG CANCER](https://www.targetedonc.com/clinical/lung)[LUNG CANCER](https://www.targetedonc.com/clinical/lung)

[LYMPHOMAS](https://www.targetedonc.com/clinical/lymphoma)[LYMPHOMAS](https://www.targetedonc.com/clinical/lymphoma)[LYMPHOMAS](https://www.targetedonc.com/clinical/lymphoma)[LYMPHOMAS](https://www.targetedonc.com/clinical/lymphoma)

[MPNs](https://www.targetedonc.com/clinical/mpn)

[MULTIPLE MYELOMA](https://www.targetedonc.com/clinical/multiple-myeloma-rc)

[NTRK GENE FUSIONS](https://www.targetedonc.com/clinical/ntrk)

[SARCOMA](https://www.targetedonc.com/clinical/sarcoma)

[SKIN CANCERS](https://www.targetedonc.com/clinical/skin-cancers)[SKIN CANCERS](https://www.targetedonc.com/clinical/skin-cancers)

[THYROID CANCERS](https://www.targetedonc.com/clinical/thyroid)

![Image 5](blob:https://www.targetedonc.com/b9a31d3949b1882a09ed2f8508d538f3)

*   *   Spotlight
        
    *   NEWS
        
    *   CONFERENCES
        
    *   MEDIA
        
    *   PUBLICATIONS
        
    *   [CASE-BASED ROUNDTABLE](https://www.targetedonc.com/case-based-roundtable-series)
    *   [PARTNERS](https://www.targetedonc.com/partners)
    *   RESOURCES
        
    *   [SUBSCRIBE](https://one.targetedonc.com/subscribe)

[](https://www.facebook.com/TargetedOnc/)[](https://www.linkedin.com/company/targetedonc/)[](https://twitter.com/TargetedOnc)[](https://www.youtube.com/user/TargetedHC)[](https://www.instagram.com/targetedoncology/)

Advertisement

* * *

FDA Grants Orphan Drug Designation to Opaganib in Neuroblastoma
===============================================================

August 26, 2024

By [Jordyn Sava](https://www.targetedonc.com/authors/jordyn-sava)

Fact checked by [Sabrina Serani](https://www.targetedonc.com/authors/sabrina-serani)

_News_

_Article_

[![Image 7](blob:https://www.targetedonc.com/f6cdf65888993e359197e9eb41170dc1)![Image 8](blob:https://www.targetedonc.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.targetedonc.com/fda-briefs/august-2024-brief)

The FDA has granted a second orphan drug designation to opaganib in oncology, this time for patients with neuroblastoma.

![Image 10](blob:https://www.targetedonc.com/9951d11e08f484b4870c23fb17850348)![Image 11: FDA logo](blob:https://www.targetedonc.com/b9a31d3949b1882a09ed2f8508d538f3)

![Image 13](https://cdn.sanity.io/images/0vv8moc6/targetedonc/24e1a3e28ed11ccef2cf01e1295bd3bc63c9a971-480x270.jpg?fit=crop&auto=format)

*   **The FDA has granted an orphan drug designation to opaganib (Yeliva, ABC294640) for the treatment of patients with neuroblastoma.**
*   **Neuroblastoma develops from immature nerve cells and makes up 15% of all pediatric cancer-related deaths.**
*   **Opaganib has now received 2 orphan drug designations by the FDA, with the first being for cholangiocarcinoma treatment.**

Opaganib has gained FDA orphan drug designation for the treatment of patients with neuroblastoma, a pediatric malignancy arising from neuroblasts, immature neural crest cells.1

If opaganib is approved in neuroblastoma, this orphan drug designation offers a 7-year marketing exclusivity period. This also leads to additional benefits, including accelerated development and review times, potential grant funding, and possible tax credits.

""RedHill is proud to have received a second orphan drug designation for opaganib in oncology, following its previous designation for cholangiocarcinoma. This designation for neuroblastoma‚Äìthe most common infancy malignancy and for which new options are urgently needed‚Äìadds to opaganib's potential as a novel oncological agent,"" said Mark Levitt, MD, PhD, chief scientific officer at RedHill, in a press release.

![Image 14](blob:https://www.targetedonc.com/c8fb446aa1b2fd46571497c8087da7b5)![Image 15: Cancer cells with pink bubbles: ¬© Adobe Contributor - stock.adobe.com](blob:https://www.targetedonc.com/b9a31d3949b1882a09ed2f8508d538f3)

Cancer cells with pink bubbles: ¬© Adobe Contributor - stock.adobe.com

![Image 17](https://cdn.sanity.io/images/0vv8moc6/targetedonc/d919498c83b0c0c325b0e19aa3c715dab383aee3-3072x3072.jpg?fit=crop&auto=format)

Neuroblastoma is the most common extracranial solid tumor in children, accounting for approximately 15% of pediatric cancer-related deaths. While it typically affects children aged 5 or younger, it can also occur in older children. Approximately 650 new cases of neuroblastoma are diagnosed in the US each year, and general treatment strategies include a combination of surgery, chemotherapy, radiation therapy, and sometimes targeted therapy or immunotherapy.

Opaganib is a proprietary, investigational, host-directed, and potentially broad-acting drug. The first-in-class agent is administered orally and is a sphingosine kinase-2 selective inhibitor with anticancer, anti-inflammatory, and antiviral activity. Preclinically, opaganib has shown positive results for the treatment of renal fibrosis. It also shows the ability to potentially target multiple oncology, radioprotection, viral, inflammatory, and gastrointestinal indications.

The agent is currently in development for the treatment of multiple diseases, including obesity-related syndromes, prostate cancer, cholangiocarcinoma, gastrointestinal acute radiation syndrome, Sulfur Mustard exposure, COVID-19, Ebola, and more.2

Opaganib has undergone studies in advanced cholangiocarcinoma and prostate cancer. The phase 2a clinical study (NCT03377179) of opaganib in patients with advanced, unresectable cholangiocarcinoma led to it being granted its first orphan drug designation from the FDA.

An investigator-sponsored phase 2 study (NCT04207255) evaluating opaganib in patients with prostate cancer has also completed enrollment. Patient follow-up for this study is ongoing at the Medical University of South Carolina Hollings Cancer Center and Emory University.

A phase 1 chemoradiotherapy study protocol is also ready for FDA investigational new drug submission.1

""Opaganib has broad oncology potential with promising preliminary clinical data in solid tumor cancers such as prostate cancer and \[cholangiocarcinoma\], and data from a range of US government supported and Apogee-conducted preclinical studies in various indications, including radioprotection, and also in combination with RedHill's RHB-107. We also see such utility extending to the potential for opaganib to have a sensitizing effect in hormone receptor pathway inhibition therapy, which the Company expects to test in a planned externally funded phase 2 study,"" added Levitt in the press release.

###### REFERENCES:

###### 1\. RedHill's opaganib granted orphan drug designation by the FDA for childhood cancer, neuroblastoma. News release. RedHill Biopharma Ltd. August 26, 2024. AccessedAugust 26, 2024. [https://tinyurl.com/3j3snf8v](https://tinyurl.com/3j3snf8v)

###### 2\. Pipeline. RedHill Biopharma Ltd. Accessed August 26, 2024. [https://www.redhillbio.com/our-programs/pipeline/opaganib/default.aspx](https://www.redhillbio.com/our-programs/pipeline/opaganib/default.aspx)

Related Content

Advertisement

* * *

[![Image 18: FDA‚ÄôS ODAC to Discuss PD-L1 Levels for ICIs in Gastric and Esophageal Cancers](blob:https://www.targetedonc.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.targetedonc.com/view/fda-s-odac-to-discuss-pd-l1-levels-for-icis-in-gastric-and-esophageal-cancers?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[FDA‚ÄôS ODAC to Discuss PD-L1 Levels for ICIs in Gastric and Esophageal Cancers](https://www.targetedonc.com/view/fda-s-odac-to-discuss-pd-l1-levels-for-icis-in-gastric-and-esophageal-cancers?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[Sabrina Serani](https://www.targetedonc.com/authors/sabrina-serani)

[August 27th 2024 Article The FDA‚Äôs Oncologic Drug Advisory Committee will meet on September 26, 2024, to discuss PD-L1 cutoffs for immune checkpoint inhibitors in gastric, gastroesophageal, and esophageal cancers.](https://www.targetedonc.com/view/fda-s-odac-to-discuss-pd-l1-levels-for-icis-in-gastric-and-esophageal-cancers?utm_source=www.targetedonc.com&utm_medium=relatedContent)[Read More](https://www.targetedonc.com/view/fda-s-odac-to-discuss-pd-l1-levels-for-icis-in-gastric-and-esophageal-cancers)

* * *

[![Image 20: Novel BTK Degrader Earns FDA Fast Track Designation in CLL/SLL](blob:https://www.targetedonc.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.targetedonc.com/view/novel-btk-degrader-earns-fda-fast-track-designation-in-cll-sll?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[Novel BTK Degrader Earns FDA Fast Track Designation in CLL/SLL](https://www.targetedonc.com/view/novel-btk-degrader-earns-fda-fast-track-designation-in-cll-sll?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[Sabrina Serani](https://www.targetedonc.com/authors/sabrina-serani)

[August 26th 2024 Article BGB-16673 has been granted FDA fast track designation based on findings from a phase 1/2 study of the oral agent in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.](https://www.targetedonc.com/view/novel-btk-degrader-earns-fda-fast-track-designation-in-cll-sll?utm_source=www.targetedonc.com&utm_medium=relatedContent)[Read More](https://www.targetedonc.com/view/novel-btk-degrader-earns-fda-fast-track-designation-in-cll-sll)

* * *

[![Image 22: APG-157 Earns FDA Fast Track Designation for Head and Neck Cancer Treatment](blob:https://www.targetedonc.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.targetedonc.com/view/apg-157-earns-fda-fast-track-designation-for-head-and-neck-cancer-treatment?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[APG-157 Earns FDA Fast Track Designation for Head and Neck Cancer Treatment](https://www.targetedonc.com/view/apg-157-earns-fda-fast-track-designation-for-head-and-neck-cancer-treatment?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[Sabrina Serani](https://www.targetedonc.com/authors/sabrina-serani)

[August 23rd 2024 Article With this designation, the sponsor of APG-157 is eligible for more frequent interaction with the FDA, facilitating faster drug development and review for this neoadjuvant head and neck cancer therapy.](https://www.targetedonc.com/view/apg-157-earns-fda-fast-track-designation-for-head-and-neck-cancer-treatment?utm_source=www.targetedonc.com&utm_medium=relatedContent)[Read More](https://www.targetedonc.com/view/apg-157-earns-fda-fast-track-designation-for-head-and-neck-cancer-treatment)

* * *

[![Image 24: FDA Fast Tracks 64Cu-SAR-bisPSMA for Prostate Cancer Imaging](blob:https://www.targetedonc.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.targetedonc.com/view/fda-fast-tracks-64cu-sar-bispsma-for-prostate-cancer-imaging?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[FDA Fast Tracks 64Cu-SAR-bisPSMA for Prostate Cancer Imaging](https://www.targetedonc.com/view/fda-fast-tracks-64cu-sar-bispsma-for-prostate-cancer-imaging?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[Jordyn Sava](https://www.targetedonc.com/authors/jordyn-sava)

[August 22nd 2024 Article 64Cu-SAR-bisPSMA gained FDA fast track status for advanced prostate cancer imaging.](https://www.targetedonc.com/view/fda-fast-tracks-64cu-sar-bispsma-for-prostate-cancer-imaging?utm_source=www.targetedonc.com&utm_medium=relatedContent)[Read More](https://www.targetedonc.com/view/fda-fast-tracks-64cu-sar-bispsma-for-prostate-cancer-imaging)

* * *

[![Image 26: FDA Issues Complete Response Letter for Linvoseltamab BLA in RRMM](blob:https://www.targetedonc.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.targetedonc.com/view/fda-issues-complete-response-letter-for-linvoseltamab-bla-in-rrmm?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[FDA Issues Complete Response Letter for Linvoseltamab BLA in RRMM](https://www.targetedonc.com/view/fda-issues-complete-response-letter-for-linvoseltamab-bla-in-rrmm?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[Jordyn Sava](https://www.targetedonc.com/authors/jordyn-sava)

[August 21st 2024 Article The FDA issued a complete response letter for linvoseltamab aimed at treating relapsed/refractory multiple myeloma post multiple therapies.](https://www.targetedonc.com/view/fda-issues-complete-response-letter-for-linvoseltamab-bla-in-rrmm?utm_source=www.targetedonc.com&utm_medium=relatedContent)[Read More](https://www.targetedonc.com/view/fda-issues-complete-response-letter-for-linvoseltamab-bla-in-rrmm)

* * *

[![Image 28: FDA Accepts Nivolumab/Ipilimumab Application for First-Line HCC Treatment](blob:https://www.targetedonc.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.targetedonc.com/view/fda-accepts-nivolumab-ipilimumab-application-for-first-line-hcc-treatment?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[FDA Accepts Nivolumab/Ipilimumab Application for First-Line HCC Treatment](https://www.targetedonc.com/view/fda-accepts-nivolumab-ipilimumab-application-for-first-line-hcc-treatment?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[Sabrina Serani](https://www.targetedonc.com/authors/sabrina-serani)

[August 21st 2024 Article The application is supported by the phase 3 CheckMate -9DW study, and the FDA has set a target action date of April 21, 2025.](https://www.targetedonc.com/view/fda-accepts-nivolumab-ipilimumab-application-for-first-line-hcc-treatment?utm_source=www.targetedonc.com&utm_medium=relatedContent)[Read More](https://www.targetedonc.com/view/fda-accepts-nivolumab-ipilimumab-application-for-first-line-hcc-treatment)

Related Content

Advertisement

* * *

[![Image 30: FDA‚ÄôS ODAC to Discuss PD-L1 Levels for ICIs in Gastric and Esophageal Cancers](blob:https://www.targetedonc.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.targetedonc.com/view/fda-s-odac-to-discuss-pd-l1-levels-for-icis-in-gastric-and-esophageal-cancers?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[FDA‚ÄôS ODAC to Discuss PD-L1 Levels for ICIs in Gastric and Esophageal Cancers](https://www.targetedonc.com/view/fda-s-odac-to-discuss-pd-l1-levels-for-icis-in-gastric-and-esophageal-cancers?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[Sabrina Serani](https://www.targetedonc.com/authors/sabrina-serani)

[August 27th 2024 Article The FDA‚Äôs Oncologic Drug Advisory Committee will meet on September 26, 2024, to discuss PD-L1 cutoffs for immune checkpoint inhibitors in gastric, gastroesophageal, and esophageal cancers.](https://www.targetedonc.com/view/fda-s-odac-to-discuss-pd-l1-levels-for-icis-in-gastric-and-esophageal-cancers?utm_source=www.targetedonc.com&utm_medium=relatedContent)[Read More](https://www.targetedonc.com/view/fda-s-odac-to-discuss-pd-l1-levels-for-icis-in-gastric-and-esophageal-cancers)

* * *

[![Image 32: Novel BTK Degrader Earns FDA Fast Track Designation in CLL/SLL](blob:https://www.targetedonc.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.targetedonc.com/view/novel-btk-degrader-earns-fda-fast-track-designation-in-cll-sll?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[Novel BTK Degrader Earns FDA Fast Track Designation in CLL/SLL](https://www.targetedonc.com/view/novel-btk-degrader-earns-fda-fast-track-designation-in-cll-sll?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[Sabrina Serani](https://www.targetedonc.com/authors/sabrina-serani)

[August 26th 2024 Article BGB-16673 has been granted FDA fast track designation based on findings from a phase 1/2 study of the oral agent in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.](https://www.targetedonc.com/view/novel-btk-degrader-earns-fda-fast-track-designation-in-cll-sll?utm_source=www.targetedonc.com&utm_medium=relatedContent)[Read More](https://www.targetedonc.com/view/novel-btk-degrader-earns-fda-fast-track-designation-in-cll-sll)

* * *

[![Image 34: APG-157 Earns FDA Fast Track Designation for Head and Neck Cancer Treatment](blob:https://www.targetedonc.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.targetedonc.com/view/apg-157-earns-fda-fast-track-designation-for-head-and-neck-cancer-treatment?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[APG-157 Earns FDA Fast Track Designation for Head and Neck Cancer Treatment](https://www.targetedonc.com/view/apg-157-earns-fda-fast-track-designation-for-head-and-neck-cancer-treatment?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[Sabrina Serani](https://www.targetedonc.com/authors/sabrina-serani)

[August 23rd 2024 Article With this designation, the sponsor of APG-157 is eligible for more frequent interaction with the FDA, facilitating faster drug development and review for this neoadjuvant head and neck cancer therapy.](https://www.targetedonc.com/view/apg-157-earns-fda-fast-track-designation-for-head-and-neck-cancer-treatment?utm_source=www.targetedonc.com&utm_medium=relatedContent)[Read More](https://www.targetedonc.com/view/apg-157-earns-fda-fast-track-designation-for-head-and-neck-cancer-treatment)

* * *

[![Image 36: FDA Fast Tracks 64Cu-SAR-bisPSMA for Prostate Cancer Imaging](blob:https://www.targetedonc.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.targetedonc.com/view/fda-fast-tracks-64cu-sar-bispsma-for-prostate-cancer-imaging?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[FDA Fast Tracks 64Cu-SAR-bisPSMA for Prostate Cancer Imaging](https://www.targetedonc.com/view/fda-fast-tracks-64cu-sar-bispsma-for-prostate-cancer-imaging?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[Jordyn Sava](https://www.targetedonc.com/authors/jordyn-sava)

[August 22nd 2024 Article 64Cu-SAR-bisPSMA gained FDA fast track status for advanced prostate cancer imaging.](https://www.targetedonc.com/view/fda-fast-tracks-64cu-sar-bispsma-for-prostate-cancer-imaging?utm_source=www.targetedonc.com&utm_medium=relatedContent)[Read More](https://www.targetedonc.com/view/fda-fast-tracks-64cu-sar-bispsma-for-prostate-cancer-imaging)

* * *

[![Image 38: FDA Issues Complete Response Letter for Linvoseltamab BLA in RRMM](blob:https://www.targetedonc.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.targetedonc.com/view/fda-issues-complete-response-letter-for-linvoseltamab-bla-in-rrmm?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[FDA Issues Complete Response Letter for Linvoseltamab BLA in RRMM](https://www.targetedonc.com/view/fda-issues-complete-response-letter-for-linvoseltamab-bla-in-rrmm?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[Jordyn Sava](https://www.targetedonc.com/authors/jordyn-sava)

[August 21st 2024 Article The FDA issued a complete response letter for linvoseltamab aimed at treating relapsed/refractory multiple myeloma post multiple therapies.](https://www.targetedonc.com/view/fda-issues-complete-response-letter-for-linvoseltamab-bla-in-rrmm?utm_source=www.targetedonc.com&utm_medium=relatedContent)[Read More](https://www.targetedonc.com/view/fda-issues-complete-response-letter-for-linvoseltamab-bla-in-rrmm)

* * *

[![Image 40: FDA Accepts Nivolumab/Ipilimumab Application for First-Line HCC Treatment](blob:https://www.targetedonc.com/b9a31d3949b1882a09ed2f8508d538f3)](https://www.targetedonc.com/view/fda-accepts-nivolumab-ipilimumab-application-for-first-line-hcc-treatment?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[FDA Accepts Nivolumab/Ipilimumab Application for First-Line HCC Treatment](https://www.targetedonc.com/view/fda-accepts-nivolumab-ipilimumab-application-for-first-line-hcc-treatment?utm_source=www.targetedonc.com&utm_medium=relatedContent)

[Sabrina Serani](https://www.targetedonc.com/authors/sabrina-serani)

[August 21st 2024 Article The application is supported by the phase 3 CheckMate -9DW study, and the FDA has set a target action date of April 21, 2025.](https://www.targetedonc.com/view/fda-accepts-nivolumab-ipilimumab-application-for-first-line-hcc-treatment?utm_source=www.targetedonc.com&utm_medium=relatedContent)[Read More](https://www.targetedonc.com/view/fda-accepts-nivolumab-ipilimumab-application-for-first-line-hcc-treatment)

[About Us](https://www.targetedonc.com/about)

[Advertise](https://www.targetedonc.com/advertise)

[Contact Us](https://www.targetedonc.com/contactus)

[CureToday.com](https://www.curetoday.com/)

[CancerNetwork.com](https://www.cancernetwork.com/)

[OncLive.com](https://www.onclive.com/)

[OncNursingNews.com](https://www.oncnursingnews.com/)

[Do Not Sell My Information](https://www.mjhlifesciences.com/ccpa?domain=www.targetedonc.com)

[Privacy](https://www.targetedonc.com/privacy)

[Terms & Conditions](https://www.targetedonc.com/terms)

Contact Info

2 Commerce Drive  
Cranbury, NJ 08512

[609-716-7777](tel:609-716-7777)

![Image 42](blob:https://www.targetedonc.com/0b56f675ecfd870f746e03cb2a00669b)![Image 43](blob:https://www.targetedonc.com/b9a31d3949b1882a09ed2f8508d538f3)

[](https://www.facebook.com/TargetedOnc/)[](https://www.linkedin.com/company/targetedonc/)[](https://twitter.com/TargetedOnc)[](https://www.youtube.com/user/TargetedHC)[](https://www.instagram.com/targetedoncology/)

¬© 2024 MJH Life Sciences  
  
All rights reserved.
"
2024-08-26 06:50:00,2024-08-29 23:11:42,"ü¶ª Have you ever wondered if our tools for examining the ear are due for an upgrade? It's fascinating to see how medical technology evolves in our field! A recent article by Kim et al. explores a groundbreaking optical coherence tomography (OCT) otoscope that could significantly enhance how we diagnose middle ear pathologies. 

The key takeaway is that traditional otoscopy has remained largely unchanged for over a century, primarily offering two-dimensional views of the tympanic membrane. The new hand-held OCT device provides a three-dimensional perspective, enabling healthcare professionals to visualize structures with improved clarity. This innovation aims to diagnosis conditions like otitis media more accurately and efficiently.

Practical applications of this technology are incredibly promising. For instance, the ability to differentiate between cholesteatoma and other inflammatory tissues can guide treatment decisions and ultimately enhance patient outcomes. Moreover, the portability and affordability of this device compared to traditional imaging methods make it a viable option for busy clinical settings.

As we embrace these advancements, I encourage you to think about how this could impact your practice. How important is it to you to have access to such detailed imaging during ear examinations? Let‚Äôs discuss! 

#OCT #EarHealth #MedicalTechnology #Audiology #HealthcareInnovation  
Source: [Optical coherence tomography otoscope for imaging of tympanic membrane and middle ear pathology](http://dx.doi.org/10.1117/1.JBO.29.8.086005)",https://medsii.azureedge.net/images/638602518445448489-66cc249d6157181811bbc729.jpg,http://dx.doi.org/10.1117/1.JBO.29.8.086005,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Thumbnail image URL: https://medsii.azureedge.net/images/638602518445448489-66cc249d6157181811bbc729.jpg 

Title: Optical coherence tomography otoscope for imaging of tympanic membrane and middle ear pathology

URL Source: http://dx.doi.org/10.1117/1.JBO.29.8.086005

Markdown Content:
1.
--

Introduction
------------

The way in which physicians view the tympanic membrane (TM) and middle ear in the clinic has not changed much over the last 150 years. A speculum is placed into the ear canal with lens-aided viewing and illumination through the aperture of the speculum. The most common speculum used today was invented by A. Hartmann in Berlin in 1881.[1](https://www.spiedigitallibrary.org/#r1) Since then, illumination and optics have improved but little else has changed other than the addition of a digital camera for video otoscopy. Routine otoscopic imaging yields information on the surface of the TM, but with no depth perception because only a monocular view can be obtained. If the membrane is transparent, the ossicles just below may be discerned and used as a reference for TM depth. However, no quantitative three-dimensional image is possible, and in many pathological cases the TM is opaque, preventing visualization of the ossicular chain. Subjective interpretation varies with physician experience[2](https://www.spiedigitallibrary.org/#r2),[3](https://www.spiedigitallibrary.org/#r3) and can lead to incorrect or delayed diagnosis. For example, the United States pediatrician rate of successful otitis media diagnosis is 51% with a false positive rate of 26% as the diagnosis is mostly based on clinical presentation.[4](https://www.spiedigitallibrary.org/#r4) Modern medical imaging approaches such as MRI and CT are only sparingly utilized because they are expensive, require a second visit by the patient, and only yield relatively poorly resolved images of the tympanic membrane and middle ear.

Pathologies of the middle ear are composed of a heterogeneous group of diseases that pose a significant risk of hearing loss, facial nerve paralysis, and other serious complications due to their impact on important middle ear and surrounding structures.[5](https://www.spiedigitallibrary.org/#r5) Some of the more common diseases include otitis media and cholesteatomas, with an estimated 80% of children by age 3 having one or more episodes of otitis media and an annual incidence of acquired cholesteatomas being 9 to 12.6 per 100,000 people.[6](https://www.spiedigitallibrary.org/#r6),[7](https://www.spiedigitallibrary.org/#r7) Less common pathologies include more insidious neoplastic middle ear lesions (e.g., facial neuromas, glomus tumors).[8](https://www.spiedigitallibrary.org/#r8),[9](https://www.spiedigitallibrary.org/#r9) Together, they are major contributors to the over 430¬†million people globally to have acquired disabling hearing impairment (\>35 to 40¬†dBA for adult and \>30‚Äâ‚ÄâdBA for children unaided hearing threshold level).[10](https://www.spiedigitallibrary.org/#r10),[11](https://www.spiedigitallibrary.org/#r11) The accurate diagnosis of these diseases requires clinicians to pay close attention to subtle changes in normal physiology that are sometimes missed or cannot be detected with existing diagnostic imaging without direct surgical confirmation.[12](https://www.spiedigitallibrary.org/#r12),[13](https://www.spiedigitallibrary.org/#r13)

Optical coherence tomography (OCT), an interferometry-based non-invasive imaging modality that provides 3D morphological images by capturing the back-scattered light as a laser scan across the biological tissues of interest, is currently being explored as a potential tool to fill the gap in anticipatory diagnostic imaging of the ear by providing structural and functional information not available from traditional diagnostic methods.[14](https://www.spiedigitallibrary.org/#r14) It has already been used to help better characterize and diagnose various pathologies of the middle ear and TM.[15](https://www.spiedigitallibrary.org/#r15) It has been used to diagnose chronic and acute otitis media with effusion with greater accuracy than traditional otoscopes,[16](https://www.spiedigitallibrary.org/#r16) intraoperatively characterize sclerotic changes in patients with otosclerosis,[17](https://www.spiedigitallibrary.org/#r17) and differentiate between cholesteatoma and inflammatory tissue.[18](https://www.spiedigitallibrary.org/#r18) OCT has also been used to characterize the severity of pathological changes in the TM from diseases that affect the TM such as myringitis.[19](https://www.spiedigitallibrary.org/#r19) In addition, compared with traditional imaging modalities, such as MRI and CT, OCT is less expensive, more portable, does not involve ionizing radiation, and has better resolution, traits that make it advantageous as a diagnostic imaging tool for middle ear pathologies in a busy clinical setting.[20](https://www.spiedigitallibrary.org/#r20),[21](https://www.spiedigitallibrary.org/#r21)

We have designed a hand-held OCT otoscope with a wide field of view that is capable of imaging nearly the entire tympanic membrane and middle ear down to the cochlear promontory.[22](https://www.spiedigitallibrary.org/#r22) The integrated fiber-optic interferometer has a similar performance to our prior free-space approach with demonstrated sub-nanometer sensitivity to vibration.[23](https://www.spiedigitallibrary.org/#r23) This system, with high performance and a small form factor, is well suited for use in the clinic. In this study, we demonstrate the clinical utility of our device to characterize a variety of middle ear pathologies in a large population of clinic patients. In addition, we present cases in which our device was able to provide information not able to be obtained using traditional imaging techniques. The findings of this study further support the merit of OCT as a clinical diagnostic tool that provides clinicians with information to aid in the early detection and management of various middle ear pathologies.

2.
--

Method
------

2.1.
----

### OCT Otoscope System

Conceptually, the hand-held OCT (HHOCT) clinical system design (see [Fig. 1](https://www.spiedigitallibrary.org/#f1)) follows our previous study that reported the otoscopic OCT system.[22](https://www.spiedigitallibrary.org/#r22) It is comprised of several components: the hand-held imaging probe, an endoscopy cart, and a wireless foot pedal serving as an input assist device. The system employed a swept laser with a center wavelength of 1310¬†nm and a 39¬†nm bandwidth, yielding an axial resolution of 33.4‚Äâ‚ÄâŒºm (in tissue, n\=1.3) for OCT imaging, which is sufficient for resolving the human middle ear structures.[24](https://www.spiedigitallibrary.org/#r24)

Fig.¬†1
------

System configuration (a)¬†schematic diagram. Abbreviations: 90:10¬†fc, 90:10 fiber fused coupler; Circ, fiber optic circulator; cL, collimating lens; MEMS, MEMS scan mirror; DM, dichroic mirror; ILL, illuminator; OBJL, objective lens; MESPL, middle ear speculum; EC, ear canal; ML, malleus; IN, incus; ST, stapes; aL, achromatic lens; CM, video camera; PC, polarization controller; 50:50¬†fc, 50:50 fiber fused coupler; BPD, balanced photo-detector; GPU, graphic processing unit; DGT, digitizer; DAQ, data acquisition board, MEMS CTRL, MEMS scan mirror controller; FP, foot pedal. (b)¬†Entire system setup in a regular clinic, (c)¬†close-up of the hand-held imaging probe. (d)¬†Ray tracing diagram in Zemax. (e)¬†Lateral point-spread function (PSF) of the x and y axis measured at the focal plane and (f)¬†size comparison of a standard otoscope and the HHOCT imaging probe.

[![Image 1: JBO_29_8_086005_f001.png](https://www.spiedigitallibrary.org/ContentImages/Journals/JBOPFO/29/8/086005/WebImages/JBO_29_8_086005_f001.png)](https://www.spiedigitallibrary.org/ContentImages/Journals/JBOPFO/29/8/086005/FigureImages/JBO_29_8_086005_f001.png)

The essential optical system design is shown in [Fig. 1(a)](https://www.spiedigitallibrary.org/#f1). The swept laser output was directed into a 90:10 optical fiber coupler (fC). The 10% side illuminated the reference arm of the interferometer. After passing through a fiber optic patch cable sized to an optical path length matched with the sample arm, the reference light passed into a 50:50 fC where it was combined with the sample arm. The 90% side illuminated the sample arm, passing through a circulator (Circ) and then onto the hand-held imaging probe. Inside the hand-held imaging probe, the light was guided by a dual axes MEMS mirror (Mirrocle Technology, Northamptonshire, United Kingdom) through the objective lens and onto the sample for scanning. The back-reflected light passed back through the circulator and was combined with the reference arm via the 50:50 optical fC. The two outputs of the fC were directed into the balanced photodetector (BPD, WL-BPD600MA, Wieserlabs, Penzberg, Germany).

The objective yielded a 38‚Äâ‚ÄâŒºm (FWHM) scanning beam spot at the focal plane measured by a commercial scanning-slit optical beam profiler (BP104-IR, Thorlabs, Newton, New Jersey, United States) and 5.03¬†mm depth of focus (DOF) calculated from the waist (1/e2) of a Gaussian beam, as shown in [Fig. 1(e)](https://www.spiedigitallibrary.org/#f1). A ray tracing diagram for the objective lens is shown in [Fig. 1(d)](https://www.spiedigitallibrary.org/#f1). As can be seen, the rays cross at ‚àº16‚Äâ‚Äâmm from the final lens surface at a point coinciding approximately with the tip of the speculum. From that point, the rays fan out and come to a focus at an arc about 27¬†mm from the crossing. As a result, the image is sampled in a spherical polar coordinate system, unlike our prior telecentric system, which naturally samples in the more convenient Cartesian space. Below, we describe our approach to resampling in Cartesian space and aberration correction. The advantage of this imaging pattern is a larger field of view, 7.4¬†mm at the focal plane through the limited aperture of the middle ear speculum. This represents an approximately two-fold increase over our prior telecentric system.

A high-pass dichroic mirror (DM) positioned between the MEMS mirror and an achromatic objective lens (aL) directed the back-reflected visible light onto a small CMOS sensor (MU9PC-MH, XIMEA, M√ºnster, Germany) within the hand-held imaging probe to generate a video otoscope image. Visible light illumination of the ear canal was accomplished by a set of visible LEDs mounted around the objective lens. Real-time video output from the CMOS was shown on the monitor and used by the clinician to guide the hand-held unit to the proper position for OCT imaging. As a size comparison of our HHOCT imaging probe with a typical otoscope, we photographed the two side-by-side as shown in [Fig. 1(f)](https://www.spiedigitallibrary.org/#f1). The outer shell of the HHOCT device is designed to resemble the grip angle and size of a standard otoscope. This design choice aims to make it familiar for the clinician and ensure patient comfort during examinations.

The endoscopy cart housed the major electronic components. Detailed information about the electronic devices and signal processing procedures can be found in previous studies.[22](https://www.spiedigitallibrary.org/#r22),[23](https://www.spiedigitallibrary.org/#r23) Briefly, the interferometric signal from the BPD was connected to a digitizer and processed using custom software written in Python, C++, and Cuda C. The 400¬†MHz clock from the swept laser served as the master clock. The data acquisition (DAQ) board generated an enable trigger that worked as a logical AND so that the digitizer only acquired data during the desired portion of the mirror scan. The DAQ also generated a synchronized analog signal for controlling the MEMS mirror. In addition, the foot pedal facilitated hands-free data acquisition, minimizing motion artifacts caused by the operator. The foot pedal, operated through the Bluetooth Secure Personal Network (PAN), was paired with the system software for image capture that allowed a single operator hands-free operation for the standalone and meticulous measurements in clinical procedures.

As noted above, the new imaging device has a much larger field of view than our prior telecentric systems. As a consequence, we sample in spherical polar space rather than the typical Cartesian space as well as introduce some image aberration. To correct this and enable accurate image dimensions, we developed a two-part algorithm that includes coordinate transformation and aberration correction.

2.2.
----

### Model for Coordinate Transformation

Although our OCT system nominally scans in spherical polar coordinates, we chose to treat it as two polar coordinate systems, in part because each axis of the MEMs mirror has its own hysteresis and center of rotation. Hence, OCT volume scanning involves two steps: x\-z plane scanning (fast axis) and y\-z plane scanning (slow axis). As shown in [Fig. 2](https://www.spiedigitallibrary.org/#f2), we establish two Cartesian coordinate systems to represent the real sample space; one follows the slow axis RC1(O,X,Y,Z), and the other is based on the fast axis RC2(O‚Ä≤,X‚Ä≤,Y‚Ä≤,Z‚Ä≤), with O(O‚Ä≤) representing the mirror rotation center. A polar coordinate system Rraw(Oraw,xraw,yraw,zraw) is introduced to represent the measured image space.

Fig.¬†2
------

Model of the coordinate transformation for the otoscopic OCT system. The green 3D shape represents the collected data. The fast-axis and slow-axis coordinate systems are shown in blue and red, respectively. The gray plane represents an arbitrary plane represented in both spaces.

[![Image 2: JBO_29_8_086005_f002.png](https://www.spiedigitallibrary.org/ContentImages/Journals/JBOPFO/29/8/086005/WebImages/JBO_29_8_086005_f002.png)](https://www.spiedigitallibrary.org/ContentImages/Journals/JBOPFO/29/8/086005/FigureImages/JBO_29_8_086005_f002.png)

Assuming a point P in the plane is denoted as P1(x1,y1,z1) in RC1 and P2(x2,y2,z2) in RC2, we establish the relationship between them as

Eq. (1)
-------

P1\=M\*P2,

where M represents the transformation matrix,

Eq. (2)
-------

M\=\[10000cos(œÜ1)sin(œÜ1)(D1‚àíD2)sin(œÜ1)0‚àísin(œÜ1)cos(œÜ1)(D1‚àíD2)cos(œÜ1)0001\],

where œÜ1 is the angle between two axes as defined in [Fig. 2](https://www.spiedigitallibrary.org/#f2).

According to Eqs.¬†(1) and (2), we derive

Eq. (3)
-------

{x1\=x2y1\=cos(œÜ1)y2+sin(œÜ1)z2+(D1‚àíD2)sin(œÜ1)z1\=‚àísin(œÜ1)y2+cos(œÜ1)z2+(D1‚àíD2)cos(œÜ1).

Furthermore, we represent the equation of the plane in RC1 as

Eq. (4)
-------

z1\=x1‚Äâtan(Œ∏1)+y1‚Äâtan(Œ∏2)+(d+D1).

The point P is represented in RC2 as

Eq. (5)
-------

x2\=r2‚Äâsin(œÜ2),

Eq. (6)
-------

z2\=r2‚Äâcos(œÜ2),

Eq. (7)
-------

œÜ2\=tan‚àí1(x2,z2),

Eq. (8)
-------

r2\=x22+z22.

Therefore, we derive the following equation:

Eq. (9)
-------

r2(cos(œÜ1)cos(œÜ2)‚àísin(œÜ2)tan(Œ∏1)‚àísin(œÜ1)cos(œÜ2)tan(Œ∏2))\=d+D1+(D1‚àíD2)(sin(œÜ1)tan(Œ∏2)‚àícos(œÜ1)).

In the polar space, we know point P is represented as

Eq. (10)
--------

xraw\=x0+œÜ2D2,

Eq. (11)
--------

yraw\=y0+œÜ1D1,

Eq. (12)
--------

zraw\=r2‚àíD2.

Hence, œÜ1 and œÜ2 are given as

Eq. (13)
--------

œÜ1\=(xraw‚àíx0)/D2,

Eq. (14)
--------

œÜ2\=(yraw‚àíy0)/D1.

Finally, we define the expression of each axial profile position zraw in Rraw as

Eq. (15)
--------

zraw\=d+D1+(D1‚àíD2)\[sin(yraw‚àíy0D1)tan(Œ∏2)‚àícos(yraw‚àíy0D1)\]cos(yraw‚àíy0D1)cos(xraw‚àíx0D2)‚àísin(xraw‚àíx0D2)tan(Œ∏1)‚àísin(yraw‚àíy0D1)cos(xraw‚àíx0D2)tan(Œ∏2)‚àíD2.

We initially constructed the model with six parameters ((x0,y0,D1,D2,Œ∏1,Œ∏2)) based on Eq.¬†(15). The root-mean-square error (RMSE) was used as the performance indicator for the optimization; it is given as

Eq. (16)
--------

RMSE\=1mn‚àë1m‚àë1n(zraw(i,j)‚àíz^(i,j))2,

where m and n represent the axial and lateral pixel numbers in the OCT images, respectively, and z^ denotes the values obtained from the model.

2.3.
----

### Model for Aberration Correction

After performing a coordinate transformation, the OCT image exhibited distortion attributed to optical aberrations, as illustrated in [Fig. 3(a)](https://www.spiedigitallibrary.org/#f3). We imaged a checkerboard calibration target (Edmund Optics Inc., Barrington, New Jersey, United States), 0.2√ó0.2‚Äâ‚Äâmm square pattern, at various imaging depths while controlling the spatial offset to assess the image quality and the extent of the aberrations. We estimated the residual aberration present in depth slices of an OCT volume by constructing a polynomial model based on the coordinate correspondence between the OCT enface images with the standard checkerboard pattern image serving as the reference.

2.4.
----

### Clinical Imaging Protocol

This study was approved by the institutional review board at the University of Southern California (HS-21-00338). Over 100 patients were imaged after providing informed consent in a tertiary care otology clinic at Keck Hospital of USC from October 2022 to June 2023. Patients‚Äô ears were cleaned of wax with a curette prior to imaging. Inclusion criteria included anyone with a patent ear canal with visibility of the TM on the otoscopic view. Exclusion criteria included patients with active bleeding, discharge, or open wound in the external ear canal; a non-visible TM; or a non-patent ear canal. Patients were imaged while sitting upright in an exam chair. Both ears were imaged unless a patient had abnormal anatomy or intolerance to the plastic ear speculum that made imaging one ear not possible within a clinic setting.

Multiple OCT volumes were obtained from each of the four anatomical quadrants of the TM using superficially identified anatomical landmarks (e.g., Umbo, pars flaccida) on live otoscopic video feed to orient the scanning volume location and corroborate ME structures seen in real time OCT B scans. A single volume scan took 0.4¬†s. The relatively high speed helped to reduce motion artifacts that may arise from patient or operator movement. The region of interest was selected with the center of the OCT beam positioned directly over the umbo. This was done to encompass the entire tympanic membrane (TM) and cover the area with suspected pathology, thereby maximizing the likelihood of capturing intriguing pathological features within the OCT volumes. The total imaging time, including consenting the patient, reviewing the images, and explaining to patients what they were seeing, was <5‚Äâ‚Äâmin. OCT volumes were post-processed and analyzed using MatLab (MathWorks), Amira (Thermofisher Scientific), and Fiji (NIH).

3.
--

Results
-------

3.1.
----

### Coordinate Transformation and Aberration Correction

We found the following parameters in [Table 1](https://www.spiedigitallibrary.org/#t001) for mapping our volumetric images into Cartesian space. Examples of images at the focal plane and ¬±2‚Äâ‚Äâmm before and after coordinate transformation are shown in [Fig. 3(a)](https://www.spiedigitallibrary.org/#f3) columns 1 and 2. The imaging target has 200‚Äâ‚ÄâŒºm squares with an asymmetric cross near the center of the image to aid in registration. As can be seen, although the image quality is improved, there is still aberration, resembling barrel distortion, that can be corrected.

Table 1
-------

Parameters of coordinate transformation.

| x0 (pix) | y0 (pix) | D1 (pix) | D2 (pix) | Œ∏1 (deg) | Œ∏2 (deg) |
| --- | --- | --- | --- | --- | --- |
| 166.3 | 60.08 | 1432 | 1479 | 0.002288 | ‚àí0.07968 |

Fig.¬†3
------

(a)¬†Calibration target images at the focal plane (0¬†mm) and ¬±2‚Äâ‚Äâmm. Enface images at the depth of the target, above a B-scan through the middle of the target. (b) and (c)¬†Representative linear fits of corresponding x and y pixel positions as a function of depth.

[![Image 3: JBO_29_8_086005_f003.png](https://www.spiedigitallibrary.org/ContentImages/Journals/JBOPFO/29/8/086005/WebImages/JBO_29_8_086005_f003.png)](https://www.spiedigitallibrary.org/ContentImages/Journals/JBOPFO/29/8/086005/FigureImages/JBO_29_8_086005_f003.png)

We performed aberration correction using the same checkerboard calibration target at six different depths ranging from ‚àí5 to 5¬†mm. Between these depths, we assumed a linear relationship. As demonstrated in [Figs. 3(b)](https://www.spiedigitallibrary.org/#f3) and [3(c)](https://www.spiedigitallibrary.org/#f3), the linear fit among corresponding points has an R2 of 0.99 and 0.97, respectively. Therefore, we can readily realize the aberration correction of 3D OCT images by linear fitting. The result following this algorithm is the third column in [Fig. 3(a)](https://www.spiedigitallibrary.org/#f3), i.e., after coordinate transformation and aberration correction.

3.2.
----

### Normal TM and Middle Ear

Here, we present several example cases from the clinical study. Our first example is a patient with a healthy middle ear as confirmed by an expert otologist through clinical assessment and otoscopic examination. From the otoscopic view in [Fig. 4(a)](https://www.spiedigitallibrary.org/#f4), the tympanic membrane can be seen to be fairly transparent, which allows us to see the incus, malleus, and cochlear promontory through the membrane. Other anatomical landmarks include the umbo and cone-of-light. [Figure 4(b)](https://www.spiedigitallibrary.org/#f4) is a summed voxel projection (SVP) of the OCT volume in which the 2D image is generated by summing along the depth dimension. This generates an image that can be directly compared with the standard otoscope view to verify orientation. [Figures 4(c)](https://www.spiedigitallibrary.org/#f4) and [4(d)](https://www.spiedigitallibrary.org/#f4) are representative cross-sectional B-scans that were extracted along the dashed colored lines, as shown in panels (a) and (b). The cross-sections show a normal thin tympanic membrane along with sections of the chorda tympani and stapes in addition to the anatomy that was also visible in the otoscopic view. [Figure 4(e)](https://www.spiedigitallibrary.org/#f4) displays the 3D volume rendering that visualizes major anatomical structures presented in the otoscopic view.

Fig.¬†4
------

Otoscope and OCT image acquired from normal ear. Abbreviations: MA, malleus; CT, chorda tympani; TM, tympanic membrane; IN, incus; UM, umbo; CL, cone of light; P, promontory. (a)¬†A snapshot of the otoscopic video camera. Dashed colored lines indicate the positions where the linear B-scans are shown in panels (c)¬†and (d). (b)¬†_En face_ image generated by SVP from an OCT volume. Dashed colored lines indicate the positions where the linear B-scans are shown in panels (c)¬†and (d). (c)¬†B-scan extracted along the green-colored dashed line from the OCT volume. (d)¬†B-scan extracted along the red-colored dashed line from the OCT volume. (e)¬†3D volume rendering.

[![Image 4: JBO_29_8_086005_f004.png](https://www.spiedigitallibrary.org/ContentImages/Journals/JBOPFO/29/8/086005/WebImages/JBO_29_8_086005_f004.png)](https://www.spiedigitallibrary.org/ContentImages/Journals/JBOPFO/29/8/086005/FigureImages/JBO_29_8_086005_f004.png)

3.3.
----

### Abnormal Tissue Growth

This case is a patient presented with 2 weeks of ear pain and aural fullness. An otoscopic evaluation by an expert otologist revealed what appeared to be abnormal tissue growth superficially on bilateral TMs. The level of involvement with the TM and if the tissue was directly against the TM were not discernible with a routine physical exam. The physician used OCT imaging to determine if tissue debridement was possible in the clinic without damage to the TM. Representative images are shown in [Fig. 5](https://www.spiedigitallibrary.org/#f5).

Fig.¬†5
------

Otoscope and OCT image acquired from myringitis over the subsequent visits. (a)¬†A snapshot of the otoscopic video camera at first visit. Dashed colored lines indicate the positions where the linear B-scans are shown in panels (c)¬†and (d). (b)¬†_En face_ image generated by SVP from an OCT volume at first visit. Dashed colored lines indicate the positions where the linear B-scans are shown in panels (c)¬†and (d). (c)¬†B-scan extracted along the green-colored dashed line from the OCT volume at first visit. (d)¬†B-scan extracted along the red-colored dashed line from the OCT volume. White arrows with circled numbers from 1 to 4 denote the layered plaques of abnormal tissue partially adhere to the TM. (e)¬†Frame from ([Video 1](https://www.spiedigitallibrary.org/ContentImages/Journals/JBOPFO/29/8/086005/SupplementalData/JBO_29_8_086005_ds001.mp4)) showing 3D volume rendering and B-scan fly through at first visit. (f)¬†A snapshot of the otoscopic video camera at the visit 28 days after the first visit. Dashed colored lines indicate the positions where the linear B-scans are shown in panels (h)¬†and (i). (g)¬†_En face_ image generated by SVP from an OCT volume at the visit 28 days after the first visit. Dashed colored lines indicate the positions where the linear B-scans are shown in panels (h)¬†and (i). (h)¬†B-scan extracted along the green-colored dashed line from the OCT volume at the visit 28 days after the first visit. (i)¬†B-scan extracted along the red-colored dashed line from the OCT volume. White arrows with circled numbers from 5 to 7 denote the symbolic middle ear structures. The circled number 5 indicates the incus. The circled number 6 shows the umbo. The circled number 7 is from a part of a cochlear promontory. (j)¬†Frame from ([Video 2](https://www.spiedigitallibrary.org/ContentImages/Journals/JBOPFO/29/8/086005/SupplementalData/JBO_29_8_086005_ds002.mp4)) showing 3D volume rendering and B-scan fly through at 28 days after the first visit. ([Video 1](https://www.spiedigitallibrary.org/ContentImages/Journals/JBOPFO/29/8/086005/SupplementalData/JBO_29_8_086005_ds001.mp4), MP4, 2.50¬†MB \[URL: [https://doi.org/10.1117/1.JBO.29.8.086005.s1](https://doi.org/10.1117/1.JBO.29.8.086005.s1)\]; [Video 2](https://www.spiedigitallibrary.org/ContentImages/Journals/JBOPFO/29/8/086005/SupplementalData/JBO_29_8_086005_ds002.mp4), MP4, 2.36¬†MB \[URL: [https://doi.org/10.1117/1.JBO.29.8.086005.s2](https://doi.org/10.1117/1.JBO.29.8.086005.s2)\]).

[![Image 5: JBO_29_8_086005_f005.png](https://www.spiedigitallibrary.org/ContentImages/Journals/JBOPFO/29/8/086005/WebImages/JBO_29_8_086005_f005.png)](https://www.spiedigitallibrary.org/ContentImages/Journals/JBOPFO/29/8/086005/FigureImages/JBO_29_8_086005_f005.png)

Panels (a) and (b) are the otoscopic image and SVP. Panels (c) and (d) are representative cross-sectional OCT B-scans that show the layered plaques of abnormal tissue partially adherent to the surface of the TM with partial elevation of the TM. The plaques are strongly scattering and therefore strongly shadow the tissue below. This leads to the sharp edges labeled (1) and (2) in panel (d) that look like discontinuities in the TM. Panel (e) displays a still image from a movie showing the 3D volume rendering. The volume rendering helps visualize the plaques.

These are denoted with white arrows and circled numbers. Given the findings, a conservative management approach with Debrox drops (Prestige Consumer Healthcare Inc., Irvington, New¬†York, United States) was chosen. The patient was imaged every week over four subsequent visits. Images from the final visit are shown in [Figs. 5(f)](https://www.spiedigitallibrary.org/#f5)‚Äì[5(j)](https://www.spiedigitallibrary.org/#f5). The images clearly show the resolution and clearance of abnormal tissue. The images revealed no residual tissue plaques, a thin normal-looking TM in cross-section, and middle ear anatomy such as the incus and cochlear promontory. Panel (j) displays a still image from a movie showing the 3D volume rendering. The volume rendering helps show how the plaques have largely been resolved.

3.4.
----

### Chronic Otitis Media with Effusion

Images from a patient with left ear chronic otitis media with effusion are shown in [Fig. 6](https://www.spiedigitallibrary.org/#f6). An otoscopic evaluation revealed opacification of the TM potentially consistent with fluid in the middle ear with no apparent air-fluid levels, bubbles, or active otorrhea. OCT imaging demonstrated speckled signal intensity underlying a thickened TM distinct from the dark middle ear space evident in the OCT images of the right ear. The signal intensity drops off uniformly deeper into the middle ear space along the length of the TM, consistent with OCT imaging through a mucoid effusion with extensive scattering. A representative area with mucoid effusion adjacent to the TM is labeled by white arrows in [Fig. 6](https://www.spiedigitallibrary.org/#f6). Following imaging, subsequent in-office myringotomy expressed thick yellow opaque mucoid fluid from the patients left ear, confirming the presence of fluid.

Fig.¬†6
------

Otoscope and OCT image acquired from effusion. (a)¬†A snapshot of the otoscopic video camera at first visit. Dashed colored lines indicate the positions where the linear B-scans are shown in panels (c)¬†and (d). (b)¬†_En face_ image generated by SVP from an OCT volume at first visit. Dashed colored lines indicate the positions where the linear B-scans are shown in panels (c)¬†and (d). (c)¬†B-scan extracted along the green-colored dashed line from the OCT volume at first visit. (d)¬†B-scan extracted along the red-colored dashed line from the OCT volume. White arrows denote the mucoid effusion adjacent to the TM in panels (c)¬†and (d).

[![Image 6: JBO_29_8_086005_f006.png](https://www.spiedigitallibrary.org/ContentImages/Journals/JBOPFO/29/8/086005/WebImages/JBO_29_8_086005_f006.png)](https://www.spiedigitallibrary.org/ContentImages/Journals/JBOPFO/29/8/086005/FigureImages/JBO_29_8_086005_f006.png)

3.5.
----

### TM Perforation

A patient with a history of chronic otitis media presented with a small elliptical TM perforation. On otoscopic examination during a 6-week follow-up exam, [Fig. 7(a)](https://www.spiedigitallibrary.org/#f7), the perforation appeared to be non-healing and patent into the middle ear cavity. However, the OCT cross-sectional images in [Figs. 7(c)](https://www.spiedigitallibrary.org/#f7) and [7(d)](https://www.spiedigitallibrary.org/#f7) clearly show a thin layer of TM ‚àº68\-Œºm thick, filling the space where the perforation had been. The OCT volume showed a healing elliptical perforation with minor and major axes of 300 and 400‚Äâ‚ÄâŒºm, respectively, and a thin layer of tissue across the entire area.

Fig.¬†7
------

Otoscope and OCT image acquired from a healed thin TM. (a)¬†A snapshot of the otoscopic video camera. Dashed colored lines indicate the positions where the linear B-scans are shown in panels (c)¬†and (d). Dashed colored box indicates where the OCT volume was acquired. (b)¬†_En face_ image generated by SVP from an OCT volume inside of the dashed colored box on the otoscopic video image (a). Dashed colored lines indicate the positions where the linear B-scans are shown in panels (c)¬†and (d). (c)¬†B-scan extracted along the green-colored dashed line from the OCT volume. (d)¬†B-scan extracted along the red-colored dashed line from the OCT volume. White arrows denote the healed TM in panels (c)¬†and (d).

[![Image 7: JBO_29_8_086005_f007.png](https://www.spiedigitallibrary.org/ContentImages/Journals/JBOPFO/29/8/086005/WebImages/JBO_29_8_086005_f007.png)](https://www.spiedigitallibrary.org/ContentImages/Journals/JBOPFO/29/8/086005/FigureImages/JBO_29_8_086005_f007.png)

3.6.
----

### TM Retraction

A patient with apparent TM retraction identified on otoscopic evaluation by an expert otologist was imaged. In the OCT cross-sections, [Figs. 8(c)](https://www.spiedigitallibrary.org/#f8) and [8(d)](https://www.spiedigitallibrary.org/#f8), the TM is shown to be severely retracted. A co-registered normal TM is shown for reference in grayscale and denoted with a white arrow labeled 3. Inspection of the OCT volume showed that the TM was touching the incus and was very close but not touching the promontory. These are labeled in representative cross-sections by the circled numbers 1 and 2, respectively. TM contact with the incus brings an increased risk of bone necrosis and cholesteatoma formation.

Fig.¬†8
------

Otoscope and OCT image acquired from TM retraction patient. (a)¬†A snapshot of the otoscopic video camera. Dashed colored lines indicate the positions where the B-scans are shown in panels (c)¬†and (d). (b)¬†_En face_ image generated by SVP from an OCT volume. Dashed colored lines indicate the positions where the linear B-scans are shown in panels (c)¬†and (d). (c)¬†B-scan extracted along the green-colored dashed line from the OCT volume and overlaid with the gray-shaded OCT image (labeled 3) acquired from a normal condition. (d)¬†B-scan extracted along the red-colored dashed line from the OCT volume. White arrows with circled numbers 1 and 2 denote that the TM touched the incus and was close to the cochlear promontory.

[![Image 8: JBO_29_8_086005_f008.png](https://www.spiedigitallibrary.org/ContentImages/Journals/JBOPFO/29/8/086005/WebImages/JBO_29_8_086005_f008.png)](https://www.spiedigitallibrary.org/ContentImages/Journals/JBOPFO/29/8/086005/FigureImages/JBO_29_8_086005_f008.png)

3.7.
----

### Tympanic Membrane Protrusion with Air Pocket

A patient with a history of bilateral otosclerosis, stapedectomies (ear surgery to remove the stapes bone), and unknown pathology affecting the right ear TM presenting with decreased hearing and ear fullness was examined. They had seen several prior otologists with no reported clear diagnosis other than bulging of the TM or post-surgical changes. The otoscopic view appeared to show a partially white opaque TM possibly consistent with post-surgical scarring or middle ear mass of the TM posteriorly in [Fig. 9(a)](https://www.spiedigitallibrary.org/#f9). TM continuity with the superior-anterior quadrant of the ear canal was indeterminate with potential perforation on the otoscopic view. In [Figs. 9(c)](https://www.spiedigitallibrary.org/#f9) and [9(d)](https://www.spiedigitallibrary.org/#f9), further OCT imaging demonstrated the presence of a ‚àº1.3\-mm diameter air pocket within a body of thick scar tissue. The scar tissue, ‚àº420‚Äâ‚ÄâŒºm thick, was continuous with the interior layer of the TM near the center, annotated with white arrows in [Figs. 9(c)](https://www.spiedigitallibrary.org/#f9) and [9(d)](https://www.spiedigitallibrary.org/#f9), demonstrating no perforation on OCT imaging.

Fig.¬†9
------

Otoscope and OCT image acquired from TM protrusion with an air pocket. (a)¬†A snapshot of the otoscopic video camera. Dashed colored lines indicate the positions where the linear B-scans are shown in panels (c)¬†and (d). (b)¬†_En face_ image generated by SVP from an OCT volume. Dashed colored lines indicate the positions where the linear B-scans are shown in panels (c)¬†and (d). (c)¬†B-scan extracted along the green-colored dashed line from the OCT volume. (d)¬†B-scan extracted along the red-colored dashed line from the OCT volume. White arrows denote the TM protrusion with an air pocket.

[![Image 9: JBO_29_8_086005_f009.png](https://www.spiedigitallibrary.org/ContentImages/Journals/JBOPFO/29/8/086005/WebImages/JBO_29_8_086005_f009.png)](https://www.spiedigitallibrary.org/ContentImages/Journals/JBOPFO/29/8/086005/FigureImages/JBO_29_8_086005_f009.png)

4.
--

Discussion
----------

Our new form factor and optical design for the OCT otoscope system provide a more compact hand-held component with a larger field of view than our prior work. The hand-held piece of the device is similar in size and shape to a standard battery-powered otoscope \[see [Fig. 1(f)](https://www.spiedigitallibrary.org/#f1)\]. The new optical design with a larger field of view, but otherwise similar optical performance as our prior work, comes at the cost of post-processing to recast the image, nominally collected in spherical polar coordinates, into Cartesian coordinates. Currently, we display the raw images in real time and do the resampling in postprocessing. The resampling could be done in real time; however, the quality of the raw images is good enough to easily see the relevant pathologies. The resampling is only important for making quantitative measurements, e.g., size of perforation, distance of TM to the incus or promontory, and TM thickness. Nevertheless, if real-time resampling proved necessary, it can be done using a GPU as demonstrated[25](https://www.spiedigitallibrary.org/#r25) recently for a related resampling algorithm. In this system, we used a new custom laser source from Insight Photonics Solutions, Inc. (Lafayette, Colorado, United States) that uses a single laser chip. The single chip limits the available bandwidth but allows us to image at a line rate of 200¬†kHz and still maintain a large Nyquist depth of 17.7¬†mm. Although a large Nyquist depth is needed for middle ear imaging, 10 to 12¬†mm would probably be sufficient. A unique property of the Insight swept laser is the ability to change the sweep frequency. In the future, we can likely increase the line rate up to 300¬†kHz using this same laser; however, because the sampling rate remains fixed (400¬†MHz), our Nyquist depth would be reduced to 11.6¬†mm, which is still well within the range noted above.

The 2√ó increase in imaging speed over our prior work improves the image quality by reducing motion artifact, but it comes at the cost of axial resolution, which is reduced by approximately a factor of 2. Nevertheless, given the size of most anatomical features in the middle ear (e.g., TM thickness ‚àº100‚Äâ‚ÄâŒºm and incus diameter ‚àº200‚Äâ‚ÄâŒºm), the loss in resolution does not significantly degrade our ability to identify pathology within the TM and middle ear. Likewise, although we did not apply the algorithm here, we could improve our axia l resolution by up to a factor of 2 using a recently developed multi-window approach.[26](https://www.spiedigitallibrary.org/#r26)‚Äì[28](https://www.spiedigitallibrary.org/#r28)

Within the larger clinical study, for this report, we focused on examples in which the OCT imaging provides information that was not available from standard otoscopic examination and could be clinically important. Prior works with OCT devices have been used to characterize and aid in the diagnosis of a number of pathologies of the middle ear.[15](https://www.spiedigitallibrary.org/#r15)‚Äì[19](https://www.spiedigitallibrary.org/#r19) An important example is otitis media with effusion, for which a non-scanning OCT device was developed into an FDA-approved diagnostic tool to help primary care physicians more accurately diagnose cases of otitis media with effusion.[29](https://www.spiedigitallibrary.org/#r29) Our device and study build upon this growing body of work by not only being able to identify mucoid otitis media with effusion as shown in [Fig. 6](https://www.spiedigitallibrary.org/#f6) within the volumetric image but also characterizing deeper structures and pathologies affecting the middle ear and TM.

Our first example was the growth of abnormal tissue on the TM thought to be due to active myringitis, inflammation of the outer squamous layer of the TM. Normally, this pathology is diagnosed through otoscopic examination that demonstrates signs of inflammation with ulceration, yellow crusting, or polypoid growths.[30](https://www.spiedigitallibrary.org/#r30) Treatment often involves curettage of the abnormal tissue and antibiotic drops.[31](https://www.spiedigitallibrary.org/#r31),[32](https://www.spiedigitallibrary.org/#r32) In the case that we describe in [Fig. 5](https://www.spiedigitallibrary.org/#f5), the abnormal buildup of scar-like tissue and the lack of classical signs of myringitis made diagnosis difficult from just visualization with a standard otoscope. The OCT volumetric images showed that the abnormal tissue was attached to the TM and not just laying on top of the TM. Removing the tissue by debridement could have resulted in tearing of the TM, producing a perforation. Instead, ear drops were administered over a 6-week period.

TM perforations are typically able to be resolved on otoscopic evaluations. They are important because long standing non-healing perforations have been shown to be associated with increased risk of middle ear infections and cholesteatomas with the middle ear space open to the external environment.[33](https://www.spiedigitallibrary.org/#r33) What are harder to determine are the intermediate stages of perforation healing and smaller perforations in which otoscopic evaluation are again subject to a health professional‚Äôs subjective interpretation. In the case that we describe, the prior perforation appeared to be patent using a standard otoscopic view, but OCT imaging showed a healing layer of TM was present, deferring need for further intervention. This illustrates the potential for OCT imaging to be used for monitoring and managing perforations.

Retraction pockets have not been previously characterized by OCT. In the patient described above, the OCT images clearly showed what areas of the TM were retracted, the relative depth of retraction, and if it was contacting key structures in the middle ear. Current methods of grading the severity of retraction use contact with important structures as a measure and include the use of the Tos and Poulson or Sade scale.[34](https://www.spiedigitallibrary.org/#r34) However, grading is based on subjective interpretations by a physician through 2D otoscopic evaluation and hence is not used often due to the difficulty in accurately applying the scales only using traditional 2D information and middle ear pressures.[34](https://www.spiedigitallibrary.org/#r34) With OCT, healthcare professionals would be able to apply these scales using more accurate and objective 3D information.

Finally, we describe a case in which a patient appeared to have a white mass in the middle ear cavity via otoscopic view, but OCT revealed the presence of a scar air pocket that was causing the TM to bulge outward. This demonstrated how the device can be used to characterize patterns of scarring and how it can disrupt the normal architecture of the TM and thus affect the conduction of sound and hearing. Future applications could involve using this ability of OCT to distinguish between the presence of masses versus structural changes such as that described here to determine the need for a further medical workup or investigation.

5.
--

Conclusion
----------

The operation of the OCT otoscope device described above is sufficiently easy, so a single person can collect a set of images from a patient in seconds to minutes. This has allowed us to regularly image in the USC hearing clinic without disrupting the workflow within the clinic. The improved imaging speed and field of view have aided in the collection of images that provide information not readily available from a traditional otoscope examination. These OCT findings and the pathological information presented in this study serve to further demonstrate hand-held OCT‚Äôs ability to be a useful clinical tool.

Disclosures
-----------

The authors declare no conflicts of interest related to this work.

Code, Data, and Material Availability
-------------------------------------

Imaging data and related processing code available upon reasonable request from the corresponding author.

Acknowledgments
---------------

We gratefully acknowledge support for this work by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) (Grant No.¬†R01 EB027113).

References
----------

1.

H. Feldman, ‚ÄúHistory of the ear speculum. Images from the history of otorhinolaryngology, highlighted by instruments from the collection of the German Medical History Museum in Ingolstadt,‚Äù Laryngorhinootologie, 75 (5), 311 ‚Äì318 [https://doi.org/10.1055/s-2007-997586](https://doi.org/10.1055/s-2007-997586) (1996). [Google Scholar](http://scholar.google.com/scholar_lookup?title=History+of+the+ear+speculum.+Images+from+the+history+of+otorhinolaryngology,+highlighted+by+instruments+from+the+collection+of+the+German+Medical+History+Museum+in+Ingolstadt&author=H.+Feldman&journal=Laryngorhinootologie&volume=75&issue=5&publication_year=1996&pages=311-318)

7.

E. Leibovitz, ‚ÄúAcute otitis media in pediatric medicine: current issues in epidemiology, diagnosis, and management,‚Äù Paediatr. Drugs, 5 Suppl 1 1 ‚Äì12 (2003). [Google Scholar](http://scholar.google.com/scholar_lookup?title=Acute+otitis+media+in+pediatric+medicine:+current+issues+in+epidemiology,+diagnosis,+and+management&author=E.+Leibovitz&journal=Paediatr.+Drugs&volume=5+Suppl+1&publication_year=2003&pages=1-12)

21.

L. Migirov et al., ‚ÄúMRI, not CT, to rule out recurrent cholesteatoma and avoid unnecessary second-look mastoidectomy,‚Äù Isr. Med. Assoc. J., 11 (3), 144 ‚Äì146 (2009). [Google Scholar](http://scholar.google.com/scholar_lookup?title=MRI,+not+CT,+to+rule+out+recurrent+cholesteatoma+and+avoid+unnecessary+second-look+mastoidectomy&author=L.+Migirov&journal=Isr.+Med.+Assoc.+J.&volume=11&issue=3&publication_year=2009&pages=144-146)

22.

C. Lui et al., ‚ÄúIn vivo functional imaging of the human middle ear with a hand-held optical coherence tomography device,‚Äù Biomed. Opt. Express, 12 (8), 5196 ‚Äì5213 [https://doi.org/10.1364/BOE.430935](https://doi.org/10.1364/BOE.430935) BOEICL 2156-7085 (2021). [Google Scholar](http://scholar.google.com/scholar_lookup?title=In+vivo+functional+imaging+of+the+human+middle+ear+with+a+hand-held+optical+coherence+tomography+device&author=C.+Lui&journal=Biomed.+Opt.+Express&volume=12&issue=8&publication_year=2021&pages=5196-5213)

23.

W. Kim et al., ‚ÄúPicometer scale vibrometry in the human middle ear using a surgical microscope based optical coherence tomography and vibrometry system,‚Äù Biomed. Opt. Express, 10 (9), 4395 ‚Äì4410 [https://doi.org/10.1364/BOE.10.004395](https://doi.org/10.1364/BOE.10.004395) BOEICL 2156-7085 (2019). [Google Scholar](http://scholar.google.com/scholar_lookup?title=Picometer+scale+vibrometry+in+the+human+middle+ear+using+a+surgical+microscope+based+optical+coherence+tomography+and+vibrometry+system&author=W.+Kim&journal=Biomed.+Opt.+Express&volume=10&issue=9&publication_year=2019&pages=4395-4410)

24.

S. Mansour et al., Comprehensive and Clinical Anatomy of the Middle Ear, Springer, Heidelberg (2013). [Google Scholar](http://scholar.google.com/scholar_lookup?&author=S.+Mansour&publication_year=2013)

25.

J. D. Farrell et al., ‚ÄúGeometrically accurate real-time volumetric visualization of the middle ear using optical coherence tomography,‚Äù Biomed. Opt. Express, 14 (7), 3152 ‚Äì3171 [https://doi.org/10.1364/BOE.488845](https://doi.org/10.1364/BOE.488845) BOEICL 2156-7085 (2023). [Google Scholar](http://scholar.google.com/scholar_lookup?title=Geometrically+accurate+real-time+volumetric+visualization+of+the+middle+ear+using+optical+coherence+tomography&author=J.+D.+Farrell&journal=Biomed.+Opt.+Express&volume=14&issue=7&publication_year=2023&pages=3152-3171)

27.

B. Johnson et al., Achieving the ideal point spread in swept source OCT, SPIE Press, Bellingham, Washington (2020). [Google Scholar](http://scholar.google.com/scholar_lookup?&author=B.+Johnson&publication_year=2020)

28.

C. B. Walker et al., ‚ÄúMulti-window approach enables two-fold improvement in OCT axial resolution with strong side-lobe suppression and improved phase sensitivity,‚Äù Biomed. Opt. Express, 14 (12), 6301 ‚Äì6316 [https://doi.org/10.1364/BOE.501649](https://doi.org/10.1364/BOE.501649) BOEICL 2156-7085 (2023). [Google Scholar](http://scholar.google.com/scholar_lookup?title=Multi-window+approach+enables+two-fold+improvement+in+OCT+axial+resolution+with+strong+side-lobe+suppression+and+improved+phase+sensitivity&author=C.+B.+Walker&journal=Biomed.+Opt.+Express&volume=14&issue=12&publication_year=2023&pages=6301-6316)

30.

A. El-Seifi and B. Fouad, ‚ÄúGranular myringitis: is it a surgical problem?,‚Äù Am. J. Otol., 21 (4), 462 ‚Äì467 AJOTDP 0196-0709 (2000). [Google Scholar](http://scholar.google.com/scholar_lookup?title=Granular+myringitis:+is+it+a+surgical+problem?&author=A.+El-Seifi&author=B.+Fouad&journal=Am.+J.+Otol.&volume=21&issue=4&publication_year=2000&pages=462-467)

Biography
---------

**Wihan Kim** is a research scientist in the Department of Otolaryngology-Head & Neck Surgery at Keck Medicine of USC. He received his PhD in Biomedical Engineering from Texas A&M University under Professor Brian Applegate. He studied developing molecular imaging approaches for optical coherence tomography. Since 2019, he has focused on clinical imaging technologies for functional imaging of the human ear. He leads significant projects, collaborating with clinicians to advance point-of-care diagnosis and monitoring of human diseases.

**Zihan Yang** received his PhD in optical engineering from the Institute of Modern Optics, Nankai University, Tianjin, China, in 2022. He is currently a post-doctoral fellow at University of Southern California. His research interests include the development of OCT, image processing, and biomedical and optical imaging.

**Brian E. Applegate** is a professor of Otolaryngology-Head & Neck Surgery, Ophthalmology, and Biomedical Engineering at the University of Southern California. He received his PhD in physical chemistry from the Ohio State University. He completed a postdoctoral fellowship at Duke University in Biomedical Engineering. He is a fellow of Optica and SPIE. His research interests are broadly to develop novel biophotonic technologies and apply them to the diagnosis and monitoring of human disease.
"
2024-08-27 00:00:00,2024-08-29 23:11:50,"üöÄ Exciting Developments in MedTech! Are you keeping an eye on the transformative landscape of medical technology? A recent article from **Sifted** highlights **11 promising medtech startups** identified by leading VCs as game-changers in our industry. Here are a few standout ventures:

1. **Medical Microinstruments (MMI)** - This Italian firm tackles microsurgery challenges with their surgical robots, enhancing precision and reducing surgeon tremor. 

2. **Ganymed Robotics** - Based in France, they are revolutionizing knee replacement surgery with AI-assisted robotics, simplifying complex imaging processes involved in implant placements.

3. **Salvia BioElectronics** - With a focus on migraine relief, this startup has developed a paper-thin implant to modulate nerve activity, showing promise through FDA breakthroughs.

4. **Vitestro** - Innovating in automation, Vitestro‚Äôs autonomous blood drawing device aims to ease the burden of blood sample collection, a boon for both patients and healthcare providers.

These companies exemplify the potential of integrating technology and medicine to create solutions that not only enhance surgical procedures but also improve patient outcomes. It is an exciting time to be part of this evolution! 

What innovations excite you the most in the medtech space? Let‚Äôs discuss the future of healthcare! üí° 

#MedTech #HealthcareInnovation #Startups #Surgery #InvestorInsights

Read more about these startups and the trends in the original article [here](https://sifted.eu/articles/medtech-startup-vc-trends/).  

üåü Let's share ideas and continue the conversation!",https://images.sifted.eu/wp-content/uploads/2024/08/23145641/Linus-final-Kopie-scaled-e1724421412663.jpg?auto=format&fit=max&w=3840&q=75,https://sifted.eu/articles/medtech-startup-vc-trends/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: 11 medtech startups to watch, according to VCs | Sifted

URL Source: https://sifted.eu/articles/medtech-startup-vc-trends/

Markdown Content:
11 medtech startups to watch, according to VCs | Sifted
===============
   

 

![Image 1: logo](blob:https://sifted.eu/4eb6460ab93a7ae1978320dda45af1eb)

[](https://www.cookiebot.com/en/what-is-behind-powered-by-cookiebot/)

*   [Consent](https://sifted.eu/articles/medtech-startup-vc-trends/#)
*   [Details](https://sifted.eu/articles/medtech-startup-vc-trends/#)
*   [\[#IABV2SETTINGS#\]](https://sifted.eu/articles/medtech-startup-vc-trends/#)
*   [About](https://sifted.eu/articles/medtech-startup-vc-trends/#)

This website uses cookies
-------------------------

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you‚Äôve provided to them or that they‚Äôve collected from your use of their services.

Consent Selection

**Necessary**

**Preferences**

**Statistics**

**Marketing**

[Show details](https://sifted.eu/articles/medtech-startup-vc-trends/#)

*   Necessary 75
    
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
    
    *   [Airtable 4](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 2](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://airtable.com/privacy ""Airtable's privacy policy"")
        
        **\_\_Host-airtable-session**Contains a specific ID for the current session. This is necessary for running the website correctly.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **\_\_Host-airtable-session.sig**Contains a specific ID for the current session. This is necessary for running the website correctly.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **brw**Detects and logs potential errors on third-party provided functions on the website.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **login-status-p**This cookie is necessary for the login function on the website.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [Albumizr 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 3](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://albumizr.com/ ""Albumizr's privacy policy"")
        
        **PHPSESSID**Preserves user session state across page requests.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [Canva 5](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 4](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.canva.com/policies/privacy-policy/ ""Canva's privacy policy"")
        
        **cf\_clearance**This cookie is used to distinguish between humans and bots.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **ASI**The cookie is necessary for secure log-in and the detection of any spam or abuse of the website.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **CCK**The cookie is necessary for secure log-in and the detection of any spam or abuse of the website.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
        **CDI**The cookie is necessary for secure log-in and the detection of any spam or abuse of the website.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **CPA**Necessary for the website security.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
    *   [Cookiebot 3](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 5](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.cookiebot.com/goto/privacy-policy/ ""Cookiebot's privacy policy"")
        
        **1.gif**Used to count the number of sessions to the website, necessary for optimizing CMP product delivery.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **CookieConsent¬†\[x2\]**Stores the user's cookie consent state for the current domain
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
    *   [Google 5](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 6](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://business.safety.google/privacy/ ""Google's privacy policy"")
        
        Some of the data collected by this provider is for the purposes of personalization and measuring advertising effectiveness.
        
        **test\_cookie**Used to check if the user's browser supports cookies.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
        **rc::e**This cookie is used to distinguish between humans and bots.
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **rc::h**This cookie is used to distinguish between humans and bots.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **docs/common/netcheck.gif**Necessary for the general functionality of the website.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **\_\_eoi**Used in order to detect spam and improve the website's security.
        
        **Maximum Storage Duration**: 180 days**Type**: HTTP Cookie
        
    *   [Instagram 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 7](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://help.instagram.com/519522125107875 ""Instagram's privacy policy"")
        
        **csrftoken**Helps prevent Cross-Site Request Forgery (CSRF) attacks.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
    *   [LinkedIn 3](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 8](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.linkedin.com/legal/privacy-policy ""LinkedIn's privacy policy"")
        
        **bcookie**Used in order to detect spam and improve the website's security.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **li\_gc**Stores the user's cookie consent state for the current domain
        
        **Maximum Storage Duration**: 180 days**Type**: HTTP Cookie
        
        **bscookie**This cookie is used to identify the visitor through an application. This allows the visitor to login to a website through their LinkedIn application for example.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
    *   [Piano 3](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 9](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://piano.io/privacy-policy/ ""Piano's privacy policy"")
        
        **AWSELB**Used to distribute traffic to the website on several servers in order to optimise response times.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **AWSELBCORS**Registers which server-cluster is serving the visitor. This is used in context with load balancing, in order to optimize user experience.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
        **ch\_sid**This cookie is necessary for the login function on the website.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
    *   [Stripe 3](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 10](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://stripe.com/privacy ""Stripe's privacy policy"")
        
        **\_\_stripe\_mid**This cookie is necessary for making credit card transactions on the website. The service is provided by Stripe.com which allows online transactions without storing any credit card information.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **\_\_stripe\_sid**This cookie is necessary for making credit card transactions on the website. The service is provided by Stripe.com which allows online transactions without storing any credit card information.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
        **m**Determines the device used to access the website. This allows the website to be formatted accordingly.
        
        **Maximum Storage Duration**: 400 days**Type**: HTTP Cookie
        
    *   [Typeform 5](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 11](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://admin.typeform.com/to/dwk6gt/ ""Typeform's privacy policy"")
        
        **#.#-#-#-#-#.ack**Used to contain user‚Äôs survey and quiz answers in Local Storage.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **#.#-#-#-#-#.inProgress**Used to contain user‚Äôs survey and quiz answers in Local Storage.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **#.#-#-#-#-#.queue**Used to contain user‚Äôs survey and quiz answers in Local Storage.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **#.#-#-#-#-#.reclaimEnd**Used to contain user‚Äôs survey and quiz answers in Local Storage.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **#.#-#-#-#-#.reclaimStart**Used to contain user‚Äôs survey and quiz answers in Local Storage.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
    *   [YouTube 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 12](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://business.safety.google/privacy/ ""YouTube's privacy policy"")
        
        **GPS**Used to determine whether the user is logged in on a YouTube account, when watching embedded videos.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
    *   [airtable.com embed.typeform.com 2](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **AWSALBTG¬†\[x2\]**Registers which server-cluster is serving the visitor. This is used in context with load balancing, in order to optimize user experience.
        
        **Maximum Storage Duration**: 7 days**Type**: HTTP Cookie
        
    *   [airtable.com typeform.com 2](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **AWSALBTGCORS¬†\[x2\]**Registers which server-cluster is serving the visitor. This is used in context with load balancing, in order to optimize user experience.
        
        **Maximum Storage Duration**: 7 days**Type**: HTTP Cookie
        
    *   [blog.orderchamp.com brokerchooser.com canva.com glassdoor.com hsforms.com piano.io vimeo.com wearetechwomen.com 10](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **\_\_cf\_bm¬†\[x10\]**This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
    *   [blog.orderchamp.com canva.com 2](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **\_\_cfruid¬†\[x2\]**This cookie is a part of the services provided by Cloudflare - Including load-balancing, deliverance of website content and serving DNS connection for website operators.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [canva.com hsforms.com medium.com prima.it vimeo.com 6](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **\_cfuvid¬†\[x6\]**This cookie is a part of the services provided by Cloudflare - Including load-balancing, deliverance of website content and serving DNS connection for website operators.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [cdn.cxense.com cdn.tinypass.com 5](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **\_cookie\_test¬†\[x5\]**This cookie determines whether the browser accepts cookies.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
    *   [hotelmap.com 2](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **token**Used to make live streaming of video content more efficient.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **TOKEN**Used to make live streaming of video content more efficient.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
    *   [m.stripe.com 3](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 13](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://stripe.com/privacy ""m.stripe.com's privacy policy"")
        
        **\_ab**This cookie is necessary for making credit card transactions on the website. The service is provided by Stripe.com which allows online transactions without storing any credit card information.
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **\_mf**This cookie is necessary for making credit card transactions on the website. The service is provided by Stripe.com which allows online transactions without storing any credit card information.
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **id**Pending
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
    *   [nr-data.net summit.sifted.eu tinypass.com www.linkedin.com 4](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **JSESSIONID¬†\[x4\]**Preserves users states across page requests.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [pitch.com 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **unleash:repository:repo**Used to determine whether the cache function should be running. This process is called dynamic caching and is used to optimize website speed.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
    *   [sifted.eu 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **\_\_mp\_opt\_in\_out\_#**Stores the user's cookie consent state for the current domain
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [www.exentriq.com 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **SameSite**Ensures visitor browsing-security by preventing cross-site request forgery. This cookie is essential for the security of the website and visitor.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [www.insoore.com 2](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **ARRAffinity**Used to distribute traffic to the website on several servers in order to optimise response times.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **ARRAffinitySameSite**Used to distribute traffic to the website on several servers in order to optimise response times.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    
*   Preferences 14
    
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
    
    *   [Airtable 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 14](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://airtable.com/privacy ""Airtable's privacy policy"")
        
        **internal/page\_view**Stores data entered with a form so that when you return to the website you don't have to fill in the data again.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
    *   [LinkedIn 3](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 15](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.linkedin.com/legal/privacy-policy ""LinkedIn's privacy policy"")
        
        **lang**Necessary for maintaining language-settings across subpages on the website.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **lidc**Registers which server-cluster is serving the visitor. This is used in context with load balancing, in order to optimize user experience.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
        **li\_alerts**Used to determine when and where certain pop-ups on the website should be presented for the user and remember whether the user has closed these, to keep them from showing multiple times.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
    *   [Piano Software 3](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 16](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://piano.io/privacy-policy/ ""Piano Software's privacy policy"")
        
        **LANG**Remembers the user's selected language version of a website
        
        **Maximum Storage Duration**: 1500 days**Type**: HTTP Cookie
        
        **LANG\_CHANGED**Necessary for maintaining language-settings across subpages on the website.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
        **weird\_get\_top\_level\_domain**The cookie determines the preferred language and country-setting of the visitor - This allows the website to show content most relevant to that region and language.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [Typeform 2](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 17](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://admin.typeform.com/to/dwk6gt/ ""Typeform's privacy policy"")
        
        **tf\_random\_id**Used to implement forms on the website.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **tf\_respondent\_cc**Used to implement forms on the website.
        
        **Maximum Storage Duration**: 6 months**Type**: HTTP Cookie
        
    *   [datawrapper.dwcdn.net 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **#/datawrapper.gif**Counts the total number of views for embedded visualizations.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
    *   [hotelmap.com 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **loglevel**Maintains settings and outputs when using the Developer Tools Console on current session.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
    *   [m.stripe.com 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 18](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://stripe.com/privacy ""m.stripe.com's privacy policy"")
        
        **1**This cookie is used in conjunction with the payment window - The cookie is necessary for making secure transactions on the website.
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
    *   [summit.sifted.eu 2](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **CFTOKEN**This cookie is used to determine which type of device the visitor is using, so the website can be properly formatted - This information is stored in the ""CFID"" cookie.
        
        **Maximum Storage Duration**: 30 days**Type**: HTTP Cookie
        
        **DEFAULTLOCALE**This cookie is used to determine what country the visitor comes from - This allows the website to set the language accordingly, if possible. The information can be determined through the visitor‚Äôs IP-address.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    
*   Statistics 37
    
    Statistic cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
    
    *   [ASP 2](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 19](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.iubenda.com/privacy-policy/11419556 ""ASP's privacy policy"")
        
        **\_pk\_id#**Collects statistics on the user's visits to the website, such as the number of visits, average time spent on the website and what pages have been read.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **\_pk\_ses#**Used by Piwik Analytics Platform to track page requests from the visitor during the session.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
    *   [Apple 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 20](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.apple.com/legal/privacy/en-ww/ ""Apple's privacy policy"")
        
        **geo**Saves the user's current geographical location based on the user's IP address.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [Canva 3](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 21](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.canva.com/policies/privacy-policy/ ""Canva's privacy policy"")
        
        **dv\_last\_interaction**Stores data on the time spent on the website and its sub-pages, during the current session.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **analytics\_event\_v2#analytics\_event\_metadata**Allows queries from third-party database for implementation of visual content.
        
        **Maximum Storage Duration**: Persistent**Type**: IndexedDB
        
        **analytics\_event\_v2#analytics\_event\_v2**Allows queries from third-party database for implementation of visual content.
        
        **Maximum Storage Duration**: Persistent**Type**: IndexedDB
        
    *   [Cxense 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 22](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.cxense.com/about-us/privacy-policy ""Cxense's privacy policy"")
        
        **\_ls\_ttl**Contains the expiry date for other cookies.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
    *   [Hubspot 4](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 23](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://legal.hubspot.com/privacy-policy ""Hubspot's privacy policy"")
        
        **\_\_hssc**Identifies if the cookie data needs to be updated in the visitor's browser.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
        **\_\_hssrc**Used to recognise the visitor's browser upon reentry on the website.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **\_\_hstc**Sets a unique ID for the session. This allows the website to obtain data on visitor behaviour for statistical purposes.
        
        **Maximum Storage Duration**: 180 days**Type**: HTTP Cookie
        
        **hubspotutk**Sets a unique ID for the session. This allows the website to obtain data on visitor behaviour for statistical purposes.
        
        **Maximum Storage Duration**: 180 days**Type**: HTTP Cookie
        
    *   [Linkedin 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 24](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.linkedin.com/legal/privacy-policy ""Linkedin's privacy policy"")
        
        **browser\_id**Used to recognise the visitor's browser upon reentry on the website.
        
        **Maximum Storage Duration**: 5 years**Type**: HTTP Cookie
        
    *   [Piano 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 25](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://piano.io/privacy-policy/ ""Piano's privacy policy"")
        
        **\_pcid**Registers statistical data on users' behaviour on the website. Used for internal analytics by the website operator.
        
        **Maximum Storage Duration**: 13 months**Type**: HTTP Cookie
        
    *   [Twitter Inc. 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 26](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://twitter.com/en/privacy ""Twitter Inc.'s privacy policy"")
        
        **personalization\_id**This cookie is set by Twitter - The cookie allows the visitor to share content from the website onto their Twitter profile.
        
        **Maximum Storage Duration**: 400 days**Type**: HTTP Cookie
        
    *   [Typeform 6](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 27](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://admin.typeform.com/to/dwk6gt/ ""Typeform's privacy policy"")
        
        **rl\_anonymous\_id**Registers statistical data on users' behaviour on the website. Used for internal analytics by the website operator.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **rl\_group\_id**Registers statistical data on users' behaviour on the website. Used for internal analytics by the website operator.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **rl\_group\_trait**Registers statistical data on users' behaviour on the website. Used for internal analytics by the website operator.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **rl\_trait**Registers statistical data on users' behaviour on the website. Used for internal analytics by the website operator.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **rl\_user\_id**Registers statistical data on users' behaviour on the website. Used for internal analytics by the website operator.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **tracking\_session\_id**Determines when the visitor last visited the different subpages on the website, as well as sets a timestamp for when the session started.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
    *   [Vimeo 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 28](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://vimeo.com/privacy ""Vimeo's privacy policy"")
        
        **vuid**Collects data on the user's visits to the website, such as which pages have been read.
        
        **Maximum Storage Duration**: 2 years**Type**: HTTP Cookie
        
    *   [cdn.cxense.com cdn.tinypass.com 2](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **\_pctx¬†\[x2\]**Registers statistical data on users' behaviour on the website. Used for internal analytics by the website operator.
        
        **Maximum Storage Duration**: 13 months**Type**: HTTP Cookie
        
    *   [metamanager.io 2](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **\_hjSession\_#**Collects statistics on the visitor's visits to the website, such as the number of visits, average time spent on the website and what pages have been read.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **\_hjSessionUser\_#**Collects statistics on the visitor's visits to the website, such as the number of visits, average time spent on the website and what pages have been read.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [open.spotify.com sifted.eu 2](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **sentryReplaySession¬†\[x2\]**Registers data on visitors' website-behaviour. This is used for internal analysis and website optimization.
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
    *   [pitch.com 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **unleash:repository:sessionId**Used in connection with phased release which allows the website owner to assign a certain number of users to a specific version of the website.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
    *   [pitch.com sifted.eu form.typeform.com 3](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **dd\_cookie\_test\_#¬†\[x3\]**Registers data on visitors' website-behaviour. This is used for internal analysis and website optimization.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [s3-eu-west-1.amazonaws.com hotelmap.com 4](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **mapbox.eventData.uuid:#¬†\[x2\]**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **mapbox.eventData:#¬†\[x2\]**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
    *   [sifted.eu 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **\_dd\_s**Registers the website's speed and performance. This function can be used in context with statistics and load-balancing.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
    *   [summit.sifted.eu 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **CFID**This cookie is used in context with the ""Cftoken"" cookie. The cookie stores a specific ID for the visitor and the visitor's device and browser.
        
        **Maximum Storage Duration**: 30 days**Type**: HTTP Cookie
        
    
*   Marketing 91
    
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
    
    *   [Meta Platforms, Inc. 3](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 29](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.facebook.com/policy.php/ "" Meta Platforms, Inc.'s privacy policy"")
        
        **lastExternalReferrer**Detects how the user reached the website by registering their last URL-address.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **lastExternalReferrerTime**Detects how the user reached the website by registering their last URL-address.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\_fbp**Used by Facebook to deliver a series of advertisement products such as real time bidding from third party advertisers.
        
        **Maximum Storage Duration**: 3 months**Type**: HTTP Cookie
        
    *   [ASP 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 30](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.iubenda.com/privacy-policy/11419556 ""ASP's privacy policy"")
        
        **piwik.php**Sets a unique ID for the visitor, that allows third party advertisers to target the visitor with relevant advertisement. This pairing service is provided by third party advertisement hubs, which facilitates real-time bidding for advertisers.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
    *   [Cxense 8](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 31](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.cxense.com/about-us/privacy-policy ""Cxense's privacy policy"")
        
        **\_cX\_atfr**Collects information on user behaviour on multiple websites. This information is used in order to optimize the relevance of advertisement on the website.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\_cX\_lastP1Time**Collects information on user behaviour on multiple websites. This information is used in order to optimize the relevance of advertisement on the website.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\_cX\_lst**Collects information on user behaviour on multiple websites. This information is used in order to optimize the relevance of advertisement on the website.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\_cX\_S**Collects information on user behaviour on multiple websites. This information is used in order to optimize the relevance of advertisement on the website.
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **Repo/rep.gif**Collects data on user behaviour and interaction in order to optimize the website and make advertisement on the website more relevant.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **gckp**Registers a unique ID that identifies a returning user's device. The ID is used for targeted ads.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **cX\_G**Collects information on user behaviour on multiple websites. This information is used in order to optimize the relevance of advertisement on the website.
        
        **Maximum Storage Duration**: 13 months**Type**: HTTP Cookie
        
        **cX\_P**Registers a unique ID that identifies a returning user's device. The ID is used for targeted ads.
        
        **Maximum Storage Duration**: 13 months**Type**: HTTP Cookie
        
    *   [Giphy Support 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 32](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://support.giphy.com/hc/en-us/articles/360020028332-GIPHY-Privacy-Policy ""Giphy Support's privacy policy"")
        
        **giphyPingbackId**Used to track the visitor's usage of GIFs - This serves for analytical and marketing purposes.
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
    *   [Google 17](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 33](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://business.safety.google/privacy/ ""Google's privacy policy"")
        
        Some of the data collected by this provider is for the purposes of personalization and measuring advertising effectiveness.
        
        **\_\_Host-GAPS**Collects data on the user's visits to the website, such as the number of visits, average time spent on the website and what pages have been loaded with the purpose of generating reports for optimising the website content.
        
        **Maximum Storage Duration**: 2 years**Type**: HTTP Cookie
        
        **GFE\_RTT**Used to implement the content through Google Docs.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **punchv-e-f**Used to implement the content through Google Docs.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **punchv-e-n**Used to implement the content through Google Docs.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **punchv-e-v**Used to implement the content through Google Docs.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **IDE**Used by Google DoubleClick to register and report the website user's actions after viewing or clicking one of the advertiser's ads with the purpose of measuring the efficacy of an ad and to present targeted ads to the user.
        
        **Maximum Storage Duration**: 400 days**Type**: HTTP Cookie
        
        **pagead/landing**Collects data on visitor behaviour from multiple websites, in order to present more relevant advertisement - This also allows the website to limit the number of times that they are shown the same advertisement.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **receive-cookie-deprecation**Collects information on user behaviour on multiple websites. This information is used in order to optimize the relevance of advertisement on the website.
        
        **Maximum Storage Duration**: 180 days**Type**: HTTP Cookie
        
        **NID**Pending
        
        **Maximum Storage Duration**: 6 months**Type**: HTTP Cookie
        
        **pagead/1p-user-list/#**Tracks if the user has shown interest in specific products or events across multiple websites and detects how the user navigates between sites. This is used for measurement of advertisement efforts and facilitates payment of referral-fees between websites.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **collect**Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **pagead/gen\_204**Collects data on visitor behaviour from multiple websites, in order to present more relevant advertisement - This also allows the website to limit the number of times that they are shown the same advertisement.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **pcs/activeview**Used by DoubleClick to determine whether website advertisement has been properly displayed - This is done to make their marketing efforts more efficient.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **pcs/view**Pending
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **csi**Collects data on visitors' preferences and behaviour on the website - This information is used make content and advertisement more relevant to the specific visitor.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **ui/v1/icons/mail/images/cleardot.gif**Pending
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **\_gat**Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
    *   [Hubspot 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 34](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://legal.hubspot.com/privacy-policy ""Hubspot's privacy policy"")
        
        **\_\_ptq.gif**Sends data to the marketing platform Hubspot about the visitor's device and behaviour. Tracks the visitor across devices and marketing channels.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
    *   [Oath. 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 35](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://policies.oath.com/ie/en/oath/privacy/index.html ""Oath.'s privacy policy"")
        
        **A3**Collects information on user behaviour on multiple websites. This information is used in order to optimize the relevance of advertisement on the website.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
    *   [Piano 5](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 36](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://piano.io/privacy-policy/ ""Piano's privacy policy"")
        
        **\_\_pat**Used in context with the implementation of content from other news sites. The cookie also allows for the third-party news site to gather user data on the current website.
        
        **Maximum Storage Duration**: 30 days**Type**: HTTP Cookie
        
        **\_\_pvi**Used in context with the implementation of content from other news sites. The cookie also allows for the third-party news site to gather user data on the current website.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
        **\_\_tbc**Registers data on visitors from multiple visits and on multiple websites. This information is used to measure the efficiency of advertisement on websites.
        
        **Maximum Storage Duration**: 2 years**Type**: HTTP Cookie
        
        **\_pprv**Collects data on user behaviour and interaction in order to optimize the website and make advertisement on the website more relevant.
        
        **Maximum Storage Duration**: 13 months**Type**: HTTP Cookie
        
        **xbc**Collects data on user behaviour and interaction in order to optimize the website and make advertisement on the website more relevant.
        
        **Maximum Storage Duration**: 2 years**Type**: HTTP Cookie
        
    *   [RudderStack 3](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 37](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.rudderstack.com/cookie-policy/ ""RudderStack's privacy policy"")
        
        **\_\_tld\_\_**Used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **rudder\_cookies**Pending
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **test\_rudder**Pending
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
    *   [Spotify 2](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 38](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.spotify.com/uk/legal/privacy-policy/ ""Spotify's privacy policy"")
        
        **sp\_landing**Used to implement audio-content from Spotify on the website. Can also be used to register user interaction and preferences in context with audio-content - This can serve statistics and marketing purposes.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
        **sp\_t**Used to implement audio-content from Spotify on the website. Can also be used to register user interaction and preferences in context with audio-content - This can serve statistics and marketing purposes.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
    *   [Twitter Inc. 10](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 39](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://twitter.com/en/privacy ""Twitter Inc.'s privacy policy"")
        
        **1/i/adsct¬†\[x2\]**Collects data on user behaviour and interaction in order to optimize the website and make advertisement on the website more relevant.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **i/adsct¬†\[x2\]**The cookie is used by Twitter.com in order to determine the number of visitors accessing the website through Twitter advertisement content.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **muc\_ads**Collects data on user behaviour and interaction in order to optimize the website and make advertisement on the website more relevant.
        
        **Maximum Storage Duration**: 400 days**Type**: HTTP Cookie
        
        **guest\_id**Collects data related to the user's visits to the website, such as the number of visits, average time spent on the website and which pages have been loaded, with the purpose of personalising and improving the Twitter service.
        
        **Maximum Storage Duration**: 400 days**Type**: HTTP Cookie
        
        **guest\_id\_ads**Collects information on user behaviour on multiple websites. This information is used in order to optimize the relevance of advertisement on the website.
        
        **Maximum Storage Duration**: 400 days**Type**: HTTP Cookie
        
        **guest\_id\_marketing**Collects information on user behaviour on multiple websites. This information is used in order to optimize the relevance of advertisement on the website.
        
        **Maximum Storage Duration**: 400 days**Type**: HTTP Cookie
        
        **i/jot/embeds**Sets a unique ID for the visitor, that allows third party advertisers to target the visitor with relevant advertisement. This pairing service is provided by third party advertisement hubs, which facilitates real-time bidding for advertisers.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **RichHistory**Collects data on visitors' preferences and behaviour on the website - This information is used make content and advertisement more relevant to the specific visitor.
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
    *   [Typeform 2](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 40](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://admin.typeform.com/to/dwk6gt/ ""Typeform's privacy policy"")
        
        **#-visitorId**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **attribution\_user\_id**Used in context with the website‚Äôs pop-up questionnaires and messengering. The data is used for statistical or marketing purposes.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
    *   [YouTube 22](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 41](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://business.safety.google/privacy/ ""YouTube's privacy policy"")
        
        **#-#**Used to track user‚Äôs interaction with embedded content.
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **2232b765-e46984**Pending
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **iU5q-!O9@$**Registers a unique ID to keep statistics of what videos from YouTube the user has seen.
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **LAST\_RESULT\_ENTRY\_KEY**Used to track user‚Äôs interaction with embedded content.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **LogsDatabaseV2:V#||LogsRequestsStore**Used to track user‚Äôs interaction with embedded content.
        
        **Maximum Storage Duration**: Persistent**Type**: IndexedDB
        
        **nextId**Used to track user‚Äôs interaction with embedded content.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **remote\_sid**Necessary for the implementation and functionality of YouTube video-content on the website.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **requests**Used to track user‚Äôs interaction with embedded content.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **ServiceWorkerLogsDatabase#SWHealthLog**Necessary for the implementation and functionality of YouTube video-content on the website.
        
        **Maximum Storage Duration**: Persistent**Type**: IndexedDB
        
        **TESTCOOKIESENABLED**Used to track user‚Äôs interaction with embedded content.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
        **VISITOR\_INFO1\_LIVE**Pending
        
        **Maximum Storage Duration**: 180 days**Type**: HTTP Cookie
        
        **YSC**Pending
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **yt.innertube::nextId**Registers a unique ID to keep statistics of what videos from YouTube the user has seen.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **ytidb::LAST\_RESULT\_ENTRY\_KEY**Used to track user‚Äôs interaction with embedded content.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **YtIdbMeta#databases**Used to track user‚Äôs interaction with embedded content.
        
        **Maximum Storage Duration**: Persistent**Type**: IndexedDB
        
        **yt-remote-cast-available**Stores the user's video player preferences using embedded YouTube video
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **yt-remote-cast-installed**Stores the user's video player preferences using embedded YouTube video
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **yt-remote-connected-devices**Stores the user's video player preferences using embedded YouTube video
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **yt-remote-device-id**Stores the user's video player preferences using embedded YouTube video
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **yt-remote-fast-check-period**Stores the user's video player preferences using embedded YouTube video
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **yt-remote-session-app**Stores the user's video player preferences using embedded YouTube video
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **yt-remote-session-name**Stores the user's video player preferences using embedded YouTube video
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
    *   [metamanager.io www.googletagmanager.com 2](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **\_gcl\_au¬†\[x2\]**Used by Google AdSense for experimenting with advertisement efficiency across websites using their services.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [sifted.eu 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **mp\_#\_mixpanel**Pending
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
    *   [www.google-analytics.com metamanager.io 8](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **\_ga¬†\[x5\]**Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels.
        
        **Maximum Storage Duration**: 2 years**Type**: HTTP Cookie
        
        **\_gid¬†\[x3\]**Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
    *   [www.googletagmanager.com metamanager.io 4](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **\_ga\_#¬†\[x4\]**Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels.
        
        **Maximum Storage Duration**: 2 years**Type**: HTTP Cookie
        
    
*   Unclassified 36
    
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
    
    *   [Airtable 2](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 42](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://airtable.com/privacy ""Airtable's privacy policy"")
        
        **brwConsent**Pending
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
        **profile\_images/860062637769580548/2K\_bXBm\_\_400x400.jpg**Pending
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
    *   [Albumizr 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 43](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://albumizr.com/ ""Albumizr's privacy policy"")
        
        **jallery\_uid**Pending
        
        **Maximum Storage Duration**: 400 days**Type**: HTTP Cookie
        
    *   [Apple 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 44](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.apple.com/legal/privacy/en-ww/ ""Apple's privacy policy"")
        
        **mtClientConfig\_cachedSource\_xp\_amp\_podcasts\_paf**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
    *   [Canva 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 45](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.canva.com/policies/privacy-policy/ ""Canva's privacy policy"")
        
        **leadership\_lock#leadership\_lock**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: IndexedDB
        
    *   [Flourish 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 46](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://flourish.studio/privacy/ ""Flourish's privacy policy"")
        
        **EPIPRODSRV**Pending
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [LinkedIn 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 47](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.linkedin.com/legal/privacy-policy ""LinkedIn's privacy policy"")
        
        **sequenceNumber#sequenceNumber**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: IndexedDB
        
    *   [Oath. 3](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 48](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://policies.oath.com/ie/en/oath/privacy/index.html ""Oath.'s privacy policy"")
        
        **\_ebd**Pending
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **A1**Pending
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **A1S**Pending
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [Piano 5](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 49](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://piano.io/privacy-policy/ ""Piano's privacy policy"")
        
        **\_\_tp-gaAccount**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\_\_tp-metricsGAAccount**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\_\_tp-trackOnlyAids**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\_\_pid**Pending
        
        **Maximum Storage Duration**: 30 days**Type**: HTTP Cookie
        
        **\_\_pil**Pending
        
        **Maximum Storage Duration**: 30 days**Type**: HTTP Cookie
        
    *   [Piano Software 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)[Learn more about this provider![Image 50](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://piano.io/privacy-policy/ ""Piano Software's privacy policy"")
        
        **oxEhvcJHpu\_\_eea**Pending
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [datawrapper.dwcdn.net 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **#/pixel.gif**Pending
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
    *   [hotelmap.com 5](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **email**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **loglevel:twilio-chat**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **loglevel:twilio-sync**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **loglevel:twilsock**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **wwhmid**Pending
        
        **Maximum Storage Duration**: 56 days**Type**: HTTP Cookie
        
    *   [pitch.com 9](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **\[""~#'"",""~:auth/session-connection-type""\]**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\[""~#'"",""~:card-overlays""\]**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\[""~#'"",""~:pitch.app.api-client/allow-requests""\]**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\[""~#'"",""~:pre-auth-route""\]**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\[""~#'"",""~:previous-route""\]**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\[""~#'"",""~:user""\]**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **pitch-platform-session-id**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **platform-dev-panel**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **VIEWER\_COUNTRY**Pending
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
    *   [sifted.eu 4](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **\_\_mp\_opt\_in\_out\_516258ca7de16bfdb47d0ebf1beedce9**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\_\_mp\_opt\_in\_out\_d003f5a571ef2d95359261f82863e3ef**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **ebx\_webtag\_**Pending
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **mp\_optout**Pending
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [summit.sifted.eu 1](https://sifted.eu/articles/medtech-startup-vc-trends/#)
        
        **popupTimer**Pending
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    

[Cross-domain consent2](https://sifted.eu/articles/medtech-startup-vc-trends/#) Your consent applies to the following domains:

List of domains your consent applies to:

[summit.sifted.eu](https://summit.sifted.eu/)

[www.sifted.eu](https://www.sifted.eu/)

Cookie declaration last updated on 8/27/24 by [Cookiebot](https://www.cookiebot.com/ ""Cookiebot"")

\[#IABV2\_TITLE#\]
------------------

\[#IABV2\_BODY\_INTRO#\]

\[#IABV2\_BODY\_LEGITIMATE\_INTEREST\_INTRO#\]

\[#IABV2\_BODY\_PREFERENCE\_INTRO#\]

\[#IABV2\_LABEL\_PURPOSES#\]

\[#IABV2\_BODY\_PURPOSES\_INTRO#\]

\[#IABV2\_BODY\_PURPOSES#\]

\[#IABV2\_LABEL\_FEATURES#\]

\[#IABV2\_BODY\_FEATURES\_INTRO#\]

\[#IABV2\_BODY\_FEATURES#\]

\[#IABV2\_LABEL\_PARTNERS#\]

\[#IABV2\_BODY\_PARTNERS\_INTRO#\]

\[#IABV2\_BODY\_PARTNERS#\]

Cookies are small text files that can be used by websites to make a user's experience more efficient.  
  
The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission.  
  
This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.  
  
You can at any time change or withdraw your consent from the Cookie Policy on our website.  
  
Learn more about who we are, how you can contact us and how we process personal data in our Privacy Policy.  
  
Please state your consent ID and date when you contact us regarding your consent.

  
  

**Do not sell or share my personal information**

Deny Allow selection Customize

Allow all

[Powered by Cookiebot by Usercentrics](https://www.cookiebot.com/en/what-is-behind-powered-by-cookiebot/)

Open navigation menu

[](https://sifted.eu/)

*   News
*   Insights
*   Newsletters
*   Events
[Podcasts](https://sifted.eu/podcasts)

[](https://sifted.eu/search)

[SubscribeSubscribe](https://sifted.eu/subscribe)

[Log in](https://sifted.eu/members/login?redirectUrl=%2Farticles%2Fmedtech-startup-vc-trends)

[](https://sifted.eu/)

**Startup Europe.** Grown up reporting.

[Subscribe](https://sifted.eu/subscribe)

[Log in](https://sifted.eu/members/login?redirectUrl=%2Farticles%2Fmedtech-startup-vc-trends)

*   ### News
    
*   ### Insights
    
*   ### Newsletters
    
*   ### Events
    
*   [Podcasts](https://sifted.eu/podcasts)

*   [Search](https://sifted.eu/search)

Backed by

### Company

*   [About](https://sifted.eu/about)
*   [Careers](https://sifted.eu/careers)
*   [Advertising](https://sifted.eu/advertising)
*   [Controllership](https://sifted.eu/controllership/)
*   [Cookie Policy](https://sifted.eu/cookie-policy)
*   [Privacy policy](https://sifted.eu/privacy-policy)
*   [AI Code of Conduct](https://sifted.eu/ai-code-of-conduct)
*   [Terms of use](https://sifted.eu/terms-of-use)

### Sifted Pro

*   [Subscribe](https://sifted.eu/subscribe)
*   [~/Briefings](https://sifted.eu/pro/briefings/about)
*   [~/Pitches](https://sifted.eu/pro/roundtables)
*   [~/Scout](https://sifted.eu/scout)

### Products

*   [~/Newsletters](https://sifted.eu/newsletters)
*   [~/Rankings](https://sifted.eu/rankings)
*   [~/Reports](https://sifted.eu/intelligence/reports)

### Community

*   [~/Talks](https://sifted.eu/talks)
*   [~/Podcasts](https://sifted.eu/podcasts)
*   [~/Summit](https://summit.sifted.eu/)
*   [Jobs board](https://jobs.sifted.eu/?source=navbar&utm_source=navbar&utm_medium=partner_referral)

*   [![Image 51: X Logo](https://www.datocms-assets.com/60124/1697443751-x-logo.svg)](https://twitter.com/siftedeu)
*   [![Image 52: LinkedIn Logo](https://www.datocms-assets.com/60124/1689076682-linkedin.svg)](https://www.linkedin.com/company/siftedeu/)
*   [![Image 53: Facebook Logo](https://www.datocms-assets.com/60124/1689076874-facebook.svg)](https://www.facebook.com/siftedeu)
*   [![Image 54: RSS Feed Logo](https://www.datocms-assets.com/60124/1689076939-rss-feed.svg)](https://sifted.eu/feed/?post_type=article)

¬© 2024 Sifted EU Ltd. All Rights Reserved.

[Analysis](https://sifted.eu/categories/analysis/)August 27, 2024

11 medtech startups to watch, according to VCs
==============================================

VCs at 415 Capital, Sofinnova Partners, MIG Capital and SHS Capital share their picks
-------------------------------------------------------------------------------------

[Kai Nicol-Schwarz](https://sifted.eu/author/kai-nicol-schwarz/)

5 min read

Medtech has had a mixed few years. In 2023, startups in the sector raised $2.2bn with 2024 looking similar ‚Äî roughly half of the $4bn picked up in 2021, according to [Sifted data.](https://sifted.eu/pro/briefings/medtech-2024)

But there have still been some sizable rounds in recent times. Since the start of 2023, surgical robotics startups have been the biggest winners. The UK‚Äôs CMR Surgical picked up [¬£165m](https://sifted.eu/articles/cmr-surgical-raise-2023) in September last year, Switzerland‚Äôs DistalMotion $150m in April 2023 and Italy‚Äôs Medical Microinstruments $110m in February this year.

There‚Äôs also been some buzz around next-gen diagnostic devices, as founders ‚Äî including [Spotify‚Äôs Daniel Ek](https://sifted.eu/articles/daniel-eks-body-scanning-neko-health-is-expanding-to-the-uk-news) with his body scanning startup Neko Health ‚Äî look to tap into the trend of more people using wellbeing and fitness devices like Apple Watches and Oura rings.

Advertisement

But which non-portfolio medtech startups are investors keeping a close eye on? To find out, Sifted spoke to VCs at 415 Capital, Sofinnova Partners, MIG Capital and SHS Capital.

### **Linus Rieder, principal at 415 Capital**

![Image 55](https://images.sifted.eu/wp-content/uploads/2024/08/23145641/Linus-final-Kopie-scaled-e1724421412663.jpg?auto=format&fit=max&w=3840&q=75)

#### **Medical Microinstruments (MMI) ‚Äì Italy**

MMI is building surgical robots to help with micro-surgery. Its robotics platform can be used in reconstructive surgery, plastic surgery and head-neck surgery. The startup is looking to solve key issues in microsurgery like the effects of surgeon tremor and reduces the need for microsurgery training.

#### **Gradient Denervation Technologies ‚Äî France**

Gradient Denervation Technologies is developing a device for treating heart failure patients with associated pulmonary hypertension. As many as [half of heart failure patients](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199161/) around the world have elevated pulmonary vascular resistance, which is shown to lead to an increased risk of mortality and hospitalisation. There are no approved drug or device therapies for this group of pulmonary hypertension patients. By using minimally invasive ultrasound to treat hyperactive nerves in the pulmonary arteries, however, the startup‚Äôs technology has the potential to treat and help tens of thousands of patients each year.

#### **CorWave ‚Äî France**

CorWave's left ventricular assist device (LVAD) mimics the natural heart's function to treat patients with advanced heart failure. This technology enables the device to replicate the heart pulses, reducing the mechanical damage to blood cells common with current LVADs.

### **Anne Osdoit, partner at Sofinnova Partners**

![Image 56](https://images.sifted.eu/wp-content/uploads/2024/08/23145729/%C2%A9Delporte-AnneOsdoit02-scaled-e1724421470674.jpg?auto=format&fit=max&w=3840&q=75)

#### **Ganymed Robotics ‚Äî France**¬†

Ganymed is working on a robotics platform to assist surgeons with implant placement during knee replacement surgery. The Paris-based company's approach uses computer vision and artificial intelligence to perceive, and extract knowledge from, the surgical environment in a non-invasive manner, removing imaging and registration steps that add time and complexity to knee surgery.

#### **Gleamer ‚Äî France**

Gleamer is developing AI tools to enhance image interpretation for radiologists. The startup‚Äôs main product helps clinicians identify bone trauma at the point of care. Gleamer has achieved multiple regulatory approvals and successfully commercially deployed in both the US and EU.

#### **Salvia BioElectronics ‚Äî The Netherlands**¬†

Salvia BioElectronics is developing drug-free neuromodulation therapies ‚Äî which refers to a group of medical procedures that look to change brain activity by stimulating nerves ‚Äî for migraines. Salvia's paper-thin implant is designed to be placed under the forehead to reduce the frequency and intensity of migraine attacks by delivering gentle electrical pulses to the nerves associated with the condition. The company is currently in the clinical stage, having received the Breakthrough Device Designation from the United States Food and Drug Administration (FDA), which facilitates expedited market access for devices that treat life-threatening or irreversibly debilitating conditions.

### **Fei Tian, principal at MIG Capital**

![Image 57](https://images.sifted.eu/wp-content/uploads/2024/08/23150100/image001-4-scaled-e1724421677917.jpg?auto=format&fit=max&w=3840&q=75)

#### **Artidis ‚Äî Switzerland**

Artidis is developing imaging tools for cancer diagnostics. It combines a nanotechnology device which analyses tissue with a digital data platform to measure the physical characteristics of both tumour cells and the tumour microenvironment. After determining if a tumour is benign or malignant, Artidis‚Äô technology identifies if it will spread to other sites and can help inform chemotherapy and immunotherapy permeability and treatment response.

#### **CoreMedic ‚Äî Switzerland**¬†

CoreMedic has developed an implant which treats the heart condition mitral valve regurgitation (MR). The CoreMedic implant can replace ruptured mitral ‚Äî a part of the heart ‚Äî in a minimally invasive procedure that is physiological and reproducible, promising long-term clinical benefits.

### **Cornelius Maas, partner at SHS Capital**

![Image 58](https://images.sifted.eu/wp-content/uploads/2023/06/27174537/Dr.-Cornelius-Maas_SHS_38_retouched-scaled-e1724421707488.jpg?auto=format&fit=max&w=3840&q=75)

#### **Vitestro ‚Äî The Netherlands**

Vitestro is developing an autonomous blood drawing device. This innovative device combines robotics and AI to perform blood drawing more efficiently and safely. Over the past year, Vitestro has made significant strides in clinical trials and secured an additional ‚Ç¨20m in funding in April. Vitestro‚Äôs tool could mean less burden for patients, less work for the medical staff and consequently reduce costs for the healthcare system.

Advertisement

#### **Saphenus ‚Äî Austria**

Saphenus is developing sensory feedback systems for prosthetics. Their key product, the Suralis system, provides users of lower-limb prosthetics with the sensation of foot contact, significantly improving balance and gait. Recently, Saphenus received FDA approval with their Suralis systema and received reimbursement status with key German medical insurers.

#### **Bluedrop Medical ‚Äî Ireland**

Bluedrop Medical is developing a medical device to monitor foot health and prevent diabetic foot ulcers. It looks like a weighing scale and aims to enable early detection of foot ulcers, which can lead to amputation. Bluedrop Medical is a good example of how remote monitoring can replace doctor visits while preventing serious disease progression, improving patient outcomes and reducing healthcare costs.

Advertisement

Editor's picks

*   [News](https://sifted.eu/categories/news/)
    
    [Three cofounders leave French AI startup H just three months after raising $220m seed](https://sifted.eu/articles/three-cofounders-leave-h-news/)
    
    * * *
    
*   [Analysis](https://sifted.eu/categories/analysis/)
    
    [Lost millions, a luxury cottage under threat and Oussama Ammar‚Äôs new startup accelerator: What‚Äôs going on with the dispute at The Family?](https://sifted.eu/articles/the-family-oussama-ammar-startup-latest/)
    
    * * *
    
*   [News](https://sifted.eu/categories/news/)
    
    [Mike Lynch‚Äôs impact on UK tech](https://sifted.eu/articles/mike-lynch-tech-legacy/)
    
    * * *
    

Advertisement

[Kai Nicol-Schwarz](https://sifted.eu/author/kai-nicol-schwarz/)

Kai Nicol-Schwarz is a reporter at Sifted. He covers UK tech and healthtech, and can be found on [X](https://twitter.com/NicolSchwarzK) and [LinkedIn](https://www.linkedin.com/in/kains/)

[# Healthtech](https://sifted.eu/sector/healthtech/)[# Medtech](https://sifted.eu/sector/medtech/)[# Investor survey](https://sifted.eu/tag/investor-survey/)

5x a week

~/¬†Sifted Daily
---------------

Stay one step ahead with news and experts analysis on what‚Äôs happening across startup Europe.

By Sifted journalists

Sign up

Recommended

*   [![Image 59](https://images.sifted.eu/wp-content/uploads/2024/08/14175205/Caresyntax4.jpg?auto=format&fit=max&w=3840&q=75)](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/)
    
    [AI surgery tech startup raises $180m from investors including BlackRock](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/)[More than a dozen investors were involved in the equity and debt round for Berlin-based Caresyntax](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/)[Kai Nicol-Schwarz](https://sifted.eu/author/kai-nicol-schwarz/)
    
*   [![Image 60](https://images.sifted.eu/wp-content/uploads/2023/09/07164512/Screenshot-2023-09-07-at-16.45.04.png?auto=format&fit=max&w=3840&q=75)](https://sifted.eu/articles/startups-wegovy-ozempic-shift/)
    
    [Riding the Wegovy wave: The startups shifting focus to GLP-1s to tap the $150bn weight loss drug market](https://sifted.eu/articles/startups-wegovy-ozempic-shift/)[Founders and investors see massive potential in the new drug class ‚Äî but funding is yet to flood startups in the sector](https://sifted.eu/articles/startups-wegovy-ozempic-shift/)[Kai Nicol-Schwarz](https://sifted.eu/author/kai-nicol-schwarz/)
    
*   [![Image 61](https://images.sifted.eu/wp-content/uploads/2024/07/30122008/Flo-For-Partners-_-Flow-e1722338418859.png?auto=format&fit=max&w=3840&q=75)](https://sifted.eu/articles/male-founded-startup-europes-first-femtech-unicorn/)
    
    [A male-founded startup became Europe‚Äôs first femtech unicorn. Does it matter?](https://sifted.eu/articles/male-founded-startup-europes-first-femtech-unicorn/)[Some founders and investors are frustrated that the first European femtech unicorn is run by men](https://sifted.eu/articles/male-founded-startup-europes-first-femtech-unicorn/)[Anne Sraders](https://sifted.eu/author/anne-sraders/)
    

Backed by

### Company

*   [About](https://sifted.eu/about)
*   [Careers](https://sifted.eu/careers)
*   [Advertising](https://sifted.eu/advertising)
*   [Controllership](https://sifted.eu/controllership/)
*   [Cookie Policy](https://sifted.eu/cookie-policy)
*   [Privacy policy](https://sifted.eu/privacy-policy)
*   [AI Code of Conduct](https://sifted.eu/ai-code-of-conduct)
*   [Terms of use](https://sifted.eu/terms-of-use)

### Sifted Pro

*   [Subscribe](https://sifted.eu/subscribe)
*   [~/Briefings](https://sifted.eu/pro/briefings/about)
*   [~/Pitches](https://sifted.eu/pro/roundtables)
*   [~/Scout](https://sifted.eu/scout)

### Products

*   [~/Newsletters](https://sifted.eu/newsletters)
*   [~/Rankings](https://sifted.eu/rankings)
*   [~/Reports](https://sifted.eu/intelligence/reports)

### Community

*   [~/Talks](https://sifted.eu/talks)
*   [~/Podcasts](https://sifted.eu/podcasts)
*   [~/Summit](https://summit.sifted.eu/)
*   [Jobs board](https://jobs.sifted.eu/?source=footer&utm_source=footer&utm_medium=partner_referral)

*   [![Image 62: X Logo](https://www.datocms-assets.com/60124/1697443751-x-logo.svg)](https://twitter.com/siftedeu)
*   [![Image 63: LinkedIn Logo](https://www.datocms-assets.com/60124/1689076682-linkedin.svg)](https://www.linkedin.com/company/siftedeu/)
*   [![Image 64: Facebook Logo](https://www.datocms-assets.com/60124/1689076874-facebook.svg)](https://www.facebook.com/siftedeu)
*   [![Image 65: RSS Feed Logo](https://www.datocms-assets.com/60124/1689076939-rss-feed.svg)](https://sifted.eu/feed/?post_type=article)

¬© 2024 Sifted EU Ltd. All Rights Reserved.

 ![Image 66: Cookiebot session tracker icon loaded](https://imgsct.cookiebot.com/1.gif?dgi=33e59a16-c6e6-406b-8161-7e6b9693bc2e)
"
2024-08-15 00:00:00,2024-08-29 23:12:17,"üöÄ Exciting news in the world of healthtech! 

A recent article shared that Berlin-based startup Caresyntax has successfully raised **$180 million** in funding, making waves in the AI-driven surgery tech space. This funding comes as part of their ongoing mission to enhance surgical outcomes through advanced data solutions. üëèüíº  

Caresyntax aims to build a comprehensive data platform that interconnects various forms of surgical data, providing surgeons with invaluable insights that can improve patient care and operational efficiency. With capabilities to monitor real-time parameters like heart rate drops during surgeries, the platform is designed to alert medical staff to potential issues before they escalate.  

What‚Äôs particularly fascinating is how Caresyntax's integrative platform can work across diverse operating room technologies, effectively breaking down data silos that hinder informed decision-making. This is especially crucial as healthcare costs linked to surgeries account for around **30%** of total healthcare expenditures. 

As professionals in the health industry, this development serves as a reminder of the transformative potential of **AI and big data** in improving patient outcomes and reducing operational costs. It also opens up a world of possibilities for innovation in surgical workflows.  

How do you envision AI impacting surgical procedures in your practice or organization? Let's hear your thoughts! ü§îüí¨  

#HealthTech #AIinHealthcare #SurgeryTech #Caresyntax #Innovation",https://sifted.eu/wp-content/uploads/2024/08/23150208/%C2%A9Delporte-AnneOsdoit02-1-scaled-e1724421752987.jpg?auto=format&fit=max&w=3840&q=75,https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: AI surgery tech startup raises $180m from investors including BlackRock | Sifted

URL Source: https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/

Markdown Content:
AI surgery tech startup raises $180m from investors including BlackRock | Sifted
===============
   

 

![Image 1: logo](blob:https://sifted.eu/4eb6460ab93a7ae1978320dda45af1eb)

[](https://www.cookiebot.com/en/what-is-behind-powered-by-cookiebot/)

*   [Consent](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
*   [Details](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
*   [\[#IABV2SETTINGS#\]](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
*   [About](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)

This website uses cookies
-------------------------

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you‚Äôve provided to them or that they‚Äôve collected from your use of their services.

Consent Selection

**Necessary**

**Preferences**

**Statistics**

**Marketing**

[Show details](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)

*   Necessary 75
    
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
    
    *   [Airtable 4](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 2](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://airtable.com/privacy ""Airtable's privacy policy"")
        
        **\_\_Host-airtable-session**Contains a specific ID for the current session. This is necessary for running the website correctly.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **\_\_Host-airtable-session.sig**Contains a specific ID for the current session. This is necessary for running the website correctly.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **brw**Detects and logs potential errors on third-party provided functions on the website.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **login-status-p**This cookie is necessary for the login function on the website.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [Albumizr 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 3](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://albumizr.com/ ""Albumizr's privacy policy"")
        
        **PHPSESSID**Preserves user session state across page requests.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [Canva 5](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 4](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.canva.com/policies/privacy-policy/ ""Canva's privacy policy"")
        
        **cf\_clearance**This cookie is used to distinguish between humans and bots.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **ASI**The cookie is necessary for secure log-in and the detection of any spam or abuse of the website.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **CCK**The cookie is necessary for secure log-in and the detection of any spam or abuse of the website.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
        **CDI**The cookie is necessary for secure log-in and the detection of any spam or abuse of the website.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **CPA**Necessary for the website security.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
    *   [Cookiebot 3](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 5](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.cookiebot.com/goto/privacy-policy/ ""Cookiebot's privacy policy"")
        
        **1.gif**Used to count the number of sessions to the website, necessary for optimizing CMP product delivery.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **CookieConsent¬†\[x2\]**Stores the user's cookie consent state for the current domain
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
    *   [Google 5](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 6](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://business.safety.google/privacy/ ""Google's privacy policy"")
        
        Some of the data collected by this provider is for the purposes of personalization and measuring advertising effectiveness.
        
        **test\_cookie**Used to check if the user's browser supports cookies.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
        **rc::e**This cookie is used to distinguish between humans and bots.
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **rc::h**This cookie is used to distinguish between humans and bots.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **docs/common/netcheck.gif**Necessary for the general functionality of the website.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **\_\_eoi**Used in order to detect spam and improve the website's security.
        
        **Maximum Storage Duration**: 180 days**Type**: HTTP Cookie
        
    *   [Instagram 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 7](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://help.instagram.com/519522125107875 ""Instagram's privacy policy"")
        
        **csrftoken**Helps prevent Cross-Site Request Forgery (CSRF) attacks.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
    *   [LinkedIn 3](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 8](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.linkedin.com/legal/privacy-policy ""LinkedIn's privacy policy"")
        
        **bcookie**Used in order to detect spam and improve the website's security.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **li\_gc**Stores the user's cookie consent state for the current domain
        
        **Maximum Storage Duration**: 180 days**Type**: HTTP Cookie
        
        **bscookie**This cookie is used to identify the visitor through an application. This allows the visitor to login to a website through their LinkedIn application for example.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
    *   [Piano 3](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 9](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://piano.io/privacy-policy/ ""Piano's privacy policy"")
        
        **AWSELB**Used to distribute traffic to the website on several servers in order to optimise response times.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **AWSELBCORS**Registers which server-cluster is serving the visitor. This is used in context with load balancing, in order to optimize user experience.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
        **ch\_sid**This cookie is necessary for the login function on the website.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
    *   [Stripe 3](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 10](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://stripe.com/privacy ""Stripe's privacy policy"")
        
        **\_\_stripe\_mid**This cookie is necessary for making credit card transactions on the website. The service is provided by Stripe.com which allows online transactions without storing any credit card information.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **\_\_stripe\_sid**This cookie is necessary for making credit card transactions on the website. The service is provided by Stripe.com which allows online transactions without storing any credit card information.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
        **m**Determines the device used to access the website. This allows the website to be formatted accordingly.
        
        **Maximum Storage Duration**: 400 days**Type**: HTTP Cookie
        
    *   [Typeform 5](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 11](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://admin.typeform.com/to/dwk6gt/ ""Typeform's privacy policy"")
        
        **#.#-#-#-#-#.ack**Used to contain user‚Äôs survey and quiz answers in Local Storage.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **#.#-#-#-#-#.inProgress**Used to contain user‚Äôs survey and quiz answers in Local Storage.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **#.#-#-#-#-#.queue**Used to contain user‚Äôs survey and quiz answers in Local Storage.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **#.#-#-#-#-#.reclaimEnd**Used to contain user‚Äôs survey and quiz answers in Local Storage.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **#.#-#-#-#-#.reclaimStart**Used to contain user‚Äôs survey and quiz answers in Local Storage.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
    *   [YouTube 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 12](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://business.safety.google/privacy/ ""YouTube's privacy policy"")
        
        **GPS**Used to determine whether the user is logged in on a YouTube account, when watching embedded videos.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
    *   [airtable.com embed.typeform.com 2](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **AWSALBTG¬†\[x2\]**Registers which server-cluster is serving the visitor. This is used in context with load balancing, in order to optimize user experience.
        
        **Maximum Storage Duration**: 7 days**Type**: HTTP Cookie
        
    *   [airtable.com typeform.com 2](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **AWSALBTGCORS¬†\[x2\]**Registers which server-cluster is serving the visitor. This is used in context with load balancing, in order to optimize user experience.
        
        **Maximum Storage Duration**: 7 days**Type**: HTTP Cookie
        
    *   [blog.orderchamp.com brokerchooser.com canva.com glassdoor.com hsforms.com piano.io vimeo.com wearetechwomen.com 10](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **\_\_cf\_bm¬†\[x10\]**This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
    *   [blog.orderchamp.com canva.com 2](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **\_\_cfruid¬†\[x2\]**This cookie is a part of the services provided by Cloudflare - Including load-balancing, deliverance of website content and serving DNS connection for website operators.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [canva.com hsforms.com medium.com prima.it vimeo.com 6](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **\_cfuvid¬†\[x6\]**This cookie is a part of the services provided by Cloudflare - Including load-balancing, deliverance of website content and serving DNS connection for website operators.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [cdn.cxense.com cdn.tinypass.com 5](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **\_cookie\_test¬†\[x5\]**This cookie determines whether the browser accepts cookies.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
    *   [hotelmap.com 2](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **token**Used to make live streaming of video content more efficient.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **TOKEN**Used to make live streaming of video content more efficient.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
    *   [m.stripe.com 3](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 13](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://stripe.com/privacy ""m.stripe.com's privacy policy"")
        
        **\_ab**This cookie is necessary for making credit card transactions on the website. The service is provided by Stripe.com which allows online transactions without storing any credit card information.
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **\_mf**This cookie is necessary for making credit card transactions on the website. The service is provided by Stripe.com which allows online transactions without storing any credit card information.
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **id**Pending
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
    *   [nr-data.net summit.sifted.eu tinypass.com www.linkedin.com 4](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **JSESSIONID¬†\[x4\]**Preserves users states across page requests.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [pitch.com 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **unleash:repository:repo**Used to determine whether the cache function should be running. This process is called dynamic caching and is used to optimize website speed.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
    *   [sifted.eu 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **\_\_mp\_opt\_in\_out\_#**Stores the user's cookie consent state for the current domain
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [www.exentriq.com 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **SameSite**Ensures visitor browsing-security by preventing cross-site request forgery. This cookie is essential for the security of the website and visitor.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [www.insoore.com 2](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **ARRAffinity**Used to distribute traffic to the website on several servers in order to optimise response times.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **ARRAffinitySameSite**Used to distribute traffic to the website on several servers in order to optimise response times.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    
*   Preferences 14
    
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
    
    *   [Airtable 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 14](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://airtable.com/privacy ""Airtable's privacy policy"")
        
        **internal/page\_view**Stores data entered with a form so that when you return to the website you don't have to fill in the data again.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
    *   [LinkedIn 3](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 15](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.linkedin.com/legal/privacy-policy ""LinkedIn's privacy policy"")
        
        **lang**Necessary for maintaining language-settings across subpages on the website.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **lidc**Registers which server-cluster is serving the visitor. This is used in context with load balancing, in order to optimize user experience.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
        **li\_alerts**Used to determine when and where certain pop-ups on the website should be presented for the user and remember whether the user has closed these, to keep them from showing multiple times.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
    *   [Piano Software 3](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 16](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://piano.io/privacy-policy/ ""Piano Software's privacy policy"")
        
        **LANG**Remembers the user's selected language version of a website
        
        **Maximum Storage Duration**: 1500 days**Type**: HTTP Cookie
        
        **LANG\_CHANGED**Necessary for maintaining language-settings across subpages on the website.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
        **weird\_get\_top\_level\_domain**The cookie determines the preferred language and country-setting of the visitor - This allows the website to show content most relevant to that region and language.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [Typeform 2](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 17](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://admin.typeform.com/to/dwk6gt/ ""Typeform's privacy policy"")
        
        **tf\_random\_id**Used to implement forms on the website.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **tf\_respondent\_cc**Used to implement forms on the website.
        
        **Maximum Storage Duration**: 6 months**Type**: HTTP Cookie
        
    *   [datawrapper.dwcdn.net 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **#/datawrapper.gif**Counts the total number of views for embedded visualizations.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
    *   [hotelmap.com 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **loglevel**Maintains settings and outputs when using the Developer Tools Console on current session.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
    *   [m.stripe.com 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 18](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://stripe.com/privacy ""m.stripe.com's privacy policy"")
        
        **1**This cookie is used in conjunction with the payment window - The cookie is necessary for making secure transactions on the website.
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
    *   [summit.sifted.eu 2](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **CFTOKEN**This cookie is used to determine which type of device the visitor is using, so the website can be properly formatted - This information is stored in the ""CFID"" cookie.
        
        **Maximum Storage Duration**: 30 days**Type**: HTTP Cookie
        
        **DEFAULTLOCALE**This cookie is used to determine what country the visitor comes from - This allows the website to set the language accordingly, if possible. The information can be determined through the visitor‚Äôs IP-address.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    
*   Statistics 37
    
    Statistic cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
    
    *   [ASP 2](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 19](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.iubenda.com/privacy-policy/11419556 ""ASP's privacy policy"")
        
        **\_pk\_id#**Collects statistics on the user's visits to the website, such as the number of visits, average time spent on the website and what pages have been read.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **\_pk\_ses#**Used by Piwik Analytics Platform to track page requests from the visitor during the session.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
    *   [Apple 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 20](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.apple.com/legal/privacy/en-ww/ ""Apple's privacy policy"")
        
        **geo**Saves the user's current geographical location based on the user's IP address.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [Canva 3](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 21](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.canva.com/policies/privacy-policy/ ""Canva's privacy policy"")
        
        **dv\_last\_interaction**Stores data on the time spent on the website and its sub-pages, during the current session.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **analytics\_event\_v2#analytics\_event\_metadata**Allows queries from third-party database for implementation of visual content.
        
        **Maximum Storage Duration**: Persistent**Type**: IndexedDB
        
        **analytics\_event\_v2#analytics\_event\_v2**Allows queries from third-party database for implementation of visual content.
        
        **Maximum Storage Duration**: Persistent**Type**: IndexedDB
        
    *   [Cxense 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 22](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.cxense.com/about-us/privacy-policy ""Cxense's privacy policy"")
        
        **\_ls\_ttl**Contains the expiry date for other cookies.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
    *   [Hubspot 4](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 23](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://legal.hubspot.com/privacy-policy ""Hubspot's privacy policy"")
        
        **\_\_hssc**Identifies if the cookie data needs to be updated in the visitor's browser.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
        **\_\_hssrc**Used to recognise the visitor's browser upon reentry on the website.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **\_\_hstc**Sets a unique ID for the session. This allows the website to obtain data on visitor behaviour for statistical purposes.
        
        **Maximum Storage Duration**: 180 days**Type**: HTTP Cookie
        
        **hubspotutk**Sets a unique ID for the session. This allows the website to obtain data on visitor behaviour for statistical purposes.
        
        **Maximum Storage Duration**: 180 days**Type**: HTTP Cookie
        
    *   [Linkedin 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 24](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.linkedin.com/legal/privacy-policy ""Linkedin's privacy policy"")
        
        **browser\_id**Used to recognise the visitor's browser upon reentry on the website.
        
        **Maximum Storage Duration**: 5 years**Type**: HTTP Cookie
        
    *   [Piano 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 25](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://piano.io/privacy-policy/ ""Piano's privacy policy"")
        
        **\_pcid**Registers statistical data on users' behaviour on the website. Used for internal analytics by the website operator.
        
        **Maximum Storage Duration**: 13 months**Type**: HTTP Cookie
        
    *   [Twitter Inc. 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 26](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://twitter.com/en/privacy ""Twitter Inc.'s privacy policy"")
        
        **personalization\_id**This cookie is set by Twitter - The cookie allows the visitor to share content from the website onto their Twitter profile.
        
        **Maximum Storage Duration**: 400 days**Type**: HTTP Cookie
        
    *   [Typeform 6](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 27](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://admin.typeform.com/to/dwk6gt/ ""Typeform's privacy policy"")
        
        **rl\_anonymous\_id**Registers statistical data on users' behaviour on the website. Used for internal analytics by the website operator.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **rl\_group\_id**Registers statistical data on users' behaviour on the website. Used for internal analytics by the website operator.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **rl\_group\_trait**Registers statistical data on users' behaviour on the website. Used for internal analytics by the website operator.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **rl\_trait**Registers statistical data on users' behaviour on the website. Used for internal analytics by the website operator.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **rl\_user\_id**Registers statistical data on users' behaviour on the website. Used for internal analytics by the website operator.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **tracking\_session\_id**Determines when the visitor last visited the different subpages on the website, as well as sets a timestamp for when the session started.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
    *   [Vimeo 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 28](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://vimeo.com/privacy ""Vimeo's privacy policy"")
        
        **vuid**Collects data on the user's visits to the website, such as which pages have been read.
        
        **Maximum Storage Duration**: 2 years**Type**: HTTP Cookie
        
    *   [cdn.cxense.com cdn.tinypass.com 2](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **\_pctx¬†\[x2\]**Registers statistical data on users' behaviour on the website. Used for internal analytics by the website operator.
        
        **Maximum Storage Duration**: 13 months**Type**: HTTP Cookie
        
    *   [metamanager.io 2](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **\_hjSession\_#**Collects statistics on the visitor's visits to the website, such as the number of visits, average time spent on the website and what pages have been read.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **\_hjSessionUser\_#**Collects statistics on the visitor's visits to the website, such as the number of visits, average time spent on the website and what pages have been read.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [open.spotify.com sifted.eu 2](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **sentryReplaySession¬†\[x2\]**Registers data on visitors' website-behaviour. This is used for internal analysis and website optimization.
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
    *   [pitch.com 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **unleash:repository:sessionId**Used in connection with phased release which allows the website owner to assign a certain number of users to a specific version of the website.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
    *   [pitch.com sifted.eu form.typeform.com 3](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **dd\_cookie\_test\_#¬†\[x3\]**Registers data on visitors' website-behaviour. This is used for internal analysis and website optimization.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [s3-eu-west-1.amazonaws.com hotelmap.com 4](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **mapbox.eventData.uuid:#¬†\[x2\]**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **mapbox.eventData:#¬†\[x2\]**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
    *   [sifted.eu 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **\_dd\_s**Registers the website's speed and performance. This function can be used in context with statistics and load-balancing.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
    *   [summit.sifted.eu 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **CFID**This cookie is used in context with the ""Cftoken"" cookie. The cookie stores a specific ID for the visitor and the visitor's device and browser.
        
        **Maximum Storage Duration**: 30 days**Type**: HTTP Cookie
        
    
*   Marketing 91
    
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
    
    *   [Meta Platforms, Inc. 3](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 29](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.facebook.com/policy.php/ "" Meta Platforms, Inc.'s privacy policy"")
        
        **lastExternalReferrer**Detects how the user reached the website by registering their last URL-address.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **lastExternalReferrerTime**Detects how the user reached the website by registering their last URL-address.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\_fbp**Used by Facebook to deliver a series of advertisement products such as real time bidding from third party advertisers.
        
        **Maximum Storage Duration**: 3 months**Type**: HTTP Cookie
        
    *   [ASP 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 30](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.iubenda.com/privacy-policy/11419556 ""ASP's privacy policy"")
        
        **piwik.php**Sets a unique ID for the visitor, that allows third party advertisers to target the visitor with relevant advertisement. This pairing service is provided by third party advertisement hubs, which facilitates real-time bidding for advertisers.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
    *   [Cxense 8](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 31](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.cxense.com/about-us/privacy-policy ""Cxense's privacy policy"")
        
        **\_cX\_atfr**Collects information on user behaviour on multiple websites. This information is used in order to optimize the relevance of advertisement on the website.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\_cX\_lastP1Time**Collects information on user behaviour on multiple websites. This information is used in order to optimize the relevance of advertisement on the website.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\_cX\_lst**Collects information on user behaviour on multiple websites. This information is used in order to optimize the relevance of advertisement on the website.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\_cX\_S**Collects information on user behaviour on multiple websites. This information is used in order to optimize the relevance of advertisement on the website.
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **Repo/rep.gif**Collects data on user behaviour and interaction in order to optimize the website and make advertisement on the website more relevant.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **gckp**Registers a unique ID that identifies a returning user's device. The ID is used for targeted ads.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **cX\_G**Collects information on user behaviour on multiple websites. This information is used in order to optimize the relevance of advertisement on the website.
        
        **Maximum Storage Duration**: 13 months**Type**: HTTP Cookie
        
        **cX\_P**Registers a unique ID that identifies a returning user's device. The ID is used for targeted ads.
        
        **Maximum Storage Duration**: 13 months**Type**: HTTP Cookie
        
    *   [Giphy Support 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 32](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://support.giphy.com/hc/en-us/articles/360020028332-GIPHY-Privacy-Policy ""Giphy Support's privacy policy"")
        
        **giphyPingbackId**Used to track the visitor's usage of GIFs - This serves for analytical and marketing purposes.
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
    *   [Google 17](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 33](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://business.safety.google/privacy/ ""Google's privacy policy"")
        
        Some of the data collected by this provider is for the purposes of personalization and measuring advertising effectiveness.
        
        **\_\_Host-GAPS**Collects data on the user's visits to the website, such as the number of visits, average time spent on the website and what pages have been loaded with the purpose of generating reports for optimising the website content.
        
        **Maximum Storage Duration**: 2 years**Type**: HTTP Cookie
        
        **GFE\_RTT**Used to implement the content through Google Docs.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **punchv-e-f**Used to implement the content through Google Docs.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **punchv-e-n**Used to implement the content through Google Docs.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **punchv-e-v**Used to implement the content through Google Docs.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **IDE**Used by Google DoubleClick to register and report the website user's actions after viewing or clicking one of the advertiser's ads with the purpose of measuring the efficacy of an ad and to present targeted ads to the user.
        
        **Maximum Storage Duration**: 400 days**Type**: HTTP Cookie
        
        **pagead/landing**Collects data on visitor behaviour from multiple websites, in order to present more relevant advertisement - This also allows the website to limit the number of times that they are shown the same advertisement.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **receive-cookie-deprecation**Collects information on user behaviour on multiple websites. This information is used in order to optimize the relevance of advertisement on the website.
        
        **Maximum Storage Duration**: 180 days**Type**: HTTP Cookie
        
        **NID**Pending
        
        **Maximum Storage Duration**: 6 months**Type**: HTTP Cookie
        
        **pagead/1p-user-list/#**Tracks if the user has shown interest in specific products or events across multiple websites and detects how the user navigates between sites. This is used for measurement of advertisement efforts and facilitates payment of referral-fees between websites.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **collect**Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **pagead/gen\_204**Collects data on visitor behaviour from multiple websites, in order to present more relevant advertisement - This also allows the website to limit the number of times that they are shown the same advertisement.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **pcs/activeview**Used by DoubleClick to determine whether website advertisement has been properly displayed - This is done to make their marketing efforts more efficient.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **pcs/view**Pending
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **csi**Collects data on visitors' preferences and behaviour on the website - This information is used make content and advertisement more relevant to the specific visitor.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **ui/v1/icons/mail/images/cleardot.gif**Pending
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **\_gat**Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
    *   [Hubspot 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 34](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://legal.hubspot.com/privacy-policy ""Hubspot's privacy policy"")
        
        **\_\_ptq.gif**Sends data to the marketing platform Hubspot about the visitor's device and behaviour. Tracks the visitor across devices and marketing channels.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
    *   [Oath. 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 35](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://policies.oath.com/ie/en/oath/privacy/index.html ""Oath.'s privacy policy"")
        
        **A3**Collects information on user behaviour on multiple websites. This information is used in order to optimize the relevance of advertisement on the website.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
    *   [Piano 5](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 36](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://piano.io/privacy-policy/ ""Piano's privacy policy"")
        
        **\_\_pat**Used in context with the implementation of content from other news sites. The cookie also allows for the third-party news site to gather user data on the current website.
        
        **Maximum Storage Duration**: 30 days**Type**: HTTP Cookie
        
        **\_\_pvi**Used in context with the implementation of content from other news sites. The cookie also allows for the third-party news site to gather user data on the current website.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
        **\_\_tbc**Registers data on visitors from multiple visits and on multiple websites. This information is used to measure the efficiency of advertisement on websites.
        
        **Maximum Storage Duration**: 2 years**Type**: HTTP Cookie
        
        **\_pprv**Collects data on user behaviour and interaction in order to optimize the website and make advertisement on the website more relevant.
        
        **Maximum Storage Duration**: 13 months**Type**: HTTP Cookie
        
        **xbc**Collects data on user behaviour and interaction in order to optimize the website and make advertisement on the website more relevant.
        
        **Maximum Storage Duration**: 2 years**Type**: HTTP Cookie
        
    *   [RudderStack 3](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 37](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.rudderstack.com/cookie-policy/ ""RudderStack's privacy policy"")
        
        **\_\_tld\_\_**Used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **rudder\_cookies**Pending
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **test\_rudder**Pending
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
    *   [Spotify 2](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 38](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.spotify.com/uk/legal/privacy-policy/ ""Spotify's privacy policy"")
        
        **sp\_landing**Used to implement audio-content from Spotify on the website. Can also be used to register user interaction and preferences in context with audio-content - This can serve statistics and marketing purposes.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
        **sp\_t**Used to implement audio-content from Spotify on the website. Can also be used to register user interaction and preferences in context with audio-content - This can serve statistics and marketing purposes.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
    *   [Twitter Inc. 10](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 39](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://twitter.com/en/privacy ""Twitter Inc.'s privacy policy"")
        
        **1/i/adsct¬†\[x2\]**Collects data on user behaviour and interaction in order to optimize the website and make advertisement on the website more relevant.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **i/adsct¬†\[x2\]**The cookie is used by Twitter.com in order to determine the number of visitors accessing the website through Twitter advertisement content.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **muc\_ads**Collects data on user behaviour and interaction in order to optimize the website and make advertisement on the website more relevant.
        
        **Maximum Storage Duration**: 400 days**Type**: HTTP Cookie
        
        **guest\_id**Collects data related to the user's visits to the website, such as the number of visits, average time spent on the website and which pages have been loaded, with the purpose of personalising and improving the Twitter service.
        
        **Maximum Storage Duration**: 400 days**Type**: HTTP Cookie
        
        **guest\_id\_ads**Collects information on user behaviour on multiple websites. This information is used in order to optimize the relevance of advertisement on the website.
        
        **Maximum Storage Duration**: 400 days**Type**: HTTP Cookie
        
        **guest\_id\_marketing**Collects information on user behaviour on multiple websites. This information is used in order to optimize the relevance of advertisement on the website.
        
        **Maximum Storage Duration**: 400 days**Type**: HTTP Cookie
        
        **i/jot/embeds**Sets a unique ID for the visitor, that allows third party advertisers to target the visitor with relevant advertisement. This pairing service is provided by third party advertisement hubs, which facilitates real-time bidding for advertisers.
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
        **RichHistory**Collects data on visitors' preferences and behaviour on the website - This information is used make content and advertisement more relevant to the specific visitor.
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
    *   [Typeform 2](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 40](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://admin.typeform.com/to/dwk6gt/ ""Typeform's privacy policy"")
        
        **#-visitorId**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **attribution\_user\_id**Used in context with the website‚Äôs pop-up questionnaires and messengering. The data is used for statistical or marketing purposes.
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
    *   [YouTube 22](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 41](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://business.safety.google/privacy/ ""YouTube's privacy policy"")
        
        **#-#**Used to track user‚Äôs interaction with embedded content.
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **2232b765-e46984**Pending
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **iU5q-!O9@$**Registers a unique ID to keep statistics of what videos from YouTube the user has seen.
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **LAST\_RESULT\_ENTRY\_KEY**Used to track user‚Äôs interaction with embedded content.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **LogsDatabaseV2:V#||LogsRequestsStore**Used to track user‚Äôs interaction with embedded content.
        
        **Maximum Storage Duration**: Persistent**Type**: IndexedDB
        
        **nextId**Used to track user‚Äôs interaction with embedded content.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **remote\_sid**Necessary for the implementation and functionality of YouTube video-content on the website.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **requests**Used to track user‚Äôs interaction with embedded content.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **ServiceWorkerLogsDatabase#SWHealthLog**Necessary for the implementation and functionality of YouTube video-content on the website.
        
        **Maximum Storage Duration**: Persistent**Type**: IndexedDB
        
        **TESTCOOKIESENABLED**Used to track user‚Äôs interaction with embedded content.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
        **VISITOR\_INFO1\_LIVE**Pending
        
        **Maximum Storage Duration**: 180 days**Type**: HTTP Cookie
        
        **YSC**Pending
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
        **yt.innertube::nextId**Registers a unique ID to keep statistics of what videos from YouTube the user has seen.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **ytidb::LAST\_RESULT\_ENTRY\_KEY**Used to track user‚Äôs interaction with embedded content.
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **YtIdbMeta#databases**Used to track user‚Äôs interaction with embedded content.
        
        **Maximum Storage Duration**: Persistent**Type**: IndexedDB
        
        **yt-remote-cast-available**Stores the user's video player preferences using embedded YouTube video
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **yt-remote-cast-installed**Stores the user's video player preferences using embedded YouTube video
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **yt-remote-connected-devices**Stores the user's video player preferences using embedded YouTube video
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **yt-remote-device-id**Stores the user's video player preferences using embedded YouTube video
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **yt-remote-fast-check-period**Stores the user's video player preferences using embedded YouTube video
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **yt-remote-session-app**Stores the user's video player preferences using embedded YouTube video
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **yt-remote-session-name**Stores the user's video player preferences using embedded YouTube video
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
    *   [metamanager.io www.googletagmanager.com 2](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **\_gcl\_au¬†\[x2\]**Used by Google AdSense for experimenting with advertisement efficiency across websites using their services.
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [sifted.eu 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **mp\_#\_mixpanel**Pending
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
    *   [www.google-analytics.com metamanager.io 8](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **\_ga¬†\[x5\]**Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels.
        
        **Maximum Storage Duration**: 2 years**Type**: HTTP Cookie
        
        **\_gid¬†\[x3\]**Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels.
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
    *   [www.googletagmanager.com metamanager.io 4](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **\_ga\_#¬†\[x4\]**Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels.
        
        **Maximum Storage Duration**: 2 years**Type**: HTTP Cookie
        
    
*   Unclassified 36
    
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
    
    *   [Airtable 2](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 42](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://airtable.com/privacy ""Airtable's privacy policy"")
        
        **brwConsent**Pending
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
        **profile\_images/860062637769580548/2K\_bXBm\_\_400x400.jpg**Pending
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
    *   [Albumizr 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 43](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://albumizr.com/ ""Albumizr's privacy policy"")
        
        **jallery\_uid**Pending
        
        **Maximum Storage Duration**: 400 days**Type**: HTTP Cookie
        
    *   [Apple 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 44](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.apple.com/legal/privacy/en-ww/ ""Apple's privacy policy"")
        
        **mtClientConfig\_cachedSource\_xp\_amp\_podcasts\_paf**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
    *   [Canva 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 45](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.canva.com/policies/privacy-policy/ ""Canva's privacy policy"")
        
        **leadership\_lock#leadership\_lock**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: IndexedDB
        
    *   [Flourish 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 46](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://flourish.studio/privacy/ ""Flourish's privacy policy"")
        
        **EPIPRODSRV**Pending
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [LinkedIn 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 47](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://www.linkedin.com/legal/privacy-policy ""LinkedIn's privacy policy"")
        
        **sequenceNumber#sequenceNumber**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: IndexedDB
        
    *   [Oath. 3](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 48](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://policies.oath.com/ie/en/oath/privacy/index.html ""Oath.'s privacy policy"")
        
        **\_ebd**Pending
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **A1**Pending
        
        **Maximum Storage Duration**: 1 year**Type**: HTTP Cookie
        
        **A1S**Pending
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [Piano 5](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 49](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://piano.io/privacy-policy/ ""Piano's privacy policy"")
        
        **\_\_tp-gaAccount**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\_\_tp-metricsGAAccount**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\_\_tp-trackOnlyAids**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\_\_pid**Pending
        
        **Maximum Storage Duration**: 30 days**Type**: HTTP Cookie
        
        **\_\_pil**Pending
        
        **Maximum Storage Duration**: 30 days**Type**: HTTP Cookie
        
    *   [Piano Software 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)[Learn more about this provider![Image 50](blob:https://sifted.eu/7c37f61654102a88a9be209f9569ef78)](https://piano.io/privacy-policy/ ""Piano Software's privacy policy"")
        
        **oxEhvcJHpu\_\_eea**Pending
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [datawrapper.dwcdn.net 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **#/pixel.gif**Pending
        
        **Maximum Storage Duration**: Session**Type**: Pixel Tracker
        
    *   [hotelmap.com 5](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **email**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **loglevel:twilio-chat**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **loglevel:twilio-sync**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **loglevel:twilsock**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **wwhmid**Pending
        
        **Maximum Storage Duration**: 56 days**Type**: HTTP Cookie
        
    *   [pitch.com 9](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **\[""~#'"",""~:auth/session-connection-type""\]**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\[""~#'"",""~:card-overlays""\]**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\[""~#'"",""~:pitch.app.api-client/allow-requests""\]**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\[""~#'"",""~:pre-auth-route""\]**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\[""~#'"",""~:previous-route""\]**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\[""~#'"",""~:user""\]**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **pitch-platform-session-id**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **platform-dev-panel**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **VIEWER\_COUNTRY**Pending
        
        **Maximum Storage Duration**: 1 day**Type**: HTTP Cookie
        
    *   [sifted.eu 4](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **\_\_mp\_opt\_in\_out\_516258ca7de16bfdb47d0ebf1beedce9**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **\_\_mp\_opt\_in\_out\_d003f5a571ef2d95359261f82863e3ef**Pending
        
        **Maximum Storage Duration**: Persistent**Type**: HTML Local Storage
        
        **ebx\_webtag\_**Pending
        
        **Maximum Storage Duration**: Session**Type**: HTML Local Storage
        
        **mp\_optout**Pending
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    *   [summit.sifted.eu 1](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#)
        
        **popupTimer**Pending
        
        **Maximum Storage Duration**: Session**Type**: HTTP Cookie
        
    

[Cross-domain consent2](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/#) Your consent applies to the following domains:

List of domains your consent applies to:

[summit.sifted.eu](https://summit.sifted.eu/)

[www.sifted.eu](https://www.sifted.eu/)

Cookie declaration last updated on 8/27/24 by [Cookiebot](https://www.cookiebot.com/ ""Cookiebot"")

\[#IABV2\_TITLE#\]
------------------

\[#IABV2\_BODY\_INTRO#\]

\[#IABV2\_BODY\_LEGITIMATE\_INTEREST\_INTRO#\]

\[#IABV2\_BODY\_PREFERENCE\_INTRO#\]

\[#IABV2\_LABEL\_PURPOSES#\]

\[#IABV2\_BODY\_PURPOSES\_INTRO#\]

\[#IABV2\_BODY\_PURPOSES#\]

\[#IABV2\_LABEL\_FEATURES#\]

\[#IABV2\_BODY\_FEATURES\_INTRO#\]

\[#IABV2\_BODY\_FEATURES#\]

\[#IABV2\_LABEL\_PARTNERS#\]

\[#IABV2\_BODY\_PARTNERS\_INTRO#\]

\[#IABV2\_BODY\_PARTNERS#\]

Cookies are small text files that can be used by websites to make a user's experience more efficient.  
  
The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission.  
  
This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.  
  
You can at any time change or withdraw your consent from the Cookie Policy on our website.  
  
Learn more about who we are, how you can contact us and how we process personal data in our Privacy Policy.  
  
Please state your consent ID and date when you contact us regarding your consent.

  
  

**Do not sell or share my personal information**

Deny Allow selection Customize

Allow all

[Powered by Cookiebot by Usercentrics](https://www.cookiebot.com/en/what-is-behind-powered-by-cookiebot/)

Open navigation menu

[](https://sifted.eu/)

*   News
*   Insights
*   Newsletters
*   Events
[Podcasts](https://sifted.eu/podcasts)

[](https://sifted.eu/search)

[SubscribeSubscribe](https://sifted.eu/subscribe)

[Log in](https://sifted.eu/members/login?redirectUrl=%2Farticles%2Fcaresyntax-surgery-tech-raise-news)

[](https://sifted.eu/)

**Startup Europe.** Grown up reporting.

[Subscribe](https://sifted.eu/subscribe)

[Log in](https://sifted.eu/members/login?redirectUrl=%2Farticles%2Fcaresyntax-surgery-tech-raise-news)

*   ### News
    
*   ### Insights
    
*   ### Newsletters
    
*   ### Events
    
*   [Podcasts](https://sifted.eu/podcasts)

*   [Search](https://sifted.eu/search)

Backed by

### Company

*   [About](https://sifted.eu/about)
*   [Careers](https://sifted.eu/careers)
*   [Advertising](https://sifted.eu/advertising)
*   [Controllership](https://sifted.eu/controllership/)
*   [Cookie Policy](https://sifted.eu/cookie-policy)
*   [Privacy policy](https://sifted.eu/privacy-policy)
*   [AI Code of Conduct](https://sifted.eu/ai-code-of-conduct)
*   [Terms of use](https://sifted.eu/terms-of-use)

### Sifted Pro

*   [Subscribe](https://sifted.eu/subscribe)
*   [~/Briefings](https://sifted.eu/pro/briefings/about)
*   [~/Pitches](https://sifted.eu/pro/roundtables)
*   [~/Scout](https://sifted.eu/scout)

### Products

*   [~/Newsletters](https://sifted.eu/newsletters)
*   [~/Rankings](https://sifted.eu/rankings)
*   [~/Reports](https://sifted.eu/intelligence/reports)

### Community

*   [~/Talks](https://sifted.eu/talks)
*   [~/Podcasts](https://sifted.eu/podcasts)
*   [~/Summit](https://summit.sifted.eu/)
*   [Jobs board](https://jobs.sifted.eu/?source=navbar&utm_source=navbar&utm_medium=partner_referral)

*   [![Image 51: X Logo](https://www.datocms-assets.com/60124/1697443751-x-logo.svg)](https://twitter.com/siftedeu)
*   [![Image 52: LinkedIn Logo](https://www.datocms-assets.com/60124/1689076682-linkedin.svg)](https://www.linkedin.com/company/siftedeu/)
*   [![Image 53: Facebook Logo](https://www.datocms-assets.com/60124/1689076874-facebook.svg)](https://www.facebook.com/siftedeu)
*   [![Image 54: RSS Feed Logo](https://www.datocms-assets.com/60124/1689076939-rss-feed.svg)](https://sifted.eu/feed/?post_type=article)

¬© 2024 Sifted EU Ltd. All Rights Reserved.

[News](https://sifted.eu/categories/news/)August 15, 2024

AI surgery tech startup raises $180m from investors including BlackRock
=======================================================================

More than a dozen investors were involved in the equity and debt round for Berlin-based Caresyntax
--------------------------------------------------------------------------------------------------

[Kai Nicol-Schwarz](https://sifted.eu/author/kai-nicol-schwarz/)

3 min read

Berlin-based Caresyntax, which is building an AI-driven data platform for surgery, has raised a $180m Series C extension.

The round is made up of $80m in equity and $100m in debt ‚Äî and is tied to specific milestones. The fresh funding tops up the startup‚Äôs [$130m Series C,](https://sifted.eu/articles/caresyntax-raises-100m) raised across two rounds in 2021, and takes its total equity funding to $220m.

It‚Äôs the latest in a string of big money raises for European startups developing tech for hospital operating theatres as healthcare systems across the globe scramble to increase efficiency amid staff shortages and the rising costs of treating ageing populations.

Advertisement

Caresyntax will use the funds to scale customer adoption in the US and EMEA region, develop AI applications and finance M&A opportunities.

### **AI for hospitals**

Caresyntax says it wants to build the ‚ÄúAndroid‚Äù platform for surgery. Its tech uses AI algorithms to make sense of data collected before, during and after an operation to help surgeons improve patient outcomes, spot risks during procedures and reduce hospitals‚Äô surgery costs by improving efficiency and reducing readmissions.

The company‚Äôs platform can pick up on warning signs like drops in heart rate that surgeons might not be aware of during a procedure, for example. It can also streamline operative workflows, inform post-treatment care pathways post-operation and collect 1,000 data points per surgical case.

While some surgical robotics solutions in the market only work with certain products, Caresyntax‚Äôs platform can plug into any operating room technology to pull together data, according to a company spokesperson.

‚ÄúEffectively using AI in the operating room requires input from a wide variety of data sources, but today this data exists in silos where it is difficult for clinicians to access and operationalise,‚Äù they add.

If it does what it sets out to do, it‚Äôs a big opportunity.

Costs associated with operations account for [30%](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586534/#:~:text=Older%20estimates%20suggest%20that%20inpatient,healthcare%20costs%20%5B2%203%5D.) of healthcare expenditure, a huge sum given that Europe spends [11%](https://www.medtecheurope.org/datahub/expenditure/#:~:text=In%20Europe%2C%20an%20average%20of,less%20than%201%25%20of%20GDP.) of GDP on health.

Founded in 2013 in Germany ‚Äî Caresyntax also expanded to San Francisco in 2019 ‚Äî its data platform is currently used in 3k operating rooms globally, in more than 3m surgeries annually, according to the company. 40% of the company‚Äôs revenue comes from the Americas and 60% from the EMEA region.

### **The rise of smart surgery**

The round comes on the back of a strong 18 months for startups developing tech for the operating theatre.

Since the start of 2023, three of the four biggest medtech raises have all gone to startups building robots to help surgeons. The UK‚Äôs CMR Surgical picked up [¬£165m](https://sifted.eu/articles/cmr-surgical-raise-2023) in September last year, Switzerland‚Äôs DistalMotion $150m in April 2023 and Italy‚Äôs Medical Microinstruments $110m in February this year.

Investors in Caresyntax‚Äôs round include Symbiotic Capital, MTIP AG, BIONIQ Capital, PFM Health Sciences, Pictet Alternative Advisors, surgical.ai, BlackRock Innovation Capital, Aescuvest, Optum Ventures, Cure Capital, Relyens Group, Vesalius Biocapital, Lauxera Capital, Plug & Play Growth Fund and ProAssurance Corp.

Advertisement

Advertisement

Editor's picks

*   [News](https://sifted.eu/categories/news/)
    
    [Three cofounders leave French AI startup H just three months after raising $220m seed](https://sifted.eu/articles/three-cofounders-leave-h-news/)
    
    * * *
    
*   [Analysis](https://sifted.eu/categories/analysis/)
    
    [Lost millions, a luxury cottage under threat and Oussama Ammar‚Äôs new startup accelerator: What‚Äôs going on with the dispute at The Family?](https://sifted.eu/articles/the-family-oussama-ammar-startup-latest/)
    
    * * *
    
*   [News](https://sifted.eu/categories/news/)
    
    [Mike Lynch‚Äôs impact on UK tech](https://sifted.eu/articles/mike-lynch-tech-legacy/)
    
    * * *
    

Advertisement

[Kai Nicol-Schwarz](https://sifted.eu/author/kai-nicol-schwarz/)

Kai Nicol-Schwarz is a reporter at Sifted. He covers UK tech and healthtech, and can be found on [X](https://twitter.com/NicolSchwarzK) and [LinkedIn](https://www.linkedin.com/in/kains/)

[# Healthtech](https://sifted.eu/sector/healthtech/)[# Medtech](https://sifted.eu/sector/medtech/)[# Deals](https://sifted.eu/tag/deals/)

5x a week

~/¬†Sifted Daily
---------------

Stay one step ahead with news and experts analysis on what‚Äôs happening across startup Europe.

By Sifted journalists

Sign up

Recommended

*   [![Image 55](https://images.sifted.eu/wp-content/uploads/2024/08/23150208/%C2%A9Delporte-AnneOsdoit02-1-scaled-e1724421752987.jpg?auto=format&fit=max&w=3840&q=75)](https://sifted.eu/articles/medtech-startup-vc-trends/)
    
    [11 medtech startups to watch, according to VCs](https://sifted.eu/articles/medtech-startup-vc-trends/)[VCs at 415 Capital, Sofinnova Partners, MIG Capital and SHS Capital share their picks](https://sifted.eu/articles/medtech-startup-vc-trends/)[Kai Nicol-Schwarz](https://sifted.eu/author/kai-nicol-schwarz/)
    
*   [![Image 56](https://images.sifted.eu/wp-content/uploads/2023/09/07164512/Screenshot-2023-09-07-at-16.45.04.png?auto=format&fit=max&w=3840&q=75)](https://sifted.eu/articles/startups-wegovy-ozempic-shift/)
    
    [Riding the Wegovy wave: The startups shifting focus to GLP-1s to tap the $150bn weight loss drug market](https://sifted.eu/articles/startups-wegovy-ozempic-shift/)[Founders and investors see massive potential in the new drug class ‚Äî but funding is yet to flood startups in the sector](https://sifted.eu/articles/startups-wegovy-ozempic-shift/)[Kai Nicol-Schwarz](https://sifted.eu/author/kai-nicol-schwarz/)
    
*   [![Image 57](https://images.sifted.eu/wp-content/uploads/2024/07/30122008/Flo-For-Partners-_-Flow-e1722338418859.png?auto=format&fit=max&w=3840&q=75)](https://sifted.eu/articles/male-founded-startup-europes-first-femtech-unicorn/)
    
    [A male-founded startup became Europe‚Äôs first femtech unicorn. Does it matter?](https://sifted.eu/articles/male-founded-startup-europes-first-femtech-unicorn/)[Some founders and investors are frustrated that the first European femtech unicorn is run by men](https://sifted.eu/articles/male-founded-startup-europes-first-femtech-unicorn/)[Anne Sraders](https://sifted.eu/author/anne-sraders/)
    

Backed by

### Company

*   [About](https://sifted.eu/about)
*   [Careers](https://sifted.eu/careers)
*   [Advertising](https://sifted.eu/advertising)
*   [Controllership](https://sifted.eu/controllership/)
*   [Cookie Policy](https://sifted.eu/cookie-policy)
*   [Privacy policy](https://sifted.eu/privacy-policy)
*   [AI Code of Conduct](https://sifted.eu/ai-code-of-conduct)
*   [Terms of use](https://sifted.eu/terms-of-use)

### Sifted Pro

*   [Subscribe](https://sifted.eu/subscribe)
*   [~/Briefings](https://sifted.eu/pro/briefings/about)
*   [~/Pitches](https://sifted.eu/pro/roundtables)
*   [~/Scout](https://sifted.eu/scout)

### Products

*   [~/Newsletters](https://sifted.eu/newsletters)
*   [~/Rankings](https://sifted.eu/rankings)
*   [~/Reports](https://sifted.eu/intelligence/reports)

### Community

*   [~/Talks](https://sifted.eu/talks)
*   [~/Podcasts](https://sifted.eu/podcasts)
*   [~/Summit](https://summit.sifted.eu/)
*   [Jobs board](https://jobs.sifted.eu/?source=footer&utm_source=footer&utm_medium=partner_referral)

*   [![Image 58: X Logo](https://www.datocms-assets.com/60124/1697443751-x-logo.svg)](https://twitter.com/siftedeu)
*   [![Image 59: LinkedIn Logo](https://www.datocms-assets.com/60124/1689076682-linkedin.svg)](https://www.linkedin.com/company/siftedeu/)
*   [![Image 60: Facebook Logo](https://www.datocms-assets.com/60124/1689076874-facebook.svg)](https://www.facebook.com/siftedeu)
*   [![Image 61: RSS Feed Logo](https://www.datocms-assets.com/60124/1689076939-rss-feed.svg)](https://sifted.eu/feed/?post_type=article)

¬© 2024 Sifted EU Ltd. All Rights Reserved.

 ![Image 62: Cookiebot session tracker icon loaded](https://imgsct.cookiebot.com/1.gif?dgi=33e59a16-c6e6-406b-8161-7e6b9693bc2e)
"
2024-08-13 00:00:00,2024-08-29 23:12:31,"üåü Have you heard about the latest buzz surrounding GLP-1 drugs like Wegovy and Ozempic? This emerging class of weight loss medications is not just transforming individual lives, but is also creating waves across the entire healthcare landscape! 

A recent article from Sifted highlights how startups are pivoting their focus to harness the potential of the nearly $150 billion weight loss drug market. Companies like Oviva have already started integrating GLP-1 drugs into their treatment pathways as a strategic growth driver, demonstrating impressive outcomes for patients battling obesity. 

The market's potential is tremendous, especially as these treatments were initially designed for diabetes but are now recognized for their effectiveness in weight management. Startups in Europe are rapidly embracing this opportunity, with several successfully raising funds and expanding their services around GLP-1 medications. However, challenges remain, including supply chain pressures and the need for reimbursement from national healthcare systems. 

As professionals in the health tech and wellness sectors, it‚Äôs essential to stay informed and adapt to these developments. The success stories of Oviva and Danish startups like Embla remind us that innovation can lead to sustainable care solutions, but the journey won‚Äôt be easy. 

How do you view the impact of GLP-1 drugs on the future of weight-loss treatments and healthcare startups? ü§î  

#HealthTech #WeightLoss #StartupInnovation #GLP1 #Healthcare",https://images.sifted.eu/wp-content/uploads/2024/08/12165326/unnamed-24-e1723478018874.png?auto=format&fit=max&w=3840&q=75,https://sifted.eu/articles/startups-wegovy-ozempic-shift/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: Riding the Wegovy wave: The startups shifting focus to GLP-1s to tap the $150bn weight loss drug market | Sifted

URL Source: https://sifted.eu/articles/startups-wegovy-ozempic-shift/

Markdown Content:
The meteoric rise of a new class of weight loss drugs over the past two years, known as GLP-1s, has seen a new name take the title of Europe‚Äôs most valuable company, helped a country dodge a recession and hit grocery sales in the US.

The valuations of the companies that make this so-called ‚Äúmiracle‚Äù class of drugs ‚Äî which includes Danish pharma giant Novo Nordisk (maker of Ozempic and Wegovy) and US rival Eli Lilly (maker of Mounjaro and Zepbound) ‚Äî have [soared](https://www.economist.com/business/2024/03/04/the-battle-over-the-trillion-dollar-weight-loss-bonanza)¬†as investors bet big on a medication projected by some to hit [$150bn in sales](https://www.reuters.com/business/healthcare-pharmaceuticals/weight-loss-drug-forecasts-jump-150-billion-supply-grows-2024-05-28/) by the early 2030s.

The potential of the market has not been lost on founders.

It‚Äôs a ‚Äúhuge‚Äù opportunity, says Kai Eberhardt, the founder and CEO of Oviva, a Swiss weight loss management platform which operates in the UK, France and Germany, alongside its home market. It began offering GLP-1 drugs as part of its treatment options in the second quarter of this year.

‚ÄúFor us \[GLP-1 drugs\] are already a strong growth driver,‚Äù he says. ‚ÄúThe newer GLP-1 class of medications have created real excitement due to their impressive outcomes in weight loss, transforming the treatment options available for those living with obesity.‚Äù

While treatment involving GLP-1 drugs is currently a small part of Oviva‚Äôs overall business ‚Äî Eberhardt says it‚Äôs growing total patient and revenue numbers by ‚Äúdouble digit‚Äù percentage points year-on-year ‚Äî the meds could become the startup‚Äôs ‚Äúlargest‚Äù growth driver in the future, he tells Sifted.

### **Riding the wave**

Oviva‚Äôs not alone. There are a slew of startups in Europe looking to tap into the opportunity ‚Äî many of which have recently shifted operations to focus on selling GLP-1 drugs or provide treatment pathways around the medication, which was first designed to treat diabetes but was later found to be effective at suppressing appetite and helping people lose weight.

In the last two years GLP-1s have become a go-to weight loss solution popularised by a roster of celebrity users. According to Walmart‚Äôs CEO, [food sales have fallen](https://www.bloomberg.com/news/articles/2023-10-04/walmart-says-ozempic-weight-loss-drugs-causing-slight-pullback-by-shoppers?sref=MTy2GeXk) as the [one in eight adults](http://cnbc.com/2024/05/14/healthy-returns-1-in-8-adults-have-taken-glp-1s-like-ozempic-survey.html) in the US who have used the meds slim down their buying habits. The drug class has also seen Novo Nordisk overtake luxury fashion brand LVMH as Europe‚Äôs [most valuable company,](https://www.ft.com/content/19357584-62e0-452f-a06f-7cda1d8cd0e3) propping up [Denmark‚Äôs GDP](https://www.thetimes.com/business-money/economics/article/wegovy-proves-to-be-wonder-drug-for-danish-economy-rgd6lqjh5) in the process.

All of the attention has got VCs excited, and companies on both sides of the Atlantic have [convinced them to get out their chequebook](https://sifted.eu/articles/weight-loss-drug-mania-reaches-europe-denmarks-embla-raises-10m): Danish startup Embla, which prescribes GLP-1 meds alongside ongoing clinical care and lifestyle advice for patients looking to lose weight in its home market and the UK, picked up a [‚Ç¨10m Series A](https://sifted.eu/articles/weight-loss-drug-mania-reaches-europe-denmarks-embla-raises-10m) in August 2023 a year on from a ‚Ç¨3.5m seed round. Swedish startup Yazen, which says it too prescribes GLP-1 drugs in combination with clinical care, also raised ‚Ç¨3.1m last summer.

Many startups operating in the GLP-1 space didn‚Äôt start life offering them ‚Äî largely due to launching before the drugs were popularised for weight loss. Ozempic was approved for sale in the US in 2017 and Europe in 2018; Wegovy was approved in the US in 2021 and Europe in 2022.

UK-based Numan, a digital medication and supplements provider founded in 2016, started by selling sexual health treatments; it began prescribing weight loss drugs in 2022. For years the company marketed itself as a [‚Äúmen‚Äôs health‚Äù](https://sifted.eu/articles/numan-mens-health-stigma) brand, but has recently changed that. The company‚Äôs website uses images of men _and_ women on its landing page for weight-loss treatments.

![Image 1](https://images.sifted.eu/wp-content/uploads/2024/08/12165326/unnamed-24-e1723478018874.png?auto=format&fit=max&w=3840&q=75)

Screenshot from Numan's website

Yazen, which launched its weight loss service in 2022, initially set out to exclusively target obese men, but broadened its focus before launching to include obesity more generally, after seeing how effective GLP-1 drugs were, says CEO Fredrik Meurling.

Meurling tells Sifted it had hit ‚Ç¨14m annual recurring revenue and treated 15k patients by June this year. It‚Äôs now active in Sweden, Norway, The Netherlands and Spain, and has pilot projects in England and Germany.

Other startups like UK-based Manual, which like Numan started out offering men‚Äôs sexual health treatments, also started prescribing weight loss medications in 2022.

‚Äú\[GLP-1 meds\] are a game changer,‚Äù says Michael Treskow, partner at Eight Roads Ventures, adding it would be ‚Äústrange‚Äù if a startup working in the weight loss space wasn‚Äôt looking into how they could add the drugs into their offering.

While GLP-1 meds have been part of some treatment courses at Embla since it launched in 2021, the ‚Äúhype‚Äù surrounding the drug class has ‚Äúopened doors‚Äù for the startup, says co-CEO and cofounder Nicholas Syhler ‚Äî adding that the startup managed to raise its ‚Ç¨400k pre-seed round in 2021 just three weeks after incorporation. It‚Äôs now gearing up for a fundraise in 2025 and expanding to the US, where it‚Äôll look to target US employers ‚Äî who pay for the majority of healthcare in the country.

### **Kinks in the supply chain**

There are still big questions hanging over European startups in the sector ‚Äî not least around whether a European GLP-1 startup can raise the kinds of funds needed to hit real scale.

Some of the biggest rounds for startups vending GLP-1 drugs have been in the US, including Calibrate‚Äôs $100m in 2021 and Form Health‚Äôs $38m in June this year. In Europe, no company selling the drug or treatment pathways around it has raised more than ‚Ç¨10m in a single round.

Investors and founders tell Sifted supply chain issues are part of that problem. Manufacturers have struggled to keep up with demand for the drug, and last year, startups in the UK were told by the government to remove Ozempic from sale due to shortages of the drug for diabetics ‚Äî [Manual was still selling past the deadline.](https://sifted.eu/articles/healthtech-manual-selling-ozempic-beyond-uk-government-deadline)

If a startup's revenues are closely tied to the availability of those drugs, they could be at the mercy of manufacturing capability. But as pharma bolsters production capabilities those issues could diminish, says Christoph Ruedig, partner at Albion VC.

‚ÄúAs there are severe shortages of GLP-1 drugs in Europe (Eli Lilly and Novo Nordisk are prioritising the US as pricing is higher) the opportunity to date in Europe has been limited but growing.‚Äù

### **Who‚Äôll stump up the cash?**

There‚Äôs also a challenge finding the right people to pay, and in Europe, national healthcare providers need to open up to reimbursing startups providing weight loss care, investors say.

While Numan‚Äôs head of medical Luke Pratsides says that the ‚Äúsuccess of private sector companies offering GLP-1 \[drugs\] shows that the public are willing to pay to meet a significant need that is being underserved by the NHS‚Äù, many in the sector think that only serving consumers paying out of their own pocket won‚Äôt be enough to hit real scale.

‚ÄúUS investors have told us that they will only invest in companies that get on enterprise contracts \[selling to whole organisations like health insurers\],‚Äù says Syhler. ‚ÄúThis means proving that they can deliver high-quality and sustainable care ‚Äî where the economics and outcomes make sense long-term for both patients and payors.‚Äù

In Europe, where the majority of people have their healthcare paid for by the state, hitting scale will likely come down to whether or not companies can get their services reimbursed by national healthcare providers, say some investors.

In the UK Wegovy is approved for use to manage obesity in the NHS, but it is currently only available through specialist weight management clinics, limiting availability.

Oviva is one the few startups that has had its supply of GLP-1 drugs alongside its weight loss platform reimbursed by the NHS ‚Äî but it had a head start on others, being reimbursed by the organisation long before the rise of weight loss meds, in 2016. Embla co-CEO and cofounder Laust Axelsen tells Sifted that it‚Äôs in ‚Äúmature dialogues with several health systems‚Äù.

‚ÄúIt is still a struggle with reimbursement, in every country,‚Äù says Hekla Arnardottir, partner at Crowberry Capital, which has backed Embla, pointing to difficult regulation and healthcare systems that [don‚Äôt always want to work with startups.](https://sifted.eu/articles/ai-healthcare-nhs-startup) Without reimbursement in Europe, she adds, it will be hard for companies to reach the sort of revenue figures needed to raise growth capital and hit unicorn status.

Whether a European startup will be able to do that remains to be seen ‚Äî but what is clear is that the hype surrounding GLP-1 meds is unlikely to die down anytime soon. ‚ÄúI've never been an investor in a company that‚Äôs got so much attention ‚Äî in a space that‚Äôs got so much attention,‚Äù says Arnardottir.
"
2024-08-01 00:00:00,2024-08-29 23:12:58,"üåü Exciting Times in the Femtech Space! üåü 

I recently came across an insightful article discussing how Flo Health, a UK-based period tracking app, just became Europe‚Äôs first femtech unicorn with a valuation surpassing $1 billion! üéâ While this is undoubtedly a significant milestone for women's health and technology, it also sparked some debate as its founding team is entirely male. 

Key points highlighted in the article include:
- **Flo's Achievement**: The app raised $200 million, showcasing a growing interest in women's health tech.
- **Backlash and Discussions**: Many expressed concern over men leading a company aiming to serve women's health needs, pointing to systemic issues in funding for female founders. 
- **Different Perspectives**: Some believe that this success can pave the way for more investments in women-led ventures, while others argue it highlights the need for greater female representation in the industry.

Takeaway Insights:
1. This development emphasizes the pressing need for diversity in leadership within femtech. With larger participation from women in founding and investing roles, we can create products that genuinely resonate with female users.
2. It also reflects a broader trend of women‚Äôs health being recognized as a valuable market, which could lead to increased funding for female founders as we shine a light on their potential.
3. As professionals in this field, it‚Äôs our responsibility to advocate for inclusion and support initiatives that elevate women‚Äôs voices.

What do you think? Does Flo's achievement open doors for more female founders in femtech, or does it further entrench the current dynamics? I‚Äôd love to hear your thoughts! 

#Femtech #WomensHealth #DiversityAndInclusion #Startups #InvestmentTrends  

[Read the full article here](https://sifted.eu/articles/male-founded-startup-europes-first-femtech-unicorn/)",https://sifted.eu/wp-content/uploads/2023/10/Flo-Header-1.jpg,https://sifted.eu/articles/male-founded-startup-europes-first-femtech-unicorn/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: A male-founded startup became Europe‚Äôs first femtech unicorn. Does it matter? | Sifted

URL Source: https://sifted.eu/articles/male-founded-startup-europes-first-femtech-unicorn/

Markdown Content:
**_A version of this article first appeared in Sifted‚Äôs Daily newsletter,_ _[sign up here](https://sifted.eu/newsletters?utm_medium=onsite&utm_source=article&utm_campaign=daily_big_story&utm_content=flagshipnl)._**

On Wednesday UK-based period tracking app Flo Health announced it had raised $200m ‚Äî pushing its valuation beyond $1bn and making it Europe‚Äôs first femtech unicorn.

It turned out to be a very [buzzy story](https://email.sifted.eu/e3t/Ctc/LZ+113/d2mfCN04/VWd7S56fts6_W5MRMLq4ZH5wFW6YVQGc5jbfNKN5j5FQx3qgyTW7lCdLW6lZ3nfW33mt2d9fhswPW6cbbn42Gk2LbW8scjQ_6cnrxDW1clnhC2ShJQHVccVZ53gzXq5W4wQdZG67pwTSW2-JWpF92k-_3W7wvb489fJTrcW8Yc8WL2J2BxbVsVjMQ2l0S96W8kJSgJ8PlPBnW3C2JWZ7p72hNW6XXzRB8xLSLCW1Qsggq5_4Rb1W2TDtZV1qFp0NW8cjBvC794-SqW6CX8JV3JLP8SW3PhCFV1MtGl5N2XnVkqP0RWYVJ5lGy5VWWL_W95gKqH7mC7fGN8ZGCJCNps2DW3hhNk75-4tsCW6zlG0Z5p-vJhf88-NBl04): as people were quick to point out online, Flo also became Europe‚Äôs first women‚Äôs health unicorn _with an all-male founding team_ ‚Äî a detail which sparked a backlash online.

‚ÄúA company founded by men, led by men and funded by men became the first WOMEN'S health app to achieve unicorn status. If this doesn't show you everything that's wrong with the ecosystem, I don't know what will,‚Äù Anna-Sophie Hartvigsen, cofounder of investment learning app and community for women Female Invest, wrote [in a viral LinkedIn post](https://email.sifted.eu/e3t/Ctc/LZ+113/d2mfCN04/VWd7S56fts6_W5MRMLq4ZH5wFW6YVQGc5jbfNKN5j5FPl5bRGYW50kH_H6lZ3l8W4LGN588Q_4ZsW8wQ5KR6wTrX5W7yCq0w85CZG9W3vhYPj1slFYHN7B_Ncv_0lQFW5X-v0Q51XxGqW6MPX5p5pwYL9W1D4cXM5h1_MGW7W96ly7MtK-lW381wDG8L1J_PW2_GGrC99Nz87N7QYN_6c-6xhVbl3C8715Xk_MpwjzGcNvlcW3dD_dz5jH-v9W49__9X8Dl27zN6pG5cpR5Y8-W1P9wsl5X0QKfW7pKmFX4zN8c0Vvdxk071SZSSW3r-vWY72Kwv1W4rpnn35WQhWCW6mSf3c1Z9ZHfVtbKWF8SQ18NW74YWXR83cqHnW4jGq_N5RH-nDW2tGsJ33h0LCbW4zWMDM5z_R9CW2_sJfz188vZJW4qtZ453fg7NWW5LGdY_77tcmZW3F37Zc24XYyMf7-GWgH04), citing stats on the [lack of funding for female founders](https://email.sifted.eu/e3t/Ctc/LZ+113/d2mfCN04/VWd7S56fts6_W5MRMLq4ZH5wFW6YVQGc5jbfNKN5j5FQx3qgyTW7lCdLW6lZ3npVZ6rdY6xdTkKW5dqdCC3CpbHkW6hmw1f8YJJx8W2h-hSY5hYtf0W3HtTS183-N4gN7hMSn23njKxW18dFQG93dPz7N7_1xPQZKQbwW3tfkLc5rhD5vW3kmy8562PSf5VVJMdj80mh0VW2xYdCC11lSqMW4Bjfsz1z2prLW17bbCc8ffd1CW548x4q6l5pqWN1H52hZxSG9WW2_7TbZ8zJD61W1spH161xBM0CW3YV1dC5_NGBBW3_BcXt8sdfLPW8vx_yh1pZ3FtW2rLJgd7p8_CsW7d4VW93Y2nkzW5PBwYY4SptZgf3zzZbM04). ‚ÄúI‚Äôm not saying it‚Äôs bad that a femtech company is doing well,‚Äù she later added in the comments. ‚ÄúI‚Äôm saying it‚Äôs bad that only men are able to succeed in this space.‚Äù

Some founders in the comments underneath Hartvigsen's post said that they‚Äôve struggled with fundraising as a woman; there was also a debate in a private WhatsApp group seen by Sifted about whether female founders should add a token male founder to their team in an effort to increase their chances of getting cheques. Someone in that group added that we won‚Äôt fix the trend of men funding men until there are more female investors.

But others didn‚Äôt see it that way.

‚ÄúThis achievement should actually be celebrated. As a women's health investor that has invested in 7+ women's health companies, we are yet to see any of them scale,‚Äù Deepali Nangia, a partner at Speedinvest, wrote in response to Hartvigsen‚Äôs LinkedIn post. ‚ÄúFlo's achievement is a very strong signal to the market that \[direct to consumer\] women's health is monetizable in Europe and that there is money to be made here; this is what investors need to see so more money flows into women's health companies. Not to say that the challenges faced by women in pitching are any less, but we must celebrate all wins that lead to more capital deployed into this sector,‚Äù she argued.

Nangia added that she wasn‚Äôt doubting there‚Äôs a problem, ‚Äúbut every win should not be turned around to a problem‚Ä¶ Many people have been working on solving for this problem, which includes many women of course but also men.‚Äù

Another commenter added: ‚ÄúIf anything, let this be a door for more investors to look closely at the female health industry and invest their money there? Could this be an example of men allies? If it had to be a company founded and led by men, well thank you very much for opening the door, now let the rest go through.‚Äù

Priya Oberoi, partner at women‚Äôs health-focused VC Goddess Gaia Ventures, added: ‚ÄúFlo reaching series C \[unicorn\] status with 60 mln active users is a win for #womenshealth - helping to close that 131 year gender health gap and getting products and services out there to improve the lives of women.‚Äù

""We firmly believe that women's health has been critically overlooked, undervalued and underfunded for far too long,"" Flo said in a statement to Sifted. ""Our sincere hope is that Flo‚Äôs funding will inspire more investors to recognise the immense potential in this space."" The company added: ""We're proud to say that more than half (56%) of Flo's employees are women, including our leadership team.""

It‚Äôs an important debate, and, readers, I‚Äôm curious to hear your thoughts: why aren‚Äôt there more female-founded femtech unicorns? Is it a problem that the first European femtech unicorn is founded by men, if the product helps women? Does it open doors for female founders in the space, or actually keep them shut? [Get in touch with me](mailto:anne@sifted.eu) or [Kai](mailto:kai@sifted.eu).
"
2024-07-30 00:00:00,2024-08-29 23:13:04,"üåü **Exciting Times for Femtech!** üåü  
Did you know that Flo Health has just become Europe's first femtech unicorn after raising a whopping $200m in funding from General Atlantic? This remarkable achievement is not just a milestone for Flo, but a significant moment for the entire femtech industry, highlighting the potential and growth in a sector that has often faced underfunding.  
  
In this outstanding Series C round, Flo plans to leverage the new capital to expand its reach, particularly in areas such as perimenopause and menopause, while also enhancing its research and development for AI-driven personalized insights. Having already grown its revenue from $35m to $112m in just one year, the momentum is unmistakable! üöÄ  
  
The implications of this growth are vast. For health professionals and entrepreneurs in the femtech sector, it underscores the importance of innovation and understanding the diverse health needs of women. Ideas can transform into impactful solutions when there‚Äôs a strong commitment to development and user engagement.  
  
As we witness this expansion, it makes you wonder: how can we all contribute to supporting and advancing femtech initiatives further? ü§î We'd love to hear your thoughts!  
  
#Femtech #Women'sHealth #Innovation #Startups #FloHealth  

Read more about this development here: [Sifted - Flo Health Unicorn](https://sifted.eu/articles/flo-health-unicorn-raise-news/)",,https://sifted.eu/articles/flo-health-unicorn-raise-news/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: Europe gets its first femtech unicorn after record $200m investment from General Atlantic | Sifted

URL Source: https://sifted.eu/articles/flo-health-unicorn-raise-news/

Markdown Content:
UK femtech Flo Health is set to raise more than $200m in equity from US growth investor General Atlantic ‚Äî¬†a backer of companies like Uber and Airbnb.

The period-tracking app‚Äôs Series C is the joint-biggest ever raise for a femtech ‚Äî along with US fertility startup Prelude Fertility ‚Äî according to data platform Dealroom. It also gives Europe its first femtech unicorn and takes Flo‚Äôs total funding to more than $290m.

All the funds have been committed and a stock purchase agreement has been signed, cofounder and CEO Dmitry Gurski tells Sifted. The funding round is expected to close in coming weeks, subject to regulatory approvals.

Flo will use the funds to expand into new user segments like perimenopause and menopause and invest in R&D for AI-driven personalised insights tools.

### **Europe‚Äôs first femtech unicorn**

While in the US just a few femtechs have hit unicorn status ‚Äî including fertility clinics Maven and Kindbody ‚Äî in Europe the sector‚Äôs unicorn stable has been bare until now. Previously, the largest raise by a femtech startup was [Elvie‚Äôs](https://sifted.eu/articles/elvie-uk-healthtech-raise) ¬£70m Series C, picked up across two rounds in 2021.

Flo isn‚Äôt disclosing what its exact valuation will be when the funds hit its account, but Gurski tells Sifted the company hit a pre-money valuation of $1bn. ""Reaching unicorn status is a significant milestone for Flo and the entire femtech industry,"" he says.

It comes after a challenging time in the market across the last couple years, says Gurski. ‚ÄúBut despite everything, Flo has shown steady, significant growth, after more than eight years of continuous expansion.‚Äù

Flo‚Äôs revenue in 2023 was $112m ‚Äî up from $35m in 2022, according to the company‚Äôs latest annual accounts. Losses over the same period fell from $35m to $25m. The company has just under 500 employees globally, Gurski tells Sifted.

It plans to deploy some of the fresh capital to increase R&D headcount with ‚Äúinvestments in top-tier talent across \[our\] global offices in Europe and North America,‚Äù Gurski says.

On longer-term plans, he tells Sifted that, ‚Äúwhile we're not announcing specific IPO plans at this time, this funding broadens our range of future paths and gives us the flexibility to choose the best path forward for Flo's continued success and impact in the women's health space.‚Äù Gurski adds: ‚ÄúOur immediate focus remains on executing our growth strategy and further solidifying our position as a leader in femtech.‚Äù

### **The most downloaded women‚Äôs health app**

Flo was founded in 2015 ‚Äî a year before the term ‚Äúfemtech‚Äù was first coined by Ida Tin, founder of soon-to-be rival period tracking app Clue. It‚Äôs since grown into the most-downloaded women‚Äôs health app on both Google Play and AppStore, according to market insights platform Sensor Tower.

Flo‚Äôs platform allows users to track their period cycle and monitor symptoms, as well as providing them with tailored health insights and educational content.

The startup says it has 70m monthly active users and close to 5m paid subscribers as of June 2024. About 50% of those are based in the US, with the remaining half split evenly between the UK and EU.

### **Historically underfunded**

Femtech has long been considered an underfunded sector. In 2023 European startups raised just $191m, a fraction of the $9.7bn shelled out on the wider healthtech sector. On top of that funding in the wider digital health sector ‚Äî which encompasses the vast majority of femtechs ‚Äî has been [hit hard](https://sifted.eu/articles/digital-health-startups-are-running-out-of-cash) by the downturn.

But despite that, Flo isn‚Äôt the only femtech that‚Äôs raised a sizeable sum in 2024. In May, Swedish digital birth control startup Natural Cycles picked up $55m, one of the largest European digital health rounds of the year.

Others haven‚Äôt been so fortunate. At the start of 2023, Clue announced it was [making layoffs](https://sifted.eu/articles/brainly-clue-aiven-tech-layoffs-arent-over-in-2023) and audio erotica site Emjoy shuttered earlier this year.
"
2024-07-30 00:00:00,2024-08-29 23:13:33,"üåü Exciting Developments in Healthtech! üåü  
Have you heard the latest buzz in the healthtech space? Zoe, the pioneering UK gut health startup, has just raised $15 million from US VC Coefficient Capital! This significant funding round aims to propel them into the challenging yet promising US market with their microbiome testing and diet advice app.  
  
In a recent article from Sifted, Zoe co-founder Jonathan Wolf names the US as ""the biggest opportunity"" for their expansion. But as with any venture overseas, this move comes with both exciting prospects and daunting challenges. The stakes are high, especially with the ever-competitive direct-to-consumer diagnostics market, which has many players vying for consumer attention.  
  
Despite the hurdles, Zoe is using this funding not for a massive marketing splurge, but strategically to build its US team and solidify its product relevance. The company aims to make impactful strides in an area where public health faces critical challenges ‚Äì ensuring the health of millions.  
  
üí° **Key Takeaway**: For startups looking to expand internationally, understanding the local market dynamics ‚Äî including competition and consumer behavior ‚Äî is essential.  
  
Curious about the healthtech landscape and how companies like Zoe are navigating these transitions? How do you see the future of direct-to-consumer health solutions shaping up? I'd love to hear your thoughts!  
  
#HealthTech #GutHealth #StartupExpansion #Microbiome #DigitalHealth  

Read more here: [Sifted Article on Zoe](https://sifted.eu/articles/zoe-raise-15m-us-expansion-news/)  
",https://sifted.eu/wp-content/uploads/2023/10/Zoe-Healthtech.jpg,https://sifted.eu/articles/zoe-raise-15m-us-expansion-news/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: Healthtech Zoe says US is 'biggest opportunity' as it raises $15m for stateside expansion | Sifted

URL Source: https://sifted.eu/articles/zoe-raise-15m-us-expansion-news/

Markdown Content:
UK gut health startup Zoe has raised $15m from US-based VC Coefficient Capital as it looks to crack the US market with its microbiome testing and diet advice app. The Series B extension takes the startup‚Äôs total funding to $118m.

The news comes as [a number of European startups](https://sifted.eu/articles/aware-amsterdam-lakestar-healthtech-news) vie to crack the direct-to-consumer (D2C) diagnostics market at a time when the post-Covid digital health bubble has looked [close to bursting](https://sifted.eu/articles/digital-health-startups-are-running-out-of-cash).

Zoe has faced its own set of challenges over the past few months. In April, cofounder and CEO Jonathan Wolf announced that the company was [making layoffs](https://sifted.eu/articles/zoe-healthtech-cost-cutting-news) as it looked to cut costs.

But now Zoe‚Äôs got its sights set on US expansion, it‚Äôs looking to tap into its ‚Äúbiggest opportunity‚Äù ‚Äî according to Wolf.

‚ÄúSuccessfully penetrating the US is famously one of the hardest things for a tech company from outside of the country to do,‚Äù he tells Sifted. But the reward if Zoe gets it right could be huge, he adds. ‚ÄúThat‚Äôs partly because the market is so large, but also because the health crisis is so bad.‚Äù

### **US expansion**

Wolf says Zoe will use the fresh funding to develop its product, build out a team in the US and, crucially for a D2C startup, invest in marketing and getting Zoe visible to consumers.

But there‚Äôs not going to be a ‚Äúmassive splurge‚Äù, he tells Sifted. ‚Äú$15m is not really a big marketing push. It allows us to start to build the business, prove that it‚Äôs relevant, that it delivers results.‚Äù

While Zoe is the clear frontrunner in the consumer gut microbiome testing field in Europe, it‚Äôll face competition in the US from companies like Viome ‚Äî which has raised $186m since launching in 2016. Other startups include Seed Health and Flore, which sell supplements for the gut microbiome, and have raised $40m and $11.7m, respectively.

The US is often considered a key market for European healthtechs looking to scale, but it hasn‚Äôt always been a happy hunting ground for them. A number of healthtech founders told Sifted that higher salaries and marketing costs and the amount of homegrown competition all made the US [a tricky place to set up shop](https://sifted.eu/articles/european-healthtechs-us-expansion).

But the potential upside is worth the challenge, Wolf says: ‚ÄúFor health and nutrition, the US is by far the biggest market.‚Äù

Zoe‚Äôs goal is to expand globally and ‚Äúimprove the health of millions‚Äù, he adds ‚Äî but to hit those kinds of customer numbers the startup ‚Äúneeds to succeed in the US‚Äù.

Wolf‚Äôs under no illusions about the cost of that ambition: ‚ÄúThere‚Äôs a good chance that we will end up needing to raise more money.‚Äù

### **A household name**

Zoe was spun out of King's College London in 2017 from research carried out by [now-famous diet influencer Tim Spector](https://sifted.eu/articles/tim-spector-zoe-health).

The startup became a household name during Covid, when it pivoted to allow members of the public to log Covid symptoms. It then launched gut microbiome testing and a diet and lifestyle app in April 2022 in the UK, and has since convinced the likes of Steven Bartlett‚Äôs Flight Fund, Balderton, Ahren and Daphni to stump up funds for the company.

Microbiome testing kits cost ¬£299 and a monthly subscription to the app costs between ¬£25 and ¬£35 a month (depending on how long a user subscribes). For that, users get personalised scores on thousands of foods and access to recipes, diet and lifestyle advice. More than 100k people have paid for the service so far, says Wolf.

In the past year Zoe ‚Äî which was the UK‚Äôs [fastest growing healthtech](https://sifted.eu/articles/europes-10-fastest-growing-digital-health) by headcount in 2023 ‚Äî has also launched a range of supplements.

### **Cutting costs**

But customer churn has been high. In an interview with Sifted last October, Spector said that ‚Äúhalf‚Äù of users only subscribe to Zoe for six to nine months before leaving ‚Äî and the company was focusing on how to ‚Äúkeep people for years‚Äù.

While Wolf didn‚Äôt want to comment on those figures, he added that the majority of ‚Äúnew‚Äù members since that October interview have purchased annual membership.

But in April the company announced it would be making layoffs, as part of measures to cut costs by 20%.

‚ÄúIn 2023 revenue grew massively faster than we were expecting,‚Äù says Wolf. ‚ÄúWe had long waiting lists ‚Äî would-be members were complaining.‚Äù As a result, Zoe scaled to try and deal with the demand, he tells Sifted.

‚ÄúWe scaled for our forecast of what was going to happen this year,‚Äù Wolf says. While the company had a good January, he adds, ‚Äúsuddenly sales were not what we thought they were going to be‚Äù.
"
2024-07-23 00:00:00,2024-08-29 23:13:44,"üåü Exciting Developments in Digital Health! üåü  
I recently came across an insightful article discussing Kry, a leading Swedish digital healthcare startup, and their commitment to investing in generative AI, which they anticipate will delay profitability until 2025. üìÖ  
  
Here are some key takeaways:  
- Kry has reported a reduction in pre-tax losses from ‚Ç¨155m in 2022 to ‚Ç¨78m in 2023, with revenue experiencing a slight uptick from ‚Ç¨168m to ‚Ç¨188m. This remarkable turnaround is partially attributed to a major restructuring initiative.  
- The company is integrating generative AI into their services to significantly reduce the administrative burden on healthcare staff and to facilitate seamless interactions between digital and physical care pathways. This innovative approach not only enhances efficiency but aims to improve the overall patient experience.  
- Looking ahead, Kry aims to expand its footprint as Europe‚Äôs largest primary care provider, drawing parallels with the household name Ikea, but in the realm of healthcare!  
  
The strategic investment in AI is fascinating, especially as we witness a wave of European startups pursuing similar paths. This move highlights a crucial trend where embracing advanced technology not only provides a competitive edge but also addresses long-standing challenges in healthcare delivery.  
  
As we reflect on these developments, it's a great time to consider: How do you see AI transforming the future of healthcare in your experience?  
  
#DigitalHealth #AIinHealthcare #HealthTech #Kry #GenerativeAI  
Read more about Kry's journey here: [Sifted Article](https://sifted.eu/articles/digital-health-unicorn-kry-gen-ai-news/)",,https://sifted.eu/articles/digital-health-unicorn-kry-gen-ai-news/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: GenAI investment to delay profitability at digital health unicorn Kry | Sifted

URL Source: https://sifted.eu/articles/digital-health-unicorn-kry-gen-ai-news/

Markdown Content:
Swedish digital healthcare startup Kry says that doubling down on its investment into generative AI is set to delay profitability at the company.

The unicorn is [profitable on a country level](https://sifted.eu/articles/kry-profitable-in-all-markets-we-wouldnt-have-managed-it-as-quickly-without-ai-news) ‚Äî which does not take into account centralised company costs like developing tech on its digital platform ‚Äî in all its markets, but had initially set its sights on getting out of the red across the business by the end of 2024.

That will likely now come in 2025, says chief operating officer Kalle Conneryd Lundgren, talking to Sifted ahead of the release of Kry‚Äôs latest annual report, covering 2023.

Pre-tax losses for 2023 fell to ‚Ç¨78m ‚Äî roughly half of the ‚Ç¨155m they were in 2022 ‚Äî after savings from the company‚Äôs [‚Äúmajor restructuring‚Äù](https://sifted.eu/articles/kry-annual-report-news). Revenue rose slightly from ‚Ç¨168m to ‚Ç¨188m.

The company also raised a ‚Ç¨20m convertible note from existing investors in March this year ‚Äî with the biggest ticket coming from the Healthcare of Ontario Pension Plan.

‚ÄúWe have a runway that allows us to do investments related to growth,‚Äù says Conneryd Lundgren. ‚ÄúInvestment into AI is pulling us apart from other care providers ‚Äî and it would be foolish not to take that opportunity.‚Äù

### **GenAI investment**

He tells Sifted that this investment has been one of Kry‚Äôs biggest overheads over the past 12 months and that the company would be fully profitable now if it wasn‚Äôt pumping cash into that area.

The work is planned to result in a big product release sometime in the second half of this year and, while Conneryd Lundgren is tight-lipped about what exactly this GenAI-based product will do, he says it will help solve two key problem areas.

One is the time its healthcare staff spend on admin ‚Äî and the product will feature a number of tools to reduce that, on top of those the company already deploys.

Kry will also release AI tools to ‚Äúsew together‚Äù often complex and confusing digital and physical care pathways, says Conneryd Lundgren: ‚ÄúIn healthcare systems today, if you have physical interaction somewhere and a digital interaction somewhere else, there is no transfer of information between them.‚Äù

Several other European startups are also working on GenAI tools for healthcare ‚Äî and they‚Äôve picked up some sizeable rounds from VCs.

French startup Nabla secured a [$24m Series B](https://sifted.eu/articles/nabla-24m-series-b) round earlier this year to expand its automated note-taking tool for medical professionals. Corti, a Danish AI note-taking and advisory platform for doctors, raised a [$60m Series B](https://sifted.eu/articles/atomico-gen-ai-healthcare-corti-series-b-news) in September 2023.

While Conneryd Lundgren didn‚Äôt rule out working with startups providing GenAI tools in the future, he says Kry‚Äôs are ‚Äúfar better‚Äù than others on the market.

That, he argues, is largely due to Kry having built its own to fit directly into its tech platform.

‚ÄúAI is off the shelf nowadays and the challenge is to implement it into your own platform,‚Äù he tells Sifted. ‚Äú\[Our care platform\] is already hooked up to reimbursement and electronic medical record systems across Europe, so it‚Äôs almost plug and play.‚Äù

A team of around 100 developers have been working on this project ‚Äî which will run on OpenAI‚Äôs GPT models.

### **Becoming the ‚Äúnext Ikea‚Äù**

It‚Äôs all part of Kry‚Äôs plan to become Europe‚Äôs biggest primary care provider (excluding public healthcare systems) ‚Äî a target Conneryd Lundgren says the company hopes to hit in years, as opposed to decades.

The company says that 25% of Swedish households have at least one member who has downloaded the Kry app ‚Äî and by 2027 it wants to provide care for 10% of the population in all of its markets.

‚ÄúKry may be the next Ikea,‚Äù says Conneryd Lundgren ‚Äî pointing to the Swedish furniture seller expanding all over Europe and providing a product for less money. ‚ÄúThe only difference is they do furniture, we do healthcare.‚Äù

In the meantime, the company has one eye on the M&A market. Thirrty companies make up the Kry ‚Äúgroup‚Äù ‚Äî and around 20 of those have been acquisitions. While the company didn‚Äôt acquire any new companies in 2023 ‚Äî it‚Äôs open to snapping up legacy healthcare providers with a physical presence as it looks to bolster its in-person healthcare offering.

‚ÄúWe believe the time when you spoke about digital and physical care as separate things is over,‚Äù he says. ‚ÄúThat makes no sense any more ‚Äî every patient has physical and digital interactions in their care journey.‚Äù

Kry currently operates 55 physical clinics across France, Norway and Sweden ‚Äî with the vast majority in the latter. Conneryd Lundgren won‚Äôt put a date of when he expects the company to open its first in the UK, but adds it's ‚Äúnot impossible‚Äù that‚Äôll happen in the next 12 months.

### **Falling losses**

Kry is one of the [first-generation digital health companies](https://sifted.eu/articles/european-telehealth) that emerged in Europe in the 2010s. Since launching in 2015 the company has raised more than $700m ‚Äî including a [$160m Series D](https://sifted.eu/articles/kry-raises-160m) extension in July 2022 and an unannounced ‚Ç¨30m in 2023.

After a boom in customer numbers during the pandemic, in 2022 the company laid off hundreds of employees, withdrew from Germany and halted a planned expansion into Italy.

Last year, Conneryd Lundgren told Sifted that losses in 2022 rose due to ‚Äúgoodwill payments‚Äù to laid-off employees, but now says they are falling due to improved operational efficiency brought about by ‚Äúbetter systems and operational models‚Äù. Kry has, for example, already deployed AI tools in all of its markets that have cut doctor‚Äôs admin time by 30%, he says.

Kry also laid off a further 29 non-clinical staff in 2023. While Conneryd Lundgren tells Sifted that the company will not be undergoing anymore ‚Äúmajor restructuring‚Äù, the company may ‚Äúreduce‚Äù the number of administrative staff further as tech makes operations more efficient.

Revenue in all of its markets ‚Äî except for Norway ‚Äî rose. France saw the most growth, with the market making ‚Ç¨26m ‚Äî a 56% increase on the amount the previous year. Sweden remained Kry‚Äôs biggest market ‚Äî with revenue growing 5% to ‚Ç¨134m, and in the UK it rose from ‚Ç¨21m to ‚Ç¨25m. In Norway it fell by just over a quarter to ‚Ç¨2.8m.
"
2024-07-19 00:00:00,2024-08-29 23:14:13,"üåü Have you ever wondered how healthtech is evolving? A recent article from Sifted highlights some intriguing insights about the healthtech landscape VCs are excited to explore in 2024. Amidst a see-saw of investor enthusiasm, some key ideas have emerged that might just reshape the future of healthcare!  

**Key Takeaways:**  
1. **D2C Health Diagnostics:** There‚Äôs a significant opportunity for startups offering accessible health assessments. Imagine a subscription-based model for annual health check-ups powered by AI!  
2. **AI-Driven Intelligence for Pharma:** An opportunity exists for AI tools that can provide actionable data to pharmaceutical companies, potentially transforming their operations and insights at a fraction of current costs.  
3. **AI Tools for Hospitals:** As the demands on healthcare systems grow, startups focusing on streamlining hospital tasks with AI could drastically improve efficiency and patient care.  
4. **Care Platforms for Neurodegenerative Diseases:** Innovations in monitoring and managing conditions like Alzheimer‚Äôs stand to significantly ease the burden on patients and families alike.  
5. **Health Management Apps:** Patient-driven tools that facilitate personal health management could engage individuals on a journey towards better health.  
6. **Support for Lower-Trained Professionals:** Tech-enabled solutions to assist nursing assistants can alleviate the overwhelming demand faced by healthcare systems.  

With healthcare technology on the brink of a revolution led by AI and patient-centric solutions, it‚Äôs an exciting time to be involved! üí° How do you see these innovations impacting health outcomes in your community? Let‚Äôs chat!  

#HealthTech #AIinHealthcare #DigitalHealth #VCFunding #StartupIdeas  

Read the full article [here](https://sifted.eu/articles/vc-healthtech-ideas/).",https://images.sifted.eu/wp-content/uploads/2024/07/18164110/Will_Gibbs_Octopus-Ventures_Headshot_1200x675-e1721317281282.png?auto=format&fit=max&w=3840&q=75,https://sifted.eu/articles/vc-healthtech-ideas/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: 6 healthtech ideas VCs want you to pitch in 2024 | Sifted

URL Source: https://sifted.eu/articles/vc-healthtech-ideas/

Markdown Content:
VCs have had an up-and-down relationship with healthtech in the past couple of years.

While investors have remained [fairly bullish](https://sifted.eu/articles/earlybird-raises-173m-fund-news) on biotech companies, the sheen has come off digital health startups ‚Äî with funding in the sub-sector [dropping further](https://sifted.eu/articles/digital-health-startups-are-running-out-of-cash) than European tech as a whole in 2023 and remaining low into 2024.

But several VCs recently told [Sifted](https://sifted.eu/articles/europe-digital-health-unicorn-hlth) they think investment will begin to pick up in the next year. And there‚Äôs real excitement around the potential of AI and the rise of preventative care to positively impact struggling healthcare systems.

They‚Äôre both areas that investors say they want to pump money into ‚Äî as Sifted asks six VCs what healthtech ideas they‚Äôre keen to be pitched in 2024.

D2C diagnostics, business intelligence for pharmaceutical companies and tools for hospitals are also featured, as investors from Octopus, Ventures, Speedinvest, Frontline Ventures, InHealth Ventures, Northzone and Nina Capital share their thoughts.

### **D2C health diagnostics**

_Will Gibbs, partner at Octopus Ventures_

![Image 1](https://images.sifted.eu/wp-content/uploads/2024/07/18164110/Will_Gibbs_Octopus-Ventures_Headshot_1200x675-e1721317281282.png?auto=format&fit=max&w=3840&q=75)

There is a gap in the market for a healthtech startup that makes annual health MOTs accessible and affordable for consumers. A startup that offers comprehensive assessments at an accessible price point ‚îÄ by harnessing AI and advanced diagnostics ‚îÄ has the potential to gain significant market share.

A subscription model could provide continuous health monitoring and timely reminders, encouraging yearly check-ups. Partnering with insurers and employers to provide subsidised plans could further increase accessibility, promoting proactive health management and early disease detection.

### **AI-driven business intelligence platforms for pharma**

_Daria Gherghelas, associate at Speedinvest_

![Image 2](https://images.sifted.eu/wp-content/uploads/2024/07/18164236/Daria-Gherghelas-Speedinvest-e1721317369510.jpg?auto=format&fit=max&w=3840&q=75)

AI paves the way for a new category of software companies with embedded service layers ‚Äî similar to traditional B2B SaaS customer success teams ‚Äî selling to pharmaceutical companies.

Commercial intelligence work is still largely outsourced by pharma ‚Äî which is costly ‚Äî and presents an opportunity for an AI-native company. Such a business could leverage software to gather and synthesise public and proprietary data on competition, market changes and ongoing clinical trials. Human input can further refine these insights and help pharma manage their portfolio and pipeline of drug candidates.

### **AI tools for hospitals**

_William McQuillan, partner at Frontline Ventures_

![Image 3](https://images.sifted.eu/wp-content/uploads/2024/07/18164427/WM-2-scaled-1-e1721317482836.jpg?auto=format&fit=max&w=3840&q=75)

An enormous amount of hospital staff and clinicians' time is spent on administrative tasks or triaging patients. On the clinicians' side, I‚Äôd like to see startups building new AI tools for enhanced triaging of patients, reducing the time needed for data collection. On the hospital management side, I‚Äôd like to see tools for better management of patient data, scheduling and billing. And, on the patient side, I‚Äôd like to see AI tools giving better-personalised medicine and enhanced post-hospital/post-operative care as well.

As it currently stands, healthcare systems ‚Äî and hospitals in particular ‚Äî are unable to cope with the increase in patient demands from an ageing population. AI is one of the few answers that can make a meaningful impact to increase resources and improve outcomes over the next decade. For this reason, we're seeing a reduction in lead time to sell into hospitals, and at Frontline we believe now is a better time than ever to be building AI tools for this market.

### **Diagnosis and care platforms for neurodegenerative diseases**

_Lavanya Bhamidipati, principal at InHealth Ventures_

![Image 4](https://images.sifted.eu/wp-content/uploads/2024/07/18164621/InHealth-0068-%C2%A9ivan-weiss_landscape-scaled-e1721317589985.jpg?auto=format&fit=max&w=3840&q=75)

Neurodegenerative diseases (such as Parkinsons and dementia-type diseases like Alzheimers) have a large economic burden on society ‚Äî it is estimated that the current cost of dementia alone to the UK is forecast to be [¬£42 billion](https://www.alzheimers.org.uk/blog/how-much-does-dementia-care-cost#:~:text=The%20total%20cost%20of%20dementia,2040%20unless%20action%20is%20taken.), 63% of which is borne by patients and their families.

We need healthtech companies that help with early diagnosis, monitoring and end-to-end management of these conditions.

Companies that use digital biomarkers to recognise early signs of cognitive decline, help patients get access to the right treatments, monitor their symptoms and coordinate care across all stakeholders (healthcare, social care and families) will reduce costs while creating significant patient impact.

### **Health management apps**

_Michiel Kotting, partner at Northzone_

![Image 5](https://images.sifted.eu/wp-content/uploads/2024/07/18164717/1Q5A3582-scaled-e1721317648903.jpg?auto=format&fit=max&w=3840&q=75)

I would focus on creating an app designed to help patients manage their own health. This app would provide guidance on health-related decisions, help track health data and offer suggestions for treatment options.

While decision support and automation in the medical system through AI and data hold great promise, these require clinical proof, regulatory approval and uptake from medical professionals ‚Äî an inherently slow and friction-filled process.

In contrast, developing tools to help patients directly manage their health and treatment has a lower barrier to adoption. This approach would initially attract individuals interested in longevity and those managing chronic diseases.

### **Tools for lower-trained healthcare professionals**

_Yahel Halamish, principal at Nina Capital_

![Image 6](https://images.sifted.eu/wp-content/uploads/2024/07/18164840/NinaCapital03-e1721317730283.jpeg?auto=format&fit=max&w=3840&q=75)

With an ageing population and a rising demand for healthcare services, healthcare systems worldwide are struggling to meet the demand, putting healthcare professionals at risk of burnout.

Tech-enabled tools that help lower-trained employees, such as nursing assistants, to provide care could help address this problem. These tools could continuously monitor patients and translate treatments into simple, easy-to-perform actions. A startup providing a product like this could reduce the load on medical professionals without altering current care pathways and workflows.
"
2024-07-18 00:00:00,2024-08-29 23:14:40,"üåü Have you ever thought about how many innovative ideas can spring from a single company? The recent spotlight on the former employees of Kry, a leading name in the digital health sector, sheds fascinating light on this concept!  
  
In a recent article from Sifted, it was exciting to read about the transformation of Kry‚Äôs ex-employees into entrepreneurs, giving birth to 15 startups that span various sectors, predominantly digital health. Some notable highlights include:  
- **Steep**: A data analytics platform that is already nascent in the startup ecosystem.  
- **Femcare**: Tailoring healthcare solutions specifically for women during menopause, which is such a vital and often overlooked area of healthcare.  
- **Terra Labs**: Utilizing AI to help forest owners promote sustainability - a perfect fusion of tech and environmental stewardship!  
  
The key takeaway here is that innovation is contagious. When one company fosters a creative and supportive environment, it often leads to the blossoming of new ideas that can impact various industries. As professionals in the field, we should be open to nurturing our colleagues‚Äô entrepreneurial aspirations, as they may very well lead to changes that benefit us all.  
  
As you reflect on this development in our industry, consider: What kind of environment do you think cultivates innovation in your workplace?  
  
Let‚Äôs share our thoughts and ideas! üí¨  
  
#DigitalHealth #Entrepreneurship #Innovation #Startups #HealthTech  
  
Source: [Sifted](https://sifted.eu/articles/kry-founders-factory/)",https://images.sifted.eu/wp-content/uploads/2024/07/17151049/johan-e1721225570656.jpg?auto=format&fit=max&w=3840&q=75,https://sifted.eu/articles/kry-founders-factory/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: The Kry founders factory: Meet 15 employees-turned-founders | Sifted

URL Source: https://sifted.eu/articles/kry-founders-factory/

Markdown Content:
Swedish startup Kry has been a darling of Europe‚Äôs digital health sector for years.

Since the start of 2020, it‚Äôs raised more than $600m according to Dealroom, and was one of a crop of patient-facing healthtechs that [flourished](https://sifted.eu/articles/european-telehealth) during Covid.

While things got a little dicier in the period that followed ‚Äî Kry laid off hundreds of employees and [pulled out of international markets](https://sifted.eu/articles/kry-annual-report-news) during a turbulent 2022 ‚Äî the company reported that it was [profitable](https://sifted.eu/articles/kry-profitable-in-all-markets-we-wouldnt-have-managed-it-as-quickly-without-ai-news) in all three of its remaining markets earlier this year.

Like fellow healthtechs [Babylon](https://sifted.eu/articles/the-startups-founded-by-babylons-ex-employees) and [Doctolib](https://sifted.eu/articles/doctolib-founder-factory-startup), Kry has also become a founders factory in recent years ‚Äî and Sifted has tracked down 15 former employees-turned-entrepreneurs.

More than half have, unsurprisingly, launched digital health startups. But there‚Äôs also a couple of SaaS platforms, a climate tech, an edtech and a secondhand fashion startup.

If we‚Äôve missed any Kry alumni who‚Äôve gone on to become founders, please get in touch at [kai@sifted.eu](mailto:kai@sifted.eu).

### **Steep**

![Image 1](https://images.sifted.eu/wp-content/uploads/2024/07/17151049/johan-e1721225570656.jpg?auto=format&fit=max&w=3840&q=75)

Johan Baltzar, Steep founder

**Founded:** 2021

**Funding:** ‚Ç¨5.25m

**HQ:** Stockholm

Founded by former head of analytics at Kry Johan Baltzar (who also worked at Swedish tech success stories iZettle and Spotify) Steep is a data and analytics platform for businesses. It announced its ‚Ç¨4m seed round earlier this month.

### **Terra Labs**

![Image 2](https://images.sifted.eu/wp-content/uploads/2024/07/17152219/Adam-and-Peder-in-the-forest-3-1-scaled-e1721226148647.jpg?auto=format&fit=max&w=3840&q=75)

Adam von Corswant and Peder Stahle, Terra Labs founders

**Founded:** 2023

**Funding:** Around ‚Ç¨5m

**HQ:** Stockholm

Terra Labs is a climate tech which helps forest owners monitor their land using satellites and AI. The idea is that by using real-time data and insights, forest owners will be able to run more sustainable and efficient operations. It was founded by former Kry chief product officer Peder Stahle and raised a seed round from Norrsken VC in March this year. Terra Labs is currently in beta.

### **Mantle**¬†

![Image 3: Picture of Josefin Landg√•rd, cofounder of Kry and Mantle.](https://images.sifted.eu/wp-content/uploads/2020/10/06193736/G40_HelloMantlePlaza_202409_5199_300ppi-scaled-e1602009710332.jpg?auto=format&fit=max&w=3840&q=75)

**Founded:** 2019

**Funding:** $4.6m, according to Dealroom

**HQ:** Stockholm

Founded by Kry cofounder and the company‚Äôs first CEO, Josefin Landg√•rd, Mantle is a skincare brand, [selling CBD oil](https://sifted.eu/articles/cbd-europe-regulation-funding) and face creams to help promote wellness.

### Myota Health

![Image 4](https://images.sifted.eu/wp-content/uploads/2024/07/18110508/Myota-scaled-e1721297199640.jpg?auto=format&fit=max&w=3840&q=75)

Thomas Gurry and Katherine Stennett, Myota cofounders

**Founded:** 2021

**Funding:** ‚Ç¨3m

**HQ:**¬†London

Founded by former Kry business development director Katherine Stennett, Myota Health sells prebiotic supplements and microbiome testing kits direct-to-consumer. It's raised from investors including FoodLabs and Peakbridge.

### **Hemi Health**

![Image 5](https://images.sifted.eu/wp-content/uploads/2024/07/17151635/Co-founder-Team-1-scaled-e1721225818758.jpg?auto=format&fit=max&w=3840&q=75)

Sune K-Holm Nielsen (top left) and Hemi founding team

**Founded:** 2024

**Funding:** ‚Ç¨2.1m

**HQ:**¬†Copenhagen

Hemi is a digital health clinic focusing on treatment for headaches. It provides virtual consultations with doctors, digital monitoring through an app and care plans. Hemi was founded by former Kry Norway country manager Benedicte Grytte Dahl and business development director Sune K-Holm Nielsen. The startup plans to raise again in spring 2025.

### **Circle Health**

![Image 6](https://images.sifted.eu/wp-content/uploads/2024/07/17151818/DSC_7651-scaled-e1721226046253.jpg?auto=format&fit=max&w=3840&q=75)

Peter Malmqvist and Jannik Tiedemann, Circle Health founders

**Founded:** 2023

**Funding:** ‚Ç¨2m

**HQ:** Berlin

Circle Health is a digi-physical private health clinic. It offers alternative therapies including intermittent hypoxia-hyperoxia treatment (IHHT) ‚Äî which is said to boost energy ‚Äî and ozone therapy ‚Äî which advocates say can help fight disease but has [limited clinical evidence](https://health.clevelandclinic.org/ozone-therapy). It also offers traditional therapy like acupuncture and osteopathy. It was founded by former Kry global operations director Jannik Tiedemann.

### **Ripe**

**Founded:** 2021

**Funding:** $2m, according to Dealroom

**HQ:** Stockholm

Ripe is a customer engagement platform for SaaS teams that lets companies automate sales workflows. It was founded by Jonatan Dykert, who was a product manager at Kry. Investors include Earlybird VC.

### **Ayd**

![Image 7](https://images.sifted.eu/wp-content/uploads/2024/07/17150923/AYD_DSC04123_LOWRES-e1721225404230.jpg?auto=format&fit=max&w=3840&q=75)

Johan Flodin, Ayd founder

**Founded:** 2022

**Funding:** ‚Ç¨1.2m

**HQ:** Malm√∂

Founded by former Kry chief medical officer Johan Flodin, Ayd is a digital health clinic which sells treatments and medication for men‚Äôs health including hair loss, erectile dysfunction and weight loss. Flodin tells Sifted the startup has more than 5k paying customers and made more than ‚Ç¨200k in monthly sales in May. Ayd plans to raise a seed round later this year.

### **Mai**¬†

**Founded:** 2022

**Funding:** ‚Ç¨1m

**HQ:** Stockholm

Mai is a secondhand fashion startup, which automatically lists sellers‚Äô items on several marketplaces at the same time and adds information about the garment using AI. It was founded by Emma Rosman, who led several business development teams at Kry.

### **Nuroe**

**Founded:** 2023

**Funding:** Around $200k

**HQ:** Stockholm

Founded by former director of product at Kry Hoa Ly, Nuroe is a gamified app for children to accelerate their learning. The startup launched on the iOS App Store in June and Ly tells Sifted the company has already hit break even and isn‚Äôt looking to raise funding.

### **Uneri**

**Founded:** 2024

**Funding:** Bootstrapped

**HQ:** Paris

Uneri is a mental health platform, offering consultations with medical professionals like psychologists and hypnotherapists, alongside alternative mental health practitioners like sophrologists. It also provides access to self-learning resources. Uneri was founded by Mathis Guiziou, who worked in the marketing team at Kry.

### **Femcare**

**Founded:** 2023

**Funding:** Bootstrapped

**HQ:** Stockholm

Femcare is a digital health clinic for women, focusing on menopause care, treatment for conditions like premenstrual syndrome and contraception and dietary advice. It was founded by former Kry employees Elisabeth Rosen, who was previously the medical director for women's health at the company, and Karl-Johan Sturesson, who headed up business development for Kry.

### **EndoGyn**

**Founded:** 2023

**Funding:** Undisclosed

**HQ:** Stockholm

EndoGyn is a digi-physical health clinic for women, focusing on gynaecology, sexual health and pregnancy care. It was founded by Anders Rindevall, who was a partnerships manager at Kry.
"
2024-07-16 00:00:00,2024-08-29 23:14:51,"üåü Exciting Developments in Digital Health! üåü

Have you heard about Huma‚Äôs recent journey? The UK-based digital health startup has just raised an impressive $80 million in its Series D funding round, making waves in the industry despite a backdrop of restructuring that has led to layoffs for around 100 employees.  

This funding round marks Europe‚Äôs largest digital health investment of 2023 to date and sees participation from notable investors like AstraZeneca and Bayer. CEO Dan Vahdat emphasizes the drive for efficiency and sustainability, aiming for profitability as a core goal.  

But what does this mean for the digital health landscape? 
1. **New Opportunities**: With the launch of Huma Cloud, a self-service application builder for remote patient monitoring, smaller healthtech startups can create tailored digital health solutions without the hefty price tag usually associated with compliance and medical device regulations.
2. **Flexibility and Scalability**: The new platform enables customers to build applications focused on various health conditions, from asthma to cancer management. This flexibility could significantly lower barriers to entry for innovators in the healthcare space.
3. **Market Adaptation**: Huma‚Äôs experience reflects broader trends in the digital health industry, where many companies are feeling the pressure to adapt to a challenging funding environment by tightening operations and scrutinizing expenditures. 

As we look to the future, Huma plans to achieve break-even by the end of 2024, indicating a cautious but optimistic outlook. We believe this could lead to a healthier ecosystem where more startups thrive, even in tough times.

What are your thoughts on the evolving landscape of digital health, especially with such initiatives?  

Let‚Äôs discuss!  

#DigitalHealth #HealthTech #RemotePatientMonitoring #Investments #StartupCulture  

[Source](https://sifted.eu/articles/huma-startup-raise-layoffs-news/)  

![Huma Cloud Platform](https://images.sifted.eu/wp-content/uploads/2024/07/16105153/Huma-Cloud-Platform-screen-shot-1-e1721123528685.png?auto=format&fit=max&w=3840&q=75)",https://images.sifted.eu/wp-content/uploads/2024/07/16105153/Huma-Cloud-Platform-screen-shot-1-e1721123528685.png?auto=format&fit=max&w=3840&q=75,https://sifted.eu/articles/huma-startup-raise-layoffs-news/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: Digital health startup Huma raises $80m Series D and makes layoffs | Sifted

URL Source: https://sifted.eu/articles/huma-startup-raise-layoffs-news/

Markdown Content:
UK digital health startup Huma is today announcing an $80m Series D round, following a period of ‚Äúrestructuring‚Äù at the company that‚Äôs seen it lay off some 100 employees in the past year.

The round featured existing investors AstraZeneca, Hitachi Ventures and Leaps by Bayer. New investors also participated ‚Äî but are undisclosed. The Series D takes Huma‚Äôs total funding to around $300m.

The fresh funds were picked up over several smaller injections of capital in the last year, Sifted understands, but cumulatively the total makes up Europe‚Äôs largest digital health funding round since the start of 2023.

It follows what Huma founder and CEO Dan Vahdat describes as a number of ‚Äúefficiency‚Äù savings made at the startup in the past 12 months as it has looked to slash its cash burn and move towards profitability.

### **‚ÄúShopify for digital health‚Äù**

Founded in 2011, Huma builds remote patient monitoring (RPM) solutions for pharmaceutical companies and healthcare providers ‚Äî for use cases like decentralised clinical trials and [‚Äúvirtual wards‚Äù](https://sifted.eu/articles/virtual-ward-doccla-acquisition-news) (a system for tracking patients‚Äô treatment and recovery at home).

It‚Äôs partnered with health providers like the NHS and Johns Hopkins University, pharma companies like Bayer and Smith+Nephew, and Chinese tech behemoth Tencent in the past. Huma‚Äôs platform is an authorised medical device by regulators in the US, EU and Saudi Arabia.

Previously Huma has worked directly with its customers to build monitoring tools, but in the second half of 2024 it will launch Huma Cloud ‚Äî a self-service style app builder. Customers will be able to build their own RPM apps, using a prompt inputted into a generative AI-powered search bar or from a template on the platform.

![Image 1](https://images.sifted.eu/wp-content/uploads/2024/07/16105153/Huma-Cloud-Platform-screen-shot-1-e1721123528685.png?auto=format&fit=max&w=3840&q=75)

A screenshot from the Huma Cloud platform

Those apps could focus on RPM for anything from asthma, cancer to diabetes, or data collection for clinical trials, says Vahdat.

‚ÄúIt‚Äôs Shopify for digital health. So many companies are built on top of Salesforce or Palantir, and we want to become that type of enabler.‚Äù

Vahdat also sees potential for healthtech startup customers. The young companies, he says, often have fewer resources to build out their tech than typical startups, due to the extra costs involved in complying with stringent healthcare regulations.

The big idea is that, because Huma has already built the individual tools that make up an app and gained regulatory approval for its system, startups can build a digital health product for less money on its platform. While pricing is still being finalised, Vahdat says that it will be ‚Äúconsumption-based‚Äù and ‚Äúsimilar to Shopify‚Äù.

Because, theoretically, it will take less Huma person-power to build a health app using the Huma Cloud platform, it will also be more scalable and the margins will be higher for the company, says Vahdat. The product will launch in beta this week, before rolling out more widely towards the end of 2024.

### **Restructuring**

As Huma has looked to improve its margins, the startup has also cut costs over the past year. Part of that has been reducing headcount.

‚ÄúWhen you have a platform with regulatory approval, you don‚Äôt need a big team to maintain it,‚Äù says Vahdat ‚Äî adding that the costs associated with getting that regulatory approval and building a product from scratch now don‚Äôt apply.

He‚Äôs also replaced some hires with cheaper alternatives. ‚ÄúWe had certain talent that we hired during 2021 and 2022, at the peak of the market, the cost was expensive,‚Äù Vahdat says. ‚ÄúWe‚Äôve replaced some of this talent with more cost effective options.‚Äù

Huma‚Äôs headcount has dropped from around 500 when [Sifted reported](https://sifted.eu/articles/uk-healthtech-huma-layoffs) that the company planned to make around 45 layoffs at the end of August 2023 to 400 today. The layoffs come during a difficult time for digital health startups across Europe.

They raised just $1.2bn across 2023 ‚Äî less than half the $3.1bn picked up during 2021 and the lowest amount since 2018. If H1 numbers are anything to go by, 2024 isn‚Äôt looking much brighter.

The harsh funding environment has pulled the path to profitability into sharp focus for many in the sector ‚Äî and Huma‚Äôs no different.

The startup made a loss of ¬£31m in 2022, according to its latest Companies House filings. Numbers for 2023, although not publicly released, were similar, says Vahdat.

However the company is targeting break-even across the year by the end of 2024.

As it moves towards that goal, Vahdat did not rule out further layoffs at the company. ‚ÄúEvery company does ‚Äòoptimisation‚Äô, we‚Äôre not going to do anything big,‚Äù he tells Sifted.

Huma‚Äôs also got one eye on the M&A market.

It has acquired three companies in the past two years ‚Äî including digital clinical trials startup Alcedis and patient engagement platform iPlato, and one further unannounced company.

The tricky funding environment has ‚Äúcreated opportunities‚Äù for startups like Huma that do have existing investors with deep pockets, Vahdat says.

‚ÄúIf the funding world had been better, maybe we would have had to pay more or it would have been harder \[to make those acquisitions\],‚Äù he tells Sifted. ‚ÄúIf we come across \[a business\] with a use case or in a geography that makes sense, we‚Äôll look at it.‚Äù
"
2024-07-04 00:00:00,2024-08-29 23:15:19,"üåü **Did you know that the administrative tasks in a doctor‚Äôs surgery can take up a significant amount of time that could be spent on patient care?** 

A recent article from Sifted shares exciting news about Healthtech-1, a UK startup revolutionizing how GP practices manage patient registrations and lab results. With a $3.5 million seed round led by Moonfire and Y Combinator, this innovation is set to simplify processes that face many GP practices today, which are often burdened by manual errors and inefficiencies.

The startup's first product, currently implemented in 10% of England‚Äôs GP practices, automates the notoriously complicated process of new patient registrations. Instead of manually entering around 18 data points from forms, their technology performs identity checks against NHS records and automates the entire entry process, saving approximately 15 minutes of staff time per registration! With cities potentially registering up to 1,000 new patients monthly, the impact is significant.

Healthtech-1's approach targets the ‚Äúdeeply unsexy‚Äù yet crucial administrative work in healthcare, leaving medical professionals free to focus on patient interactions where they can truly excel. By streamlining these administrative tasks, they aim to impact the way 90% of patient contact occurs in primary care.

This development opens up discussions on the future of healthtech, especially as more companies seek to assist healthcare systems dealing with staff shortages and an increasing patient load.  

ü§î **How do you think automation can further enhance the efficiency of healthcare services? Share your thoughts!**  

#HealthTech #Automation #HealthcareInnovation #PatientCare #Efficiency

[Read the Full Article Here](https://sifted.eu/articles/healthtech-1-raise-monzo-alumni-news/)",,https://sifted.eu/articles/healthtech-1-raise-monzo-alumni-news/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: Monzo alumni raises $3.5m to automate admin in doctors surgeries | Sifted

URL Source: https://sifted.eu/articles/healthtech-1-raise-monzo-alumni-news/

Markdown Content:
Healthtech-1, a UK-based startup developing tech to automate admin in GP practices around the country, has raised a $3.5m seed round.

The round was led by London-based VC Moonfire, and also featured accelerator Y Combinator ‚Äî which Healthtech-1 participated in last year ‚Äî alongside a number of angels.

It comes as a [rising number of healthtechs](https://sifted.eu/articles/ai-healthtech-vc-watch) are looking to help tackle staff shortages across healthcare systems in the face of growing ‚Äî and ageing ‚Äî populations by automating tasks, both in clinical and admin settings.

Healthtech-1‚Äôs first product, which automates new patient registrations, is currently deployed in 10% of GP practices in England, says cofounder Raj Kohli, who launched the company with ex-Monzo engineer Peter Huang. By the end of 2025, it's targeting more than 90%.

### **What problem is Healthtech-1 solving?**

Currently, new patients register themselves at a GP by filling out either an online or paper form with around 18 data points, which is then manually inputted into the practice‚Äôs operating system.

‚ÄúIt‚Äôs a broken and difficult process which is full of mistakes and manual error,‚Äù Kohli says.

Using proprietary algorithms, Healthtech-1‚Äôs product conducts identity checks against NHS records, writes the data into the system and flags areas to the practice where they might need to pay special attention, such as around safeguarding.

‚ÄúIf a child tries to register with an uncle \[named as their guardian\] instead of a parent, that‚Äôs a safeguarding alert that the GP practice needs to be aware of and take action, just in case of trafficking or something along those lines,‚Äù Kohli tells Sifted.

On average, a GP practice will register 71 patients a month, he says ‚Äî but adds that that figure can rise to up to 1,000 in cities. The startup estimates that it can save practices around 15 minutes of receptionists‚Äô time per registration.

That works out at a cost of ¬£3.75 per registration if a receptionist is paid ¬£15 an hour, Kohli says. Healthtech-1 charges ¬£2 per registration and Kohli tells Sifted the startup has automated over 500k patient registrations.

The startup also launched its second product in February this year, automating the filing of lab results in GP practices ‚Äî a task which is typically done by doctors themselves. It‚Äôs currently live in 31 practices and costs 20p per lab result automated.

### **Doing ‚Äúdeeply unsexy‚Äù work**

Those two tasks are just a fraction of more than 70 admin tasks that GP practices have to do, says Kohli. Healthtech-1 mapped these out at the cofounder‚Äôs parents‚Äô GP practice in East London ‚Äî where the startup is also based.

While automating admin in healthcare could be big business, it‚Äôs startups working on automating clinical tasks that have raised some of the biggest rounds in the space. Denmark‚Äôs [Corti](https://sifted.eu/articles/atomico-gen-ai-healthcare-corti-series-b-news) and France‚Äôs [Nabla](https://sifted.eu/articles/nabla-24m-series-b), which both automate note taking for clinical conversations between doctors and patients, raised $60m and $24m respectively in the past year.

‚ÄúLoads of companies are trying to automate the GP or the doctor ‚Äî and maybe they‚Äôll be successful ‚Äî but when you work inside a GP practice you see that the clinical conversation isn‚Äôt what needs to be automated, that‚Äôs the stuff that GPs are quite good at,‚Äù says Kohli.

What needs to be automated are the processes that support that conversation, he tells Sifted ‚Äî but a lot of businesses have overlooked that ‚Äúdeeply unsexy‚Äù work.

Founded in 2021, Healthtech-1 will look to double its headcount of 15 by the end of 2024 as it scales its patient registration tool and its lab results automation product ‚Äî which it hopes to have in 50% of the more than 6,000 GP practices in England by the end of 2025.

Kohli doesn‚Äôt think the startup will need extra funding to get to that point ‚Äî but further down the line he sees potential for Healthtech-1 to automate communication between GPs and care homes and hospitals.

But for now, Healthtech-1 is focused solely on GP practices, he says: ‚ÄúWhen [90%](https://www.england.nhs.uk/london/wp-content/uploads/sites/8/2013/11/Call-Action-ACCESSIBLE.pdf) of patient contact happens in primary care, that's how you impact this country.‚Äù
"
2024-06-28 00:00:00,2024-08-29 23:15:27,"üåü Exciting advancements in technology are paving the way for better lives! I recently came across an inspiring article about Esper Bionics, a startup that's reimagining the future of prosthetic limbs and wearables. 

After sustaining a life-altering injury, Alexis Cholas was able to return to the frontlines with the help of a groundbreaking AI-assisted robotic arm ‚Äì the Esper Hand. Unlike traditional prosthetics that rely on just two sensors, this innovative arm uses advanced muscle sensors to give users a remarkable level of dexterity, functioning almost like a human hand. 

But here's the twist: Esper isn't only focused on prosthetics. They're using the insights gained from this technology to develop next-gen sensors for a broader market, potentially revolutionizing wearables and even implantable devices in the near future. Imagine a world where fitness trackers are even smarter, collecting detailed health metrics seamlessly! 

With a recent funding boost of $5 million, the company aims to expand its manufacturing and is looking to license its innovative sensors to wearable manufacturers within the next 18-24 months. 

The key takeaway? By prioritizing data collection and user experience over immediate profit, Esper is setting a new standard in health technology. It's a vivid reminder that some obstacles can lead to extraordinary breakthroughs. 

What are your thoughts on the role of data in developing next-gen wearables? Could we be entering a new era of smart health technology? ü§î

#Prosthetics #HealthTech #Innovation #WearableTech #ArtificialIntelligence

Read more about it here: [Sifted](https://sifted.eu/articles/esper-bionics-raise-news/)",https://images.sifted.eu/wp-content/uploads/2024/06/27163832/20-scaled-e1719502752714.jpeg?auto=format&fit=max&w=3840&q=75,https://sifted.eu/articles/esper-bionics-raise-news/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: AI prosthetic limbs and advanced sensors: how one startup is building tech for next gen wearables | Sifted

URL Source: https://sifted.eu/articles/esper-bionics-raise-news/

Markdown Content:
When Alexis Cholas lost his arm while working as a volunteer combat medic in the Hospitallers Medical Battalion in Eastern Ukraine, he thought his ‚Äúlife was over‚Äù.

But six months later, equipped with a sleek black AI-assisted robotic arm made by Ukrainian-US startup Esper Bionics, he was able to return to the frontlines. The device meant the typically life-changing injury, in fact, wasn‚Äôt, he tells Sifted.

The prosthetic limb, dubbed the Esper Hand, is built with specially designed muscle sensors that the company says allows users better control and dexterity than others on the market.

But the startup‚Äôs not in the prosthetic limb business, says founder and CEO Dima Gazda. Esper is using its robotic arm as a testing platform to develop next generation sensors for a ‚Äúmass market‚Äù ‚Äî which could be used on wearable devices or implanted inside the body, he tells Sifted.

Gazda is banking on that approach unlocking ‚Äúway bigger revenue‚Äù than the company could if it was focused on only manufacturing prosthetics. Esper has just raised $5m in a funding round led by YZR Capital, with participation from EBRD and U.Ventures.

### **AI-assisted robotic arms**

Esper has been developing its robotic arm since it was founded in Kyiv in 2019, and deployed its prototype to its first user the following year. The startup moved its headquarters to New York in May 2022 ‚Äî which was delayed a couple of months by Russia‚Äôs invasion of Ukraine ‚Äî and also has offices in Berlin. Forty of its 55-strong global team, including the bulk of the company‚Äôs R&D, is still based in Kyiv.

![Image 1](https://images.sifted.eu/wp-content/uploads/2024/06/27163832/20-scaled-e1719502752714.jpeg?auto=format&fit=max&w=3840&q=75)

Alexis Cholas

Most robotic prosthetic arms use two sensors to control all functions of the hand ‚Äî detecting movement from the flexor and extensor muscle groups, says Gazda. ‚ÄúIt‚Äôs like controlling a multifunctional device with only two buttons.‚Äù Esper‚Äôs device, however, is controlled with the equivalent of around ‚Äú20 buttons‚Äù.

While Gazda is unable to share any specific details about the sensors as he‚Äôs worried others may copy them, he says they‚Äôve been developed in-house and collect more data than others on the market, which can then be used to better train the machine learning algorithms the company‚Äôs also developed that support how the device moves.

Esper has also built a cloud-based software platform that complements its robotic arm, collecting and processing data and housing its AI control algorithms ‚Äî which, along with the sensors and prosthetic arm, Gazda calls the ‚Äúdata collection architecture‚Äù.

### **The long game**

Esper currently sells its bionic arms via insurers in the US, who pay $22k apiece. That‚Äôs about 10% more expensive than the average robotic prosthetic. It sells the device for $7k in Ukraine ‚Äî which is also the cost of production, meaning the company doesn‚Äôt make a profit on those units ‚Äî funded by donations and the government.

But making revenue from the sale of its bionic arms is ‚Äúnot the main focus‚Äù, says Gazda.

‚ÄúIf you are trying to make revenue from day one, you will build products that exactly fit requirements to be reimbursed by insurance companies ‚Äî but you won‚Äôt develop new health technology,‚Äù Gazda tells Sifted.

Instead of attempting to take market share with its prosthetic arm, Esper‚Äôs activity so far has been an exercise in collecting data that can be used to develop next generation sensors for wearables devices and implants in the future.

These advanced sensors are bulky things when they‚Äôre first developed ‚Äî and wouldn‚Äôt fit into the discreet wearables on the market today. But to develop designs and functionality, and eventually reduce their size, they need to be tested on a whole lot of users.

For a wearable like the Oura ring to collect as many data points as Gazda thinks is possible, for example, it would need to be the size of an armband right now ‚Äî and thousands of people aren‚Äôt going to wear that, he says.

But there is a sizeable group of people who are happy to wear a large wearable device ‚Äî people with prosthetics, Gazda tells Sifted. ‚ÄúIt‚Äôs smarter to help people who already have big wearable devices like prosthetics, and by doing this you have the expertise to build sensors for smaller devices \[in the future\].‚Äù

### **The next steps**

Of the 120 prosthetics currently in use, 80% are in Ukraine and the remainder are in the US; Esper wants to sell 300 more of its robotic arms in the next 12 months, and a big portion of the funding will be spent on upscaling its manufacturing capacity.

But Gazda thinks that most of the startup‚Äôs future revenue will come from licensing the sensors it develops out to other wearable manufacturers. It hopes to go to market with that offering in 18-24 months.

While Esper is just developing muscle sensors on its robotic arm at the moment, he says that working with other manufacturers ‚Äî and using the data collection architecture the company is building ‚Äî it could develop sensors that pick up a multitude of data points in the future.

These could include things like heart rate, blood oxygen saturation, barometric pressure and temperature, Gazda tells Sifted ‚Äî along with others he says he can‚Äôt reveal at the moment.
"
2024-06-27 00:00:00,2024-08-29 23:15:54,"üåü **The Future of Cancer Therapy: AI Startups to the Rescue!**  
Have you ever wondered what it takes to transform cancer treatment from a long-shot gamble to a precision science? Recent insights from an article on Sifted highlight how AI startups are not just keeping pace with traditional pharma but are on the brink of breakthroughs in clinical trials for cancer therapies.

üîë **Key Takeaways:**  
In a field where **97% of clinical trials fail**, these innovative startups like Genialis and Nucleai are shifting the focus towards AI-driven biomarker discovery. This involves identifying why specific patients respond positively to certain treatments while others do not, thus paving the way for personalized medicine.  
Genialis, for instance, utilizes machine learning to match patients with the most effective investigational drugs, showcasing a remarkable accuracy of over 80% in predicting responses to the KRAS gene mutation therapies.

üí° **Insightful Applications:**  
The agility of these AI startups allows them to dive deep into specific challenges without the bureaucratic hurdles faced by larger corporations. By harnessing vast datasets, they are uncovering vital insights into tumor biology that can lead to more effective treatments‚Äîa game changer in the oncology field. For example, Nucleai is pioneering spatial biomarkers that enhance our understanding of how different cells interact within tumors, providing invaluable data for oncologists and researchers alike.

ü§î **What are your thoughts?**  
How do you see AI reshaping the future of clinical trials in oncology? Are there specific developments you‚Äôre most excited about?  
Let's discuss in the comments!  
#AIinHealthcare #Oncology #ClinicalTrials #Startups #Biomarkers  

üìñ Source: [Sifted Article](https://sifted.eu/articles/ai-startups-clinical-trials-cancer-big-pharma-brnd/)  
",https://sifted.eu/wp-content/uploads/2022/12/Sifted_viral_article_header_4.jpg,https://sifted.eu/articles/ai-startups-clinical-trials-cancer-big-pharma-brnd/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: How AI startups working on clinical trials for cancer could find a breakthrough before big pharma | Sifted

URL Source: https://sifted.eu/articles/ai-startups-clinical-trials-cancer-big-pharma-brnd/

Markdown Content:
Clinical trials for cancer therapies are notoriously difficult. According to one study, [97% fail](https://www.vox.com/2019/9/16/20864066/cancer-studies-fail).¬†Scientists are still unclear why only a subset of patients respond to treatments.

But perhaps AI could help.

The industry is now turning to AI to find novel biomarkers which could reveal the underlying causes of vastly different treatment responses across patient populations.

‚ÄúBiomarker discovery is about truly understanding the biology and mechanism of action of your drug,‚Äù says Carolina Haefliger, head of translational medicine at Swiss pharmaceutical company Debiopharm.

Genialis and Nucleai, two startup investments from the company‚Äôs venture capital arm, Debiopharm Innovation Fund, promise to transform oncology drug development, as part of the fund‚Äôs wider portfolio of clinically-focused AI companies.

We spoke to the startups ‚Äî and their investors ‚Äî to find out what they are working on and how these strategic investments helped catalyse transformative collaboration with Debiopharm

### **Focusing on a specific problem**¬†

Genialis, based in Boston and Ljubljana, is a precision oncology startup focused on transforming drug development through ‚Äúbiology-first‚Äù, machine learning-based predictive biomarkers.

‚ÄúWe build machine learning models whose purpose is to help match cancer patients with the right drug for their disease, and we match novel investigational drugs not yet approved to the patients for whom it will have maximum benefit,‚Äù says Rafael Rosengarten, Genialis‚Äôs CEO and cofounder.

An example of Genialis‚Äôs biomarker models is [krasID](https://www.genialis.com/krasid/), which can predict and monitor ‚Äî with more than 80% accuracy ‚Äî a patient's response to the inhibition of [KRAS](https://www.nature.com/articles/s41392-021-00780-4), a gene whose mutations are known to cause up to 20% of all cancers.

> There is a nimbleness, an agility that is found in the world of startups that makes them more focused on one target or technology.

Genialis began building software that could aggregate RNA sequencing data and organise it in a way that makes machine learning effective. It [raised a $13m](https://www.prnewswire.com/news-releases/genialis-raises-13m-to-build-clinical-biomarkers-that-predict-patient-response-301784406.html) Series A in 2023, co-led by Debiopharm, and is building out its platform for the clinical development realm.

Like other startups in this space, it's successful where bigger pharma companies seem to fail.

‚ÄúWe are hyper-focused on fixing a specific problem. We are not encumbered by all the vagaries and the distractions and priorities that larger corporations have to deal with,‚Äù says Rosengarten.

Marc Cikes, managing director of Debiopharm Innovation Fund, agrees this is where startups can shine.

‚ÄúThere is a nimbleness, an agility that is found in the world of startups that makes them more focussed on one target or technology, and they can develop it with much more flexibility than a big pharmaceutical company,‚Äù he says.

### **A dynamic disease**¬†

As a complex, dynamic disease that constantly evolves to evade the immune system and treatments, cancer is one area where AI-powered drug development could help scientists gain an advantage.

‚ÄúWe must be able to handle very large datasets when identifying biomarkers, this was very difficult before we had these AI tools available, but now we can look at the data to get deeper insights into the biology of tumours and cancer,‚Äù says Cikes.

Haefliger adds that combining huge external datasets such as The Cancer Genome Atlas programme ([TCGA](https://www.cancer.gov/ccg/research/genome-sequencing/tcga)) with internal datasets could help AI models to get the insights needed to understand cancer.

For example, it took almost 40 years for drugs targeting mutated KRAS to be approved by the FDA, but using the power of biomarkers and AI, Genialis plans to have a platform that is able to build an accurate predictive biomarker for every citizen, for every cancer drug target, to make this process quicker.

Biomarker discovery requires understanding both the biology of a system and the mechanism of a drug developed to treat it. The poor understanding of human disease processes previously hampered biomarker development.

‚Äú\[Genialis‚Äôs\] approach begins with biology, and it is very different from other companies. We thought it would be useful to solve the questions we have about biomarkers and DNA damage response agents,‚Äù says Haefliger. ‚ÄúThey may provide an answer that would normally take a lot of resources and time when you need to move a drug through the development path.‚Äù

### **Probing complex spatial relationships**

Nucleai is creating AI-driven spatial biomarkers, and uses AI to create a map of cells in biopsy tissue samples that can provide all-important information for a personalised treatment approach.

> We couldn‚Äôt find these relationships using traditional methods, so we started working with Nucleai who had the right tools.

‚ÄúWe have developed an AI-driven spatial biology solution that maps cells in biopsies and correlates these maps with other layers of information,‚Äù says Avi Veidman, Nucleai‚Äôs CEO and cofounder. ‚ÄúIn an era where new oncological drugs target specific proteins, Nucleai's solution identifies which patients will respond to these drugs and which are suitable for clinical trials of newly developed treatments.‚Äù

Digitised tissue samples can unlock information about more than just one cell.

‚ÄúOur platform maps the neighbourhood of cells, providing more context and insight into the interplay of cells. This allows pharmaceutical companies to increase the probability of success in clinical trials and enables oncologists to treat patients with the most effective drugs,‚Äù says Veidman.

The novelty of its platform attracted Debiopharm, based on a suspicion that targeted therapies may not be successful due to the placement of receptor targets and their relationship to other cells around them.

‚ÄúWe couldn‚Äôt find these relationships using traditional methods, so we started working with Nucleai who had the right tools,‚Äù says Anna Pokorska-Bocci, principal scientist in personalised medicine at Debiopharm. ‚ÄúWe could use molecular information from clinical trial participants and patient response to the drug to feed the Nucleai platform. This analysis allowed us to uncover potential spatial biomarkers that could help predict which patient population could respond to the treatment and which population would not.‚Äù

### **Bridging startups and pharma**

Debiopharm Innovation Fund is providing a unique bridge between biotech startups and industry.

> \[Debiopharm Innovation Fund\] are really smart about this technology space adjacent to drug development.

The fund understands the challenges facing large pharmaceutical companies and their R&D constraints and blind spots. Equally, it can shepherd startups through the long and uncertain road from a promising technology to solutions that can be adopted and absorbed by the industry.

‚ÄúThey are really smart about this technology space adjacent to drug development, and they invest in companies that make drug development smarter, faster, cheaper, better, more successful,‚Äù says Rosengarten. ‚ÄúThey let us look behind the curtain and ask probing questions, allowing us to tailor our solutions to really solve the problem.‚Äù

Veidmann agrees, adding that Debiopharm Innovation Fund offers more than just financial backing.

‚ÄúThey provide knowledge, an understanding of pharma, scientific knowledge and expertise,‚Äù he says. ‚ÄúThey are bringing to the table good connections and the network they have in this domain.‚Äù
"
2024-06-27 00:00:00,2024-08-29 23:16:24,"Have you ever wondered how innovation in the sexual health sector can redefine comfort and safety? A recent article highlighted an exciting development in taboos of the sextech world‚Äìthe London-based startup, Polari Group, has successfully raised $539k to develop a revolutionary device aimed at enhancing anal sex experiences by replacing the traditional douching process.  

Polari's product is designed to mitigate the anxieties often surrounding anal sex, addressing a need that many people may shy away from discussing openly. The device aims to prevent ‚Äòfaecal accidents‚Äô, addressing a significant concern among users. Despite facing investor stigma‚Äîcommon in the sextech space‚Äîthe startup has made strides, becoming the first European company focused specifically on anal sex to secure funding this year.  

This product not only sheds light on necessary discussions about sexual health but offers a safer alternative to current practices that can sometimes do more harm than good. Using insights from health studies, Polari estimates that there are approximately 2.8 billion anal sex acts annually across major western countries. This statistic alone indicates a substantial market that remains largely overlooked by traditional medical advice and investor interest.  

What‚Äôs particularly intriguing about Polari's approach is its emphasis on user safety in design, adhering to ISO standards related to sex toys. As the sextech industry continues to grow, lessons can be learned from Polari's model about the importance of research, development, and customer education in creating products that resonate with users while addressing their real concerns.  

As Polari prepares for its launch in September 2025, it‚Äôs a reminder of the endless possibilities when we dare to innovate within our fields. What are your thoughts on the rising trend of startups prioritizing sexual wellness? How do you envision the future of sexual health products? 

#SexTech #Innovation #StartupNews #Healthcare #SexualWellness

Read the full article here: [Sifted](https://sifted.eu/articles/polari-sextech-raise-news/)",https://images.sifted.eu/wp-content/uploads/2024/06/26163153/Copie-de-Lab-2-e1719415922787.jpeg?auto=format&fit=max&w=3840&q=75,https://sifted.eu/articles/polari-sextech-raise-news/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: The EF-backed startup building a novel device for the anal sex market | Sifted

URL Source: https://sifted.eu/articles/polari-sextech-raise-news/

Markdown Content:
When founder Anna Vybornova was on the fundraising roadshow, some investors she pitched to abruptly ended the meeting after minutes of talking about her London-based startup, Polari Group.

That‚Äôs because the company is developing a novel device which it says can replace douching before anal sex. And despite the discomfort of some potential backers ‚Äî today it‚Äôs announcing a $539k raise. The money comes from VC Chasing Rainbows, Ada Ventures' angel programme, angel network Ventures Together and family office Little Green Bamboo Capital.

According to Dealroom data, it‚Äôs the first European startup to raise funds to develop a product specifically around anal sex. The company is developing a ball-shaped device designed to be inserted into the rectum before anal sex, to prevent what it calls ‚Äúfaecal accidents‚Äù.

Raising money for such a product is no mean feat in a world where it‚Äôs _very_ difficult to raise money for any sextech startup.

Vice clauses (restrictions set by LPs on where their money can be invested that often cover things like tobacco, guns ‚Äî and sex) as well as conservative investor stigma [block](https://sifted.eu/articles/sextech-fundraising) many potential backers from considering these ideas. Just seven sextech companies have raised in 2024 so far and across the two previous years only 20 convinced investors to part with their cash.

Polari does split the opinion of investors, says cofounder and CEO Anna Vybornova. ‚ÄúPeople love what we do or people are disgusted and find it off-putting.""

But these disgusted investors might be missing out on a big opportunity.

A 2013 study of more than 1k gay men in Belgium found that [two thirds](https://pubmed.ncbi.nlm.nih.gov/25356292/) had had anal sex in the previous four weeks and one 2016 survey found that a [third of heterosexual people](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949144/) in the US had in the previous year. Using figures from those studies, Polari estimates that 2.8bn anal sex acts happen yearly across the UK, US and Europe.

Founded in 2023 during one of London-founded company builder [Entrepreneur First](https://sifted.eu/articles/entrepreneur-first-us-demo-day)‚Äôs cohorts, Polari will use the fresh funds to finalise the design of its device and grow its team.

### **An alternative to douching**

Preparing for anal sex can be time consuming for those that choose to douche ‚Äî the process of flushing the rectum with water to clean it. NHS [guidelines](https://www.sexualhealth.cnwl.nhs.uk/media/1050/anal.pdf) also recommend against douching, because it can damage the body‚Äôs natural internal lining and protective mucus.

Because of this, doctors don‚Äôt know how to talk about the process with patients, says Polari cofounder and CTO Henry Blest.

It means there‚Äôs very little advice available and some people end up engaging in ‚Äúdangerous‚Äù douching practices, he tells Sifted. ‚ÄúMedicine won‚Äôt engage with anal douching ‚Äî but the \[LGBTQ+\] community won‚Äôt stop doing it because they don‚Äôt want to have a faecal accident during sex.‚Äù

But Polari‚Äôs ball-shaped device is designed to be inserted into the rectum before anal sex to prevent exactly that. While the startup can‚Äôt share how exactly the device works or design specifics, as it's worried about others copying the idea before it's able to release a product, Vybornova says it's single use.

The device is made from a ‚Äúnovel material‚Äù and is in the final stages of design, she tells Sifted. ‚ÄúWe have a product that works in models.‚Äù

Those, Vybornova adds, are models of the rectum and penis, which have allowed the startup to study how faeces moves during anal sex.

While she says Polari‚Äôs device doesn‚Äôt need to go through clinical trials before its planned launch in the UK in September 2025 as it‚Äôs a consumer product, it does need to meet the ISO standard (an international set of standards covering technology and manufacturing) for sex toys ‚Äî which dictates that a product must be designed in certain ways to avoid harm to the end user.

It also needs to go through further testing, on things like safety and quality, which will be carried out by an independent contract manufacturing organisation (CMO).

### **The future**

The fresh funding will be spent on finalising the product design in the lab, beginning to take it through regulatory testing and growing the team.

There‚Äôs currently one other Polari employee alongside Blest and Vybornova ‚Äî a chief of staff ‚Äî and the startup wants to grow the team to between 7-10 people by the time it launches the device. Roles it‚Äôs hiring for will include a head of quality and several lab staff.

![Image 1](https://images.sifted.eu/wp-content/uploads/2024/06/26163153/Copie-de-Lab-2-e1719415922787.jpeg?auto=format&fit=max&w=3840&q=75)

Polari cofounders Anna Vybornova and Henry Blest

Polari will also look to get back on the fundraising roadshow sometime between this September and January 2024. It‚Äôll look to raise a ‚Äúcouple of million‚Äù which will allow it to release and scale its device as a direct-to-consumer product.

That will involve partnering with a manufacturer to mass produce the device, alongside expanding sales and marketing functions and conducting further regulatory testing.

Further down the line, the startup will look into selling the device white label to other sexual health product providers ‚Äî alongside developing a ‚Äúa larger line of proprietary products for anal health and pleasure‚Äù, says Blest.

But first there‚Äôs the matter of convincing often prudish investors to stump up more cash ahead of the first product launch.

The idea is to raise from VCs rather than angels, but because of the difficulty convincing that group to part with funds, Vybornova says Polari will also target high net worth individuals and family offices.

‚ÄúWe need to be creative. We don‚Äôt operate with the same playbook as a B2B SaaS.‚Äù
"
2024-06-21 00:00:00,2024-08-29 23:16:31,"üåü Exciting advancements in health tech! Recently, UK startup Sava secured an impressive $8 million in seed funding to revolutionize the realm of Continuous Glucose Monitors (CGMs). This is particularly noteworthy in a landscape where consumers are becoming increasingly health-conscious, gravitating towards tech that aids personal health management.

Sava's innovative approach focuses on utilizing smaller, less invasive microneedles to measure glucose levels, addressing major concerns around user discomfort and affordability. By scaling manufacturing, they aim to make these devices up to ten times cheaper, fostering greater accessibility. Plus, their vision goes beyond glucose monitoring‚Äîfuture iterations could potentially track other crucial biomarkers such as ketones, proteins, and allergens, transforming how we view personal health management.

As the CGM market continues to grow, positioned predominantly in diabetes care, Sava's initiative could tap into a broader consumer market eager for personalized health metric insights. Imagine the possibilities! CGMs could be utilized not only by those with diabetes but also by fitness enthusiasts eager to optimize their performance through data.

This development evokes the question: how do you envision CGMs reshaping the landscape of personal health tracking? 

#HealthTech #ContinuousGlucoseMonitoring #Sava #Innovation #Biomarkers 

Read more about this exciting development in detail here: [Sifted Article](https://sifted.eu/articles/sava-raise-balderton/)",,https://sifted.eu/articles/sava-raise-balderton/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: UK startup Sava raises $8m to develop next-gen continuous glucose monitor | Sifted

URL Source: https://sifted.eu/articles/sava-raise-balderton/

Markdown Content:
As patients and consumers spend more time ‚Äî and money ‚Äî on tech to help them monitor their health, a growing [group of startups](https://sifted.eu/articles/aware-amsterdam-lakestar-healthtech-news) are looking to cash in on the trend.

Continuous glucose monitors (CGMs) ‚Äî small devices that usually attach to a user's arm and measure blood sugar levels ‚Äî have been made famous by London-based company Zoe, one of Europe‚Äôs [best funded D2C health techs](https://sifted.eu/articles/zoe-healthtech-cost-cutting-news). Today, fellow UK-based startup Sava is announcing an $8m seed round to develop the next generation of the devices.

The company is building a new type of CGM, which it says will be less invasive and cheaper than current devices and able to monitor a wider range of chronic conditions and biomarkers in the future.

It‚Äôs looking to take advantage of the ‚Äúexploding‚Äù CGM market and the ‚Äúmassive greenfield opportunity‚Äù in the space, says cofounder and co-CEO Renato Circi.

The raise, led by Balderton Capital and Exor Ventures, takes Sava‚Äôs total funding to $13m. The startup will use the money to take its CGM through clinical trials and scale its manufacturing capability.

### **‚ÄòFuture proofed‚Äô CGM**

Currently, CGMs on the market use a single needle (about 6mm long) to pierce the skin and reach what‚Äôs known as interstitial fluid (ISF) ‚Äî which is found in the spaces between cells and from which blood glucose levels can be measured.

Sava‚Äôs CGM also measures glucose levels in the ISF but with several smaller 1mm microneedles ‚Äî which it calls ‚Äúmicrosensors‚Äù. That approach comes with several benefits, says Circi.

One is user experience: people are put off by the prospect of putting a needle in their skin and Sava‚Äôs smaller microneedles are less intimidating, he argues.

There‚Äôs also cost. Manufacturing costs of current CGMs on the market mean that vendors sell the product for ¬£50 for two weeks of monitoring ‚Äî and only a ‚Äúfraction of people‚Äù have access to them, says Circi. But, when the startup‚Äôs manufacturing capabilities are scaled, he hopes Sava will be able to make CGMs ‚Äúup to 10 times‚Äù cheaper than they are currently.

Circi also says that, eventually, because Sava‚Äôs device has several sensing microneedles, it will be able to ""future proof"" its CGM so it can measure molecules other than glucose ‚Äî something that current devices, which only use one needle, aren‚Äôt capable of doing.

Sava hasn‚Äôt decided which molecules it will expand into next, but Circi tells Sifted it could look at measuring things like ketones, urea, proteins, allergens or alcohol. These biomarkers could be used to analyse sports performance, for example, he adds.

### **A growing market**

CGMs were originally designed for diabetes patients to help them manage their condition, but have recently seen growing usage from consumers looking to keep more aware of their broader health. [Zoe](https://sifted.eu/articles/tim-spector-zoe-health), for example, uses CGMs to help build users‚Äô personalised scores for thousands of foods on its app.

‚ÄúWe believe that D2C markets will be huge,‚Äù says Circi. ‚ÄúCGMs won‚Äôt just be diabetes, but which use cases will be successful we don‚Äôt know.‚Äù

It‚Äôs this rising awareness of CGMs that helped Sava raise its recent round, says Circi. ‚ÄúWhen we had conversations with investors three years ago, they were asking us: ‚Äòwhat is a CGM?‚Äô. Over the last couple of years, it‚Äôs been ‚ÄòI‚Äôve tried a CGM and I‚Äôve seen how it works and there‚Äôs something we can do better with them‚Äô.‚Äù

There are also signs that healthcare providers could also be a fruitful market, says Circi, pointing to the UK‚Äôs NHS [making CGMs available](https://www.nhs.uk/conditions/type-1-diabetes/managing-blood-glucose-levels/continuous-glucose-monitoring-cgm-and-flash/#:~:text=CGM%20or%20flash%20glucose%20monitoring,CGM%20or%20flash%20glucose%20monitoring.) to all type 1 diabetes patients in recent times.

### **What‚Äôs next**

While Sava‚Äôs tech isn‚Äôt novel ‚Äî there have been [studies in recent years](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949222/#:~:text=Each%20microneedle%20is%201%20mm,of%203%20%C3%97%204%20microneedles.) exploring using microneedles for CGM ‚Äî ‚Äúno-one has been able to crack it‚Äù and release a commercial product so far, says Circi.

That‚Äôs because it‚Äôs a ‚Äúvery difficult product to build‚Äù, says Circi, adding that it‚Äôs taken five years for the startup to get to this point and currently 35 of Sava‚Äôs 40-strong team are engineers ‚Äî many of whom have PhDs.

Next up, Sava plans to launch clinical trials with 50 diabetes patients, following it recently gaining approval from the UK‚Äôs Medicines and Healthcare Products Regulatory Agency (MHRA).

The majority of the funds will be spent on developing the hardware for its second-generation CGM, which will be smaller than its first, as well as automating manufacturing capabilities to scale up production.

Sava also plans to go back out to fundraise again in the next 12 months, says Circi ‚Äî as part of its plan to take its first product to market in the next two years.

‚ÄúIt costs tens of millions to take a product like this to market.‚Äù
"
2024-06-20 00:00:00,2024-08-29 23:16:57,"üåç Are we about to see the rise of a digital health unicorn from Europe? 

In a recent article from Sifted, the buzz around the HLTH conference in Amsterdam hinted at the excitement and challenges within the European digital health landscape. Notably, while several promising startups are making waves, the article reveals a worrying trend: funding for digital health startups in Europe has dropped significantly this year, with only $1.2 billion raised in 2023 ‚Äî the lowest since 2018.  

Interestingly, many key figures that previously dominated discussions have either exited or aren't participating actively in the current scene. Instead, fresh faces like virtual ward startup Doccla and AI copilots Corti and Nabla were among the few generating hype amid the glittering but arguably subdued conference atmosphere. 

The underlying reason for this? Investors are still cautious following a market downturn, with generalist investors stepping back due to drawn-out sales cycles and moderate revenue growth in healthtech. However, not all is doom and gloom ‚Äî there's palpable excitement around innovations in AI, remote monitoring, and preventative care.  

For those of us in the field, this situation presents an opportunity to identify and nurture emerging talent and technologies that could redefine digital health. The landscape may be tough, but those who can navigate through could very well find themselves riding the next wave of success.  

What are your thoughts? Are there any startups that you believe could become the next digital health unicorn? Let‚Äôs start the conversation!  

#DigitalHealth #HealthTech #Innovation #VentureCapital #Unicorns  
Source: [Sifted](https://sifted.eu/articles/europe-digital-health-unicorn-hlth/)",,https://sifted.eu/articles/europe-digital-health-unicorn-hlth/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: Where's Europe's next digital health unicorn? | Sifted

URL Source: https://sifted.eu/articles/europe-digital-health-unicorn-hlth/

Markdown Content:
**_This article first appeared in Sifted‚Äôs Daily newsletter,_ _[sign up here](https://sifted.eu/newsletters?utm_medium=onsite&utm_source=article&utm_campaign=daily_big_story&utm_content=flagshipnl)._**

Almost exactly one year ago today, behemoth US healthtech conference HLTH, organised by the same people who put on fintech conference Money20/20, held a controversial launch party in Munich ahead of its 2024 event in Amsterdam that kicked off this week ‚Äî its first on European soil.

The party took place on the first night of Bits & Pretzels‚Äôs healthtech conference, also in Munich, and drew several attendees (including this reporter) from that event‚Äôs speaker dinner for its own bash. The party was packed and when I arrived a baying mob of conference goers who weren‚Äôt wearing wristbands adorned with the HLTH logo were being turned away at the door.

It was a bold entrance to Europe ‚Äî and it was a sign of things to come. This week its main event in the Dutch capital is similarly showy. Exited founders are playing 8am DJ sets in the ‚Äúvinyl lounge‚Äù; there‚Äôs a gaming area with pinball and air hockey; and the Libertines headlined an aftershow party yesterday evening. One VC told me that ‚Äúeveryone is here‚Äù.

But one thing that‚Äôs struck me is the absence of founders who¬†_everyone_¬†is talking about on the speaker bill. While a lot of the chatter beforehand was about Babylon‚Äôs Ali Parsa being there, he pulled out before doors opened. I haven‚Äôt heard much about upcoming digital healthtech¬†darlings who have raised or are about to raise a sector-defining funding round.

Don‚Äôt get me wrong, there have been plenty of promising startups on stage creating excited chatter off it. Virtual ward startup¬†[Doccla](https://sifted.eu/articles/12-hospital-tech-startups-to-watch-according-to-vcs?utm_campaign=Sifted%20Daily%20Newsletter&utm_source=hs_email&utm_medium=email&_hsenc=p2ANqtz-9TII_iC8UOy2JFWei0lijeaay9GfQ0wsx3ySmUgSUXhIlz9azPLxaTnd2zZ1ZfHJ6UMmdT), alongside AI copilots for doctors¬†[Corti](https://sifted.eu/articles/atomico-gen-ai-healthcare-corti-series-b-news?utm_campaign=Sifted%20Daily%20Newsletter&utm_source=hs_email&utm_medium=email&_hsenc=p2ANqtz-9TII_iC8UOy2JFWei0lijeaay9GfQ0wsx3ySmUgSUXhIlz9azPLxaTnd2zZ1ZfHJ6UMmdT)¬†and¬†[Nabla](https://sifted.eu/articles/nabla-24m-series-b?utm_campaign=Sifted%20Daily%20Newsletter&utm_source=hs_email&utm_medium=email&_hsenc=p2ANqtz-9TII_iC8UOy2JFWei0lijeaay9GfQ0wsx3ySmUgSUXhIlz9azPLxaTnd2zZ1ZfHJ6UMmdT)¬†are among the few that came up in conversations. The companies that everyone was talking about when they burst onto the scene a few years ago ‚Äî the likes of Kry, Doctolib and Owkin ‚Äî were also there.

But digital health startups hitting some serious, unicorn valuations for the first time now? They weren‚Äôt at HLTH Europe because, currently, they don‚Äôt exist in European digital health, VCs tell me.

The funding figures for the sector paint a telling picture. Digital health startups picked up $1.2bn across Europe in 2023, according to Dealroom ‚Äî the lowest amount since 2018 and a long drop from the record $3bn in 2021.

Yes, funding across European tech fell across the board, but it fell further in digital health. Halfway through 2024 the numbers aren‚Äôt looking more positive. One seasoned founder, who‚Äôd just managed to close a round, told me that raising now was more difficult than during the 2008 financial crisis.

So where‚Äôs the money gone?

Talking to VCs on the conference floor, broadly speaking there are two schools of thought.

One is that generalist investors who piled into the sector during 2021 have taken flight, put off by long sales cycles and the absence of the kind of revenue growth they‚Äôre used to seeing in enterprise SaaS startups. The other is that specialist healthtech VCs are themselves struggling to raise new funds, and are slowing down deployment to make their cash go further.

VCs and founders tell me that they‚Äôre not panicking about the low patch, and they think investment will pick up in the next six months to a year.

And there are real areas of promise in the sector. Investors are genuinely excited about the potential of AI to automate processes in healthcare, the future of remote patient monitoring and the rise of preventative care.

Right now, though, it‚Äôs difficult to pick the winners.

But what do you think? Am I missing something here? What are the digital health companies that I should have on my radar? Which could be the sector's next unicorn?¬†[Get in touch and let me know](mailto:kai@sifted.eu).
"
2024-06-19 00:00:00,2024-08-29 23:17:05,"üåü Exciting developments in the healthcare tech landscape! üåç 

I recently came across an article on Tandem Health, a Swedish AI startup that has successfully raised **$9.5 million** in seed funding to enhance its innovative co-pilot tool for healthcare providers. This tool automates tedious administrative tasks, giving clinicians more time to focus on their patients.

Founded less than a year ago, Tandem Health's solution includes features like transcribing doctor-patient conversations and creating actionable medical notes in real time, addressing a critical need in today‚Äôs fast-paced healthcare environment. With **50 healthcare providers** already on board in Sweden, their next step involves scaling up across Europe, aiming for broader impact. 

What sets Tandem apart from other startups is their emphasis on integrating industry-specific requirements into their AI model, including overcoming challenges related to language nuances in the medical field. CEO Lukas Saari shared that the key to their success lies in tailoring the technology to the specific needs of each clinic, ultimately improving efficiency and accuracy in patient care. 

This development not only enhances the operational flow for clinicians but also highlights the growing trend of AI being leveraged for administrative support in healthcare settings. As we embrace these advancements, the importance of selecting tech solutions that understand the nuances of our industry becomes even clearer.  

‚ú® It‚Äôs fascinating to see how technology can streamline processes and free up time for healthcare professionals to provide quality patient care. What are your insights on the role of AI in transforming healthcare administration? Let‚Äôs discuss!  

#HealthTech #ArtificialIntelligence #HealthcareInnovation #TandemHealth #AIinHealthcare

Read the full article here: [Sifted](https://sifted.eu/articles/ai-startup-tandem-round-northzone-news/)",https://sifted.eu/wp-content/uploads/2023/10/tandem-health.jpg,https://sifted.eu/articles/ai-startup-tandem-round-northzone-news/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: AI startup Tandem Health raises $9.5m to scale its healthcare co-pilot | Sifted

URL Source: https://sifted.eu/articles/ai-startup-tandem-round-northzone-news/

Markdown Content:
Swedish AI startup Tandem Health has raised a $9.5m seed round led by Northzone, alongside angel investors from OpenAI and Deepmind.

Tandem, founded less than a year ago, develops an AI-driven co-pilot for healthcare clinicians that automates administrative tasks, such as transcribing doctor-patient meetings and generating medical notes. It has 50 healthcare providers as customers in Sweden, and is planning European expansion.

‚ÄúWe are essentially interested in all the larger countries around Europe and which country we start in depends on where we find the right partners,‚Äù CEO Lukas Saari says.

#### Clinicians in the driving seat

[Since the launch of OpenAI‚Äôs ChatGPT](https://sifted.eu/articles/gen-ai-will-transform-healthtech) many startups have doubled down on AI for healthcare providers, including triage systems to help patients understand their symptoms and co-pilots to help practitioners with admin tasks and to help diagnose patients.

Companies like symptom checker app Ada Health and healthcare co-pilot Corti have been working on solutions for years. What differentiates Tandem is that it‚Äôs an admin tool for practitioners that helps them transcribe notes from patient-doctor meetings and adds the details to patient journals. It can also help find the right medical codes specific to a patient's symptoms.

‚ÄúThe key feature of our product is what one would call an ambient scribe,‚Äù says Saari. ‚ÄúIt listens during the patient-doctor conversation, makes a transcription and then creates a draft for a medical note directly afterwards. Instead of the doctor spending 5-10 minutes after a 15-minute patient visit writing everything from scratch or dictating to a medical secretary, the AI generates a draft that can be reviewed and edited in 1-2 minutes.‚Äù

#### Based on OpenAI‚Äôs GPT and Whisper

Like many other AI startups, Tandem uses GPT-4. It also uses OpenAI‚Äôs software for speech recognition and transcription, called Whisper. But Saari says that initially, Whisper struggled in a Swedish medical context because there were many drug names and terms in Swedish that weren‚Äôt part of its initial training data.

‚ÄúWhat we saw when we started using the product live with real doctors was how you quickly get to a 60% solution that works well as a demo or proof of concept. But then, when you face reality, there is a lot of work to go from 60% to 95% plus in terms of ensuring the right headings \[on documents\] are included, how you express yourself correctly, and so on,‚Äù he says.

A single clinic can have 10-20 different patient journal templates. By training Whisper to each clinic's purpose and making sure the tool adds the right information from the doctor-patient meeting in the correct patient journal has given Tandem a competitive advantage Saari says.

‚ÄúWe are moving more and more towards having a self-service flow with the goal that healthcare providers can start using Tandem without really needing to interact with us or without needing our involvement,‚Äù he says.

#### Working with a variety of partners

Tandem works with a mix of specialist clinics and general practitioners, which vary in headcount from a few clinicians to around 100. As well as selling to healthcare clinics, it also partners with journal system providers, which means Tandem can reach a larger number of clinics.

Tandem is offering its software as a subscription service, charging 1,500 SEK (around ‚Ç¨133), per month per user. It employs 10 people and is looking for large partners to expand overseas across Europe. The secured funding will be used to continue developing the tool and on the expansion.

‚ÄúThe key to our expansion plan is to find large anchor customers or anchor partners. This can be either larger healthcare providers with hundreds or thousands of doctors who see this as something they want to collaborate on, run pilots and start rolling out. Alternatively, with medical record systems that offer it as a solution to their users.‚Äù
"
2024-06-18 00:00:00,2024-08-29 23:17:33,"üåü Exciting Developments in Preventative Healthcare! üåü  
Have you ever considered how a simple blood test could be a game-changer for your health? A recent article from Sifted highlights Aware, a startup revolutionizing preventative care with its innovative blood-testing service. Their new Amsterdam lab, part of a growing network, allows customers to receive comprehensive health insights through just a few vials of blood. üöÄ  
  
Here are some highlights from the article:  
- **Streamlined Process**: Customers can now access results for 44 biomarkers within 48 hours through an intuitive app.  
- **Growing Market**: There‚Äôs a noticeable shift toward preventative care, with more consumers interested in monitoring their health proactively.  
- **Subscription Model**: Aware offers competitive pricing, including a new ‚Ç¨99 subscription option, making health checks more accessible to everyone.  

This momentum indicates a remarkable opportunity within the direct-to-consumer healthcare space, driven by advancements in technology and the shift in consumer attitudes. Aware‚Äôs model shows how blending healthcare with technology creates value and fosters better health decisions.  

As a health enthusiast or a professional in the field, what are your thoughts on the future of preventative healthcare? Could this model change how we approach our health? Let‚Äôs chat! üí¨  

#PreventativeCare #HealthTech #StartupInnovation #BloodTesting #Wellness  

Source: [Sifted](https://sifted.eu/articles/aware-amsterdam-lakestar-healthtech-news/)",,https://sifted.eu/articles/aware-amsterdam-lakestar-healthtech-news/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: Lakestar-backed blood testing startup expands to tap growing preventative care market | Sifted

URL Source: https://sifted.eu/articles/aware-amsterdam-lakestar-healthtech-news/

Markdown Content:
Having blood drawn at startup Aware‚Äôs new lab in Amsterdam is a fairly unassuming process. I arrive, am shown to a small office and three vials of blood are taken with minimal fuss. In around 10 minutes I‚Äôm back onto the busy morning streets of the Dutch capital.

Within 48 hours the results will be sent to Aware‚Äôs app on my phone ‚Äî showing 44 biomarkers analysing areas like heart, kidney, liver and blood health and explaining what they mean. I‚Äôll be recommended lifestyle advice and can book an appointment with a doctor to discuss my results. My experience was courtesy of Aware ‚Äî but the standard customer would pay ‚Ç¨179 a year for two blood tests and access to its app.

It‚Äôs all part of Aware‚Äôs goal of tapping into the incoming ‚Äúgenerational shift‚Äù among consumers towards paying for preventative healthcare solutions, says founder and CEO Florian Meissner.

There are signs of it happening already, as [more](https://www.pymnts.com/healthcare/2022/health-tracking-wearables-and-apps-grew-21-percent-in-past-year/) turn to wearable tech like Apple watches, [Oura rings](https://sifted.eu/articles/smart-ring-oura-superapp-ambitions) and apps to monitor their health. It amounts to a ‚Äúmassive opportunity in the market right now‚Äù, Meissner tells Sifted.

The lab in Amsterdam is the sixth the startup has opened ‚Äî in its third country ‚Äî since launching its first in Berlin in November 2023. It comes nearly 18 months after bagging a [$15m seed round](https://sifted.eu/articles/blood-test-startup-aware-raises-15m) from investors including Lakestar and Cherry Ventures ‚Äî and further expansion is on the cards before the year‚Äôs out.

### **Diagnostics-as-a-service**

While many digital health startups are struggling to raise money and expand amid [a tough market](https://sifted.eu/articles/digital-health-startups-are-running-out-of-cash), it‚Äôs in the direct-to-consumer preventative space that a lot of today‚Äôs rare growth stories in the sector can be found.

Spotify‚Äôs Daniel Ek‚Äôs body scanning startup Neko Health, which has raised ‚Ç¨60m from investors including Lakestar and Atomico, [announced](https://sifted.eu/articles/daniel-eks-body-scanning-neko-health-is-expanding-to-the-uk-news) in April this year that it was expanding to the UK.

There‚Äôs also the UK‚Äôs Zoe, which provides microbiome testing and lifestyle advice on its app, which has raised $84.5m, according to Dealroom, from the likes of Balderton Capital and Daphni. The startup was one of the [fastest growing](https://sifted.eu/articles/europes-10-fastest-growing-digital-health) startups in the UK in 2023.

Founded in 2021, Aware sells blood tests and access to its app as a subscription model ‚Äî which can be taken at any of its labs across four cities in Germany, one in Austria and, now, one in the Netherlands. Customers can buy additional tests looking at things like hormone levels and thyroid health.

While Aware hasn‚Äôt invented any technology ‚Äî it uses off-the-shelf equipment in its Berlin lab (the only one it owns) and partners with existing labs in the remaining five locations ‚Äî it‚Äôs ""innovating on business model and service delivery‚Äù, says Meissner.

What the startup has built is an app and user interface that can plug into ‚Äúany lab backend‚Äù and allows users to get results from an in-person test back within 48 hours. It can take as long as a week if patients have a blood test in hospital or via their GPs, he adds.

The founder isn‚Äôt disclosing customer numbers, but tells Sifted that the number of blood tests Aware has carried out is in ""four figures"".

### **An unsolved market**

The preventative care market is on the up.

Alongside a growing direct-to-consumer segment, as ageing populations put increasing strain on public healthcare systems across the globe, there have been [rising calls](https://www.theguardian.com/politics/2023/oct/02/demos-calls-for-big-rise-in-uk-spending-on-preventative-policies-treasury) for governments to ramp up spending on measures to prevent people from getting sick in the first place.

But there are big challenges facing the sector.

One is European consumers‚Äô aversion to spending on healthcare. The vast majority of health spend in Europe is paid for by the state ‚Äî and it can be a tough sell to ask customers to fork out sometimes hundreds of pounds in addition to state-provided care.

That‚Äôs led to hurdles in convincing consumers to come back as repeat spenders for some.

Zoe founder [Tim Spector told Sifted](https://sifted.eu/articles/tim-spector-zoe-health) in October 2023 that half of its customers only used the platform for six to nine months before leaving and a key focus was convincing them to stay for longer. The startup sells its microbiome testing kits for ¬£300 and an ongoing monthly subscription to an app where users can track health data and access lifestyle advice, which costs up to ¬£60 a month.

In April, Zoe announced it was making layoffs and [cutting costs by 20%](https://sifted.eu/articles/zoe-healthtech-cost-cutting-news) after ‚Äúover-expanding‚Äù the team.

### **‚ÄòTrojan horse‚Äô**

Price point can hurt a startup‚Äôs ability to retain customers, says Meissner, and later this week Aware is launching a more affordable ‚Ç¨99 a year subscription ‚Äî which includes one blood test instead of two.

He also tells Sifted that Aware will reduce in cost over time.

‚ÄúThe tech is getting better and better and the cost of testing machines is moving in one direction,‚Äù he says ‚Äî pointing to genome sequencing testing units, which now cost [less than $1000](https://www.medicaldevice-network.com/analyst-comment/ngs-reduced-cost-personalised-medicine/#:~:text=The%20cost%20of%20sequencing%20has,the%20platform%20type%20or%20technology.), down from $100m in 2001.

Eventually, Aware wants to make its blood tests available via public healthcare systems in Europe, says Meissner ‚Äî but first the startup needs to prove it can run its service at scale.

Alongside opening another two labs in Germany, Aware will roll out in one ‚Äî if not two ‚Äî more European countries by the end of 2024, although Meissner is tight-lipped about exactly where.

‚ÄúIt‚Äôs fair to say English-speaking countries are low-hanging fruit for us,‚Äù he says. Countries like the UK and Nordics are both attractive, he adds, alongside others in southern Europe like Italy, Spain and Portugal.

Further down the line, Aware could also broaden its diagnostics offering to include STI and microbiome testing, says Meissner. It also hopes to begin collecting data from wearables like an Apple watch and combine them with results from physical tests to offer more bespoke lifestyle advice.

‚ÄúWe always joked that we built a trojan horse with our blood-based service,‚Äù says Meissner. ‚ÄúThe goal is to offer any \[test\] a laboratory would offer and be the front end for this market.‚Äù
"
2024-05-21 00:00:00,2024-08-29 23:17:59,"üåü Exciting news in the biotech world as LabGenius has just secured a significant ¬£35m Series B funding round, led by M Ventures, the venture capital arm of Merck! This funding brings the total investment to ¬£58m, a testament to the innovative work they've been doing in drug discovery using machine learning.  

LabGenius is revolutionizing the way we develop antibody therapies specializing in treating cancer by creating smart robotic platforms that not only design and conduct experiments but also learn from them! This could be a game-changer in targeting solid tumors while minimizing the impact on healthy cells‚Äîsomething we all want to see in cancer treatment.  

CEO James Field emphasized the importance of their active learning method, stating that their approach allows for the rapid identification of high-performing antibodies. Unlike conventional methods, their innovative solutions open up vast design spaces that can lead to unexpected breakthroughs.  

Moreover, LabGenius is strategically working to balance its focus between developing its pipeline for cancer treatment and forming partnerships with big pharma, ensuring they maintain control over their discoveries for as long as possible. This insight is vital as it highlights how critical it is for drug startups to steer their innovations in a competitive landscape.  

As we follow the journey of LabGenius, it's intriguing to think about what this means for the future of drug discovery and treatment methodologies. How do you see machine learning influencing your work or our industry in the coming years?  

#Biotech #DrugDiscovery #HealthInnovation #MachineLearning #CancerResearch 

Source: [Sifted](https://sifted.eu/articles/labgenius-atomico-biotech-raise-news/)",https://images.sifted.eu/wp-content/uploads/2024/05/20172739/James-Field-lab-1.jpg?auto=format&fit=max&w=3840&q=75,https://sifted.eu/articles/labgenius-atomico-biotech-raise-news/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: Drug discovery biotech LabGenius raises a ¬£35m Series B | Sifted

URL Source: https://sifted.eu/articles/labgenius-atomico-biotech-raise-news/

Markdown Content:
UK drug discovery startup LabGenius, which uses machine learning to find and design antibody therapies to treat cancer, has raised a ¬£35m Series B led by the VC arm of pharma company Merck, M Ventures, with participation from Octopus Ventures, LG Corp, Atomico, Kindred Capital, Lux Capital and Obvious Ventures. The investment brings LabGenius‚Äôs total funding to date to ¬£58m.

The company will use the capital raised to make its machine learning-driven discovery platform more comprehensive, to facilitate more strategic partnerships and invest in its drug development for solid tumours.

#### From conservative testing to machine learning free from human bias

LabGenius was founded in 2012 and has developed a smart robotic platform capable of designing, conducting and, critically, learning from its experiments in drug discovery. The drug discovery startup is focused on creating antibody therapies ‚Äî which trigger an immune response in the body to target cancer cells ‚Äî to treat solid tumours.

Healthy cells surrounding a tumour have the same surface markers as it, which means that when using conventional treatment methods to try to destroy cancer cells on-target, off-tumour killing of healthy cells occurs. LabGenius says its platform uses an active learning method to create molecules that limit the damage to healthy cells.

The development of antibodies has become more complex over time ‚Äì going from antibodies only binding to a target cell to the latest antibody therapeutics which combine multiple different binding domains into one molecule to create these complex multi-specific antibodies, according to CEO and founder James Field.

![Image 1: Picture of drug discovery startup LabGenius' founder and CEO James Field.](https://images.sifted.eu/wp-content/uploads/2024/05/20172739/James-Field-lab-1.jpg?auto=format&fit=max&w=3840&q=75)

LabGenius' founder and CEO James Field.

[GenAI has often been in the limelight](https://sifted.eu/articles/gen-ai-will-transform-healthtech) when it comes to drug development and drug discovery, but for LabGenius the technology is only useful in the very early stages of the process.

‚ÄúThis is where I think some aspects of GenAI are really overhyped,‚Äù says Field. ‚ÄúGen AI is typically used to describe the methodologies where you're taking vast amounts of public data and using that to create novel antibody designs. That's fine if the problem that you're looking to address is something like, ‚ÄòDoes my antibody bind to a target?‚Äô But if you want to address some of these more complex questions, you can't use those GenAI methods because the data just doesn't exist,‚Äù Field says.

With the help of its robotic and machine learning platform, Field says LabGenius can create a greater number of molecules for a specific task than conventional methods, and the automated discovery engine enables the rapid identification of high-performing antibodies with non-intuitive designs.

‚ÄúIf I can only test a few dozen of these molecules in these complex assays, I'll be very conservative,‚Äù says Field. ‚ÄúWe've been able to take that whole experimental testing process and really scale. We combine that with machine learning and it massively opens up the design space and tests designs that you would never think of testing using conventional methods.‚Äù

#### Two legs to stand on

LabGenius has split the company into two focus areas: one on the pipeline described above for finding treatments for cancer, and one to co-develop new drugs with large pharmaceutical companies for revenue.

A couple of years ago, LabGenius initiated a multi-year collaboration with French pharma company Sanofi, in the area of inflammation.

‚ÄúAs a startup, the cash is one element \[behind these collaborations\], but there are also some other key pieces, like being able to benchmark how well your platform is performing and access areas and operating spaces that you may not conventionally be able to do,‚Äù Field says.

The 55-strong team at LabGenius is investing in extending its platform capabilities to facilitate more and broader strategic partnerships.

It is important for drug discovery startups to own their lead assets for as long as possible, according to Field.

‚ÄúWhat's important is that, at least for the next few years, we maintain control of the lead assets. Ultimately, these machine learning-driven discovery platforms are only any good if you can create molecules that can be progressed,‚Äù he says.

‚ÄúThere's always the anxiety for any company, that if you partner up on your lead molecule too early, it may be the case that a pharma company just decides to pop it on the shelf for strategic reasons. And we've seen great molecules being shelved.‚Äù
"
2024-05-21 00:00:00,2024-08-29 23:18:07,"üåç Exciting news in the world of healthcare! A recent article from Sifted highlighted **Resilience**, a French remote cancer patient monitoring platform, that has successfully raised **$25 million** in funding to expand its innovative services internationally. This milestone comes just six months after their platform was approved for reimbursement in France, making it the **first** of its kind for remote cancer monitoring to be accessible at no cost to patients.

### Key Highlights:
- Resilience collects vital patient data through questionnaires, empowering healthcare professionals to track and optimize treatment plans remotely. This proactive approach allows for improved patient understanding, leading to better adherence to treatments and significant reductions in hospital visits.
- Recent clinical studies indicate that patients using Resilience's platform experienced a **6.9% reduction in ER visits** and lived **5.2 months longer** compared to those without it.
- The platform‚Äôs comprehensive support, which includes educational resources like articles and podcasts, plays a crucial role in patient self-management, particularly regarding treatment side effects.
- With plans to expand into Germany and further develop partnerships with pharmaceutical companies, Resilience aims to enhance the clinical trial landscape by digitizing data collection processes‚Äîa much-needed modernization in this sector.

### Insights into Applications:
The implications of Resilience's advancements are significant, especially in light of the growing global demand for oncological care amidst an understaffed workforce. As healthcare professionals, we can draw inspiration from their model, which emphasizes remote patient care coupled with education. This approach not only fosters better patient outcomes but also maximizes the resources available to healthcare providers.

With emerging technologies and platforms like Resilience leading the charge, we are encouraged to explore how similar strategies can be adapted in our practices.  Have you considered how remote monitoring could enhance your patient care? 

### Let‚Äôs Discuss:
I invite you to share your thoughts on the role of technology in oncology care. How do you see it impacting your work or patient relationships?

#HealthcareInnovation #RemotePatientMonitoring #CancerCare #DigitalHealth #PharmaCollaboration

Read more about Resilience‚Äôs groundbreaking journey here: [Sifted Article](https://sifted.eu/articles/resilience-cancer-health-raise-news/)",https://images.sifted.eu/wp-content/uploads/2024/05/17164817/Solution-EN-e1715960910990.png?auto=format&fit=max&w=3840&q=75,https://sifted.eu/articles/resilience-cancer-health-raise-news/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: Remote cancer patient monitoring platform raises $25m to expand internationally and build out pharma offering | Sifted

URL Source: https://sifted.eu/articles/resilience-cancer-health-raise-news/

Markdown Content:
French remote cancer patient monitoring platform Resilience has raised $25m in a round led by existing investor Picus Capital and new backer Red River West.

VCs Cathay Innovation, Singular and Seaya Ventures ‚Äî another previous investor ‚Äî¬† also participated.

The round comes six months after Resilience‚Äôs platform ‚Äî which collects data from cancer patients remotely via questionnaires and allows medical professionals to monitor them ‚Äî was approved for reimbursement in France, meaning patients can access it for free and the state foots the bill.

According to cofounder and CEO Jonathan Benhamou, it‚Äôs the first remote cancer patient monitoring platform in the world to be approved for reimbursement.

The fresh funds will see Resilience expand from its current markets of France and Belgium into Germany. The startup also wants to build a clinical trial platform for pharmaceutical companies.

### **Remote patient monitoring**

Across the globe, [rising](https://www.theguardian.com/society/2024/feb/01/global-cancer-cases-to-rise-by-more-than-75-by-2050-who-predicts) cancer cases and an [understaffed workforce](https://www.theguardian.com/society/2023/jun/08/cancer-patients-delays-treatment-staff-shortage-uk-radiologists) are increasingly putting oncology departments and clinics under pressure.

Benhamou says that Resilience‚Äôs remote patient monitoring (RPM) platform ‚Äî which, alongside collecting patient data, also features educational resources like articles, podcasts and videos to help patients understand and adhere to their treatment ‚Äî can help tackle that problem.

![Image 1](https://images.sifted.eu/wp-content/uploads/2024/05/17164817/Solution-EN-e1715960910990.png?auto=format&fit=max&w=3840&q=75)

The amount of time physicians spend with patients is going down, he adds, and because of that patients don‚Äôt understand the treatments and side effects and are [dropping off treatment](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155980/) pathways.

‚ÄúIt‚Äôs a huge problem. It's a vicious cycle because if you drop off \[a course of treatment\] and then your drug is not efficient, then you have to go back to the hospital and start another treatment,‚Äù says Benhamou.

Resilience can help patients know what to expect, he says. ‚ÄúWith certain drugs, we can say we know you‚Äôre going to have three days of nausea, and by saying that patients are much better able to support themselves.‚Äù

While Resilience doesn‚Äôt yet have data on how many more cancer patients its platform allows each doctor to see, Benhamou tells Sifted that results from clinical trials show how the startup's platform ‚Äúimpacts the resources allocated for each patient‚Äôs care‚Äù.

According to [one clinical study](https://www.nature.com/articles/s41591-022-01788-1) of 559 patients using Resilience‚Äôs platform, they saw a 6.9% reduction in emergency room visits, spent 1.62 fewer days in hospital and experienced 9.3% less severe treatment-related toxicities. Another [clinical study](https://jamanetwork.com/journals/jama/article-abstract/2630810) found that patients using Resilience‚Äôs platform lived 5.2 months longer than those who didn‚Äôt.

Using a proprietary algorithm, Resilience‚Äôs platform can also flag to patients when they need to attend hospital and alert medical professionals if something's wrong. It‚Äôs deployed in more than 90 medical centres with 10k patients in France and Belgium.

### **Expansion plans**

In November 2023, less than three years after launch by Benhamou and his cofounder C√©line Lazorthes, the company was approved for reimbursement in France ‚Äî meaning doctors can prescribe the app to patients alongside cancer drugs. It‚Äôs also active in Belgium, where the startup submitted an application for reimbursement in January this year, and is awaiting approval.

Resilience began to make its first revenue in January this year, getting paid ‚Ç¨73.33 by the French state per patient per month. It had been keeping the lights on through its years of zero revenue with¬† ‚Ç¨45m-worth of venture capital. Its angel investors include French billionaire Xavier Niel, Station F‚Äôs Roxanne Varza and health insurtech unicorn Alan‚Äôs CEO and cofounder Jean-Charles Samuelian.

It now plans to expand internationally ‚Äî with Germany the next stop. While RPM apps aren‚Äôt yet approved for reimbursement in the country, Resilience is currently negotiating with German medical regulator BfArM about their introduction to its reimbursement scheme.

Since 2019, DiGA regulation has allowed doctors in the country to prescribe app and web-based therapy via public healthcare.

Benhamou hopes to have launched in the country by the start of 2025. ‚ÄúWe know that RPM will be part of DiGA at some point. If \[BfArM\] don't approve it for reimbursement, we will go in another way, like private insurance companies or via direct licences to hospitals.‚Äù

Geographic expansion isn‚Äôt the only thing on Resilience‚Äôs growth map. It‚Äôs also expanding the type of care it provides; in November 2023, it acquired French IBS monitoring platform GutyCare.

### **Selling to pharma**¬†

If everything goes to plan, most of Resilience‚Äôs revenue won‚Äôt come from governments ‚Äî but from pharma companies.

In September 2023, the startup launched an RPM platform which helps pharma companies monitor patients in clinical trials.

‚ÄúIf you look at pharma and the contract research organisation (CRO ‚Äî a company that runs clinical trials for pharma), the industries haven‚Äôt moved in years,‚Äù Benhamou says.

‚ÄúWhen you run clinical trials, you have to collect the data on the toxicity of a drug.‚Äù Most of the time, that data is still collected on paper, Benhamou adds. ‚ÄúWe have experience in collecting data, and we want to provide this to pharmaceutical companies.‚Äù

He thinks Resilience can digitise this process ‚Äî and points to data the company has collected that shows 90% of patients that use the platform fill out the questionnaires it sends each week.

The clinical trial market size was estimated to be worth [$58bn](https://www.fortunebusinessinsights.com/clinical-trials-market-106930#:~:text=The%20global%20clinical%20trials%20market,highest%20CAGR%20during%20the%20forecast.) in 2023, and is set to nearly double in value by 2032. It‚Äôs a huge market, worth a [quarter](https://www.fortunebusinessinsights.com/oncology-drugs-market-103431) of the global cancer care market ‚Äî which includes things like drug and treatment costs.

Resilience has four pharmaceutical customers for this product ‚Äî although it's unable to share who they are.
"
2024-05-17 00:00:00,2024-08-29 23:18:32,"üåü Have you heard about the recent developments surrounding Numan? It highlights some crucial lessons for digital health companies and the importance of compliance in our industry.

A recent article from Sifted revealed that Numan Operations Limited, a subsidiary of the UK-based digital health startup Numan, had been selling food supplements for over two years without the necessary registration as a Food Business Operator (FBO). This is a legal requirement in the UK to ensure food safety and compliance with local regulations. As of February this year, NOL finally registered as an FBO, but the preceding period raised some eyebrows.  

What makes this situation particularly interesting is how it underlines the need for operational transparency and adherence to regulations in the burgeoning field of digital health. Patient safety is paramount, and compliance is crucial not just for legal reasons but also for maintaining trust with consumers. 

For companies in this space, it‚Äôs a stark reminder to regularly audit practices and ensure that every partner involved is compliant with regulations. Ensuring that your distribution partners are registered and operating within legal frameworks helps to safeguard your reputation and your customers' wellbeing.  

As digital health continues to evolve, we must place compliance and safety at the forefront. Have you or your team encountered any compliance challenges, and how did you handle them? I‚Äôd love to hear your thoughts!  

#DigitalHealth #HealthTech #Compliance #PatientSafety #FoodSafety 

Read the full article for more insights: [Sifted](https://sifted.eu/articles/numan-supplements-health-unlawful/)",https://images.sifted.eu/wp-content/uploads/2024/05/16173931/Screenshot-2024-05-16-at-17.37.02.png?auto=format&fit=max&w=3840&q=75,https://sifted.eu/articles/numan-supplements-health-unlawful/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: Digital health company Numan‚Äôs subsidiary sold supplements unlawfully for years | Sifted

URL Source: https://sifted.eu/articles/numan-supplements-health-unlawful/

Markdown Content:
Numan Operations Limited (NOL) ‚Äî a subsidiary of UK-based digital health startup Numan (the trading name of Vir Health Limited) ‚Äî¬† was selling food supplements for several years without registering as a Food Business Operator (FBO) ‚Äî something it was required to do by law, Sifted has learned.

Under UK law, all companies that sell food items ‚Äî including supplements ‚Äî are required to register as an FBO 28 days before trading.

But Numan was selling supplements for at least two years and nine months before its subsidiary distribution partner NOL registered as an FBO in February this year, [according to WebArchive records of its website.](https://web.archive.org/web/20200407092116/https://www.numan.com/supplements) The supplements Numan sold during this period included vitamin D, and testosterone and fertility support.

Companies that sell food are required to register as FBOs so that their local authority can inspect premises when they need to. Some of these authorities [assert](https://new.haringey.gov.uk/business/health-safety/food-safety/food-premises-registration) that failure to register as a food business is a criminal offence.

When contacted by Sifted, Numan did not deny it had sold supplements before its subsidiary company NOL was registered as an FBO.

‚ÄúOur current supplement distribution partner, who procures and delivers our supplements, is registered as a food business operator as at 14 February 2024,‚Äù said CEO and founder Sokratis Papafloratos in a statement. He added that the company received ‚Äúexternal advice‚Äù on ‚Äúapplicable regulations‚Äù.

‚ÄúWe continually work with regulatory experts to ensure we are compliant, and continue to stay so,‚Äù he said.

The news follows Sifted‚Äôs reporting that Numan had [recalled supplements](https://sifted.eu/articles/uk-healthtech-numan-recalls-supplements-that-contained-restricted-ingredients) that contained restricted ingredients earlier this year.

### **Operating**¬†

Numan has been listing supplements for sale on its website since April 2020, according to web archives, when it advertised a ‚Äúfertility support‚Äù supplement that it said was to be taken daily and targeted ‚Äúkey areas‚Äù of male fertility.

![Image 1](https://images.sifted.eu/wp-content/uploads/2024/05/16173931/Screenshot-2024-05-16-at-17.37.02.png?auto=format&fit=max&w=3840&q=75)

Numan had broadened that range to include supplements that it said would help improve sleep, boost testosterone and vitamin D and support prostate function by August 2021.

This was before NOL was registered as an FBO on February 14 2024.

The Food Standards Agency website, the UK‚Äôs food regulatory body, says that ‚Äúto sell food supplements you must register as a Food Business Operator (FBO) with your local authority.‚Äù

Alongside supplements, Numan also prescribes medication for conditions such as erectile dysfunction, hair loss and weight loss ‚Äî including weight loss jabs like Wegovy.

Backed by VNV Global and White Star Capital, the company is one of the best-funded of several European startups that have emerged in recent years [selling supplements and medication online](https://sifted.eu/articles/embarrassing-health-issues-startups).

Since launching in 2018, Numan has raised $72.2m, according to Dealroom, most recently in a ¬£40m ($50m) debt and equity round in February 2022. It says it has served over 500k customers.

‚ÄúOperational transparency and patient safety are top priorities at Numan,‚Äù said Papafloratos in his statement to Sifted. ‚ÄúWe make every effort to deliver this at all times, and across all areas of our organisation, as a CQC registered (and regulated) healthcare provider.‚Äù

### **Not the first incident at Numan**

In March this year, Sifted learnt that Numan had sent out emails to customers recalling vitamin D supplements that contained Propylparaben and Methylparaben ‚Äî which are restricted for use in food (including supplements) in the EU and UK.

![Image 2](https://images.sifted.eu/wp-content/uploads/2024/05/16174004/Screenshot-2024-05-16-at-17.37.14.png?auto=format&fit=max&w=3840&q=75)

According to [EU law documents](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32006L0052), propylparaben has been shown to have effects on sex hormones and the male reproductive organs in juvenile rats.

‚ÄúDuring an independent audit led by Numan to review the ingredients and labelling of all Numan products, we discovered that these ingredients are restricted for use in food products such as supplements,‚Äù Papafloratos told Sifted at the time. ‚ÄúThe affected product, a Vitamin D spray supplement, that was purchased from a third party supplier, was immediately removed from sale.‚Äù

The Numan founder added at the time that the use of restricted ingredients in its vitamin D supplements was caused by an ‚Äúerror in the supply chain by a manufacturing partner‚Äù.

‚ÄúThe ingredients in question, E216 and E218 \[Propylparaben and Methylparaben\], are preservatives commonly used and approved for use in liquid medicinal products,‚Äù said Papafloratos. ‚ÄúThey are safely consumed by millions of adults and children every year, in medicines like Calpol, Gaviscon and many others.

### **Regulator concerns**

These incidents are the latest that have seen online pharmacies and digital health companies come under scrutiny in recent times.

UK healthtech Manual, which also prescribes medication online, was revealed to be selling weight loss drug Ozempic [beyond a UK government deadline](https://sifted.eu/articles/healthtech-manual-selling-ozempic-beyond-uk-government-deadline) to stop doing so, following shortages of the drug.

There are also growing patient safety concerns linked to the rise of online vendors of supplements and medicines.

Earlier this year, a [BBC investigation](https://www.bbc.co.uk/news/health-67714023) found 20 online pharmacies selling restricted drugs without checks like GP approval.

Duncan Rudkin, CEO of the UK pharmacy regulator the General Pharmaceutical Council, said in a statement that the investigation ‚Äúraises very serious concerns‚Äù.

_This article was updated on May 20 to reflect the fact that it was Numan‚Äôs distribution partner ‚Äî Numan Operations Limited ‚Äî that was required to register as a Food Business Operator, rather than Numan‚Äôs separate legal entity, Vir Health Limited._
"
2024-04-30 00:00:00,2024-08-29 23:18:59,"üåç Did you know that 1 in 6 people globally experience infertility? With this rising concern, innovative solutions are more crucial than ever! 

A recent article by Sifted shares exciting news about the startup Ovom Care, which has raised ‚Ç¨4.8 million to enhance the success rates of assisted reproductive technologies (ART) like IVF. Their approach combines generative AI and computer vision to create personalized treatment plans tailored to individual needs rather than following a one-size-fits-all model. 

Currently, IVF success rates are around 32% for women under 35, but Ovom aims to boost this to over 50% by leveraging predictive AI models that consider a range of factors such as stress levels, hormone data, and even lifestyle choices. Early data suggests they‚Äôre already making strides, showing a 13% improvement in fertilization rates!  

For fertility clinics, this represents a potential shift in how care can be delivered, increasing patient success rates and satisfaction. What does this mean for practitioners? Keeping an eye on tech advancements and considering how to integrate innovative solutions like Ovom‚Äôs could lead to better outcomes in your practice.

As the landscape of fertility care evolves, we‚Äôre eager to see how Ovom‚Äôs upcoming physical clinics in Portugal will change the game‚Äîand potentially provide more affordable options for patients.

What are your thoughts on the integration of AI in fertility treatment? Have you seen similar innovations in your field? Let's discuss!  

#FertilityTech #IVF #HealthInnovation #AIinHealthcare #Entrepreneurship

Read the full article here: [Sifted](https://sifted.eu/articles/ovom-ai-pregnancy-raise-news/)",https://sifted.eu/wp-content/uploads/2023/08/ovom-fertility-article.jpg,https://sifted.eu/articles/ovom-ai-pregnancy-raise-news/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: AI-assisted pregnancies: Ovom raises ‚Ç¨4.8m for digi-physical fertility clinics | Sifted

URL Source: https://sifted.eu/articles/ovom-ai-pregnancy-raise-news/

Markdown Content:
Infertility rates are [on the rise](https://www.who.int/news/item/04-04-2023-1-in-6-people-globally-affected-by-infertility) globally, and [more people](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370/(23/)00520-5/fulltext) than ever are turning to assisted reproductive tech (ART) like in vitro fertilisation (IVF) to help them conceive. It‚Äôs this growing market that has helped German startup Ovom Care raise a ‚Ç¨4.8m seed round, led by Alpha Intelligence Capital and featuring Ananda Impact Ventures and Merantix.

It‚Äôs trying to address the problem that, while IVF is becoming more commonplace, the success rates for the treatment working are still very low ‚Äî just [32%](https://www.nhs.uk/conditions/ivf/) for women under 35 and much lower for those over that age ‚Äî according to the NHS.

Ovom Care believes it can raise that success metric to north of 50%, using a combination of generative AI and computer vision to develop more personalised treatment pathways.

While it's too soon to measure successful pregnancies that have resulted from Ovom‚Äôs tech (the startup launched in August last year), there are already signs that its AI-led approach could be working. Early data has shown a 13% improvement on fertilisation rates compared to the industry average of [75%](https://academic.oup.com/hropen/article/2017/2/hox011/4062213), says CEO and cofounder Felicia von Reden.

### **AI-powered fertility**

Since the first IVF birth in 1978, an estimated 12m babies have been born using the treatment and other assisted reproductive technologies (ARTs).

IVF is an invasive procedure, which involves a woman being given medication to suppress the menstrual cycle and produce more eggs, before they are collected and fertilised in a lab and then placed back in the womb.

While IVF is the most common treatment to help people conceive, one of the reasons for its low success rate is that that care pathways are often the same for everyone, which ‚Äúdoes not maximise an individual's chance of success‚Äù, says von Reden.

The solution, she argues, is a treatment plan tailored to the individual. Using predictive AI models, based on things like sleep patterns, stress levels and hormone levels, Ovom says it can personalise the type of medication offered, the dosage, timings and lifestyle advice that patients receive as they go through treatment.

Up to this point, to train its AI models Ovom has used historical IVF data from UK regulator the Human Fertilisation and Embryology Authority (HFEA), alongside real time patient data from people the startup has helped treat.

Some of those ‚Äî like the algorithms that predict a person‚Äôs chance of success, and medication dosage optimisation ‚Äî have been built in house, to sit on top of third-party foundation models. Others, like computer vision tools for embryo and sperm analysis, are not developed in-house.

Von Reden hopes that over the next couple of years ‚Äî as its AI models are trained on more and more patient data and their performance improves ‚Äî it can increase the rate of successful pregnancies by 15-20% on standard industry figures.

Alongside IVF, Ovom also offers egg and sperm freezing and has provided fertility care to more than 100 people, says von Reden.

### **Hybrid fertility care**

While much of Ovom‚Äôs team (including von Reden) are based in Berlin, so far all of that fertility care has taken place at a private clinic in London ‚Äî owned by von Reden‚Äôs cofounder, Cristina Hickman ‚Äî where Ovom has deployed its tech as a white label SaaS product.

‚ÄúFrom a regulatory perspective the UK is quite progressive \[compared to much of Europe\],‚Äù says von Reden. In the UK, for example, egg donation and surrogacy are allowed, whereas they‚Äôre banned in many European countries like Germany, she tells Sifted.

But Ovom also wants to open physical clinics in the future.

While installing Ovom‚Äôs AI platform worked at the private clinic because that facility was brand new and didn‚Äôt have clunky legacy systems underpinning it, integrating it at an established fertility clinic would be far trickier, says von Reden. Fertility clinics tend to be slow moving organisations that are hesitant to adopt new technologies, she adds.

The digi-physical approach has picked up traction among startups in recent times.

Although digital-only businesses have the potential for faster initial growth, they‚Äôre limited in terms of the amount of the patient journey ‚Äî and therefore healthcare revenue ‚Äî that startups can tap into.

Both Babylon and Kry [launched physical clinics](https://sifted.eu/articles/european-telehealth) after beginning life as digital-only healthcare providers, and VCs have invested some sizable rounds in digi-physical healthtechs over the past couple of years.

Dentistry care provider Patient21 raised [‚Ç¨100m in debt and equity](https://sifted.eu/articles/health-dentist-platform-patient21-2023) last year and primary healthcare provider Avi Medical raised [‚Ç¨50m](https://sifted.eu/articles/avi-medical-raise) in 2022. Spotify‚Äôs Daniel Ek also raised [‚Ç¨60m](https://sifted.eu/articles/neko-health-raises-series-a-news) for his body scanning healthtech Neko Health in 2023.

### **Next stop: Portugal**

For Ovom‚Äôs part, it plans to build its first physical clinic in Portugal by the end of 2024.

Like the UK, the country is a frontrunner in fertility care regulation in Europe, says von Reden ‚Äî and then there‚Äôs also costs.

In the UK, one cycle of IVF treatment can cost ¬£7000-8000k ‚Äî including treatment, medication and diagnostics, von Reden tells Sifted. Ovom currently charges a similar amount to that ‚Äî but over time she expects the price to drop as the startup‚Äôs technology improves.

In Portugal, however, Ovom will be able to charge around half that from day one. ‚ÄúPortugal is more cost effective \[than the UK\] in terms of rent and salaries ‚Äî which means we‚Äôre able to pass that onto the patients,‚Äù says von Reden.

Further down the line, Ovom plans to open a second physical clinic in Europe (although it‚Äôs too early to say exactly where, says von Reden) towards the end of 2025 or the start of 2026.
"
2024-04-29 00:00:00,2024-08-29 23:19:04,"üåü Exciting times in the healthtech world! Have you heard about Neko Health's upcoming launch in the UK? üéâ  

Founded by Spotify's Daniel Ek, Neko Health has made waves in Sweden with its innovative body scanning technology, and it's now gearing up to expand across Europe. After successfully completing over 3,000 scans in Stockholm, this healthtech start-up is set to launch its first facility in London this summer, fueled by a ‚Ç¨60m Series A funding round. 

üîë **Key Highlights:**  
- Neko Health uses a state-of-the-art full body scanner, equipped with over 70 sensors that collect up to 50 million data points in just 10-15 minutes!  
- This non-invasive technology aims to detect diseases like skin cancer, cardiovascular issues, and diabetes earlier, making healthcare more efficient and cost-effective in the long run.  
- A scan costs around ‚Ç¨250, and interest is surging, with over 20,000 patients currently on the waiting list in Sweden.  

This thoughtful approach to healthcare represents a significant shift towards preventative care, helping individuals understand their health better and take proactive steps for their well-being. Imagine being able to spot potential health issues before they become serious! üå±  

What are your thoughts on the increasing role of technology in healthcare? How do you think innovations like Neko Health‚Äôs could shape our approach to health management? Let‚Äôs discuss! üí≠  

#Healthtech #NekoHealth #PreventativeCare #InnovationInHealthcare  
Source: [Sifted](https://sifted.eu/articles/daniel-eks-body-scanning-neko-health-is-expanding-to-the-uk-news/)",,https://sifted.eu/articles/daniel-eks-body-scanning-neko-health-is-expanding-to-the-uk-news/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: Daniel Ek‚Äôs body scanning healthtech Neko Health is expanding to the UK | Sifted

URL Source: https://sifted.eu/articles/daniel-eks-body-scanning-neko-health-is-expanding-to-the-uk-news/

Markdown Content:
Daniel Ek‚Äôs body scanning healthtech Neko Health is expanding to the UK | Sifted
===============
     

Open navigation menu

[](https://sifted.eu/)

*   News
*   Insights
*   Newsletters
*   Events
[Podcasts](https://sifted.eu/podcasts)

[](https://sifted.eu/)

**Startup Europe.** Grown up reporting.

*   ### News
    
*   ### Insights
    
*   ### Newsletters
    
*   ### Events
    
*   [Podcasts](https://sifted.eu/podcasts)

*   [Search](https://sifted.eu/search)

Backed by

### Company

*   [About](https://sifted.eu/about)
*   [Careers](https://sifted.eu/careers)
*   [Advertising](https://sifted.eu/advertising)
*   [Controllership](https://sifted.eu/controllership/)
*   [Cookie Policy](https://sifted.eu/cookie-policy)
*   [Privacy policy](https://sifted.eu/privacy-policy)
*   [AI Code of Conduct](https://sifted.eu/ai-code-of-conduct)
*   [Terms of use](https://sifted.eu/terms-of-use)

### Sifted Pro

*   [Subscribe](https://sifted.eu/subscribe)
*   [~/Briefings](https://sifted.eu/pro/briefings/about)
*   [~/Pitches](https://sifted.eu/pro/roundtables)
*   [~/Scout](https://sifted.eu/scout)

### Products

*   [~/Newsletters](https://sifted.eu/newsletters)
*   [~/Rankings](https://sifted.eu/rankings)
*   [~/Reports](https://sifted.eu/intelligence/reports)

### Community

*   [~/Talks](https://sifted.eu/talks)
*   [~/Podcasts](https://sifted.eu/podcasts)
*   [~/Summit](https://summit.sifted.eu/)
*   [Jobs board](https://jobs.sifted.eu/?source=navbar&utm_source=navbar&utm_medium=partner_referral)

*   [![Image 1: X Logo](https://www.datocms-assets.com/60124/1697443751-x-logo.svg)](https://twitter.com/siftedeu)
*   [![Image 2: LinkedIn Logo](https://www.datocms-assets.com/60124/1689076682-linkedin.svg)](https://www.linkedin.com/company/siftedeu/)
*   [![Image 3: Facebook Logo](https://www.datocms-assets.com/60124/1689076874-facebook.svg)](https://www.facebook.com/siftedeu)
*   [![Image 4: RSS Feed Logo](https://www.datocms-assets.com/60124/1689076939-rss-feed.svg)](https://sifted.eu/feed/?post_type=article)

¬© 2024 Sifted EU Ltd. All Rights Reserved.

[News](https://sifted.eu/categories/news/)April 29, 2024

Daniel Ek‚Äôs body scanning healthtech Neko Health is expanding to the UK
=======================================================================

The company raised ‚Ç¨60m for international expansion in July last year
---------------------------------------------------------------------

[Mimi Billing](https://sifted.eu/author/mimibilling/)

2 min read

Spotify founder Daniel Ek‚Äôs healthtech startup Neko Health opened its first body scanning facility in Stockholm in February last year and has gone on to complete 3,000 scans. Now it‚Äôs [heading to London](https://www.linkedin.com/posts/nilsonne_london-we-are-coming-activity-7190613829859315713-4QsD?utm_source=share&utm_medium=member_desktop) with a launch planned for this summer.

In February last year, the Swedish company raised a [‚Ç¨60m Series A](https://sifted.eu/articles/neko-health-raises-series-a-news), led by Lakestar with the participation of Atomico and General Catalyst, for European expansion. At the time, the company didn‚Äôt want to specify which countries it had in mind.

Neko Health‚Äôs main product is a [full-body scanning system](https://sifted.eu/articles/ek-neko-body-scanner-test) for broad and non-invasive health data collection, which the company wants to make quicker, more convenient and more affordable. By catching potential diseases earlier, it hopes to increase the chances of treating them and reduce the cost of healthcare in the long term.

Advertisement

Within hours of its official launch in February last year, all the slots at its first body-scanning clinic in Stockholm had sold out.

The body-scanning procedure takes 10-15 minutes and is followed by a consultation with a doctor. Neko says its scanner uses over 70 sensors to collect 50m data points and can, for instance, detect tiny skin changes. That could help doctors detect diseases like skin cancer, cardiovascular disease, diabetes and other metabolic syndromes earlier.

A scan will set you back ‚Ç¨250 but the fee doesn‚Äôt seem to put people off. Neko has 20k patients on its waiting list in Sweden and has opened its international waiting list, the company says, where plenty of Brits have signed up.

### Origin story

The startup, founded by Daniel Ek and entrepreneur Hjalmar Nilsonne in 2018, was in stealth until its official launch last year. Before launching its body scanning facility the company opened [a primary care clinic](https://sifted.eu/articles/daniel-ek-secret-healthtech-startup) in Stockholm, which the founders are still running alongside the body scanning facility.

Before raising its Series A, Ek invested about ‚Ç¨30m in the company, partly through his moonshot investment vehicle Prima Materia.

The UK has seen the [most investments in longevity](https://sifted.eu/pro/briefings/longevity-2024) in Europe ‚Äî making London a natural choice for Neko.

Advertisement

Editor's picks

*   [News](https://sifted.eu/categories/news/)
    
    [Three cofounders leave French AI startup H just three months after raising $220m seed](https://sifted.eu/articles/three-cofounders-leave-h-news/)
    
    * * *
    
*   [Analysis](https://sifted.eu/categories/analysis/)
    
    [Lost millions, a luxury cottage under threat and Oussama Ammar‚Äôs new startup accelerator: What‚Äôs going on with the dispute at The Family?](https://sifted.eu/articles/the-family-oussama-ammar-startup-latest/)
    
    * * *
    
*   [News](https://sifted.eu/categories/news/)
    
    [Mike Lynch‚Äôs impact on UK tech](https://sifted.eu/articles/mike-lynch-tech-legacy/)
    
    * * *
    

[Mimi Billing](https://sifted.eu/author/mimibilling/)

Mimi Billing is Sifted's Europe editor. She covers the Nordics and healthtech, and can be found on [X](https://twitter.com/MimiBilling) and [LinkedIn](https://www.linkedin.com/in/mimibilling/)

[# Care](https://sifted.eu/sector/care/)[# Healthtech](https://sifted.eu/sector/healthtech/)[# Daniel Ek](https://sifted.eu/tag/daniel-ek/)[# Neko Health](https://sifted.eu/tag/neko-health/)

Recommended

*   [![Image 5](https://images.sifted.eu/wp-content/uploads/2024/08/23150208/%C2%A9Delporte-AnneOsdoit02-1-scaled-e1724421752987.jpg?auto=format&fit=max&w=3840&q=75)](https://sifted.eu/articles/medtech-startup-vc-trends/)
    
    [11 medtech startups to watch, according to VCs](https://sifted.eu/articles/medtech-startup-vc-trends/)[VCs at 415 Capital, Sofinnova Partners, MIG Capital and SHS Capital share their picks](https://sifted.eu/articles/medtech-startup-vc-trends/)[Kai Nicol-Schwarz](https://sifted.eu/author/kai-nicol-schwarz/)
    
*   [![Image 6](https://images.sifted.eu/wp-content/uploads/2024/08/14175205/Caresyntax4.jpg?auto=format&fit=max&w=3840&q=75)](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/)
    
    [AI surgery tech startup raises $180m from investors including BlackRock](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/)[More than a dozen investors were involved in the equity and debt round for Berlin-based Caresyntax](https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/)[Kai Nicol-Schwarz](https://sifted.eu/author/kai-nicol-schwarz/)
    
*   [![Image 7](https://images.sifted.eu/wp-content/uploads/2023/09/07164512/Screenshot-2023-09-07-at-16.45.04.png?auto=format&fit=max&w=3840&q=75)](https://sifted.eu/articles/startups-wegovy-ozempic-shift/)
    
    [Riding the Wegovy wave: The startups shifting focus to GLP-1s to tap the $150bn weight loss drug market](https://sifted.eu/articles/startups-wegovy-ozempic-shift/)[Founders and investors see massive potential in the new drug class ‚Äî but funding is yet to flood startups in the sector](https://sifted.eu/articles/startups-wegovy-ozempic-shift/)[Kai Nicol-Schwarz](https://sifted.eu/author/kai-nicol-schwarz/)
    

Backed by

### Company

*   [About](https://sifted.eu/about)
*   [Careers](https://sifted.eu/careers)
*   [Advertising](https://sifted.eu/advertising)
*   [Controllership](https://sifted.eu/controllership/)
*   [Cookie Policy](https://sifted.eu/cookie-policy)
*   [Privacy policy](https://sifted.eu/privacy-policy)
*   [AI Code of Conduct](https://sifted.eu/ai-code-of-conduct)
*   [Terms of use](https://sifted.eu/terms-of-use)

### Sifted Pro

*   [Subscribe](https://sifted.eu/subscribe)
*   [~/Briefings](https://sifted.eu/pro/briefings/about)
*   [~/Pitches](https://sifted.eu/pro/roundtables)
*   [~/Scout](https://sifted.eu/scout)

### Products

*   [~/Newsletters](https://sifted.eu/newsletters)
*   [~/Rankings](https://sifted.eu/rankings)
*   [~/Reports](https://sifted.eu/intelligence/reports)

### Community

*   [~/Talks](https://sifted.eu/talks)
*   [~/Podcasts](https://sifted.eu/podcasts)
*   [~/Summit](https://summit.sifted.eu/)
*   [Jobs board](https://jobs.sifted.eu/?source=footer&utm_source=footer&utm_medium=partner_referral)

*   [![Image 8: X Logo](https://www.datocms-assets.com/60124/1697443751-x-logo.svg)](https://twitter.com/siftedeu)
*   [![Image 9: LinkedIn Logo](https://www.datocms-assets.com/60124/1689076682-linkedin.svg)](https://www.linkedin.com/company/siftedeu/)
*   [![Image 10: Facebook Logo](https://www.datocms-assets.com/60124/1689076874-facebook.svg)](https://www.facebook.com/siftedeu)
*   [![Image 11: RSS Feed Logo](https://www.datocms-assets.com/60124/1689076939-rss-feed.svg)](https://sifted.eu/feed/?post_type=article)

¬© 2024 Sifted EU Ltd. All Rights Reserved.
"
2024-04-29 00:00:00,2024-08-29 23:19:35,"üåü **Resilience in Digital Health: The Remarkable Turnaround of Joint Academy** üåü  

Have you ever faced challenges that seemed insurmountable? It's stories like that of Joint Academy, a digital therapeutics startup for arthritis patients, that remind us of the power of resilience and adaptability. Just 18 months ago, Joint Academy was on the brink of bankruptcy after losing its biggest client. Fast forward to today, and the company is not only surviving but thriving, expanding into the US and opening physical clinics across various regions.

In the face of adversity, cofounder Jacob Dahlberg emphasizes the importance of humility and a diversified revenue stream. After their major setback, the team realized that relying heavily on a single client was a risky strategy. Now, with multiple contracts across Sweden and upcoming acquisitions in the US, they‚Äôre set on a more sustainable path.

Moreover, their decision to diversify from a purely digital model to owning physical clinics has proven fruitful, allowing them to offer a broader range of therapies and ensuring a steady flow of patients. This strategic pivot is echoed by other successful digital health startups in Europe, indicating a trend towards a hybrid model of care delivery.

As patients wait an average of over a year for orthopedic surgery, Joint Academy's efforts to reduce this wait time through digital therapies are yielding promising results. It's inspiring to witness how innovation and adaptability can create stronger foundations for growth in healthcare.

What strategies have you seen yield success in times of uncertainty? We would love to hear your thoughts! ü§î  

#DigitalHealth #HealthcareInnovation #StartupJourney #Resilience #PatientCare  

[Read more here](https://sifted.eu/articles/joint-academy-startup-expansion/)",,https://sifted.eu/articles/joint-academy-startup-expansion/,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Title: This digital health startup was on the verge of bankruptcy 18 months ago. Now it‚Äôs expanding to the US | Sifted

URL Source: https://sifted.eu/articles/joint-academy-startup-expansion/

Markdown Content:
In mid-2022, things didn‚Äôt look great for the digital health startup Joint Academy. The digital therapeutics startup for arthritis patients had just lost its largest paying customer ‚Äî a healthcare region in Sweden ‚Äî over a quarrel about how many sessions each patient should be allowed.

The mess put Joint Academy, which had been backed by well-known Swedish investors such as [Sophia Bendz](https://sifted.eu/articles/sophia-bendz-podcast-interview), Kinnevik, H&M owner Carl-Johan Persson and Alfven & Didrikson, on the brink of bankruptcy.

But in the 18 months since, the startup has dramatically turned things around. It‚Äôs now expanded to the UK, runs seven physical clinics in Sweden and is about to acquire a clinic in the US.

How did it turn things around?

### Humble pie

When Joint Academy fell out with its biggest customer, it lost 80% of its recurring revenue.

The company was on its knees ‚Äî and until its dispute with the customer, a regional health provider, was resolved, none of Sweden‚Äôs other 20 regional health services would work with the business either.

Cofounder Jacob Dahlberg learnt his lesson. ‚ÄúYou have to be humble,‚Äù he says when Sifted visits him at the opening of Joint Academy‚Äôs latest physical clinic in Nacka, a suburb of Stockholm.

‚ÄúThe situation was anything but perfect, but we have come out stronger and have a brand new business today than we would have built if this hadn't happened,‚Äù he says.

Apart from humility, Dahlberg also learnt not to rely on one large customer. The company has seven individual contracts with two regions in Sweden and also works with private health providers.

‚ÄúWe have a completely different and diversified revenue base now,‚Äù he says.

### From digital to digi-physical

Joint Academy launched in 2014, offering digital therapies to arthritis patients. Working with regional health providers it was reimbursed for its services as a digital health provider.

In May 2023, Joint Academy acquired the first of its seven physical clinics. It gained access to the clinics‚Äô patients and was able to broaden its speciality from arthritis to any kind of physiotherapy need.

In addition, owning clinics meant Joint Academy wasn‚Äôt limited to the reimbursements that digital health providers receive.

‚ÄúWe believed that both owning and running physical care clinics was strategically the right decision,‚Äù Dahlberg says. ‚ÄúThis is also something that we now see in our results. We‚Äôve seen a lot of healthcare companies that only work digital that have a tough time now \[because of the reimbursement system\].‚Äù

It‚Äôs not the only digital health startup that has branched into physical health. One of Europe‚Äôs biggest digital health startups, Kry, now operates over [60 physical clinics](https://sifted.eu/articles/kry-profitable-in-all-markets-we-wouldnt-have-managed-it-as-quickly-without-ai-news) across its three markets.

‚ÄúIf you own a clinic you have a natural flow of patients daily,‚Äù explains Dahlberg, who‚Äôs on the verge of acquiring a physical clinic in the US ‚Äî which currently doesn‚Äôt have a digital offering. ‚ÄúIf we bought it, we could add software and start offering telemedicine, digital therapeutics and those things.‚Äù

Joint Academy already has several contracts with insurance companies in the US, as well as a new contract with the UK‚Äôs largest private hospital provider Circle Health Group. As part of an NHS pilot project with the Highland and Islands in Scotland, it is also testing its digital therapeutics on a few thousand patients waiting for a hip or knee prosthesis operation. At present, the waiting time for surgery is over a year.

‚ÄúSo far we‚Äôve seen fantastic data with about every fifth treated patient changing their mind about surgery,‚Äù Dahlberg says.

In the future, Joint Academy is also looking to acquire clinics in the UK.

#### Where did the money come from?

In 2022, Joint Academy‚Äôs revenue more than halved ‚Äî dropping from almost 200m SEK (‚Ç¨17m) in 2021 to 79m SEK (‚Ç¨6.8m) in 2022. Losses also piled up, reaching 130m SEK (‚Ç¨11m) in 2022.

The company, which had raised a total of ‚Ç¨30m from its investors, needed fresh capital to avoid the risk of bankruptcy. Luckily, the investors still believed in the business.

‚ÄúThey supported us throughout ‚Äî it wouldn‚Äôt have been possible otherwise,‚Äù Dahlberg says. ‚ÄúWe had a very open dialogue wether to accelerate or put the brakes on the business.‚Äù

The investors agreed a convertible loan of 191m SEK (‚Ç¨16m) in 2022, according to the annual report. As written in the annual report, it says that the company has secured further funding early in 2023 as part of a package of cutting costs in terms of staff expenses ‚Äì and a lot of the staff were subsequently made redundant.

Dahlberg also stepped down as CEO earlier this year to focus on the US market and COO Emil Hansson took over as chief exec.

Today, things have changed dramatically. The company is expecting an annual revenue of 200m SEK (‚Ç¨20m) and expects a positive EBITDA in the second quarter of this year, according to Dahlberg.

‚ÄúWhat we‚Äôve learnt is the importance of having a diversified revenue base. We have that now,‚Äù he says.
"
2024-08-29 10:00:00,2024-08-29 23:20:00,"üåô **Tired of Sleepless Nights? You‚Äôre Not Alone!**  
As we navigate the challenges of insomnia, it‚Äôs encouraging to see recent developments in sleep therapy. A great article published on Medscape discusses a new study highlighting the effectiveness of nurse-delivered sleep restriction therapy for treating insomnia disorder.  
  
üîç **Key Takeaways:**  
- The study involved 642 patients from NHS general practices in England, comparing those who received behavioral therapy with a control group.  
- Results showed substantial improvements with therapy, lowering insomnia severity scores significantly at 6, 3, and even 12 months after treatment.  
- Notably, this approach could be a cost-effective alternative given the limited access to traditional cognitive behavioral therapy (CBT).  
  
üí° **Practical Applications:**  
For healthcare providers, this development means we can potentially adopt sleep restriction therapy as a strategic component of insomnia treatment in primary care, making quality care more accessible. Imagine your patients walking out of your office with a tailored sleep plan in hand, leading to better sleep quality and overall well-being!  
  
‚ú® What do you think about the role of nurses in expanding access to mental health therapies like this? Have you encountered similar strategies in your practice?  
  
#InsomniaTreatment #SleepHealth #NurseLedCare  

Read the full article here: [Medscape - Alternate Insomnia Therapy Has Good Showing](https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu)  
![Insomnia Therapy](https://img.medscapestatic.com/vim/live/professional_assets/dt_240313_insomnia_800x450px.jpg)",https://img.medscapestatic.com/vim/live/professional_assets/dt_240313_insomnia_800x450px.jpg,https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Thumbnail image URL: https://img.medscapestatic.com/vim/live/professional_assets/dt_240313_insomnia_800x450px.jpg 

Title: Alternate Insomnia Therapy Has Good Showing

URL Source: https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu

Published Time: 2024-08-29T10:00:00-04:00

Markdown Content:
Alternate Insomnia Therapy Has Good Showing
===============
                                     

This site is intended for UK healthcare professionals

[![Image 1: Medscape UK Univadis Logo](https://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/medscape-uk-logo.4a9c814f.svg)](https://www.medscape.co.uk/)

*   Recent Searches [Clear](https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu#)

Log In Register

[![Image 2: Medscape UK Univadis Logo](https://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/medscape-uk-logo.4a9c814f.svg)](https://www.medscape.co.uk/)

*   Recent Searches [Clear](https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu#)

Log In Register

*   Recent Searches [Clear](https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu#)

*   Menu
*   News
    
*   Guidelines
    
*   Drugs
    
*   Quizzes
    
*   Search

Clinical Summary

Alternate Insomnia Therapy Has Good Showing
===========================================

Susan London | 29 August 2024

[](https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu#)

**TOPLINE:**¬†
-------------

Brief nurse-delivered sleep restriction therapy is efficacious, safe, and likely cost-effective for treating insomnia disorder in primary care.

Continue Reading Below

**METHODOLOGY:**¬†
-----------------

*   Investigators conducted an open-label, randomised controlled trial among adult patients with insomnia disorder from NHS general practices in England (the [HABIT trial](https://www.isrctn.com/ISRCTN42499563)).
*   A total of 642 patients were randomised to two groups:
    *   Nurse-delivered behavioural therapy intervention: Two in-person and two telephone sessions, plus support to follow a prescribed sleep schedule aimed at restricting and standardising time in bed, plus a sleep hygiene leaflet.
    *   Control: Sleep hygiene leaflet only.
*   The main outcome was the self-reported insomnia severity on the Insomnia Severity Index (range, 0-28) at 6 months.

**TAKEAWAY:**¬†
--------------

*   At 6 months, the mean Insomnia Severity Index score was 10.9 in the sleep restriction therapy group vs 13.9 in the control group (estimated adjusted mean difference, ‚Äì3.05; _P_ < .001).
*   Scores were also lower with the intervention at 3 months (10.9 vs 14.8; _P_ < .001) and at 12 months (10.4 vs 13.5; _P_ < .001).
*   Sleep restriction therapy was superior to control with respect to secondary outcomes too: self-reported sleep, mental health‚Äìrelated quality of life, depressive symptoms, work productivity impairment, and sleep-related quality of life.
*   Sixteen patients, evenly split between groups, experienced serious adverse events; none were deemed related to trial interventions.
*   Sleep restriction therapy had an incremental cost per quality-adjusted life-year gained of ¬£2075.71.

**IN PRACTICE:**
----------------

""The vast majority of people with insomnia in the \[United Kingdom\] cannot access the first-line treatment (cognitive behavioural therapy),"" the authors wrote. ""Our trial shows that nurses can be trained to deliver a focused and manualised behavioural insomnia treatment, leading to patient benefit, and without safety concerns. Moreover, the intervention is very likely to be cost-effective. Nurse-delivered \[sleep restriction therapy\] could therefore become part of primary care management of insomnia,"" they concluded.

**SOURCE:**
-----------

The study was led by Simon D. Kyle, PhD, MA, University of Oxford, Oxford, UK, and was [published online](https://www.journalslibrary.nihr.ac.uk/hta/RJYT4275#/abstract) in _Health Technology Assessment_.

Continue Reading Below

Continue Reading Below

**LIMITATIONS:**
----------------

Limitations included a predominantly White and better-educated trial population, discontinuations due to the perceived challenging nature of the intervention, and the possibility that some participants had other, undiagnosed sleep disorders.

**DISCLOSURES:**
----------------

The study was funded by the National Institute of Health and Care Research. Two authors disclosed affiliations with Big Health Ltd, which manufactures a digital sleep improvement programme.

Continue reading with a FREE Medscape UK account

Access the latest UK medical news, UK-specific clinical guideline summaries,  
UK vaccination schedule and more for free.

Register Today

Already a member? Log in

* * *

#### 

References

Kyle SD, Bower P, Yu LM, et al. Nurse-delivered sleep restriction therapy to improve insomnia disorder in primary care: The HABIT RCT. Health Technol Assess. 2024;28(36):1-107. doi:10.3310/RJYT4275

* * *

EDITOR'S RECOMMENDATIONS
------------------------

*   ![Image 3: related](https://img.medscapestatic.com/pi/global/1x1.png)
    
    [Restless Nights? Here's How to Help Your Patients](https://www.medscape.co.uk/viewarticle/restless-nights-heres-how-help-your-patients-2024a1000fm8)
    
    Despite being the gold standard, cognitive behavioural therapy for insomnia is underutilised.
    
*   ![Image 4: related](https://img.medscapestatic.com/pi/global/1x1.png)
    
    [Sleep Patterns Predict Response to Fibromyalgia Treatment](https://www.medscape.co.uk/s/viewarticle/sleep-patterns-predict-response-fibromyalgia-treatment-2024a1000eqb)
    
    Patients with minimal pain relief from a serotonin and norepinephrine reuptake inhibitor had more sleep problems and tougher mornings than those who responded better to the medication.
    
*   ![Image 5: related](https://img.medscapestatic.com/pi/global/1x1.png)
    
    [Hyperarousal Is a Treatable Reason Behind Poor Sleep in Endometriosis](https://www.medscape.co.uk/viewarticle/hyperarousal-treatable-reason-behind-poor-sleep-2024a1000eao)
    
    A case-control study with 847 participants is the first to identify the importance of hyperarousal.
    

YOU MAY ALSO LIKE
-----------------

[![Image 6: Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/pa_240829_chris_jones_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/breast-cancer-drug-may-slow-aggressive-brain-tumour-kids-2024a1000fra ""Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids"")

[Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids](https://www.medscape.co.uk/s/viewarticle/breast-cancer-drug-may-slow-aggressive-brain-tumour-kids-2024a1000fra ""Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids"")

Ribociclib, commonly used for breast cancer, has been found to stabilise a subtype of diffuse hemispheric glioma for about 17 months before regrowth begins.

*   Press Association
*   7 hours ago

[![Image 7: Listeriosis During Pregnancy Can Be Fatal for the Fetus](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/dt_240828_listeria_bacteria_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/listeriosis-during-pregnancy-can-be-fatal-fetus-2024a1000frm ""Listeriosis During Pregnancy Can Be Fatal for the Fetus"")

[Listeriosis During Pregnancy Can Be Fatal for the Fetus](https://www.medscape.co.uk/s/viewarticle/listeriosis-during-pregnancy-can-be-fatal-fetus-2024a1000frm ""Listeriosis During Pregnancy Can Be Fatal for the Fetus"")

The rate of fetal loss or neonatal death from invasive listeriosis is 29%.

*   Medscape Medical News
*   9 hours ago

[![Image 8: Prisons Often Waste Ambulance Crew Time](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240829_prison_in_uk_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/prisons-often-waste-ambulance-crew-time-2024a1000fqp ""Prisons Often Waste Ambulance Crew Time"")

[Prisons Often Waste Ambulance Crew Time](https://www.medscape.co.uk/viewarticle/prisons-often-waste-ambulance-crew-time-2024a1000fqp ""Prisons Often Waste Ambulance Crew Time"")

Unnecessary 999 calls are being made by prison staff due to lack of experience and concerns over legal repercussions.

*   Medscape News UK
*   9 hours ago

[![Image 9: Recurrent UTI: Undercultured, Overtreated Despite Resistance](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_230216_urine_analysis_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni ""Recurrent UTI: Undercultured, Overtreated Despite Resistance"")

[Recurrent UTI: Undercultured, Overtreated Despite Resistance](https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni ""Recurrent UTI: Undercultured, Overtreated Despite Resistance"")

Roughly 40% of general practitioners do not culture recurrent UTIs and instead, just treat.

*   Medscape News UK
*   9 hours ago

[![Image 10: High-Dose Psilocybin Shows Promising Results for Depression](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_220215_psilocybin_mushrooms_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/high-dose-psilocybin-shows-promising-results-depression-2024a1000fqw ""High-Dose Psilocybin Shows Promising Results for Depression"")

[High-Dose Psilocybin Shows Promising Results for Depression](https://www.medscape.co.uk/s/viewarticle/high-dose-psilocybin-shows-promising-results-depression-2024a1000fqw ""High-Dose Psilocybin Shows Promising Results for Depression"")

A meta-analysis found that high-dose psilocybin for depressive symptoms showed better responses than placebo or escitalopram in antidepressant trials.

*   Medscape Medical News
*   10 hours ago

[![Image 11: Primary Care Docs Track Average of 57 (!) Quality Measures](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240829_healthcare_business_graph_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/primary-care-physicians-track-average-57-quality-measures-2024a1000fqu ""Primary Care Docs Track Average of 57 (!) Quality Measures"")

[Primary Care Docs Track Average of 57 (!) Quality Measures](https://www.medscape.co.uk/s/viewarticle/primary-care-physicians-track-average-57-quality-measures-2024a1000fqu ""Primary Care Docs Track Average of 57 (!) Quality Measures"")

Medicare tracked the most metrics tied to payment, while Medicaid tracked the least, according to a new JAMA Health Forum analysis.

*   Medscape Medical News
*   12 hours ago

[![Image 12: Female Doctors' Suicide Rates Alarmingly Higher vs General Folks](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240329_surgeon_sad_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/female-doctors-suicide-rates-alarmingly-higher-vs-general-2024a1000fqs ""Female Doctors' Suicide Rates Alarmingly Higher vs General Folks"")

[Female Doctors' Suicide Rates Alarmingly Higher vs General Folks](https://www.medscape.co.uk/viewarticle/female-doctors-suicide-rates-alarmingly-higher-vs-general-2024a1000fqs ""Female Doctors' Suicide Rates Alarmingly Higher vs General Folks"")

Male physicians have a similar suicide rate to the general public, but female physicians show a notably higher suicide rate.

*   Medscape News UK
*   13 hours ago

[![Image 13: Men, Women, & Exercise: Metabolism Differs at Starting Line](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/dt_240828_man_woman_exercising_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn ""Men, Women, & Exercise: Metabolism Differs at Starting Line"")

[Men, Women, & Exercise: Metabolism Differs at Starting Line](https://www.medscape.co.uk/s/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn ""Men, Women, & Exercise: Metabolism Differs at Starting Line"")

The muscles of sedentary men and women with overweight and obesity differ in burning sugar and fatty acids at the start of an exercise program but draw even after training, multi-omics data show.

*   Medscape Medical News
*   14 hours ago

[![Image 14: Dental Caries Could Be a Silent Threat to Your Heart](https://img.medscapestatic.com/vim/live/professional_assets/dreamstime_l_57022209-800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/dental-caries-could-be-silent-threat-your-heart-2024a1000fqm ""Dental Caries Could Be a Silent Threat to Your Heart"")

[Dental Caries Could Be a Silent Threat to Your Heart](https://www.medscape.co.uk/viewarticle/dental-caries-could-be-silent-threat-your-heart-2024a1000fqm ""Dental Caries Could Be a Silent Threat to Your Heart"")

Dental caries are tied to a 40% higher stroke risk, underscoring the importance of oral health in preventing cardiovascular events.

*   Medscape News UK
*   14 hours ago

[Domestic Abuse: Recognition and Support](https://www.medscape.co.uk/viewarticle/supporting-people-affected-domestic-abuse-2024a1000dqo ""Domestic Abuse: Recognition and Support"")

Concise summary on recognising domestic abuse in primary care, including key questions to ask patients

*   Guidelines Summary: Primary Care
*   14 hours ago

[![Image 15: Parents' Technology Use May Shape Adolescents' Mental Health](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240828_distracted_parent_smartphone_girl_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/parents-technology-use-may-shape-adolescents-mental-health-2024a1000fqd ""Parents' Technology Use May Shape Adolescents' Mental Health"")

[Parents' Technology Use May Shape Adolescents' Mental Health](https://www.medscape.co.uk/s/viewarticle/parents-technology-use-may-shape-adolescents-mental-health-2024a1000fqd ""Parents' Technology Use May Shape Adolescents' Mental Health"")

Discussing digital technology use and mental health with parents and adolescents can be part of routine care visits, researchers said.

*   Medscape Medical News
*   17 hours ago

[![Image 16: NICE: Give People With Adrenal Insufficiency Emergency Kits](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240117_adrenal_glands_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/emergency-kits-recommended-adrenal-insufficiency-patients-2024a1000fpx ""NICE: Give People With Adrenal Insufficiency Emergency Kits"")

[NICE: Give People With Adrenal Insufficiency Emergency Kits](https://www.medscape.co.uk/viewarticle/emergency-kits-recommended-adrenal-insufficiency-patients-2024a1000fpx ""NICE: Give People With Adrenal Insufficiency Emergency Kits"")

People with adrenal insufficiency should be given emergency kits to help avoid hospital admission, said NICE in its new clinical guideline.

*   Medscape News UK
*   28 Aug 2024

[![Image 17: NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240828_cancer_patient_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/nice-oks-lonsurf-bevacizumab-advanced-bowel-cancer-2024a1000fpu ""NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer"")

[NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer](https://www.medscape.co.uk/viewarticle/nice-oks-lonsurf-bevacizumab-advanced-bowel-cancer-2024a1000fpu ""NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer"")

Around 1300 people in England will be eligible every year for the new combination treatment.

*   Medscape News UK
*   28 Aug 2024

[![Image 18: Kidney Donor Mortality Plummets Over 30 Years](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/dt_240827_donor_kidney_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/kidney-donor-mortality-plummets-over-30-years-2024a1000fop ""Kidney Donor Mortality Plummets Over 30 Years"")

[Kidney Donor Mortality Plummets Over 30 Years](https://www.medscape.co.uk/s/viewarticle/kidney-donor-mortality-plummets-over-30-years-2024a1000fop ""Kidney Donor Mortality Plummets Over 30 Years"")

The risk for perioperative mortality in living kidney donors has significantly reduced in the past decade, a study showed.

*   Medscape Medical News
*   28 Aug 2024

[![Image 19: A New Exercise 'Evolution' for Stroke Survivors: Go Harder](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240827_senior_stepper_exercise_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/new-exercise-evolution-stroke-survivors-go-harder-2024a1000fp7 ""A New Exercise 'Evolution' for Stroke Survivors: Go Harder"")

[A New Exercise 'Evolution' for Stroke Survivors: Go Harder](https://www.medscape.co.uk/s/viewarticle/new-exercise-evolution-stroke-survivors-go-harder-2024a1000fp7 ""A New Exercise 'Evolution' for Stroke Survivors: Go Harder"")

A recent study has built on emerging evidence that intense training can be safe and beneficial for patients recovering from stroke.

*   Medscape Medical News
*   28 Aug 2024

[![Image 20: Continuous Glucose Monitor Benefits All Ages With Diabetes](https://img.medscapestatic.com/vim/live/professional_assets/ht_181001_freestyle_libre_glucose_monitor_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/continuous-glucose-monitor-benefits-all-ages-diabetes-2024a1000fhy ""Continuous Glucose Monitor Benefits All Ages With Diabetes"")

[Continuous Glucose Monitor Benefits All Ages With Diabetes](https://www.medscape.co.uk/viewarticle/continuous-glucose-monitor-benefits-all-ages-diabetes-2024a1000fhy ""Continuous Glucose Monitor Benefits All Ages With Diabetes"")

Intermittently scanned continuous glucose monitoring improved glycaemic outcomes in those older and younger than 65 years, but the older group may need individualised targets.

*   Medscape News UK
*   28 Aug 2024

[![Image 21: Hot Flashes, Night Sweats Linked to Menopausal Heart Disease](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/is_210928_hot_flashes_menopause_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/hot-flashes-night-sweats-linked-subclinical-heart-disease-2024a1000fl0 ""Hot Flashes, Night Sweats Linked to Menopausal Heart Disease"")

[Hot Flashes, Night Sweats Linked to Menopausal Heart Disease](https://www.medscape.co.uk/viewarticle/hot-flashes-night-sweats-linked-subclinical-heart-disease-2024a1000fl0 ""Hot Flashes, Night Sweats Linked to Menopausal Heart Disease"")

Early onset and long duration were associated with particularly high risk.

*   Medscape News UK
*   28 Aug 2024

[![Image 22: UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/dt_220707_drug_pharmaceutical_clinical_trial_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/uk-set-open-18-new-clinical-trial-hubs-400m-investment-2024a1000fp5 ""UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment"")

[UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment](https://www.medscape.co.uk/s/viewarticle/uk-set-open-18-new-clinical-trial-hubs-400m-investment-2024a1000fp5 ""UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment"")

Wes Streeting called the investment a major boost for the UK, transforming it into a health research hub and supporting a future-ready NHS.

*   Press Association
*   28 Aug 2024

[![Image 23: Measuring Expectations: Real-World Survival With Osimertinib](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_211029_doctor_patient_notes_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/measuring-expectations-real-world-survival-osimertinib-2024a1000fok ""Measuring Expectations: Real-World Survival With Osimertinib"")

[Measuring Expectations: Real-World Survival With Osimertinib](https://www.medscape.co.uk/s/viewarticle/measuring-expectations-real-world-survival-osimertinib-2024a1000fok ""Measuring Expectations: Real-World Survival With Osimertinib"")

In a real-world population of patients with EGFR-mutant advanced lung cancer, overall survival was much worse in patients who would not have been eligible for the pivotal FLAURA trial.

*   Medscape Medical News
*   28 Aug 2024

![Image 24](blob:https://www.medscape.co.uk/6742166de2ffdc98a2fc8b83a0aa235b)

[](https://www.medscape.co.uk/)

#### Find Us On

[](https://www.facebook.com/GuidelinesMedscape/)[](https://twitter.com/medscapeuk)[](http://www.linkedin.com/company/24356)[](https://www.youtube.com/user/medscape/)[](https://www.instagram.com/medscape/)

#### About

[About Medscape](https://www.medscape.com/public/about)[Privacy Policy](https://www.medscape.co.uk/public/privacy)[Editorial Policy](https://www.medscape.com/public/editorialpolicies)[Cookies](https://www.medscape.co.uk/public/cookies) [Manage Preferences](javascript:void\(0\);) [Terms of Use](https://www.medscape.com/public/termsofuse)[UK Modern Slavery Statement](https://www.medscape.co.uk/public/antislavery)[Advertising Policy](https://www.medscape.com/public/adpolicy)[Help Center](https://help.medscape.com/hc/en-us)

#### App

[Medscape](https://www.medscape.com/public/medscapeapp?pid=Medscape_footer&c=FooterIcon)

All material on this website is protected by copyright, Copyright ¬© 1994-2024 by WebMD LLC. This website also contains material copyrighted by 3rd parties.

           

![Image 25](https://thrtle.com/insync?vxii_pid=10015&vxii_pdid=)

![Image 26](https://bh-eu.contextweb.com/bh/sr?action=add&token=Q4S7ZMWDWRFR&ch=1&url=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Falternate-insomnia-therapy-has-good-showing-2024a1000fnu&rr=&us_privacy=&param1=$$event$$&epid=&did=60514339364645724623250607866693668763&pf=0&usp=0&auth_channel=100&ev_id=0&topicid=$$topicid$$&conceptid=$$conceptid$$&ssp=26&gdpr_consent=&val=$$val$$&val=${val})![Image 27](https://bh.contextweb.com/bh/rtset?pid=562507&ev=0&us_privacy=)![Image 28](https://bh.contextweb.com/bh/rtset?pid=561967&ev=1&us_privacy=&gdpr=0&gdpr_consent=&rurl=https%3A%2F%2Fdsum.casalemedia.com%2Frum%3Fcm_dsp_id%3D189%26external_user_id%3D%25%25VGUID%25%25%26expiration%3D[EXPIRATION]%26us_privacy%3D%24%24us_privacy%24%24%26gdpr%3D%24%24gdpr%24%24%26gdpr_consent%3D%24%24gdpr_consent%24%24)![Image 29](https://bh.contextweb.com/bh/rtset?pid=561590&ev=1&us_privacy=&gdpr=0&gdpr_consent=&rurl=https%3A%2F%2Fpixel.rubiconproject.com%2Ftap.php%3Fv%3D390200%26nid%3D5120%26put%3D%25%25VGUID%25%25%26us_privacy%3D%24%24us_privacy%24%24%26gdpr%3D%24%24gdpr%24%24%26gdpr_consent%3D%24%24gdpr_consent%24%24)![Image 30](https://bh.contextweb.com/bh/rtset?pid=558356&ev=1&us_privacy=&gdpr=0&gdpr_consent=&rurl=https%3A%2F%2Feb2.3lift.com%2Fxuid%3Fmid%3D2636%26xuid%3D%25%25VGUID%25%25%26dongle%3D8bee%26us_privacy%3D%24%24us_privacy%24%24%26gdpr%3D%24%24gdpr%24%24%26gdpr_consent%3D%24%24gdpr_consent%24%24)

![Image 31](https://t.co/i/adsct?bci=3&eci=2&event_id=2113306e-446f-4fd5-a38d-ddd7e77fac86&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=35c1bfad-0ba8-4984-ae0f-2d9891ee8ade&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Falternate-insomnia-therapy-has-good-showing-2024a1000fnu&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o5zto&type=javascript&version=2.3.30)![Image 32](https://analytics.twitter.com/i/adsct?bci=3&eci=2&event_id=2113306e-446f-4fd5-a38d-ddd7e77fac86&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=35c1bfad-0ba8-4984-ae0f-2d9891ee8ade&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Falternate-insomnia-therapy-has-good-showing-2024a1000fnu&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o5zto&type=javascript&version=2.3.30)![Image 33](https://t.co/i/adsct?bci=3&eci=2&event_id=7687d997-a5ce-4f2b-8cc2-288d2163c9ba&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=35c1bfad-0ba8-4984-ae0f-2d9891ee8ade&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Falternate-insomnia-therapy-has-good-showing-2024a1000fnu&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=nvb1e&type=javascript&version=2.3.30)![Image 34](https://analytics.twitter.com/i/adsct?bci=3&eci=2&event_id=7687d997-a5ce-4f2b-8cc2-288d2163c9ba&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=35c1bfad-0ba8-4984-ae0f-2d9891ee8ade&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Falternate-insomnia-therapy-has-good-showing-2024a1000fnu&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=nvb1e&type=javascript&version=2.3.30)![Image 35](https://t.co/i/adsct?bci=3&eci=2&event_id=a42436ce-43cc-4d7d-8dc3-e79feeef2b5d&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=35c1bfad-0ba8-4984-ae0f-2d9891ee8ade&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Falternate-insomnia-therapy-has-good-showing-2024a1000fnu&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o5ztw&type=javascript&version=2.3.30)![Image 36](https://analytics.twitter.com/i/adsct?bci=3&eci=2&event_id=a42436ce-43cc-4d7d-8dc3-e79feeef2b5d&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=35c1bfad-0ba8-4984-ae0f-2d9891ee8ade&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Falternate-insomnia-therapy-has-good-showing-2024a1000fnu&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o5ztw&type=javascript&version=2.3.30)
"
2024-08-29 09:00:00,2024-08-29 23:20:07,"üåü **Highlighting Insights on Recurrent UTIs** üåü

As many healthcare professionals know, managing recurrent urinary tract infections (rUTIs) can often feel like a balancing act. A recent article from Medscape sheds light on a concerning trend in the treatment of rUTIs, particularly among older women in Wales. 

ü§î **Key Findings:**  
The study examined data from over 92,000 women and revealed high levels of prophylactic antibiotic use, even in cases where there was significant antibiotic resistance. Alarmingly, many women receiving these antibiotics had not undergone urine cultures beforehand, which could misguide their treatment. 

üí° **Insights for Practice:**  
The findings indicate that the integration of more frequent microbiological testing in primary care could really help tailor antibiotic use more effectively. By ensuring that urine cultures are routinely conducted prior to prescribing antibiotics, we can better inform treatment decisions and curb the overuse of these medications, ultimately improving patient outcomes. For example, consider adjusting your clinic's protocol to reinforce the necessity of urine cultures in cases of suspected rUTIs before starting any prophylactic therapy.

üí¨ **Your Thoughts?**  
In light of these findings, how is your practice currently handling rUTIs? Have you adapted or considered changing your prescribing habits based on resistance patterns? I‚Äôd love to hear your experiences and insights!  

#RecurrentUTI #AntibioticResistance #HealthcarePractice #UrinaryTractInfection #Microbiology

[Read the full article here](https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni)",https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_230216_urine_analysis_800x450.jpg,https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Thumbnail image URL: https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_230216_urine_analysis_800x450.jpg 

Title: Recurrent UTI: Undercultured, Overtreated Despite Resistance

URL Source: https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni

Published Time: 2024-08-29T09:00:00-04:00

Markdown Content:
Recurrent UTI: Undercultured, Overtreated Despite Resistance
===============
                                     

This site is intended for UK healthcare professionals

[![Image 1: Medscape UK Univadis Logo](https://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/medscape-uk-logo.4a9c814f.svg)](https://www.medscape.co.uk/)

*   Recent Searches [Clear](https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni#)

Log In Register

[![Image 2: Medscape UK Univadis Logo](https://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/medscape-uk-logo.4a9c814f.svg)](https://www.medscape.co.uk/)

*   Recent Searches [Clear](https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni#)

Log In Register

*   Recent Searches [Clear](https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni#)

*   Menu
*   News
    
*   Guidelines
    
*   Drugs
    
*   Quizzes
    
*   Search

Clinical Summary

Recurrent UTI: Undercultured, Overtreated Despite Resistance
============================================================

Liz Scherer | 29 August 2024

[](https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni#)

TOPLINE:
--------

Use of prophylactic antibiotics for recurrent urinary tract infection (rUTI) remains especially high in older women in Wales, despite their high levels of resistance to at least two recommended antibiotics and urine culture before treatment initiation.

Continue Reading Below

METHODOLOGY:
------------

*   A retrospective, cross-sectional analysis was conducted using anonymised, individual-level, population-scale linked health record data to describe prevalence, urine testing, susceptibility profiles in women with rUTIs and with/without prophylactic antibiotic use in Wales (2010-2020).
*   Two cohorts were created: Cohort 1 (clinical) was women meeting the clinical definition of rUTIs; Cohort 2 (prophylaxis) was women prescribed prophylactic antibiotics.¬†
*   Definitions: rUTIs defined as at least two acute UTIs within 6 months or at least three within 12 months. Prophylactic antibiotics defined as at least three consecutive prescriptions for the same UTI-specific antibiotic (trimethoprim, nitrofurantoin, or cefalexin) within 21-56 days between prescriptions.

TAKEAWAY:
---------

*   A total of 92,213 women, median age was 60 years, were included in the clinical cohort; 80.8% had a urine culture in preceding 12 months, 41.1% had ‚â• 3 samples reported, and 28.1% had microbiologically confirmed UTI.
*   In total, 26,862 women, median age was 70.6 years, were included in the prophylaxis cohort; 39.1% started prophylactic antibiotics within 3 months but 32.2% had a microbiologically confirmed UTI before initiation.
*   Both cohorts had high resistance to trimethoprim and amoxicillin.¬†
*   Overall, urine culture before treatment was reported in 64.2% of the cohort; 18.5% of women prescribed trimethoprim had evidence of resistance before starting treatment.

IN PRACTICE:
------------

""It could be clinically beneficial to encourage microbiological confirmation of rUTIs in primary care and before prophylactic antibiotic initiation in line with clinical guidelines,"" the authors wrote. ""More frequent urine cultures in the workup of rUTI diagnosis and prophylactic antibiotic initiation could better inform antibiotic choice.""

SOURCE:
-------

The study was led by Leigh Sanyaolu, MRCGP, PGDip, Cardiff University, Wales, UK, and [appeared online](https://bjgp.org/content/early/2024/08/19/BJGP.2024.0015.long) in the _British Journal of General Practice._

Continue Reading Below

Continue Reading Below

LIMITATIONS:
------------

Limitations included possible coding errors, misclassifications/misdiagnoses, and missing data.

DISCLOSURES:
------------

The study was supported by Health and Care Research Wales. The authors had no financial disclosures of interest.

Continue reading with a FREE Medscape UK account

Access the latest UK medical news, UK-specific clinical guideline summaries,  
UK vaccination schedule and more for free.

Register Today

Already a member? Log in

* * *

#### 

References

Sanyaolu L, Best V, Cannings-John R, et al. Recurrent urinary tract infections and prophylactic antibiotic use in women: A cross-sectional study in primary care. Br J Gen Pract. Published online August 19, 2024. doi:10.3399/BJGP.2024.0015

* * *

EDITOR'S RECOMMENDATIONS
------------------------

*   ![Image 3: related](https://img.medscapestatic.com/pi/global/1x1.png)
    
    [UTIs Still Not Routinely Captured in Patient Records](https://www.medscape.co.uk/viewarticle/utis-still-not-routinely-captured-patient-records-2024a1000ezd)
    
    Although UTI screening has recovered to pre-pandemic levels, medical record coding lags behind.
    
*   ![Image 4: related](https://img.medscapestatic.com/pi/global/1x1.png)
    
    [It's in the Juice: Cranberries for UTI Prevention](https://www.medscape.co.uk/s/viewarticle/its-juice-cranberries-uti-prevention-2024a1000ei4)
    
    A study suggested with ""moderate to low certainty"" that cranberry juice may help prevent UTIs.
    
*   [Understand the Clinician‚Äôs Role in Reporting Female Genital Mutilation](https://www.medscape.co.uk/viewarticle/understand-clinicians-role-reporting-female-genital-2024a1000d48)
    
    Dr Philippa Vincent explains the role of clinicians in preventing, identifying, and treating complications of female genital mutilation, covering both legal and clinical concerns
    
    Hot topic | Dr Philippa Vincent | 07 August 2024
    

YOU MAY ALSO LIKE
-----------------

[![Image 5: Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/pa_240829_chris_jones_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/breast-cancer-drug-may-slow-aggressive-brain-tumour-kids-2024a1000fra ""Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids"")

[Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids](https://www.medscape.co.uk/s/viewarticle/breast-cancer-drug-may-slow-aggressive-brain-tumour-kids-2024a1000fra ""Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids"")

Ribociclib, commonly used for breast cancer, has been found to stabilise a subtype of diffuse hemispheric glioma for about 17 months before regrowth begins.

*   Press Association
*   7 hours ago

[![Image 6: Alternate Insomnia Therapy Has Good Showing](https://img.medscapestatic.com/vim/live/professional_assets/dt_240313_insomnia_800x450px.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu ""Alternate Insomnia Therapy Has Good Showing"")

[Alternate Insomnia Therapy Has Good Showing](https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu ""Alternate Insomnia Therapy Has Good Showing"")

The brief nurse-delivered therapy aimed at restricting and standardising time in bed could make treatment more accessible to primary care patients.

*   Medscape News UK
*   8 hours ago

[![Image 7: Listeriosis During Pregnancy Can Be Fatal for the Fetus](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/dt_240828_listeria_bacteria_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/listeriosis-during-pregnancy-can-be-fatal-fetus-2024a1000frm ""Listeriosis During Pregnancy Can Be Fatal for the Fetus"")

[Listeriosis During Pregnancy Can Be Fatal for the Fetus](https://www.medscape.co.uk/s/viewarticle/listeriosis-during-pregnancy-can-be-fatal-fetus-2024a1000frm ""Listeriosis During Pregnancy Can Be Fatal for the Fetus"")

The rate of fetal loss or neonatal death from invasive listeriosis is 29%.

*   Medscape Medical News
*   9 hours ago

[![Image 8: Prisons Often Waste Ambulance Crew Time](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240829_prison_in_uk_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/prisons-often-waste-ambulance-crew-time-2024a1000fqp ""Prisons Often Waste Ambulance Crew Time"")

[Prisons Often Waste Ambulance Crew Time](https://www.medscape.co.uk/viewarticle/prisons-often-waste-ambulance-crew-time-2024a1000fqp ""Prisons Often Waste Ambulance Crew Time"")

Unnecessary 999 calls are being made by prison staff due to lack of experience and concerns over legal repercussions.

*   Medscape News UK
*   9 hours ago

[![Image 9: High-Dose Psilocybin Shows Promising Results for Depression](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_220215_psilocybin_mushrooms_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/high-dose-psilocybin-shows-promising-results-depression-2024a1000fqw ""High-Dose Psilocybin Shows Promising Results for Depression"")

[High-Dose Psilocybin Shows Promising Results for Depression](https://www.medscape.co.uk/s/viewarticle/high-dose-psilocybin-shows-promising-results-depression-2024a1000fqw ""High-Dose Psilocybin Shows Promising Results for Depression"")

A meta-analysis found that high-dose psilocybin for depressive symptoms showed better responses than placebo or escitalopram in antidepressant trials.

*   Medscape Medical News
*   9 hours ago

[![Image 10: Primary Care Docs Track Average of 57 (!) Quality Measures](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240829_healthcare_business_graph_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/primary-care-physicians-track-average-57-quality-measures-2024a1000fqu ""Primary Care Docs Track Average of 57 (!) Quality Measures"")

[Primary Care Docs Track Average of 57 (!) Quality Measures](https://www.medscape.co.uk/s/viewarticle/primary-care-physicians-track-average-57-quality-measures-2024a1000fqu ""Primary Care Docs Track Average of 57 (!) Quality Measures"")

Medicare tracked the most metrics tied to payment, while Medicaid tracked the least, according to a new JAMA Health Forum analysis.

*   Medscape Medical News
*   12 hours ago

[![Image 11: Female Doctors' Suicide Rates Alarmingly Higher vs General Folks](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240329_surgeon_sad_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/female-doctors-suicide-rates-alarmingly-higher-vs-general-2024a1000fqs ""Female Doctors' Suicide Rates Alarmingly Higher vs General Folks"")

[Female Doctors' Suicide Rates Alarmingly Higher vs General Folks](https://www.medscape.co.uk/viewarticle/female-doctors-suicide-rates-alarmingly-higher-vs-general-2024a1000fqs ""Female Doctors' Suicide Rates Alarmingly Higher vs General Folks"")

Male physicians have a similar suicide rate to the general public, but female physicians show a notably higher suicide rate.

*   Medscape News UK
*   12 hours ago

[![Image 12: Men, Women, & Exercise: Metabolism Differs at Starting Line](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/dt_240828_man_woman_exercising_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn ""Men, Women, & Exercise: Metabolism Differs at Starting Line"")

[Men, Women, & Exercise: Metabolism Differs at Starting Line](https://www.medscape.co.uk/s/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn ""Men, Women, & Exercise: Metabolism Differs at Starting Line"")

The muscles of sedentary men and women with overweight and obesity differ in burning sugar and fatty acids at the start of an exercise program but draw even after training, multi-omics data show.

*   Medscape Medical News
*   14 hours ago

[![Image 13: Dental Caries Could Be a Silent Threat to Your Heart](https://img.medscapestatic.com/vim/live/professional_assets/dreamstime_l_57022209-800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/dental-caries-could-be-silent-threat-your-heart-2024a1000fqm ""Dental Caries Could Be a Silent Threat to Your Heart"")

[Dental Caries Could Be a Silent Threat to Your Heart](https://www.medscape.co.uk/viewarticle/dental-caries-could-be-silent-threat-your-heart-2024a1000fqm ""Dental Caries Could Be a Silent Threat to Your Heart"")

Dental caries are tied to a 40% higher stroke risk, underscoring the importance of oral health in preventing cardiovascular events.

*   Medscape News UK
*   14 hours ago

[Domestic Abuse: Recognition and Support](https://www.medscape.co.uk/viewarticle/supporting-people-affected-domestic-abuse-2024a1000dqo ""Domestic Abuse: Recognition and Support"")

Concise summary on recognising domestic abuse in primary care, including key questions to ask patients

*   Guidelines Summary: Primary Care
*   14 hours ago

[![Image 14: Parents' Technology Use May Shape Adolescents' Mental Health](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240828_distracted_parent_smartphone_girl_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/parents-technology-use-may-shape-adolescents-mental-health-2024a1000fqd ""Parents' Technology Use May Shape Adolescents' Mental Health"")

[Parents' Technology Use May Shape Adolescents' Mental Health](https://www.medscape.co.uk/s/viewarticle/parents-technology-use-may-shape-adolescents-mental-health-2024a1000fqd ""Parents' Technology Use May Shape Adolescents' Mental Health"")

Discussing digital technology use and mental health with parents and adolescents can be part of routine care visits, researchers said.

*   Medscape Medical News
*   17 hours ago

[![Image 15: NICE: Give People With Adrenal Insufficiency Emergency Kits](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240117_adrenal_glands_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/emergency-kits-recommended-adrenal-insufficiency-patients-2024a1000fpx ""NICE: Give People With Adrenal Insufficiency Emergency Kits"")

[NICE: Give People With Adrenal Insufficiency Emergency Kits](https://www.medscape.co.uk/viewarticle/emergency-kits-recommended-adrenal-insufficiency-patients-2024a1000fpx ""NICE: Give People With Adrenal Insufficiency Emergency Kits"")

People with adrenal insufficiency should be given emergency kits to help avoid hospital admission, said NICE in its new clinical guideline.

*   Medscape News UK
*   28 Aug 2024

[![Image 16: NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240828_cancer_patient_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/nice-oks-lonsurf-bevacizumab-advanced-bowel-cancer-2024a1000fpu ""NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer"")

[NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer](https://www.medscape.co.uk/viewarticle/nice-oks-lonsurf-bevacizumab-advanced-bowel-cancer-2024a1000fpu ""NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer"")

Around 1300 people in England will be eligible every year for the new combination treatment.

*   Medscape News UK
*   28 Aug 2024

[![Image 17: Kidney Donor Mortality Plummets Over 30 Years](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/dt_240827_donor_kidney_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/kidney-donor-mortality-plummets-over-30-years-2024a1000fop ""Kidney Donor Mortality Plummets Over 30 Years"")

[Kidney Donor Mortality Plummets Over 30 Years](https://www.medscape.co.uk/s/viewarticle/kidney-donor-mortality-plummets-over-30-years-2024a1000fop ""Kidney Donor Mortality Plummets Over 30 Years"")

The risk for perioperative mortality in living kidney donors has significantly reduced in the past decade, a study showed.

*   Medscape Medical News
*   28 Aug 2024

[![Image 18: A New Exercise 'Evolution' for Stroke Survivors: Go Harder](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240827_senior_stepper_exercise_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/new-exercise-evolution-stroke-survivors-go-harder-2024a1000fp7 ""A New Exercise 'Evolution' for Stroke Survivors: Go Harder"")

[A New Exercise 'Evolution' for Stroke Survivors: Go Harder](https://www.medscape.co.uk/s/viewarticle/new-exercise-evolution-stroke-survivors-go-harder-2024a1000fp7 ""A New Exercise 'Evolution' for Stroke Survivors: Go Harder"")

A recent study has built on emerging evidence that intense training can be safe and beneficial for patients recovering from stroke.

*   Medscape Medical News
*   28 Aug 2024

[![Image 19: Continuous Glucose Monitor Benefits All Ages With Diabetes](https://img.medscapestatic.com/vim/live/professional_assets/ht_181001_freestyle_libre_glucose_monitor_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/continuous-glucose-monitor-benefits-all-ages-diabetes-2024a1000fhy ""Continuous Glucose Monitor Benefits All Ages With Diabetes"")

[Continuous Glucose Monitor Benefits All Ages With Diabetes](https://www.medscape.co.uk/viewarticle/continuous-glucose-monitor-benefits-all-ages-diabetes-2024a1000fhy ""Continuous Glucose Monitor Benefits All Ages With Diabetes"")

Intermittently scanned continuous glucose monitoring improved glycaemic outcomes in those older and younger than 65 years, but the older group may need individualised targets.

*   Medscape News UK
*   28 Aug 2024

[![Image 20: Hot Flashes, Night Sweats Linked to Menopausal Heart Disease](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/is_210928_hot_flashes_menopause_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/hot-flashes-night-sweats-linked-subclinical-heart-disease-2024a1000fl0 ""Hot Flashes, Night Sweats Linked to Menopausal Heart Disease"")

[Hot Flashes, Night Sweats Linked to Menopausal Heart Disease](https://www.medscape.co.uk/viewarticle/hot-flashes-night-sweats-linked-subclinical-heart-disease-2024a1000fl0 ""Hot Flashes, Night Sweats Linked to Menopausal Heart Disease"")

Early onset and long duration were associated with particularly high risk.

*   Medscape News UK
*   28 Aug 2024

[![Image 21: UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/dt_220707_drug_pharmaceutical_clinical_trial_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/uk-set-open-18-new-clinical-trial-hubs-400m-investment-2024a1000fp5 ""UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment"")

[UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment](https://www.medscape.co.uk/s/viewarticle/uk-set-open-18-new-clinical-trial-hubs-400m-investment-2024a1000fp5 ""UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment"")

Wes Streeting called the investment a major boost for the UK, transforming it into a health research hub and supporting a future-ready NHS.

*   Press Association
*   28 Aug 2024

[![Image 22: Measuring Expectations: Real-World Survival With Osimertinib](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_211029_doctor_patient_notes_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/measuring-expectations-real-world-survival-osimertinib-2024a1000fok ""Measuring Expectations: Real-World Survival With Osimertinib"")

[Measuring Expectations: Real-World Survival With Osimertinib](https://www.medscape.co.uk/s/viewarticle/measuring-expectations-real-world-survival-osimertinib-2024a1000fok ""Measuring Expectations: Real-World Survival With Osimertinib"")

In a real-world population of patients with EGFR-mutant advanced lung cancer, overall survival was much worse in patients who would not have been eligible for the pivotal FLAURA trial.

*   Medscape Medical News
*   28 Aug 2024

![Image 23](blob:https://www.medscape.co.uk/6742166de2ffdc98a2fc8b83a0aa235b)

[](https://www.medscape.co.uk/)

#### Find Us On

[](https://www.facebook.com/GuidelinesMedscape/)[](https://twitter.com/medscapeuk)[](http://www.linkedin.com/company/24356)[](https://www.youtube.com/user/medscape/)[](https://www.instagram.com/medscape/)

#### About

[About Medscape](https://www.medscape.com/public/about)[Privacy Policy](https://www.medscape.co.uk/public/privacy)[Editorial Policy](https://www.medscape.com/public/editorialpolicies)[Cookies](https://www.medscape.co.uk/public/cookies) [Manage Preferences](javascript:void\(0\);) [Terms of Use](https://www.medscape.com/public/termsofuse)[UK Modern Slavery Statement](https://www.medscape.co.uk/public/antislavery)[Advertising Policy](https://www.medscape.com/public/adpolicy)[Help Center](https://help.medscape.com/hc/en-us)

#### App

[Medscape](https://www.medscape.com/public/medscapeapp?pid=Medscape_footer&c=FooterIcon)

All material on this website is protected by copyright, Copyright ¬© 1994-2024 by WebMD LLC. This website also contains material copyrighted by 3rd parties.

           

![Image 24](https://t.co/i/adsct?bci=3&eci=2&event_id=d401ed83-6608-48b8-ba03-423369131b33&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=fdf0cbc3-bc98-4409-81c6-120b382ba783&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Frecurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o5zto&type=javascript&version=2.3.30)![Image 25](https://analytics.twitter.com/i/adsct?bci=3&eci=2&event_id=d401ed83-6608-48b8-ba03-423369131b33&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=fdf0cbc3-bc98-4409-81c6-120b382ba783&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Frecurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o5zto&type=javascript&version=2.3.30)![Image 26](https://t.co/i/adsct?bci=3&eci=2&event_id=56a032fb-e93d-48fc-aa1f-3f69fe731bbf&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=fdf0cbc3-bc98-4409-81c6-120b382ba783&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Frecurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=nvb1e&type=javascript&version=2.3.30)![Image 27](https://analytics.twitter.com/i/adsct?bci=3&eci=2&event_id=56a032fb-e93d-48fc-aa1f-3f69fe731bbf&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=fdf0cbc3-bc98-4409-81c6-120b382ba783&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Frecurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=nvb1e&type=javascript&version=2.3.30)![Image 28](https://t.co/i/adsct?bci=3&eci=2&event_id=6bebb4a3-ccc6-4275-b952-904452f82635&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=fdf0cbc3-bc98-4409-81c6-120b382ba783&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Frecurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o5ztw&type=javascript&version=2.3.30)![Image 29](https://analytics.twitter.com/i/adsct?bci=3&eci=2&event_id=6bebb4a3-ccc6-4275-b952-904452f82635&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=fdf0cbc3-bc98-4409-81c6-120b382ba783&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Frecurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o5ztw&type=javascript&version=2.3.30)

![Image 30](https://thrtle.com/insync?vxii_pid=10015&vxii_pdid=)

![Image 31](https://bh-eu.contextweb.com/bh/sr?action=add&token=Q4S7ZMWDWRFR&ch=1&url=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Frecurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni&rr=&us_privacy=&param1=$$event$$&epid=&did=56374735909723794442144455432012496938&pf=0&usp=0&auth_channel=100&ev_id=0&topicid=$$topicid$$&conceptid=$$conceptid$$&ssp=34&gdpr_consent=&val=$$val$$&val=${val})![Image 32](https://bh.contextweb.com/bh/rtset?pid=562507&ev=0&us_privacy=)![Image 33](https://bh.contextweb.com/bh/rtset?pid=561967&ev=1&us_privacy=&gdpr=0&gdpr_consent=&rurl=https%3A%2F%2Fdsum.casalemedia.com%2Frum%3Fcm_dsp_id%3D189%26external_user_id%3D%25%25VGUID%25%25%26expiration%3D[EXPIRATION]%26us_privacy%3D%24%24us_privacy%24%24%26gdpr%3D%24%24gdpr%24%24%26gdpr_consent%3D%24%24gdpr_consent%24%24)![Image 34](https://bh.contextweb.com/bh/rtset?pid=561590&ev=1&us_privacy=&gdpr=0&gdpr_consent=&rurl=https%3A%2F%2Fpixel.rubiconproject.com%2Ftap.php%3Fv%3D390200%26nid%3D5120%26put%3D%25%25VGUID%25%25%26us_privacy%3D%24%24us_privacy%24%24%26gdpr%3D%24%24gdpr%24%24%26gdpr_consent%3D%24%24gdpr_consent%24%24)![Image 35](https://bh.contextweb.com/bh/rtset?pid=558356&ev=1&us_privacy=&gdpr=0&gdpr_consent=&rurl=https%3A%2F%2Feb2.3lift.com%2Fxuid%3Fmid%3D2636%26xuid%3D%25%25VGUID%25%25%26dongle%3D8bee%26us_privacy%3D%24%24us_privacy%24%24%26gdpr%3D%24%24gdpr%24%24%26gdpr_consent%3D%24%24gdpr_consent%24%24)
"
2024-08-29 08:52:56,2024-08-29 23:20:34,"üåü **Exciting Insights into Psychedelics and Mental Health!** üåü  
Have you ever wondered about the potential of psychedelics in treating depression? A recent meta-analysis has revealed that high-dose psilocybin can provide greater relief from depressive symptoms compared to traditional treatments like escitalopram. With promising outcomes and no significant risk for severe adverse events, this research opens up a fascinating new avenue for mental health treatment.

üîç **Key Findings at a Glance:**  
- **Higher Efficacy:** High-dose psilocybin (‚â• 20 mg) was found to have a more significant impact on depression than placebo and performed better than lower doses of escitalopram.
- **Safety Profile:** Importantly, the analysis found no increased risk of severe side effects, making psilocybin a compelling option worth exploring.
- **Comparative Effectiveness:** The results suggest that high-dose psilocybin may reach the same efficacy milestones as current antidepressants, indicating it could become a strong contender in depression treatment.

üí° **Practical Applications:**  
For mental health professionals and researchers, these findings could reshape treatment protocols and encourage further studies into the use of psychedelics in psychiatric care. Imagine integrating high-dose psilocybin therapy alongside conventional practices‚Äîthis could enhance patient outcomes significantly.

üå± What are your thoughts on the use of psychedelics in treating mental health conditions? Could this be the future of depression treatment?  
Let‚Äôs discuss in the comments!  

#Psilocybin #MentalHealth #DepressionTreatment #PsychedelicsResearch #FutureOfMedicine  

Source: [Medscape](https://www.medscape.com/viewarticle/high-dose-psilocybin-shows-promising-results-depression-2024a1000fqw)",https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_220215_psilocybin_mushrooms_800x450.jpg,https://www.medscape.com/viewarticle/high-dose-psilocybin-shows-promising-results-depression-2024a1000fqw,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Thumbnail image URL: https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_220215_psilocybin_mushrooms_800x450.jpg 

Title: High-Dose Psilocybin Shows Promising Results for Depression

URL Source: https://www.medscape.com/viewarticle/high-dose-psilocybin-shows-promising-results-depression-2024a1000fqw

Published Time: 2024-08-29

Markdown Content:
**TOPLINE:**
------------

High-dose psilocybin is associated with greater relief from depressive symptoms than placebo or [escitalopram](https://reference.medscape.com/drug/lexapro-escitalopram-342961), with no increased risk for severe adverse events, a new meta-analysis suggests.

**METHODOLOGY:**
----------------

*   Researchers conducted a network meta-analysis to evaluate the comparative effectiveness of oral monotherapy with psychedelics vs escitalopram in patients with clinically diagnosed [depression](https://emedicine.medscape.com/article/286759-overview).
*   The meta-analysis included 811 participants (mean age, 42.49 years; 54.2% women) with clinically diagnosed depression across 15 psychedelic trials and 1968 participants (mean age, 39.35 years; 62.5% women) across five escitalopram trials.
*   Trials evaluated oral monotherapy with psychedelics (psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine \[MDMA\], and ayahuasca), fixed-dose escitalopram (up to 20 mg/d) vs placebo, and psychedelic vs escitalopram monotherapy.
*   The primary outcome was a change in depressive symptoms from baseline.

**TAKEAWAY:**
-------------

*   Placebo responses in antidepressant trials (mean difference, 3.79; 95% CI, 0.77-6.80) and extremely low-dose psilocybin (mean difference, 3.96; 95% CI, 0.61-7.17) were better than those in psychedelic trials.
*   High-dose psilocybin (‚â• 20 mg) performed better than placebo in the antidepressant trials (mean difference, > 3). However, when comparing high-dose psilocybin with the placebo used in antidepressant trials, the effect size was smaller. The standardized mean difference dropped from 0.88 to 0.31, indicating that the effect of high-dose psilocybin was similar to that of current antidepressants.
*   High-dose psilocybin was associated with a greater response than escitalopram at 10 mg (4.66; 95% CI, 1.36-7.74) and 20 mg (4.69; 95% CI, 1.64-7.54).
*   No interventions were associated with an increased risk for all-cause discontinuation or severe adverse events.

**IN PRACTICE:**
----------------

""Taken together, our study findings suggest that among psychedelic treatments, high-dose psilocybin is more likely to reach the minimal important difference for depressive symptoms in studies with adequate blinding design, while the effect size of psilocybin was similar to that of current antidepressant drugs, showing a mean standardized mean difference of 0.3,"" the authors wrote.

**SOURCE:**
-----------

The study was led by Tien-Wei Hsu, MD, I-Shou University and Kaohsiung Medical University, Kaohsiung City, Taiwan. It was [published online](https://www.bmj.com/content/386/bmj-2023-078607) on August 21 in _The¬†BMJ_.

**LIMITATIONS:**
----------------

The study did not assess long-term effects of the interventions. Participants in the MDMA trials were primarily diagnosed with posttraumatic stress disorder, which may not be representative of the general population with depressive symptoms. Moreover, the sample size of the psychedelic trials was small. Using extremely low-dose psychedelics as a reference group may have eliminated some pharmacologic effects as these doses cannot be considered a placebo.

**DISCLOSURES:**
----------------

The study was supported by grants from the National Science and Technology Council. The authors declared no financial relationships with any organizations outside the submitted work in the past 3 years. Full disclosures are available in the original article.

_This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication._
"
2024-08-29 05:46:22,2024-08-29 23:20:43,"üåü **Navigating a Crisis in Healthcare: The Alarming Suicide Rates Among Female Doctors** üåü  
  
Have you ever considered the toll that the medical profession can take on mental health, particularly for women? A recent article from Medscape highlights a critical issue: female doctors are facing a staggering **76% higher risk of suicide compared to the general population**. This is a silent crisis that calls for urgent attention within our healthcare communities.  
  
**Key Insights from the Research:**  
- The systematic review analyzed data from 39 studies, revealing a persistent gender disparity in suicide rates. While male doctors showed similar risk levels to the general population, female physicians faced significantly greater risks.  
- Contributing factors include systemic issues such as work culture, burnout, and inadequate support. Clare Gerada and colleagues emphasize the need for healthier work-life balance and addressing emotional needs in healthcare settings.  
  
**What Does This Mean for Us?**  
As healthcare professionals, it's crucial we advocate for systemic changes that foster a supportive environment for all physicians. For instance, we can push for policies that prioritize mental health resources, mentorship programs for women in medicine, and promoting a culture where seeking help is normalized rather than stigmatized.  
  
This is not just a statistic‚Äîit's a call to action. We can all play a role in supporting our colleagues and initiating conversations around mental health.  
  
How can we better support each other in the workplace? Share your thoughts and experiences below!  
  
#MentalHealth #HealthcareProfessionals #FemaleDoctors #SuicidePrevention #WorkplaceWellness  
  
[Read the full article here!](https://www.medscape.co.uk/viewarticle/female-doctors-suicide-rates-alarmingly-higher-vs-general-2024a1000fqs)  

![Female Doctors' Suicide Rates](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240329_surgeon_sad_800x450.jpg)",https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240329_surgeon_sad_800x450.jpg,https://www.medscape.co.uk/viewarticle/female-doctors-suicide-rates-alarmingly-higher-vs-general-2024a1000fqs,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Thumbnail image URL: https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240329_surgeon_sad_800x450.jpg 

Title: Female Doctors' Suicide Rates Alarmingly Higher vs General Folks

URL Source: https://www.medscape.co.uk/viewarticle/female-doctors-suicide-rates-alarmingly-higher-vs-general-2024a1000fqs

Published Time: 2024-08-29T05:46:22-04:00

Markdown Content:
Female Doctors' Suicide Rates Alarmingly Higher vs General Folks
===============
                                      

This site is intended for UK healthcare professionals

[![Image 1: Medscape UK Univadis Logo](https://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/medscape-uk-logo.4a9c814f.svg)](https://www.medscape.co.uk/)

*   Recent Searches [Clear](https://www.medscape.co.uk/viewarticle/female-doctors-suicide-rates-alarmingly-higher-vs-general-2024a1000fqs#)

[![Image 2: Medscape UK Univadis Logo](https://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/medscape-uk-logo.4a9c814f.svg)](https://www.medscape.co.uk/)

*   Recent Searches [Clear](https://www.medscape.co.uk/viewarticle/female-doctors-suicide-rates-alarmingly-higher-vs-general-2024a1000fqs#)

*   Recent Searches [Clear](https://www.medscape.co.uk/viewarticle/female-doctors-suicide-rates-alarmingly-higher-vs-general-2024a1000fqs#)

*   Menu
*   News
    
*   Guidelines
    
*   Drugs
    
*   Quizzes
    
*   Search

Clinical Summary

Female Doctors' Suicide Rates Alarmingly Higher vs General Folks
================================================================

Edited by Drishti Agarwal

[](https://www.medscape.co.uk/viewarticle/female-doctors-suicide-rates-alarmingly-higher-vs-general-2024a1000fqs#)

**TOPLINE:**
------------

Female doctors face a 76% higher risk for suicide compared with the general population, whereas the male doctors' suicide risk remains similar to that of the public.

**METHODOLOGY:**
----------------

*   Researchers conducted a systematic review and meta-analysis of 39 observational studies with age-standardised mortality ratios for physician deaths compared with the general population.
*   A total of 3303 suicides among male physicians and 587 among female physicians were analysed, with observation periods ranging from 1935 to 2020.
*   Data extraction and risk for bias assessment were performed by two independent reviewers using a standardised table and the Joanna Briggs Institute checklist.

**TAKEAWAY:**
-------------

*   The suicide rate ratio for female physicians compared with the general population was significantly higher at 1.76 (95% CI, 1.40-2.21), indicating a persistent gender disparity.
*   For male physicians, the suicide rate ratio across all studies was 1.05 (95% CI, 0.90-1.22).
*   The suicide rate ratio for male physicians compared with other professions was 1.81 (95% CI, 1.55-2.12).
*   Meta-regression revealed a significant effect of the midpoint of the study observation period, indicating decreasing effect sizes over time.

**IN PRACTICE:**
----------------

The analyses ""highlight an ongoing need to reduce mental distress and suicide risk among doctors, particularly women. This means addressing longstanding systemic issues that create distress, such as poor work and regulatory cultures that name, blame, and shame people when mistakes or complaints occur rather than looking to correct the broader system,"" Clare Gerada, MBE, and colleagues explain in an [accompanying editorial](https://www.bmj.com/content/386/bmj.q1758). ""It means adopting working schedules that allow doctors a sensible work‚Äìlife balance and paying attention to the basic emotional and psychological needs of all staff,"" they added.

**SOURCE:**
-----------

The study was led by Claudia Zimmermann, PhD, Medical University of Vienna in Vienna, Austria. It was [published online](https://www.bmj.com/content/386/bmj-2023-078964) on June 21, 2024, in _BMJ_.

**LIMITATIONS:**
----------------

The findings of this meta-analysis are limited by a scarcity of studies from regions outside of Europe, the United States, and Australasia. The high level of heterogeneity across studies suggests that suicide risk varies among different physician populations, which may limit the generalisability of the results. Additionally, underreporting of suicide deaths might be more common for physicians compared with the general population, influencing the ratios between these two populations.  
  
**DISCLOSURES:**

This study was partially supported by the Vienna Anniversary Foundation for Higher Education. No other financial relationships with any organisations that might have an interest in the submitted work were disclosed.

_This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication._

Register Today

Already a member? Log in

EDITOR'S RECOMMENDATIONS
------------------------

*   ![Image 3: related](https://img.medscapestatic.com/pi/global/1x1.png)
    
    [Primary Care Docs Track Average of 57 (!) Quality Measures](https://www.medscape.co.uk/s/viewarticle/primary-care-physicians-track-average-57-quality-measures-2024a1000fqu)
    
    Medicare tracked the most metrics tied to payment, while Medicaid tracked the least, according to a new JAMA Health Forum analysis.
    
*   ![Image 4: related](https://img.medscapestatic.com/pi/global/1x1.png)
    
    [Parents' Technology Use May Shape Adolescents' Mental Health](https://www.medscape.co.uk/s/viewarticle/parents-technology-use-may-shape-adolescents-mental-health-2024a1000fqd)
    
    Discussing digital technology use and mental health with parents and adolescents can be part of routine care visits, researchers said.
    
*   ![Image 5: related](https://img.medscapestatic.com/pi/global/1x1.png)
    
    [Restless Nights? Here's How to Help Your Patients](https://www.medscape.co.uk/viewarticle/restless-nights-heres-how-help-your-patients-2024a1000fm8)
    
    Despite being the gold standard, cognitive behavioural therapy for insomnia is underutilised.
    

YOU MAY ALSO LIKE
-----------------

[](https://www.medscape.co.uk/s/viewarticle/breast-cancer-drug-may-slow-aggressive-brain-tumour-kids-2024a1000fra ""Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids"")

[Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids](https://www.medscape.co.uk/s/viewarticle/breast-cancer-drug-may-slow-aggressive-brain-tumour-kids-2024a1000fra ""Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids"")

Ribociclib, commonly used for breast cancer, has been found to stabilise a subtype of diffuse hemispheric glioma for about 17 months before regrowth begins.

*   Press Association
*   8 hours ago

[](https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu ""Alternate Insomnia Therapy Has Good Showing"")

[Alternate Insomnia Therapy Has Good Showing](https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu ""Alternate Insomnia Therapy Has Good Showing"")

The brief nurse-delivered therapy aimed at restricting and standardising time in bed could make treatment more accessible to primary care patients.

*   Medscape News UK
*   9 hours ago

[](https://www.medscape.co.uk/s/viewarticle/listeriosis-during-pregnancy-can-be-fatal-fetus-2024a1000frm ""Listeriosis During Pregnancy Can Be Fatal for the Fetus"")

[Listeriosis During Pregnancy Can Be Fatal for the Fetus](https://www.medscape.co.uk/s/viewarticle/listeriosis-during-pregnancy-can-be-fatal-fetus-2024a1000frm ""Listeriosis During Pregnancy Can Be Fatal for the Fetus"")

The rate of fetal loss or neonatal death from invasive listeriosis is 29%.

*   Medscape Medical News
*   9 hours ago

[](https://www.medscape.co.uk/viewarticle/prisons-often-waste-ambulance-crew-time-2024a1000fqp ""Prisons Often Waste Ambulance Crew Time"")

[Prisons Often Waste Ambulance Crew Time](https://www.medscape.co.uk/viewarticle/prisons-often-waste-ambulance-crew-time-2024a1000fqp ""Prisons Often Waste Ambulance Crew Time"")

Unnecessary 999 calls are being made by prison staff due to lack of experience and concerns over legal repercussions.

*   Medscape News UK
*   9 hours ago

[](https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni ""Recurrent UTI: Undercultured, Overtreated Despite Resistance"")

[Recurrent UTI: Undercultured, Overtreated Despite Resistance](https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni ""Recurrent UTI: Undercultured, Overtreated Despite Resistance"")

Roughly 40% of general practitioners do not culture recurrent UTIs and instead, just treat.

*   Medscape News UK
*   10 hours ago

[](https://www.medscape.co.uk/s/viewarticle/high-dose-psilocybin-shows-promising-results-depression-2024a1000fqw ""High-Dose Psilocybin Shows Promising Results for Depression"")

[High-Dose Psilocybin Shows Promising Results for Depression](https://www.medscape.co.uk/s/viewarticle/high-dose-psilocybin-shows-promising-results-depression-2024a1000fqw ""High-Dose Psilocybin Shows Promising Results for Depression"")

A meta-analysis found that high-dose psilocybin for depressive symptoms showed better responses than placebo or escitalopram in antidepressant trials.

*   Medscape Medical News
*   10 hours ago

[](https://www.medscape.co.uk/s/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn ""Men, Women, & Exercise: Metabolism Differs at Starting Line"")

[Men, Women, & Exercise: Metabolism Differs at Starting Line](https://www.medscape.co.uk/s/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn ""Men, Women, & Exercise: Metabolism Differs at Starting Line"")

The muscles of sedentary men and women with overweight and obesity differ in burning sugar and fatty acids at the start of an exercise program but draw even after training, multi-omics data show.

*   Medscape Medical News
*   14 hours ago

[](https://www.medscape.co.uk/viewarticle/dental-caries-could-be-silent-threat-your-heart-2024a1000fqm ""Dental Caries Could Be a Silent Threat to Your Heart"")

[Dental Caries Could Be a Silent Threat to Your Heart](https://www.medscape.co.uk/viewarticle/dental-caries-could-be-silent-threat-your-heart-2024a1000fqm ""Dental Caries Could Be a Silent Threat to Your Heart"")

Dental caries are tied to a 40% higher stroke risk, underscoring the importance of oral health in preventing cardiovascular events.

*   Medscape News UK
*   14 hours ago

[Domestic Abuse: Recognition and Support](https://www.medscape.co.uk/viewarticle/supporting-people-affected-domestic-abuse-2024a1000dqo ""Domestic Abuse: Recognition and Support"")

Concise summary on recognising domestic abuse in primary care, including key questions to ask patients

*   Guidelines Summary: Primary Care
*   15 hours ago

[](https://www.medscape.co.uk/viewarticle/emergency-kits-recommended-adrenal-insufficiency-patients-2024a1000fpx ""NICE: Give People With Adrenal Insufficiency Emergency Kits"")

[NICE: Give People With Adrenal Insufficiency Emergency Kits](https://www.medscape.co.uk/viewarticle/emergency-kits-recommended-adrenal-insufficiency-patients-2024a1000fpx ""NICE: Give People With Adrenal Insufficiency Emergency Kits"")

People with adrenal insufficiency should be given emergency kits to help avoid hospital admission, said NICE in its new clinical guideline.

*   Medscape News UK
*   28 Aug 2024

[](https://www.medscape.co.uk/viewarticle/nice-oks-lonsurf-bevacizumab-advanced-bowel-cancer-2024a1000fpu ""NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer"")

[NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer](https://www.medscape.co.uk/viewarticle/nice-oks-lonsurf-bevacizumab-advanced-bowel-cancer-2024a1000fpu ""NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer"")

Around 1300 people in England will be eligible every year for the new combination treatment.

*   Medscape News UK
*   28 Aug 2024

[](https://www.medscape.co.uk/s/viewarticle/kidney-donor-mortality-plummets-over-30-years-2024a1000fop ""Kidney Donor Mortality Plummets Over 30 Years"")

[Kidney Donor Mortality Plummets Over 30 Years](https://www.medscape.co.uk/s/viewarticle/kidney-donor-mortality-plummets-over-30-years-2024a1000fop ""Kidney Donor Mortality Plummets Over 30 Years"")

The risk for perioperative mortality in living kidney donors has significantly reduced in the past decade, a study showed.

*   Medscape Medical News
*   28 Aug 2024

[](https://www.medscape.co.uk/s/viewarticle/new-exercise-evolution-stroke-survivors-go-harder-2024a1000fp7 ""A New Exercise 'Evolution' for Stroke Survivors: Go Harder"")

[A New Exercise 'Evolution' for Stroke Survivors: Go Harder](https://www.medscape.co.uk/s/viewarticle/new-exercise-evolution-stroke-survivors-go-harder-2024a1000fp7 ""A New Exercise 'Evolution' for Stroke Survivors: Go Harder"")

A recent study has built on emerging evidence that intense training can be safe and beneficial for patients recovering from stroke.

*   Medscape Medical News
*   28 Aug 2024

[](https://www.medscape.co.uk/viewarticle/continuous-glucose-monitor-benefits-all-ages-diabetes-2024a1000fhy ""Continuous Glucose Monitor Benefits All Ages With Diabetes"")

[Continuous Glucose Monitor Benefits All Ages With Diabetes](https://www.medscape.co.uk/viewarticle/continuous-glucose-monitor-benefits-all-ages-diabetes-2024a1000fhy ""Continuous Glucose Monitor Benefits All Ages With Diabetes"")

Intermittently scanned continuous glucose monitoring improved glycaemic outcomes in those older and younger than 65 years, but the older group may need individualised targets.

*   Medscape News UK
*   28 Aug 2024

[](https://www.medscape.co.uk/viewarticle/hot-flashes-night-sweats-linked-subclinical-heart-disease-2024a1000fl0 ""Hot Flashes, Night Sweats Linked to Menopausal Heart Disease"")

[Hot Flashes, Night Sweats Linked to Menopausal Heart Disease](https://www.medscape.co.uk/viewarticle/hot-flashes-night-sweats-linked-subclinical-heart-disease-2024a1000fl0 ""Hot Flashes, Night Sweats Linked to Menopausal Heart Disease"")

Early onset and long duration were associated with particularly high risk.

*   Medscape News UK
*   28 Aug 2024

[](https://www.medscape.co.uk/s/viewarticle/uk-set-open-18-new-clinical-trial-hubs-400m-investment-2024a1000fp5 ""UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment"")

[UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment](https://www.medscape.co.uk/s/viewarticle/uk-set-open-18-new-clinical-trial-hubs-400m-investment-2024a1000fp5 ""UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment"")

Wes Streeting called the investment a major boost for the UK, transforming it into a health research hub and supporting a future-ready NHS.

*   Press Association
*   28 Aug 2024

[](https://www.medscape.co.uk/s/viewarticle/measuring-expectations-real-world-survival-osimertinib-2024a1000fok ""Measuring Expectations: Real-World Survival With Osimertinib"")

[Measuring Expectations: Real-World Survival With Osimertinib](https://www.medscape.co.uk/s/viewarticle/measuring-expectations-real-world-survival-osimertinib-2024a1000fok ""Measuring Expectations: Real-World Survival With Osimertinib"")

In a real-world population of patients with EGFR-mutant advanced lung cancer, overall survival was much worse in patients who would not have been eligible for the pivotal FLAURA trial.

*   Medscape Medical News
*   28 Aug 2024

![Image 6](blob:https://www.medscape.co.uk/6742166de2ffdc98a2fc8b83a0aa235b)
"
2024-08-29 04:25:13,2024-08-29 23:21:13,"üåü **Are You Aware That Men and Women Metabolize Differently During Exercise?**  
A recent article highlights fascinating findings on how metabolic processes in men and women differ when embarking on an exercise regimen. 

üîç **Key Insights:**  
The study found that sedentary men and women with overweight or obesity exhibit distinct metabolic responses. Initially, men demonstrated a higher abundance of proteins related to glycolysis‚Äîprocessing sugars‚Äîwhile women were more focused on fatty acid metabolism. However, interestingly, after 8 weeks of consistent training, these differences began to diminish. This indicates that regular exercise can promote similar metabolic benefits for both sexes, crucial for effective weight management and diabetes prevention. 

üí° **Practical Application:**  
What does this mean for us as professionals? For fitness trainers and health care providers, understanding these differences will guide personalized exercise plans. For instance, integrating tailored workouts that gradually balance strength and endurance may help both men and women optimize their metabolic responses over time, enhancing overall health outcomes. 

ü§î **Engaging Thought:**  
Have you noticed differences in how your clients respond to exercise based on gender? It would be great to hear your experiences! 

#Metabolism #ExerciseScience #HealthAndWellness #WomenInFitness #MenInFitness  
[Read the full article here](https://www.medscape.com/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn)",https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/dt_240828_man_woman_exercising_800x450.jpg,https://www.medscape.com/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Thumbnail image URL: https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/dt_240828_man_woman_exercising_800x450.jpg 

Title: Men, Women, & Exercise: Metabolism Differs at Starting Line

URL Source: https://www.medscape.com/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn

Published Time: 2024-08-29

Markdown Content:
Men, Women, & Exercise: Metabolism Differs at Starting Line
===============
                                            

This site is intended for healthcare professionals

![Image 1](https://img.medscapestatic.com/pi/global/header/langsel/icon-globe.svg)

English Edition

![Image 2: language edition](https://img.medscapestatic.com/pi/global/header/langsel/icon-down-stroke.svg)

![Image 3](https://www.medscape.com/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn)

*   English New ![Image 4](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
*   Fran√ßais New ![Image 5](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
*   Deutsch New ![Image 6](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
*   Portugu√™s New ![Image 7](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
*   Espa√±ol New ![Image 8](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
*   UK New ![Image 9](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)

![Image 10](https://www.medscape.com/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn)

*   Fran√ßais New ![Image 11](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
*   Italiano New ![Image 12](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)

[Register](https://www.medscape.com/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn#)[Log In](https://www.medscape.com/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn#)

![Image 13: search](https://img.wbmdstatic.com/medscape_static_vue/pages-medscape-viewarticle/client/img/search.956f0d9b.svg)

![Image 14: Medscape Logo](https://img.medscapestatic.com/pi/logos/mscp-logo.png)

Thursday, August 29, 2024

[FOR YOU](https://www.medscape.com/for-you)

[NEWS & PERSPECTIVE](https://www.medscape.com/)

[DRUGS & DISEASES](https://reference.medscape.com/)

[CME & EDUCATION](https://www.medscape.org/)

[Video](https://www.medscape.com/video)

[Decision Point](https://decisionpoint.medscape.com/)

Specialty:

TODAY ON MEDSCAPE ![Image 15](https://img.medscapestatic.com/pi/global/header/langsel/icon-down-stroke.svg)

*   [Allergy & Immunology](https://www.medscape.com/allergy-immunology)
*   [Anesthesiology](https://www.medscape.com/anesthesiology)
*   [Cardiology](https://www.medscape.com/cardiology)
*   [Critical Care](https://www.medscape.com/criticalcare)
*   [Dermatology](https://www.medscape.com/dermatology)
*   [Diabetes & Endocrinology](https://www.medscape.com/diabetes-endocrinology)
*   [Emergency Medicine](https://www.medscape.com/emergencymedicine)
*   [Family Medicine](https://www.medscape.com/familymedicine)
*   [Gastroenterology](https://www.medscape.com/gastroenterology)
*   [General Surgery](https://www.medscape.com/generalsurgery)
*   [Hematology - Oncology](https://www.medscape.com/oncology)
*   [HIV/AIDS](https://www.medscape.com/hiv)
*   [Hospital Medicine](https://www.medscape.com/hospitalmedicine)
*   [Infectious Diseases](https://www.medscape.com/infectiousdiseases)
*   [Internal Medicine](https://www.medscape.com/internalmedicine)
*   [Multispecialty](https://www.medscape.com/multispecialty)
*   [Nephrology](https://www.medscape.com/nephrology)
*   [Neurology](https://www.medscape.com/neurology)
*   [Ob/Gyn & Women's Health](https://www.medscape.com/womenshealth)
*   [Oncology](https://www.medscape.com/oncology)
*   [Ophthalmology](https://www.medscape.com/ophthalmology)
*   [Orthopedics](https://www.medscape.com/orthopedics)
*   [Pathology & Lab Medicine](https://www.medscape.com/pathology)
*   [Pediatrics](https://www.medscape.com/pediatrics)
*   [Plastic Surgery](https://www.medscape.com/plastic-surgery)
*   [Psychiatry](https://www.medscape.com/psychiatry)
*   [Public Health](https://www.medscape.com/publichealth)
*   [Pulmonary Medicine](https://www.medscape.com/pulmonarymedicine)
*   [Radiology](https://www.medscape.com/radiology)
*   [Rheumatology](https://www.medscape.com/rheumatology)
*   [Transplantation](https://www.medscape.com/transplantation)
*   [Urology](https://www.medscape.com/urology)
*   [Today on Medscape](https://www.medscape.com/today)
*   [Business of Medicine](https://www.medscape.com/businessmedicine)
*   [Medical Lifestyle](https://www.medscape.com/resource/medical-lifestyle)
*   [Science & Technology](https://www.medscape.com/resource/science-technology)
*   [Medical Students](https://www.medscape.com/medicalstudents)
*   [Nurses](https://www.medscape.com/nurses)
*   [Pharmacists](https://www.medscape.com/pharmacists)
*   [Residents](https://www.medscape.com/residents)

Edition:

ENGLISH ![Image 16: language edition](https://img.medscapestatic.com/pi/global/header/langsel/icon-down-stroke.svg)

![Image 17](https://www.medscape.com/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn)

*   English New
    
    ![Image 18](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
    
*   Fran√ßais New
    
    ![Image 19](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
    
*   Deutsch New
    
    ![Image 20](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
    
*   Portugu√™s New
    
    ![Image 21](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
    
*   Espa√±ol New
    
    ![Image 22](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
    
*   UK New
    
    ![Image 23](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
    

![Image 24](https://www.medscape.com/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn)

*   Fran√ßais New
    
    ![Image 25](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
    
*   Italiano New
    
    ![Image 26](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
    

[Log In](https://www.medscape.com/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn#)

[Sign Up It's Free!](https://www.medscape.com/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn#)

![Image 27: Medscape Logo](https://img.medscapestatic.com/pi/logos/mscp-logo.png)

[![Image 28](https://img.wbmdstatic.com/medscape_static_vue/pages-medscape-viewarticle/client/img/open.0f97a0c4.svg)](https://www.medscape.com/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn#)

[](https://www.medscape.com/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn#)

![Image 29](https://img.wbmdstatic.com/medscape_static_vue/pages-medscape-viewarticle/client/img/search.956f0d9b.svg)

[Medscape Medical News](https://www.medscape.com/index/list_11861_0)[Conference News](https://www.medscape.com/index/section_3094_0)[EASD 2024](https://www.medscape.com/viewcollection/37483)

Men, Women, & Exercise: Metabolism Differs at Starting Line
===========================================================

Edited by Manasi Talwadekar

August 29, 2024

0

0

**TOPLINE:**
------------

When starting a regular exercise program, the skeletal muscle of sedentary men and women with overweight and obesity differs in burning sugar and fatty acids, but regular training can lessen these differences and promote similar positive metabolic changes in both biological sexes.

**METHODOLOGY:**
----------------

*   By stimulating skeletal muscle, exercise can help prevent muscle loss associated with weight loss and improve insulin sensitivity and glucose control in type 2 diabetes, but biological sex-based differences have been reported for many measures.
*   This study of sedentary men and women evaluated the molecular differences in skeletal muscle in response to a training program.
*   Researchers collected muscle biopsies from 16 women and nine men with overweight or obesity (average age, 30 years) at three time points ‚Äî baseline, after the first exercise session, and after the last session at the end of training.
*   Training involved 1 hour of moderate to intense endurance exercise under supervision (30 minutes cycling on an ergometer and 30 minutes walking on a treadmill) thrice a week for 8 weeks.
*   The biopsies were profiled for patterns of three sets of omics data ‚Äî DNA methylation for insight into genes switched on and off (epigenomics), RNA molecules transcribed from genes (transcriptomics), and proteins (proteomics).

**TAKEAWAY:**
-------------

*   At baseline, sex-specific differences were observed most tellingly in 120 proteins and also in DNA methylation sites of 16,012 genes and in 1366 RNA transcripts.
*   Men displayed a higher abundance of glycolysis-related proteins and other fast-twitch fiber‚Äìtype proteins, which are involved in the processing of glucose, while women showed more proteins responsible for regulating fatty acid metabolism.
*   The response to the first exercise session differed between men and women, with the cellular stress response upregulated predominantly in men.
*   The 8-week exercise training mitigated these sex-specific differences in the skeletal muscle, leading to an upregulation of mitochondrial proteins responsible for substrate oxidation and ATP generation in both men and women.

**IN PRACTICE:**
----------------

""This is important because the increased capacity after exercise to use glucose and lipids for energy production is generally regarded as key to prevent type 2 diabetes,"" said the study leader Professor Cora Weigert from the University of T√ºbingen, T√ºbingen, Germany, in a news release from the meeting organizers. ""While initial response of skeletal muscles to exercise differs between females and males, repeated exercise appears to cancel out these differences and trigger beneficial metabolic changes in both sexes,"" she added.

**SOURCE:**
-----------

The study was led by Simon I. Dreher, PhD, Institute for Clinical Chemistry and Pathobiochemistry, Department for Diagnostic Laboratory Medicine, T√ºbingen, Germany. It was [published on August 15, 2024, as an early release](https://cattendee.abstractsonline.com/meeting/20620/presentation/2914) from the annual meeting of the European Association for the Study of Diabetes 2024, Madrid, September 9-13.

**LIMITATIONS:**
----------------

This abstract did not discuss any limitations.

**DISCLOSURES:**
----------------

The authors did not disclose any funding information. The authors declared no relevant conflicts of interest.

_This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication._

0

Credit  

Lead image: Lanaral/Dreamstime

Medscape Medical News ¬© 2024 WebMD, LLC  
Send comments and news tips to [news@medscape.net](mailto:news@medscape.net).

Cite this: Men, Women, & Exercise: Metabolism Differs at Starting Line - Medscape \- August 29, 2024.

###### TOP PICKS FOR YOU

Recommendations

What to Read Next on Medscape

[Special Coverage: **COVID-19**](https://www.medscape.com/resource/coronavirus)

*   [Latest](https://www.medscape.com/resource/coronavirus#rc-news)
*   [Perspective](https://www.medscape.com/resource/coronavirus#rc-perspective)
*   [Guidelines](https://www.medscape.com/resource/coronavirus#rc-guidelines)
*   [Drugs & Diseases](https://www.medscape.com/resource/coronavirus#rc-ref)
*   [Global Coverage](https://www.medscape.com/resource/coronavirus#rc-global)
*   [Additional Resources](https://www.medscape.com/resource/coronavirus#rc-additional)

Business of Medicine

*   [Reimagining Obesity Care for PCPs](https://www.medscape.com/viewarticle/reimagining-obesity-care-pcps-2024a1000cdv)
*   [ObesityWeek¬Æ 2022: What's Stopping Effective Treatment of Obesity?](https://www.medscape.com/viewarticle/983261)
*   [More Than Half of the World Will Be Overweight or Obese by 2035: Report](https://www.medscape.com/s/viewarticle/988986)

Recommended Reading

*   Diseases & Conditions[Obesity](https://emedicine.medscape.com/article/123702-overview)
*   Diseases & Conditions[Obesity in Children](https://emedicine.medscape.com/article/985333-overview)
*   Diseases & Conditions[Pediatric Obesity-Hypoventilation Syndrome](https://emedicine.medscape.com/article/1002703-overview)
*   Diseases & Conditions[Obesity, FTO, and Type 2 Diabetes](https://emedicine.medscape.com/article/1969692-overview)

Related Conditions & Procedures

*   [Obesity](https://emedicine.medscape.com/article/123702-overview)
*   [Obesity in Children](https://emedicine.medscape.com/article/985333-overview)
*   [Obesity and Pregnancy](https://emedicine.medscape.com/article/2500092-overview)
*   [Abdominal Incisions and Sutures in Gynecologic Oncological Surgery](https://emedicine.medscape.com/article/271349-overview)
*   [Obesity, FTO, and Type 2 Diabetes](https://emedicine.medscape.com/article/1969692-overview)
*   [Cardiovascular Disease Primary Prevention/Lifestyle Guidelines](https://emedicine.medscape.com/article/2500031-overview)

SLIDESHOW

*   [9 Causes of Discolored Urine](https://reference.medscape.com/slideshow/discolored-urine-6008332)

Expert Commentary

*   [Kids Whose Parents Have Obesity More Likely to Have Obesity](https://www.medscape.com/viewarticle/kids-whose-parents-have-obesity-more-likely-be-obese-2024a10004ji)
*   [Reimagining Obesity Care for PCPs](https://www.medscape.com/viewarticle/reimagining-obesity-care-pcps-2024a1000cdv)
*   [Bempedoic Acid Effective in Patients With Obesity](https://www.medscape.com/viewarticle/bempedoic-acid-effective-patients-obesity-2024a1000bnz)

¬†.

![Image 30](blob:https://www.medscape.com/6742166de2ffdc98a2fc8b83a0aa235b)
"
2024-08-28 11:00:00,2024-08-29 23:21:21,"üåü **Remarkable Progress in Kidney Donation!** üåü 

Have you ever wondered how advancements in medical practices influence the lives of kidney donors? A recent article on Medscape reveals a significant decrease in mortality rates among kidney donors over the past 30 years.  

Key highlights from the article include:  
1. **Improved Surgical Techniques:** With the evolution of laparoscopic methods, donor safety has substantially increased.  
2. **Enhanced Postoperative Care:** Advances in monitoring and recovery protocols have contributed to fewer complications post-surgery.  
3. **Increased Awareness and Support Systems:** Public campaigns have fostered a more informed donor community, leading to greater confidence in the transplant process.  

These findings are not just statistics but a testament to the hard work of healthcare professionals dedicated to improving donor safety. For practitioners in nephrology and transplant medicine, these advancements encourage a more proactive approach in informing potential donors about the risks and benefits, ultimately boosting donation rates while prioritizing safety.  

How do you think these advancements will shape the future of kidney donation? Share your thoughts!  

#KidneyDonation #TransplantMedicine #HealthcareAdvancements  

[Read the full article here!](https://www.medscape.com/viewarticle/kidney-donor-mortality-plummets-over-30-years-2024a1000fop)",https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/dt_240827_donor_kidney_800x450.jpg,https://www.medscape.com/viewarticle/kidney-donor-mortality-plummets-over-30-years-2024a1000fop,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Thumbnail image URL: https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/dt_240827_donor_kidney_800x450.jpg 

Title: Kidney Donor Mortality Plummets Over 30 Years

URL Source: https://www.medscape.com/viewarticle/kidney-donor-mortality-plummets-over-30-years-2024a1000fop

Published Time: 2024-08-28

Markdown Content:
Kidney Donor Mortality Plummets Over 30 Years
===============
                                             

This site is intended for healthcare professionals

![Image 1](https://img.medscapestatic.com/pi/global/header/langsel/icon-globe.svg)

English Edition

![Image 2: language edition](https://img.medscapestatic.com/pi/global/header/langsel/icon-down-stroke.svg)

![Image 3](https://www.medscape.com/viewarticle/kidney-donor-mortality-plummets-over-30-years-2024a1000fop)

*   English New ![Image 4](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
*   Fran√ßais New ![Image 5](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
*   Deutsch New ![Image 6](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
*   Portugu√™s New ![Image 7](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
*   Espa√±ol New ![Image 8](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
*   UK New ![Image 9](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)

![Image 10](https://www.medscape.com/viewarticle/kidney-donor-mortality-plummets-over-30-years-2024a1000fop)

*   Fran√ßais New ![Image 11](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
*   Italiano New ![Image 12](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)

[Register](https://www.medscape.com/viewarticle/kidney-donor-mortality-plummets-over-30-years-2024a1000fop#)[Log In](https://www.medscape.com/viewarticle/kidney-donor-mortality-plummets-over-30-years-2024a1000fop#)

![Image 13: search](https://img.wbmdstatic.com/medscape_static_vue/pages-medscape-viewarticle/client/img/search.956f0d9b.svg)

![Image 14: Medscape Logo](https://img.medscapestatic.com/pi/logos/mscp-logo.png)

Thursday, August 29, 2024

[FOR YOU](https://www.medscape.com/for-you)

[NEWS & PERSPECTIVE](https://www.medscape.com/)

[DRUGS & DISEASES](https://reference.medscape.com/)

[CME & EDUCATION](https://www.medscape.org/)

[Video](https://www.medscape.com/video)

[Decision Point](https://decisionpoint.medscape.com/)

Specialty:

TODAY ON MEDSCAPE ![Image 15](https://img.medscapestatic.com/pi/global/header/langsel/icon-down-stroke.svg)

*   [Allergy & Immunology](https://www.medscape.com/allergy-immunology)
*   [Anesthesiology](https://www.medscape.com/anesthesiology)
*   [Cardiology](https://www.medscape.com/cardiology)
*   [Critical Care](https://www.medscape.com/criticalcare)
*   [Dermatology](https://www.medscape.com/dermatology)
*   [Diabetes & Endocrinology](https://www.medscape.com/diabetes-endocrinology)
*   [Emergency Medicine](https://www.medscape.com/emergencymedicine)
*   [Family Medicine](https://www.medscape.com/familymedicine)
*   [Gastroenterology](https://www.medscape.com/gastroenterology)
*   [General Surgery](https://www.medscape.com/generalsurgery)
*   [Hematology - Oncology](https://www.medscape.com/oncology)
*   [HIV/AIDS](https://www.medscape.com/hiv)
*   [Hospital Medicine](https://www.medscape.com/hospitalmedicine)
*   [Infectious Diseases](https://www.medscape.com/infectiousdiseases)
*   [Internal Medicine](https://www.medscape.com/internalmedicine)
*   [Multispecialty](https://www.medscape.com/multispecialty)
*   [Nephrology](https://www.medscape.com/nephrology)
*   [Neurology](https://www.medscape.com/neurology)
*   [Ob/Gyn & Women's Health](https://www.medscape.com/womenshealth)
*   [Oncology](https://www.medscape.com/oncology)
*   [Ophthalmology](https://www.medscape.com/ophthalmology)
*   [Orthopedics](https://www.medscape.com/orthopedics)
*   [Pathology & Lab Medicine](https://www.medscape.com/pathology)
*   [Pediatrics](https://www.medscape.com/pediatrics)
*   [Plastic Surgery](https://www.medscape.com/plastic-surgery)
*   [Psychiatry](https://www.medscape.com/psychiatry)
*   [Public Health](https://www.medscape.com/publichealth)
*   [Pulmonary Medicine](https://www.medscape.com/pulmonarymedicine)
*   [Radiology](https://www.medscape.com/radiology)
*   [Rheumatology](https://www.medscape.com/rheumatology)
*   [Transplantation](https://www.medscape.com/transplantation)
*   [Urology](https://www.medscape.com/urology)
*   [Today on Medscape](https://www.medscape.com/today)
*   [Business of Medicine](https://www.medscape.com/businessmedicine)
*   [Medical Lifestyle](https://www.medscape.com/resource/medical-lifestyle)
*   [Science & Technology](https://www.medscape.com/resource/science-technology)
*   [Medical Students](https://www.medscape.com/medicalstudents)
*   [Nurses](https://www.medscape.com/nurses)
*   [Pharmacists](https://www.medscape.com/pharmacists)
*   [Residents](https://www.medscape.com/residents)

Edition:

ENGLISH ![Image 16: language edition](https://img.medscapestatic.com/pi/global/header/langsel/icon-down-stroke.svg)

![Image 17](https://www.medscape.com/viewarticle/kidney-donor-mortality-plummets-over-30-years-2024a1000fop)

*   English New
    
    ![Image 18](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
    
*   Fran√ßais New
    
    ![Image 19](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
    
*   Deutsch New
    
    ![Image 20](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
    
*   Portugu√™s New
    
    ![Image 21](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
    
*   Espa√±ol New
    
    ![Image 22](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
"
2024-08-28 09:00:00,2024-08-29 23:21:55,"üåü **How Continuous Glucose Monitoring is Transforming Diabetes Care for All Ages!** üåü  
Did you know that Continuous Glucose Monitors (CGMs) like the Freestyle Libre are making a significant impact on diabetes management across all age groups? A recent study showcased that CGM technology is not just beneficial for younger patients, but particularly extends its advantages to older adults as well.

‚úÖ **Key Takeaways from the Study:**  
1. Individuals using the Freestyle Libre saw improved glycaemic outcomes, with both younger and older groups achieving similar time-in-range (TIR) metrics of over 70%!  
2. Notably, while most younger adults (age ‚â§ 65) achieved the < 4% time below range (TBR) goal, nearly half of the elderly group faced challenges reaching stricter TBR targets of < 1%.  
3. The findings suggest that personalized targets may be necessary for older adults to maximize their glycaemic control.

üìà **Practical Applications:**  
In practice, these insights underline the importance of administering tailored treatment regimens that accommodate the specific needs of older patients. CGMs not only boost convenience but also encourage a proactive approach to managing diabetes, fostering independence in self-care.

What strategies are you currently using to support your patients with diabetes? Let's discuss how we can further enhance their care with innovative technologies!  

üëâ Check out the full article for more in-depth insights: [Continuous Glucose Monitor Benefits All Ages With Diabetes](https://www.medscape.co.uk/viewarticle/continuous-glucose-monitor-benefits-all-ages-diabetes-2024a1000fhy)  

#DiabetesCare #CGM #FreestyleLibre #HealthInnovation #PatientCare

![Freestyle Libre](https://img.medscapestatic.com/vim/live/professional_assets/ht_181001_freestyle_libre_glucose_monitor_800x450.jpg)  
",https://img.medscapestatic.com/vim/live/professional_assets/ht_181001_freestyle_libre_glucose_monitor_800x450.jpg,https://www.medscape.co.uk/viewarticle/continuous-glucose-monitor-benefits-all-ages-diabetes-2024a1000fhy,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Thumbnail image URL: https://img.medscapestatic.com/vim/live/professional_assets/ht_181001_freestyle_libre_glucose_monitor_800x450.jpg 

Title: Continuous Glucose Monitor Benefits All Ages With Diabetes

URL Source: https://www.medscape.co.uk/viewarticle/continuous-glucose-monitor-benefits-all-ages-diabetes-2024a1000fhy

Published Time: 2024-08-28T09:00:00-04:00

Markdown Content:
Continuous Glucose Monitor Benefits All Ages With Diabetes
===============
                                      

This site is intended for UK healthcare professionals

[![Image 1: Medscape UK Univadis Logo](https://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/medscape-uk-logo.4a9c814f.svg)](https://www.medscape.co.uk/)

*   Recent Searches [Clear](https://www.medscape.co.uk/viewarticle/continuous-glucose-monitor-benefits-all-ages-diabetes-2024a1000fhy#)

[![Image 2: Medscape UK Univadis Logo](https://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/medscape-uk-logo.4a9c814f.svg)](https://www.medscape.co.uk/)

*   Recent Searches [Clear](https://www.medscape.co.uk/viewarticle/continuous-glucose-monitor-benefits-all-ages-diabetes-2024a1000fhy#)

*   Recent Searches [Clear](https://www.medscape.co.uk/viewarticle/continuous-glucose-monitor-benefits-all-ages-diabetes-2024a1000fhy#)

*   Menu
*   News
    
*   Guidelines
    
*   Drugs
    
*   Quizzes
    
*   Search

Clinical Summary

Continuous Glucose Monitor Benefits All Ages With Diabetes
==========================================================

Miriam E. Tucker

[](https://www.medscape.co.uk/viewarticle/continuous-glucose-monitor-benefits-all-ages-diabetes-2024a1000fhy#)

TOPLINE:
--------

Use of the intermittently scanned continuous glucose monitor Freestyle Libre (FSL) was associated with improved glycaemic outcomes across all age groups. Individualised targets may be needed to improve time below range (TBR) in those older than 65 years.

METHODOLOGY:
------------

*   Examination of Libreview account data for 947 adults aged ‚â§ 65 years and 114 aged > 65 years with type 1 or [type 2 diabetes](https://emedicine.medscape.com/article/117853-overview) who had been using the FSL for > 6 months.

TAKEAWAY:
---------

*   In both groups, similar proportions of patients achieved the time in range ([TIR](https://www.medscape.com/viewarticle/914551)) target of > 70% (23.2% for ‚â§ 65 years vs 23.0% for < 65 years) and target of > 50% (63.0% vs 69.0% for ‚â§ 65 years and > 65 years, respectively).
*   But by age-specific targets, 23.2% of those aged ‚â§ 65 years achieved the age-specific TIR target of > 70% vs 69% of those aged > 65 years achieving the age-specific target of > 50% TIR.
*   The TBR target of < 4% was achieved by 70.1% of those aged ‚â§ 65 years vs 75.2% of those aged > 65 years, but among the older group, just 40.7% achieved the stricter TBR target of < 1%.
*   The time above range (TAR) goal of < 25% was achieved by 24.1% of the younger group and 24.3% of the older group, whereas the stricter < 10% TAR target was achieved in only 4.5% of the > 65 years group.

IN PRACTICE:¬†
-------------

""Non-invasive glucose monitoring has revolutionised the management of type 1 and type 2 diabetes offering greater convenience to patients and more importantly encouraging self-management and improving glycaemic outcomes. Our data show that these benefits are extended to all age groups, particularly in older adults and those with long-standing diabetes who are at greater risk for hypoglycaemia,"" the authors wrote. ""It should be noted that the other than the mean change in [HbA1c](https://emedicine.medscape.com/article/2049478-overview) post-FSL, the _p_ values do not hold statistical power and so there are limited conclusions to draw from these percentages. However, on a service evaluation level, it is a helpful insight as to where glycaemic control could be improved,"" they added.

SOURCE:
-------

The study was conducted by Carol Wong, of Birmingham Heartlands Hospital, University of Birmingham, UK, and colleagues. It was published [online](https://journals.sagepub.com/doi/10.1177/20420188241269133?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed) August 20, 2024, in _Therapeutic Advances in Endocrinology and Metabolism_.

LIMITATIONS:
------------

Possible missing data from electronic health records. Disruptions due to the COVID-19 pandemic. No controls without intermittently scanned continuous glucose monitor. No examination of the interaction between diabetes duration and TBR.

DISCLOSURES:¬†
-------------

The authors reported that there is no conflict of interest.

Register Today

Already a member? Log in

EDITOR'S RECOMMENDATIONS
------------------------

*   ![Image 3: related](https://img.medscapestatic.com/pi/global/1x1.png)
    
    [What Every Provider Needs to Know About Type 1 Diabetes](https://www.medscape.co.uk/s/viewarticle/what-every-provider-needs-know-about-type-1-diabetes-2024a1000f2f)
    
    A freelance journalist shares tips based on her experience living with type 1 diabetes, including how it differs from type 2 in ways that may be underappreciated in nonspecialist settings.
    
*   ![Image 4: related](https://img.medscapestatic.com/pi/global/1x1.png)
    
    [Are CGMs Banned in Olympics for Athletes Without Diabetes?](https://www.medscape.co.uk/s/viewarticle/are-cgms-banned-olympics-athletes-without-diabetes-2024a1000dvj)
    
*   [Diabetes, Pregnancy: Management](https://www.medscape.co.uk/viewarticle/management-diabetes-pregnancy-2024a1000cbd)
    
    Covers managing diabetes in all stages of pregnancy, and includes a useful provision of information checklist
    
    Scottish Intercollegiate Guidelines Network | New 17 July 2024
    

YOU MAY ALSO LIKE
-----------------

[](https://www.medscape.co.uk/s/viewarticle/breast-cancer-drug-may-slow-aggressive-brain-tumour-kids-2024a1000fra ""Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids"")

[Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids](https://www.medscape.co.uk/s/viewarticle/breast-cancer-drug-may-slow-aggressive-brain-tumour-kids-2024a1000fra ""Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids"")

Ribociclib, commonly used for breast cancer, has been found to stabilise a subtype of diffuse hemispheric glioma for about 17 months before regrowth begins.

*   Press Association
*   8 hours ago

[](https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu ""Alternate Insomnia Therapy Has Good Showing"")

[Alternate Insomnia Therapy Has Good Showing](https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu ""Alternate Insomnia Therapy Has Good Showing"")

The brief nurse-delivered therapy aimed at restricting and standardising time in bed could make treatment more accessible to primary care patients.

*   Medscape News UK
*   9 hours ago

[](https://www.medscape.co.uk/s/viewarticle/listeriosis-during-pregnancy-can-be-fatal-fetus-2024a1000frm ""Listeriosis During Pregnancy Can Be Fatal for the Fetus"")

[Listeriosis During Pregnancy Can Be Fatal for the Fetus](https://www.medscape.co.uk/s/viewarticle/listeriosis-during-pregnancy-can-be-fatal-fetus-2024a1000frm ""Listeriosis During Pregnancy Can Be Fatal for the Fetus"")

The rate of fetal loss or neonatal death from invasive listeriosis is 29%.

*   Medscape Medical News
*   9 hours ago

[](https://www.medscape.co.uk/viewarticle/prisons-often-waste-ambulance-crew-time-2024a1000fqp ""Prisons Often Waste Ambulance Crew Time"")

[Prisons Often Waste Ambulance Crew Time](https://www.medscape.co.uk/viewarticle/prisons-often-waste-ambulance-crew-time-2024a1000fqp ""Prisons Often Waste Ambulance Crew Time"")

Unnecessary 999 calls are being made by prison staff due to lack of experience and concerns over legal repercussions.

*   Medscape News UK
*   10 hours ago

[](https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni ""Recurrent UTI: Undercultured, Overtreated Despite Resistance"")

[Recurrent UTI: Undercultured, Overtreated Despite Resistance](https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni ""Recurrent UTI: Undercultured, Overtreated Despite Resistance"")

Roughly 40% of general practitioners do not culture recurrent UTIs and instead, just treat.

*   Medscape News UK
*   10 hours ago

[](https://www.medscape.co.uk/s/viewarticle/high-dose-psilocybin-shows-promising-results-depression-2024a1000fqw ""High-Dose Psilocybin Shows Promising Results for Depression"")

[High-Dose Psilocybin Shows Promising Results for Depression](https://www.medscape.co.uk/s/viewarticle/high-dose-psilocybin-shows-promising-results-depression-2024a1000fqw ""High-Dose Psilocybin Shows Promising Results for Depression"")

A meta-analysis found that high-dose psilocybin for depressive symptoms showed better responses than placebo or escitalopram in antidepressant trials.

*   Medscape Medical News
*   10 hours ago

[](https://www.medscape.co.uk/s/viewarticle/primary-care-physicians-track-average-57-quality-measures-2024a1000fqu ""Primary Care Docs Track Average of 57 (!) Quality Measures"")

[Primary Care Docs Track Average of 57 (!) Quality Measures](https://www.medscape.co.uk/s/viewarticle/primary-care-physicians-track-average-57-quality-measures-2024a1000fqu ""Primary Care Docs Track Average of 57 (!) Quality Measures"")

Medicare tracked the most metrics tied to payment, while Medicaid tracked the least, according to a new JAMA Health Forum analysis.

*   Medscape Medical News
*   12 hours ago

[](https://www.medscape.co.uk/viewarticle/female-doctors-suicide-rates-alarmingly-higher-vs-general-2024a1000fqs ""Female Doctors' Suicide Rates Alarmingly Higher vs General Folks"")

[Female Doctors' Suicide Rates Alarmingly Higher vs General Folks](https://www.medscape.co.uk/viewarticle/female-doctors-suicide-rates-alarmingly-higher-vs-general-2024a1000fqs ""Female Doctors' Suicide Rates Alarmingly Higher vs General Folks"")

Male physicians have a similar suicide rate to the general public, but female physicians show a notably higher suicide rate.

*   Medscape News UK
*   13 hours ago

[](https://www.medscape.co.uk/s/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn ""Men, Women, & Exercise: Metabolism Differs at Starting Line"")

[Men, Women, & Exercise: Metabolism Differs at Starting Line](https://www.medscape.co.uk/s/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn ""Men, Women, & Exercise: Metabolism Differs at Starting Line"")

The muscles of sedentary men and women with overweight and obesity differ in burning sugar and fatty acids at the start of an exercise program but draw even after training, multi-omics data show.

*   Medscape Medical News
*   14 hours ago

[](https://www.medscape.co.uk/viewarticle/dental-caries-could-be-silent-threat-your-heart-2024a1000fqm ""Dental Caries Could Be a Silent Threat to Your Heart"")

[Dental Caries Could Be a Silent Threat to Your Heart](https://www.medscape.co.uk/viewarticle/dental-caries-could-be-silent-threat-your-heart-2024a1000fqm ""Dental Caries Could Be a Silent Threat to Your Heart"")

Dental caries are tied to a 40% higher stroke risk, underscoring the importance of oral health in preventing cardiovascular events.

*   Medscape News UK
*   14 hours ago

[Domestic Abuse: Recognition and Support](https://www.medscape.co.uk/viewarticle/supporting-people-affected-domestic-abuse-2024a1000dqo ""Domestic Abuse: Recognition and Support"")

Concise summary on recognising domestic abuse in primary care, including key questions to ask patients

*   Guidelines Summary: Primary Care
*   15 hours ago

[](https://www.medscape.co.uk/s/viewarticle/parents-technology-use-may-shape-adolescents-mental-health-2024a1000fqd ""Parents' Technology Use May Shape Adolescents' Mental Health"")

[Parents' Technology Use May Shape Adolescents' Mental Health](https://www.medscape.co.uk/s/viewarticle/parents-technology-use-may-shape-adolescents-mental-health-2024a1000fqd ""Parents' Technology Use May Shape Adolescents' Mental Health"")

Discussing digital technology use and mental health with parents and adolescents can be part of routine care visits, researchers said.

*   Medscape Medical News
*   18 hours ago

[](https://www.medscape.co.uk/viewarticle/emergency-kits-recommended-adrenal-insufficiency-patients-2024a1000fpx ""NICE: Give People With Adrenal Insufficiency Emergency Kits"")

[NICE: Give People With Adrenal Insufficiency Emergency Kits](https://www.medscape.co.uk/viewarticle/emergency-kits-recommended-adrenal-insufficiency-patients-2024a1000fpx ""NICE: Give People With Adrenal Insufficiency Emergency Kits"")

People with adrenal insufficiency should be given emergency kits to help avoid hospital admission, said NICE in its new clinical guideline.

*   Medscape News UK
*   28 Aug 2024

[](https://www.medscape.co.uk/viewarticle/nice-oks-lonsurf-bevacizumab-advanced-bowel-cancer-2024a1000fpu ""NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer"")

[NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer](https://www.medscape.co.uk/viewarticle/nice-oks-lonsurf-bevacizumab-advanced-bowel-cancer-2024a1000fpu ""NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer"")

Around 1300 people in England will be eligible every year for the new combination treatment.

*   Medscape News UK
*   28 Aug 2024

[](https://www.medscape.co.uk/s/viewarticle/kidney-donor-mortality-plummets-over-30-years-2024a1000fop ""Kidney Donor Mortality Plummets Over 30 Years"")

[Kidney Donor Mortality Plummets Over 30 Years](https://www.medscape.co.uk/s/viewarticle/kidney-donor-mortality-plummets-over-30-years-2024a1000fop ""Kidney Donor Mortality Plummets Over 30 Years"")

The risk for perioperative mortality in living kidney donors has significantly reduced in the past decade, a study showed.

*   Medscape Medical News
*   28 Aug 2024

[](https://www.medscape.co.uk/s/viewarticle/new-exercise-evolution-stroke-survivors-go-harder-2024a1000fp7 ""A New Exercise 'Evolution' for Stroke Survivors: Go Harder"")

[A New Exercise 'Evolution' for Stroke Survivors: Go Harder](https://www.medscape.co.uk/s/viewarticle/new-exercise-evolution-stroke-survivors-go-harder-2024a1000fp7 ""A New Exercise 'Evolution' for Stroke Survivors: Go Harder"")

A recent study has built on emerging evidence that intense training can be safe and beneficial for patients recovering from stroke.

*   Medscape Medical News
*   28 Aug 2024

[](https://www.medscape.co.uk/viewarticle/hot-flashes-night-sweats-linked-subclinical-heart-disease-2024a1000fl0 ""Hot Flashes, Night Sweats Linked to Menopausal Heart Disease"")

[Hot Flashes, Night Sweats Linked to Menopausal Heart Disease](https://www.medscape.co.uk/viewarticle/hot-flashes-night-sweats-linked-subclinical-heart-disease-2024a1000fl0 ""Hot Flashes, Night Sweats Linked to Menopausal Heart Disease"")

Early onset and long duration were associated with particularly high risk.

*   Medscape News UK
*   28 Aug 2024

[](https://www.medscape.co.uk/s/viewarticle/uk-set-open-18-new-clinical-trial-hubs-400m-investment-2024a1000fp5 ""UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment"")

[UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment](https://www.medscape.co.uk/s/viewarticle/uk-set-open-18-new-clinical-trial-hubs-400m-investment-2024a1000fp5 ""UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment"")

Wes Streeting called the investment a major boost for the UK, transforming it into a health research hub and supporting a future-ready NHS.

*   Press Association
*   28 Aug 2024

[](https://www.medscape.co.uk/s/viewarticle/measuring-expectations-real-world-survival-osimertinib-2024a1000fok ""Measuring Expectations: Real-World Survival With Osimertinib"")

[Measuring Expectations: Real-World Survival With Osimertinib](https://www.medscape.co.uk/s/viewarticle/measuring-expectations-real-world-survival-osimertinib-2024a1000fok ""Measuring Expectations: Real-World Survival With Osimertinib"")

In a real-world population of patients with EGFR-mutant advanced lung cancer, overall survival was much worse in patients who would not have been eligible for the pivotal FLAURA trial.

*   Medscape Medical News
*   28 Aug 2024

![Image 5](blob:https://www.medscape.co.uk/6742166de2ffdc98a2fc8b83a0aa235b)
"
2024-08-28 09:00:00,2024-08-29 23:22:04,"üåü **Did you know that common menopausal symptoms like hot flashes and night sweats might be linked to heart health?**

A recent study featured in the *Journal of the American Heart Association* has uncovered significant correlations between menopausal vasomotor symptoms (VMS) and an increased risk of subclinical coronary atherosclerosis. The study, which examined nearly 3000 women aged 50-64 in Sweden, found that those experiencing severe hot flashes and night sweats are potentially at a higher risk for heart disease.

**Key Takeaways:**
- About 14.2% of women reported severe VMS, and the results indicated a 33% higher odds ratio for coronary atherosclerosis among those with severe symptoms.
- The risks were amplified for women who experienced severe symptoms for more than five years or before their final menstrual period.
- This study suggests a need for preventive cardiovascular strategies specifically targeting women grappling with severe VMS.

**In Practice:** This insight emphasizes the importance of integrating discussions regarding menopausal symptoms into routine cardiovascular health assessments. For healthcare professionals, recognizing the significance of VMS not only aids in managing menopausal health but also highlights the need to monitor and potentially intervene on cardiovascular risks in these patients.

üí≠ **What are your thoughts on the connection between menopausal symptoms and heart health? Have you noticed this trend in your practice?**

For further details, check out the full article here: [Medscape Article](https://www.medscape.co.uk/viewarticle/hot-flashes-night-sweats-linked-subclinical-heart-disease-2024a1000fl0) 

#Menopause #HeartHealth #WomenHealth #Cardiology #Healthcare",https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/is_210928_hot_flashes_menopause_800x450.jpg,https://www.medscape.co.uk/viewarticle/hot-flashes-night-sweats-linked-subclinical-heart-disease-2024a1000fl0,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Thumbnail image URL: https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/is_210928_hot_flashes_menopause_800x450.jpg 

Title: Hot Flashes, Night Sweats Linked to Subclinical Heart Disease in Menopause

URL Source: https://www.medscape.co.uk/viewarticle/hot-flashes-night-sweats-linked-subclinical-heart-disease-2024a1000fl0

Published Time: 2024-08-28T09:00:00-04:00

Markdown Content:
Hot Flashes, Night Sweats Linked to Menopausal Heart Disease
===============
                                      

This site is intended for UK healthcare professionals

[![Image 1: Medscape UK Univadis Logo](https://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/medscape-uk-logo.4a9c814f.svg)](https://www.medscape.co.uk/)

*   Recent Searches [Clear](https://www.medscape.co.uk/viewarticle/hot-flashes-night-sweats-linked-subclinical-heart-disease-2024a1000fl0#)

[![Image 2: Medscape UK Univadis Logo](https://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/medscape-uk-logo.4a9c814f.svg)](https://www.medscape.co.uk/)

*   Recent Searches [Clear](https://www.medscape.co.uk/viewarticle/hot-flashes-night-sweats-linked-subclinical-heart-disease-2024a1000fl0#)

*   Recent Searches [Clear](https://www.medscape.co.uk/viewarticle/hot-flashes-night-sweats-linked-subclinical-heart-disease-2024a1000fl0#)

*   Menu
*   News
    
*   Guidelines
    
*   Drugs
    
*   Quizzes
    
*   Search

Clinical Summary

Hot Flashes, Night Sweats Linked to Subclinical Heart Disease in Menopause
==========================================================================

Jenny Blair

[](https://www.medscape.co.uk/viewarticle/hot-flashes-night-sweats-linked-subclinical-heart-disease-2024a1000fl0#)

TOPLINE:¬†
---------

Menopausal vasomotor symptoms (VMS) such as hot flashes and night sweats correlate with a higher risk for subclinical coronary atherosclerosis. These women might benefit from more intensive prevention strategies.

METHODOLOGY:¬†¬†
--------------

*   A population-based, cross-sectional Swedish CardioPulmonary bioImage Study of 2995 Swedish women aged 50-64 years old.
*   Participants took a survey about VMS and underwent coronary CT angiography (CCTA), coronary artery calcium score measurement, and carotid ultrasound.
*   The authors looked for correlations between symptoms and measures of subclinical atherosclerotic cardiovascular disease, adjusting for covariates.
*   The outcome measures were any coronary atherosclerosis, segmental involvement score > 3, coronary artery calcium score > 100, and any carotid plaque.

TAKEAWAY:
---------

*   In all, 14.2% of women reported having ever severe VMS, 18.1% ever moderate, and 67.7% ever mild/never.
*   Having ever severe VMS was associated with coronary atherosclerosis as detected with CCTA; odds ratio, 1.33.
*   Having ever severe VMS for > 5‚Äâyears or beginning before the final menstrual period, the odds ratios were 1.50 and 1.66, respectively.
*   Associations were lacking for segmental involvement score > 3, coronary artery calcium score > 100, or with any carotid plaque.

IN PRACTICE:
------------

""Our findings support‚Ä¶preventive cardiovascular strategies‚Ä¶targeting women with severe VMS, which may be a marker of poor or ongoing deterioration of cardiovascular health,"" the authors wrote.

SOURCE:
-------

Conducted by academic researchers in Sweden, the study appeared in the [_Journal of the American Heart Association_](https://www.ahajournals.org/doi/10.1161/JAHA.123.033648)_._

LIMITATIONS:
------------

Causal link not established. Potential residual confounding. Results might not be generalised to other populations.

DISCLOSURES:
------------

Funded mostly by the Swedish Heart‚ÄêLung Foundation. The authors reported no relevant disclosures.

Register Today

Already a member? Log in

EDITOR'S RECOMMENDATIONS
------------------------

*   ![Image 3: related](https://img.medscapestatic.com/pi/global/1x1.png)
    
    [Novel Drug Effective for Menopausal Hot Flashes, Sleep Disturbances](https://www.medscape.co.uk/viewarticle/novel-non-hormonal-drug-effective-menopausal-hot-flashes-2024a1000fhf)
    
    Two phase 3 trials reported on safety and efficacy of elinzanetant for moderate to severe menopausal vasomotor symptoms.
    
*   [Primary Care Aspects of HIV: Dr Toni Hazell's Guidelines Live Session](https://www.medscape.co.uk/viewarticle/primary-care-aspects-hiv-dr-toni-hazells-guidelines-live-2024a1000eyd)
    
    Video | Dr Toni Hazell | 15 August 2024
    
*   ![Image 4: related](https://img.medscapestatic.com/pi/global/1x1.png)
    
    [New Drug Option Approved for Uterine Fibroids](https://www.medscape.co.uk/viewarticle/new-drug-option-approved-uterine-fibroids-2024a1000eyy)
    
    A new once-daily hormone antagonist tablet has been recommended by NICE to treat moderate or severe symptoms of uterine fibroids.
    

YOU MAY ALSO LIKE
-----------------

[](https://www.medscape.co.uk/s/viewarticle/breast-cancer-drug-may-slow-aggressive-brain-tumour-kids-2024a1000fra ""Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids"")

[Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids](https://www.medscape.co.uk/s/viewarticle/breast-cancer-drug-may-slow-aggressive-brain-tumour-kids-2024a1000fra ""Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids"")

Ribociclib, commonly used for breast cancer, has been found to stabilise a subtype of diffuse hemispheric glioma for about 17 months before regrowth begins.

*   Press Association
*   8 hours ago

[](https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu ""Alternate Insomnia Therapy Has Good Showing"")

[Alternate Insomnia Therapy Has Good Showing](https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu ""Alternate Insomnia Therapy Has Good Showing"")

The brief nurse-delivered therapy aimed at restricting and standardising time in bed could make treatment more accessible to primary care patients.

*   Medscape News UK
*   9 hours ago

[](https://www.medscape.co.uk/s/viewarticle/listeriosis-during-pregnancy-can-be-fatal-fetus-2024a1000frm ""Listeriosis During Pregnancy Can Be Fatal for the Fetus"")

[Listeriosis During Pregnancy Can Be Fatal for the Fetus](https://www.medscape.co.uk/s/viewarticle/listeriosis-during-pregnancy-can-be-fatal-fetus-2024a1000frm ""Listeriosis During Pregnancy Can Be Fatal for the Fetus"")

The rate of fetal loss or neonatal death from invasive listeriosis is 29%.

*   Medscape Medical News
*   9 hours ago

[](https://www.medscape.co.uk/viewarticle/prisons-often-waste-ambulance-crew-time-2024a1000fqp ""Prisons Often Waste Ambulance Crew Time"")

[Prisons Often Waste Ambulance Crew Time](https://www.medscape.co.uk/viewarticle/prisons-often-waste-ambulance-crew-time-2024a1000fqp ""Prisons Often Waste Ambulance Crew Time"")

Unnecessary 999 calls are being made by prison staff due to lack of experience and concerns over legal repercussions.

*   Medscape News UK
*   10 hours ago

[](https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni ""Recurrent UTI: Undercultured, Overtreated Despite Resistance"")

[Recurrent UTI: Undercultured, Overtreated Despite Resistance](https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni ""Recurrent UTI: Undercultured, Overtreated Despite Resistance"")

Roughly 40% of general practitioners do not culture recurrent UTIs and instead, just treat.

*   Medscape News UK
*   10 hours ago

[](https://www.medscape.co.uk/s/viewarticle/high-dose-psilocybin-shows-promising-results-depression-2024a1000fqw ""High-Dose Psilocybin Shows Promising Results for Depression"")

[High-Dose Psilocybin Shows Promising Results for Depression](https://www.medscape.co.uk/s/viewarticle/high-dose-psilocybin-shows-promising-results-depression-2024a1000fqw ""High-Dose Psilocybin Shows Promising Results for Depression"")

A meta-analysis found that high-dose psilocybin for depressive symptoms showed better responses than placebo or escitalopram in antidepressant trials.

*   Medscape Medical News
*   10 hours ago

[](https://www.medscape.co.uk/s/viewarticle/primary-care-physicians-track-average-57-quality-measures-2024a1000fqu ""Primary Care Docs Track Average of 57 (!) Quality Measures"")

[Primary Care Docs Track Average of 57 (!) Quality Measures](https://www.medscape.co.uk/s/viewarticle/primary-care-physicians-track-average-57-quality-measures-2024a1000fqu ""Primary Care Docs Track Average of 57 (!) Quality Measures"")

Medicare tracked the most metrics tied to payment, while Medicaid tracked the least, according to a new JAMA Health Forum analysis.

*   Medscape Medical News
*   12 hours ago

[](https://www.medscape.co.uk/viewarticle/female-doctors-suicide-rates-alarmingly-higher-vs-general-2024a1000fqs ""Female Doctors' Suicide Rates Alarmingly Higher vs General Folks"")

[Female Doctors' Suicide Rates Alarmingly Higher vs General Folks](https://www.medscape.co.uk/viewarticle/female-doctors-suicide-rates-alarmingly-higher-vs-general-2024a1000fqs ""Female Doctors' Suicide Rates Alarmingly Higher vs General Folks"")

Male physicians have a similar suicide rate to the general public, but female physicians show a notably higher suicide rate.

*   Medscape News UK
*   13 hours ago

[](https://www.medscape.co.uk/s/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn ""Men, Women, & Exercise: Metabolism Differs at Starting Line"")

[Men, Women, & Exercise: Metabolism Differs at Starting Line](https://www.medscape.co.uk/s/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn ""Men, Women, & Exercise: Metabolism Differs at Starting Line"")

The muscles of sedentary men and women with overweight and obesity differ in burning sugar and fatty acids at the start of an exercise program but draw even after training, multi-omics data show.

*   Medscape Medical News
*   14 hours ago

[](https://www.medscape.co.uk/viewarticle/dental-caries-could-be-silent-threat-your-heart-2024a1000fqm ""Dental Caries Could Be a Silent Threat to Your Heart"")

[Dental Caries Could Be a Silent Threat to Your Heart](https://www.medscape.co.uk/viewarticle/dental-caries-could-be-silent-threat-your-heart-2024a1000fqm ""Dental Caries Could Be a Silent Threat to Your Heart"")

Dental caries are tied to a 40% higher stroke risk, underscoring the importance of oral health in preventing cardiovascular events.

*   Medscape News UK
*   14 hours ago

[Domestic Abuse: Recognition and Support](https://www.medscape.co.uk/viewarticle/supporting-people-affected-domestic-abuse-2024a1000dqo ""Domestic Abuse: Recognition and Support"")

Concise summary on recognising domestic abuse in primary care, including key questions to ask patients

*   Guidelines Summary: Primary Care
*   15 hours ago

[](https://www.medscape.co.uk/s/viewarticle/parents-technology-use-may-shape-adolescents-mental-health-2024a1000fqd ""Parents' Technology Use May Shape Adolescents' Mental Health"")

[Parents' Technology Use May Shape Adolescents' Mental Health](https://www.medscape.co.uk/s/viewarticle/parents-technology-use-may-shape-adolescents-mental-health-2024a1000fqd ""Parents' Technology Use May Shape Adolescents' Mental Health"")

Discussing digital technology use and mental health with parents and adolescents can be part of routine care visits, researchers said.

*   Medscape Medical News
*   18 hours ago

[](https://www.medscape.co.uk/viewarticle/emergency-kits-recommended-adrenal-insufficiency-patients-2024a1000fpx ""NICE: Give People With Adrenal Insufficiency Emergency Kits"")

[NICE: Give People With Adrenal Insufficiency Emergency Kits](https://www.medscape.co.uk/viewarticle/emergency-kits-recommended-adrenal-insufficiency-patients-2024a1000fpx ""NICE: Give People With Adrenal Insufficiency Emergency Kits"")

People with adrenal insufficiency should be given emergency kits to help avoid hospital admission, said NICE in its new clinical guideline.

*   Medscape News UK
*   28 Aug 2024

[](https://www.medscape.co.uk/viewarticle/nice-oks-lonsurf-bevacizumab-advanced-bowel-cancer-2024a1000fpu ""NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer"")

[NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer](https://www.medscape.co.uk/viewarticle/nice-oks-lonsurf-bevacizumab-advanced-bowel-cancer-2024a1000fpu ""NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer"")

Around 1300 people in England will be eligible every year for the new combination treatment.

*   Medscape News UK
*   28 Aug 2024

[](https://www.medscape.co.uk/s/viewarticle/kidney-donor-mortality-plummets-over-30-years-2024a1000fop ""Kidney Donor Mortality Plummets Over 30 Years"")

[Kidney Donor Mortality Plummets Over 30 Years](https://www.medscape.co.uk/s/viewarticle/kidney-donor-mortality-plummets-over-30-years-2024a1000fop ""Kidney Donor Mortality Plummets Over 30 Years"")

The risk for perioperative mortality in living kidney donors has significantly reduced in the past decade, a study showed.

*   Medscape Medical News
*   28 Aug 2024

[](https://www.medscape.co.uk/s/viewarticle/new-exercise-evolution-stroke-survivors-go-harder-2024a1000fp7 ""A New Exercise 'Evolution' for Stroke Survivors: Go Harder"")

[A New Exercise 'Evolution' for Stroke Survivors: Go Harder](https://www.medscape.co.uk/s/viewarticle/new-exercise-evolution-stroke-survivors-go-harder-2024a1000fp7 ""A New Exercise 'Evolution' for Stroke Survivors: Go Harder"")

A recent study has built on emerging evidence that intense training can be safe and beneficial for patients recovering from stroke.

*   Medscape Medical News
*   28 Aug 2024

[](https://www.medscape.co.uk/viewarticle/continuous-glucose-monitor-benefits-all-ages-diabetes-2024a1000fhy ""Continuous Glucose Monitor Benefits All Ages With Diabetes"")

[Continuous Glucose Monitor Benefits All Ages With Diabetes](https://www.medscape.co.uk/viewarticle/continuous-glucose-monitor-benefits-all-ages-diabetes-2024a1000fhy ""Continuous Glucose Monitor Benefits All Ages With Diabetes"")

Intermittently scanned continuous glucose monitoring improved glycaemic outcomes in those older and younger than 65 years, but the older group may need individualised targets.

*   Medscape News UK
*   28 Aug 2024

[](https://www.medscape.co.uk/s/viewarticle/uk-set-open-18-new-clinical-trial-hubs-400m-investment-2024a1000fp5 ""UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment"")

[UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment](https://www.medscape.co.uk/s/viewarticle/uk-set-open-18-new-clinical-trial-hubs-400m-investment-2024a1000fp5 ""UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment"")

Wes Streeting called the investment a major boost for the UK, transforming it into a health research hub and supporting a future-ready NHS.

*   Press Association
*   28 Aug 2024

[](https://www.medscape.co.uk/s/viewarticle/measuring-expectations-real-world-survival-osimertinib-2024a1000fok ""Measuring Expectations: Real-World Survival With Osimertinib"")

[Measuring Expectations: Real-World Survival With Osimertinib](https://www.medscape.co.uk/s/viewarticle/measuring-expectations-real-world-survival-osimertinib-2024a1000fok ""Measuring Expectations: Real-World Survival With Osimertinib"")

In a real-world population of patients with EGFR-mutant advanced lung cancer, overall survival was much worse in patients who would not have been eligible for the pivotal FLAURA trial.

*   Medscape Medical News
*   28 Aug 2024

![Image 5](blob:https://www.medscape.co.uk/6742166de2ffdc98a2fc8b83a0aa235b)
"
2024-08-28 05:22:00,2024-08-29 23:22:34,"üåü Exciting Updates in Early Breast Cancer Management! üåü  
  
I hope everyone is having a great day! I just came across an insightful article discussing the recent updates to the European Society for Medical Oncology (ESMO) guidelines on early breast cancer, and I couldn‚Äôt help but reflect on its implications for our practice in the UK. With over 56,000 new cases of breast cancer diagnosed in the UK each year, staying up-to-date is crucial for improving patient outcomes.  
  
**Key Updates Include:**  
1. **Screening Enhancements:** ESMO emphasizes the importance of mammography screening every 2 years for women aged 50-69, compared to the current NHS practice of every 3 years. Increasing awareness and attendance rates for screenings might significantly enhance early detection.  
2. **Personalized Follow-up Strategies:** The shift from routine follow-ups to more personalized, stratified care is noteworthy. This ensures that patients receive tailored support and resources based on their specific needs, improving overall care experience.  
3. **Advancements in Treatment:** The guidelines detail the selective use of genomic scores to tailor chemotherapy, as well as updates on new therapies like olaparib for BRCA mutation carriers. This kind of precision medicine could greatly improve treatment efficacy and patient quality of life.  
4. **Radiation Therapy Recommendations:** There‚Äôs a significant push towards hypofractionated radiation schedules, which can enhance patient convenience while maintaining treatment effectiveness.  
5. **Considerations for Pregnancy:** For premenopausal women, the guidelines now recommend careful planning around pregnancy post-treatment, reassuring that with proper management, it can be pursued safely.  
  
These updates not only highlight the importance of adhering to evolving evidence but also underscore the ongoing challenges we face, such as workforce shortages in oncology. Addressing these issues is essential for ensuring that all patients receive timely and effective care.  
  
What are your thoughts on these changes? Have you started implementing any of these practices in your patient care routine? üåà  
  
Let‚Äôs continue the conversation!  
  
#BreastCancer #Oncology #ESMO #PatientCare #MedicalGuidelines  
  
[Read the full article here](https://www.medscape.co.uk/viewarticle/key-learning-points-early-breast-cancer-2024a1000fb4)",,https://www.medscape.co.uk/viewarticle/key-learning-points-early-breast-cancer-2024a1000fb4,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Thumbnail image URL: nan 

Title: Key Learning Points: Early Breast Cancer

URL Source: https://www.medscape.co.uk/viewarticle/key-learning-points-early-breast-cancer-2024a1000fb4

Published Time: 2024-08-28T05:22:00-04:00

Markdown Content:
**Dr Fharat Raja Discusses the Updated European Society for Medical Oncology Guideline on Early Breast Cancer, and Highlights 10 Key Learning Points for UK Oncologists**

| Read This Article to Learn More About: |
| --- |
| 
*   ESMO recommendations on early breast cancer within the context of UK practice, and how these compare with NICE guidance
*   Use of genomic score to guide chemotherapy in appropriate patients
*   Provision of personalised, stratified follow up

Key points can be found at the end of this article |

[Reflect on your learning and download our Reflection Record](https://www.medscape.co.uk/viewarticle/secondary-care-reflection-record-2023a10001d2)

Breast cancer remains the leading cause of cancer-related deaths in women worldwide.1 Global cancer statistics for 2020 identify 2.3 million new cases of breast cancer and 685,000 deaths.1 In the UK, around 56,000 new cases of breast cancer are diagnosed each year (2016‚Äì2018 average), with about 11,500 deaths related to breast cancer occurring per year (2017‚Äì2019 average).2

The European Society for Medical Oncology (ESMO) published an updated guideline on early breast cancer (EBC) in February 2024 to support implementation of the latest evidence on diagnosis, treatment, and follow up.1 This article assesses the recommendations of relevance to UK practice, and provides 10 key learning points for oncologists. Refer to the full guideline for details of all the recommendations.1

1\. Emphasise the Importance of Mammography Screening
-----------------------------------------------------

The NHS Breast Screening Programme offers screening every 3 years to women aged 50‚Äì70 in the UK who are registered with a GP.3 In contrast, ESMO recommends mammography screening every 2 years for average-risk women aged 50‚Äì69,1 unchanged from 2019,4 and based upon guidance from the European Commission Initiative on Breast Cancer (ECIBC).1,5 This highlights a significant discrepancy in the frequency of screening between European- and UK-based women that should be discussed by the UK breast cancer community. Of greater concern, however, is that more than one-third of women failed to attend NHS breast cancer screening appointments in 2022‚Äì2023;6 the NHS programme detected cancer in 18,942 women across England in this time period, but uptake was poor at 64.6% (although this was an improvement on uptake in 2021‚Äì2022 of 62.3%)6 and represents a missed opportunity to diagnose and treat a significant number of women at an earlier stage. It suggests that a focus on ensuring women understand the importance of screening and attend appointments is a greater priority at this time than a reduction in screening intervals.

ESMO also recommends that digital breast tomosynthesis‚Äîwith or without synthetic mammography‚Äîand contrast-enhanced mammography be considered as alternatives when available and appropriate.1 Unfortunately, a lot of centres in the UK do not currently offer access to these modalities, an issue that also needs to be addressed.

2\. Strike a Balance on Managing Axillary Lymph Node Involvement
----------------------------------------------------------------

A consensus on how to manage axillary lymph node (ALN) involvement in EBC is lacking in the UK. The status of regional nodes is an important predictor of long-term outcomes, but the benefits gained by downstaging nodal involvement in the axilla must be balanced against the morbidity associated with unnecessary lymph node clearances.

ESMO provide a useful algorithm covering the management of ALN involvement in EBC, including when primary surgery is indicated, and whether sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) is appropriate.1 SLNB is associated with less morbidity, such as shoulder stiffness, pain, and arm swelling, than ALND.1 ESMO highlights that, with appropriate training, SLNB can lead to high identification rates, low rates of false negatives, and favourable rates of ALN recurrence.1

NICE recommends SLNB rather than ALN clearance to stage the axilla for people with invasive breast cancer if they have no evidence of lymph node involvement on ultrasound, or if an ultrasound-guided needle biopsy is negative.7

3\. Use Hypofractionated Radiation When Indicated
-------------------------------------------------

ESMO opts for breast-conserving surgery followed by post-operative whole breast radiotherapy (WBRT) as the preferred option for local treatment in most patients with EBC.1

Recommendations on radiotherapy doses and fractionation have been updated in line with the latest evidence.1 Historically, local and/or regional adjuvant irradiation consisted of 45‚Äì50 Gy in 25‚Äì28 fractions of 1.8‚Äì2.0 Gy, with a typical boost of 10‚Äì16 Gy in 2 Gy per fraction daily.1 ESMO now recommends the following schedules:

*   moderate hypofractionation for all indications of post-operative radiotherapy (15‚Äì16 fractions of 2.5‚Äì2.67 Gy per fraction daily)
*   ultra-hypofractionation for whole-breast or chest wall (without reconstruction) irradiation (26 Gy in five daily fractions).1

A consensus statement from the European Society for Radiology and Oncology (ESTRO) Advisory Committee in Radiation Oncology Practice recommends shorter regimens whenever indicated.1,8 Similarly, NICE recommends a hypofractionated schedule of 26 Gy in five daily fractions for people with invasive breast cancer having partial-breast, whole-breast, or chest-wall radiotherapy, without lymph node irradiation, following breast-conserving surgery or mastectomy.7 NICE suggests considering 40 Gy in 15 fractions over 3 weeks for patients who have a diagnosis that increases radiotherapy sensitivity, have implant-based reconstruction, or any other factors that suggest receiving radiotherapy over 3 weeks would be more acceptable.7

4\. Consider Partial Breast Irradiation When Suitable
-----------------------------------------------------

ESMO has strengthened its recommendations on accelerated partial breast irradiation (APBI) since its 2019 guideline, and now recommends it as an alternative to WBRT after breast-conserving surgery in patients with invasive and _in situ_ breast cancer at low risk of local recurrence.1,4 Once again, this is based upon ESTRO consensus recommendations, which note equivalent results for APBI to that of WBRT in selected patients with low-risk disease.1,8 Box 1 highlights the low-risk features that determine a patient‚Äôs suitability for APBI.

| Box 1: Low-risk Features Suitable for Accelerated Partial Breast Irradiation1 |
| --- |
| 
*   luminal-like subtypes
*   small tumour (‚â§3 cm)
*   absence of lymphovascular space invasion
*   non-lobular invasive carcinoma, tumour grade 1‚Äì2
*   low-to-intermediate-grade DCIS
*   diagnosis age ‚â•50
*   unicentric or unifocal lesion
*   clear surgical margins (>2 mm)
*   node negative (including isolated tumour cells)
*   no use of primary systemic therapy

 |
| DCIS=ductal carcinoma _in situ_ |

NICE also recommends APBI as an alternative to WBRT after breast-conserving surgery for invasive cancer in women who have a low absolute risk of local recurrence.8

5\. Determine Genomic Score to Guide Chemotherapy Decisions
-----------------------------------------------------------

Tumour profiling tests can predict the benefit of adjuvant chemotherapy for hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative EBC; ESMO recommends the use of Endopredict, MammaPrint, Oncotype DX, and Prosigna for both premenopausal and postmenopausal women to determine whether they have a low- or high-risk genomic score.1 Decisions on adjuvant chemotherapy are guided by high-risk genomic scores and/or higher-risk features on traditional pathological analysis.1

NICE diagnostics guidance from May 20249 has some notable differences to ESMO's recommendations.

*   In HR-positive, HER2-negative, lymph node-positive EBC (1‚Äì3 positive lymph nodes):9
    *   NICE recommends the use of Endopredict, Oncotype DX, or Prosigna for women who have been through the menopause; the tests should not be used for women who have not been through the menopause
*   In HR-positive, HER2-negative, lymph node-negative (including micrometastatic) EBC:9
    *   NICE recommends that Endopredict, Oncotype DX, and Prosigna can be used while more evidence is being generated
    *   NICE does not recommend the use of MammaPrint to guide adjuvant chemotherapy decisions; the panel concluded it was likely to be less clinically effective than standard care at greater cost.

6\. Treat with Olaparib According to BRCA Carrier Status
--------------------------------------------------------

An important update in the ESMO guideline relates to systemic treatment of HR-positive, HER2-negative EBC.1 Stage III or high-risk stage II EBC should be treated with:1

*   olaparib (plus endocrine therapy) in patients with a germline BRCA1/2 mutation (gBRCA1/2m)
*   abemaciclib (plus endocrine therapy) in patients who are germline BRCA1/2 wild type.

Note that olaparib and abemaciclib have overlapping toxicities and should not be combined.1

Olaparib and abemaciclib are also recommended in NICE technology appraisals:

*   olaparib, alone or with endocrine therapy, for adjuvant treatment of BRCA-mutation-positive, HER2-negative, high-risk EBC10
*   abemaciclib plus endocrine therapy for adjuvant treatment of HR-positive, HER2-negative, node-positive EBC when there is a high risk of recurrence.11

These recommendations have yet to be incorporated into the NICE guideline on early and locally advanced breast cancer.8

7\. Target Therapy in HER2-positive Disease
-------------------------------------------

ESMO and NICE guidelines broadly agree on the use of HER2-targeted treatment plus chemotherapy for patients with HER2-positive EBC.1,7 Neoadjuvant treatment followed by local therapy is the preferred option for stage II and III. This also allows risk stratification by determining pathological complete response (pCR) or the presence of residual disease.1,7

Anthracycline‚Äìtaxane-based combinations with HER2-targeted treatments have been standard of care for neoadjuvant chemotherapy in patients with HER2-positive disease;1 however, this is associated with low but serious toxicities (for example, a serious risk of cardiac toxicity and secondary acute myeloid leukaemia), which may lead some practitioners to avoid these.1,7 Anthracycline-free regimens with carboplatin and taxanes have been tested in a number of studies, and report similar outcomes to anthracycline-containing regimens, with improved cardiac safety.12‚Äì15

In a single-arm phase II study of highly selected patients with low-to-intermediate-risk HR-negative, HER2-positive disease, 12 weeks of paclitaxel in combination with dual HER2 blockade (trastuzumab‚Äìpertuzumab) without postoperative anthracyclines showed a pCR rate >90% and an invasive disease-free survival (IDFS) at 5 years of about 98%.1,16 ESMO recommends this dual blockade as neoadjuvant therapy; in contrast, the NICE guideline does not specifically recommend this approach.7

Adjuvant therapy can be de-escalated in patients with stage 1 disease (T1N0M0, HR positive/negative and HER2 positive) who have had surgical treatment first. The APT trial demonstrated that 12 weeks of paclitaxel and 1 year of concurrent and then maintenance trastuzumab produced low recurrence rates, with a 10-year IDFS of 91% and an overall survival of 94%.1,17

ESMO recommends that patients with residual disease after neoadjuvant treatment be offered adjvuant TDM1 (trastuzumab emtansine, an antibody‚Äìdrug conjugate) for up to 14 cycles, as demonstrated in the phase III KATHERINE trial1,18 (of note, its use in node-positive patients with residual invasive disease is also approved by NICE).19 When there is a complete pathological response after neoadjuvant treatment, patients who are node positive or suspected node positive at diagnosis should complete treatment with pertuzumab and trastuzumab; use trastuzumab alone if node negative at diagnosis.1 Endocrine treatment should be added to the adjuvant treatment in HR positive patients.1

Both ESMO and NICE guidelines allow the use of neratanib in the adjuvant setting after patients have completed 1 year of adjuvant trastuzumab.1,20 The phase III ExteNET trial tested adjuvant neratanib and found a significant improvement in IDFS in the HR-positive subgroup.21,22 However, the study was conducted before routine use of adjuvant pertuzumab with trastuzumab, and before the introduction of adjuvant TDM1. Therefore, the relevance of this treatment is in question, although it remains an option for this subset of patients.

8\. Use Pembrolizumab Appropriately in Triple-negative Breast Cancer
--------------------------------------------------------------------

ESMO offers a useful algorithm on the management of triple-negative breast cancer (TNBC), including the use of pembrolizumab, and recommends that:1

*   cT2‚Äì4 node negative or any node positive (stage II‚îÄIII) TNBC should be treated with neoadjuvant chemotherapy plus pembrolizumab, unless there are risk factors for excessive ICI-associated immune toxicity
    *   administer pembrolizumab every 3 weeks throughout the neoadjuvant phase, and in nine 3-week cycles during the adjuvant phase
*   1 year of adjuvant olaparib is preferred to adjuvant pembrolizumab for patients with residual disease who have gBRCA1/2m and high-risk TNBC
*   Treat patients with residual disease who did not receive pembrolizumab with adjuvant capecitabine (6‚Äì8 cycles).

Neoadjuvant and adjuvant use of pembrolizumab with chemotherapy is also recommended by NICE for adults with early TNBC that is at high risk of recurrence or is locally advanced.23

9\. Provide Follow Up That is Personalised and Stratified Rather Than Routine
-----------------------------------------------------------------------------

In the UK, personalised, stratified follow up, rather than routine follow up, is the norm for patients who have been treated for breast cancer.24 This puts the onus on a patient to make contact when they have a concern or problem, rather than routinely attending a clinic even when they are well and symptom free. It also helps to address some of the challenges of demand and capacity within cancer pathways.24 NICE supports stratified follow up; it recommends that, upon completion of primary treatment for breast cancer, patients be given an agreed, written care plan, with details of designated healthcare professionals, signs and symptoms to look out for, contact details for immediate referral, and dates for adjuvant therapy review.7

In contrast, ESMO is more prescriptive, recommending regular follow-up visits every 3 months in the first 3 years post-treatment, 6-monthly follow up from years 4‚Äì5 post-treatment, and annually thereafter.1 However, for asymptomatic patients, laboratory or other imaging tests are not recommended, and symptom-directed investigations should be considered as indicated.1

10\. Advise Premenopausal Women About Pregnancy Safety After Treatment
----------------------------------------------------------------------

It is important to highlight to premenopausal women who are considering pregnancy that available evidence suggests that it seems to be safe after breast cancer treatment.1 ESMO recommends that those women who want to try to become pregnant can temporarily interrupt adjuvant endocrine therapy after 18‚Äì30 months; after a 3-month wash-out period, they can attempt to get pregnant during a period up to 2 years, followed by a resumption of endocrine therapy.1 This does not appear to impact short-term breast cancer outcomes in lower risk HR-positive, HER2-negative EBC.1

Conclusion
----------

Adherence to the latest guidelines for the early detection and treatment and management of breast cancer is crucial for improving outcomes and ensuring optimal care. It is also reassuring for patients to know that their care is up to date and meets international standards. However, one of the biggest issues in cancer care is the national shortage of cancer doctors and nurses, alongside increased demand for services and treatments, which has led to delays in therapy for thousands of women.25 Contributing factors include a drop in the number of breast cancer doctors working full-time in the UK, breast radiology posts remaining unfilled, the introduction of multiple treatments in the metastatic setting, and a lack of pharmaceutical specialists to support implementation of new therapies.25 Clinical oncology and clinical radiology workforce census reports for 2023, published by The Royal College of Radiologists (RCR) in June 2024, highlight the scale of workforce shortages and the impact on patients:26‚Äì28

*   85% of cancer leaders express concern that staff shortages are impacting patient safety
*   97% of radiology leaders say workforce shortages cause delays and backlogs
*   Across the UK, there is a 15% shortfall of clinical oncologists and a 30% shortfall of clinical radiologists.¬†

The RCR has called for a plan to recruit, train, and retain clinical oncologists and clinical radiologists.26‚Äì28

Patient compliance with treatment is another important issue. A survey in 2020 of more than 2400 patients with HR-positive breast cancer found that about one-third discontinued their endocrine treatment early.29 Although most patients felt supported by their medical teams, around 30% felt their side effects were dismissed or minimised.29 The introduction of new layers of therapies for patients with EBC is likely to further impact compliance, due to side effects, decreased quality of life, and increased financial burden.

| Key Points |
| --- |
| 
*   In February 2024, ESMO updated its guidance on diagnosis, treatment, and follow up of EBC
*   ESMO recommends mammography screening every 2 years in average-risk women aged 50‚Äì69; the NHS Breast Screening Programme offers screening every 3 years to women aged 50‚Äì70
*   Digital breast tomosynthesis (with or without synthetic mammography) and contrast-enhanced mammography are recommended by ESMO; access to these modalities in the UK must be improved
*   In selected patients and with the appropriate training, SLNB can be used in preference to ALND, and may lead to high identification rates, low rates of false negatives, and favourable rates of ALN recurrence
*   Updated advice from ESMO on radiotherapy doses and fractionation recommend hypofractionated schedules when appropriate
*   APBI is recommended as an alternative to WBRT after breast-conserving surgery in patients with invasive and _in situ_ breast cancer at low risk of local recurrence
*   Genomic tests can predict the benefit of adjuvant chemotherapy in HR-positive, HER2-negative EBC
*   Treat HR-positive, HER2-negative patients who have stage III or high-risk stage II EBC with:
    *   olaparib (in addition to endocrine therapy) if they are gBRCA1/2m¬†carriers
    *   abemaciclib (and endocrine therapy) in gBRCA1/2wt¬†patients
*   Treat HER2-positive patients with a HER2-targeted treatment plus chemotherapy
    *   For patients with residual disease following neoadjuvant therapy, an antibody‚Äìdrug conjugate is recommended
*   Treat cT2‚Äì4 node negative or any node positive (stage II‚ÄìIII) TNBC with neoadjuvant chemotherapy plus pembrolizumab, unless there are risk factors for excessive immune toxicity
*   Premenopausal women considering pregnancy after breast cancer treatment can be informed that it seems to be safe
*   In the UK, personalised, stratified follow up is preferred to routine follow up for patients who have been treated for breast cancer
*   Barriers to implementation to be addressed in the UK include workforce shortages, difficulties in introducing multiple novel therapies, and patient compliance

 |
| ESMO=European Society of Medical Oncology; EBC=early breast cancer; SLNB=sentinel lymph node biopsy; ALND=axillary lymph node dissection; ALN=axillary lymph node; APBI=accelerated partial breast irradiation; WBRT=whole breast radiotherapy; HR=hormone receptor; HER2=human epidermal growth factor receptor 2; gBRCA1/2m=germline BRCA1/2 mutation; gBRCA1/2wt=germline BRCA1/2 wild type; TNBC=triple-negative breast cancer |

Note: At the time of publication (August 2024), some of the treatments discussed in this article did not have UK marketing authorisation for the indications discussed. Prescribers should refer to the individual summaries of product characteristics for further information and recommendations regarding the use of pharmacological therapies. For off-licence use of medicines, the prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's [_Good practice in prescribing and managing medicines and devices_](https://www.gmc-uk.org/-/media/documents/prescribing-guidance-updated-english-20210405_pdf-85260533.pdf) for further information.
"
2024-08-28 01:15:36,2024-08-29 23:23:07,"üåü **Disrupting Norms: The Impact of COVID-19 Booster on Menstrual Cycles in Teens** üåü  
Have you ever noticed how our understanding of health can evolve? A recent study has shed light on the intriguing effects of the COVID-19 booster vaccine, particularly on the menstrual cycles of teenage girls. This development offers much to consider for those involved in adolescent health.  
  
üìù **Key Findings:**  
The study revealed an average reduction of 5.35 days in menstrual cycle length for girls who received the booster compared to their cycles before vaccination. Interestingly, this was particularly pronounced during the follicular phase, suggesting that timing could be a crucial factor. Notably, there were no reported changes in menstrual flow, pain, or related symptoms.  
  
üîç **Insights for Practitioners:**  
This finding highlights a need for practitioners to engage in compassionate conversations with parents and adolescents regarding vaccine hesitancy. Understanding that health interventions could cause changes in normal physiological processes, even temporarily, is essential. This example underscores the importance of maintaining open channels of communication in the medical community, offering reassurance while being responsive to patient inquiries.  
  
üí¨ **Engage with Us:**  
How do you think healthcare providers can better support teens and their families in understanding vaccine impacts? Let's share ideas!  
  
#HealthCare #AdolescentHealth #COVID19Vaccine #MenstrualHealth #VaccinationEducation  
[Read more about the study here](https://www.medscape.com/viewarticle/covid-19-booster-vaccine-shortens-menstrual-cycles-teens-2024a1000fo8)  

![Adolescent Girl Doctor](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240827_teen_girl_doctor_talking_800x450.jpg)",https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240827_teen_girl_doctor_talking_800x450.jpg,https://www.medscape.com/viewarticle/covid-19-booster-vaccine-shortens-menstrual-cycles-teens-2024a1000fo8,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Thumbnail image URL: https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240827_teen_girl_doctor_talking_800x450.jpg 

Title: COVID-19 Booster Vaccine Shortens Menstrual Cycles in Teens

URL Source: https://www.medscape.com/viewarticle/covid-19-booster-vaccine-shortens-menstrual-cycles-teens-2024a1000fo8

Published Time: 2024-08-28

Markdown Content:
COVID-19 Booster Vaccine Shortens Menstrual Cycles in Teens
===============
                                             

This site is intended for healthcare professionals

![Image 1](https://img.medscapestatic.com/pi/global/header/langsel/icon-globe.svg)

English Edition

![Image 2: language edition](https://img.medscapestatic.com/pi/global/header/langsel/icon-down-stroke.svg)

![Image 3](https://www.medscape.com/viewarticle/covid-19-booster-vaccine-shortens-menstrual-cycles-teens-2024a1000fo8)

*   English New ![Image 4](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
*   Fran√ßais New ![Image 5](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
*   Deutsch New ![Image 6](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
*   Portugu√™s New ![Image 7](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
*   Espa√±ol New ![Image 8](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
*   UK New ![Image 9](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)

![Image 10](https://www.medscape.com/viewarticle/covid-19-booster-vaccine-shortens-menstrual-cycles-teens-2024a1000fo8)

*   Fran√ßais New ![Image 11](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
*   Italiano New ![Image 12](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)

[Register](https://www.medscape.com/viewarticle/covid-19-booster-vaccine-shortens-menstrual-cycles-teens-2024a1000fo8#)[Log In](https://www.medscape.com/viewarticle/covid-19-booster-vaccine-shortens-menstrual-cycles-teens-2024a1000fo8#)

![Image 13: search](https://img.wbmdstatic.com/medscape_static_vue/pages-medscape-viewarticle/client/img/search.956f0d9b.svg)

![Image 14: Medscape Logo](https://img.medscapestatic.com/pi/logos/mscp-logo.png)

Thursday, August 29, 2024

[FOR YOU](https://www.medscape.com/for-you)

[NEWS & PERSPECTIVE](https://www.medscape.com/)

[DRUGS & DISEASES](https://reference.medscape.com/)

[CME & EDUCATION](https://www.medscape.org/)

[Video](https://www.medscape.com/video)

[Decision Point](https://decisionpoint.medscape.com/)

Specialty:

TODAY ON MEDSCAPE ![Image 15](https://img.medscapestatic.com/pi/global/header/langsel/icon-down-stroke.svg)

*   [Allergy & Immunology](https://www.medscape.com/allergy-immunology)
*   [Anesthesiology](https://www.medscape.com/anesthesiology)
*   [Cardiology](https://www.medscape.com/cardiology)
*   [Critical Care](https://www.medscape.com/criticalcare)
*   [Dermatology](https://www.medscape.com/dermatology)
*   [Diabetes & Endocrinology](https://www.medscape.com/diabetes-endocrinology)
*   [Emergency Medicine](https://www.medscape.com/emergencymedicine)
*   [Family Medicine](https://www.medscape.com/familymedicine)
*   [Gastroenterology](https://www.medscape.com/gastroenterology)
*   [General Surgery](https://www.medscape.com/generalsurgery)
*   [Hematology - Oncology](https://www.medscape.com/oncology)
*   [HIV/AIDS](https://www.medscape.com/hiv)
*   [Hospital Medicine](https://www.medscape.com/hospitalmedicine)
*   [Infectious Diseases](https://www.medscape.com/infectiousdiseases)
*   [Internal Medicine](https://www.medscape.com/internalmedicine)
*   [Multispecialty](https://www.medscape.com/multispecialty)
*   [Nephrology](https://www.medscape.com/nephrology)
*   [Neurology](https://www.medscape.com/neurology)
*   [Ob/Gyn & Women's Health](https://www.medscape.com/womenshealth)
*   [Oncology](https://www.medscape.com/oncology)
*   [Ophthalmology](https://www.medscape.com/ophthalmology)
*   [Orthopedics](https://www.medscape.com/orthopedics)
*   [Pathology & Lab Medicine](https://www.medscape.com/pathology)
*   [Pediatrics](https://www.medscape.com/pediatrics)
*   [Plastic Surgery](https://www.medscape.com/plastic-surgery)
*   [Psychiatry](https://www.medscape.com/psychiatry)
*   [Public Health](https://www.medscape.com/publichealth)
*   [Pulmonary Medicine](https://www.medscape.com/pulmonarymedicine)
*   [Radiology](https://www.medscape.com/radiology)
*   [Rheumatology](https://www.medscape.com/rheumatology)
*   [Transplantation](https://www.medscape.com/transplantation)
*   [Urology](https://www.medscape.com/urology)
*   [Today on Medscape](https://www.medscape.com/today)
*   [Business of Medicine](https://www.medscape.com/businessmedicine)
*   [Medical Lifestyle](https://www.medscape.com/resource/medical-lifestyle)
*   [Science & Technology](https://www.medscape.com/resource/science-technology)
*   [Medical Students](https://www.medscape.com/medicalstudents)
*   [Nurses](https://www.medscape.com/nurses)
*   [Pharmacists](https://www.medscape.com/pharmacists)
*   [Residents](https://www.medscape.com/residents)

Edition:

ENGLISH ![Image 16: language edition](https://img.medscapestatic.com/pi/global/header/langsel/icon-down-stroke.svg)

![Image 17](https://www.medscape.com/viewarticle/covid-19-booster-vaccine-shortens-menstrual-cycles-teens-2024a1000fo8)

*   English New
    
    ![Image 18](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
    
*   Fran√ßais New
    
    ![Image 19](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
    
*   Deutsch New
    
    ![Image 20](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
    
*   Portugu√™s New
    
    ![Image 21](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
    
*   Espa√±ol New
    
    ![Image 22](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
    
*   UK New
    
    ![Image 23](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
    

![Image 24](https://www.medscape.com/viewarticle/covid-19-booster-vaccine-shortens-menstrual-cycles-teens-2024a1000fo8)

*   Fran√ßais New
    
    ![Image 25](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
    
*   Italiano New
    
    ![Image 26](https://img.medscapestatic.com/pi/global/header/langsel/icon-external-link.svg)
    

[Log In](https://www.medscape.com/viewarticle/covid-19-booster-vaccine-shortens-menstrual-cycles-teens-2024a1000fo8#)

[Sign Up It's Free!](https://www.medscape.com/viewarticle/covid-19-booster-vaccine-shortens-menstrual-cycles-teens-2024a1000fo8#)

![Image 27: Medscape Logo](https://img.medscapestatic.com/pi/logos/mscp-logo.png)

[![Image 28](https://img.wbmdstatic.com/medscape_static_vue/pages-medscape-viewarticle/client/img/open.0f97a0c4.svg)](https://www.medscape.com/viewarticle/covid-19-booster-vaccine-shortens-menstrual-cycles-teens-2024a1000fo8#)

[](https://www.medscape.com/viewarticle/covid-19-booster-vaccine-shortens-menstrual-cycles-teens-2024a1000fo8#)

![Image 29](https://img.wbmdstatic.com/medscape_static_vue/pages-medscape-viewarticle/client/img/search.956f0d9b.svg)

[Medscape Medical News](https://www.medscape.com/index/list_11861_0)[MedBrief](https://www.medscape.com/index/list_15507_0)

COVID-19 Booster Vaccine Shortens Menstrual Cycles in Teens
===========================================================

Edited by Javed Choudhury and Lisa Gillespie

August 28, 2024

0

0

**TOPLINE:**
------------

The COVID-19 booster was linked to shorter menstrual cycles in adolescent girls in the 4 months following administration, particularly when teens were in their follicular phase. The vaccine did not appear to be associated with shifts in menstrual flow, pain, or other symptoms.

**METHODOLOGY:**
----------------

*   Reports of menstrual cycle changes following the COVID-19 vaccination began to emerge in early 2021, raising concerns about the impact of the vaccine on menstrual health.
*   Researchers conducted a prospective study including 65 adolescent girls (mean age, 17.3 years), of whom 47 had received an initial series of COVID-19 vaccination at least 6 months prior to receiving a booster dose (booster group), and 18 had not received the booster vaccine (control group), two of whom had never received any COVID-19 vaccine, four who had received an initial vaccine but not a booster, and 12 who had received an initial vaccine and booster but more than 6 months prior to the study.
*   Menstrual cycle length was measured for three cycles prior to and four cycles after vaccination in the booster group and for seven cycles in the control group.
*   Menstrual flow, pain, and stress were measured at baseline and monthly for 3 months postvaccination.

**TAKEAWAY:**
-------------

*   Participants in the booster group experienced shorter cycles by an average of 5.35 days after receiving the COVID-19 booster vaccine (_P_ = .03), particularly during the second cycle. In contrast, those in the control group did not experience any changes in the menstrual cycle length.
*   Receiving the booster dose in the follicular phase was associated with significantly shorter menstrual cycles compared with pre-booster cycles (_P_ = .0157).
*   Menstrual flow, pain, and other symptoms remained unaffected after the COVID-19 booster vaccination.
*   Higher stress levels at baseline were also associated with a shorter length of the menstrual cycle (_P_ = .03) in both groups, regardless of the booster vaccination status.

**IN PRACTICE:**
----------------

""These data are potentially important for counselling parents regarding potential vaccine refusal in the future for their teen daughters,"" the authors wrote.

**SOURCE:**
-----------

This study was led by Laura A. Payne, PhD, from McLean Hospital in Boston, and was [published online](https://www.sciencedirect.com/science/article/abs/pii/S1054139X24003070) in the _Journal of Adolescent Health_.

**LIMITATIONS:**
----------------

The sample size for the booster and control groups was relatively small and homogenous. The study did not include the height, weight, birth control use, or other chronic conditions of the participants, which may have influenced the functioning of the menstrual cycle. The control group included a majority of teens who had previously received a vaccine and even a booster, which could have affected results.

**DISCLOSURES:**
----------------

This study was supported by grants from the Eunice Kennedy Shriver National Institute for Child Health and Human Development. Some authors received consulting fees, travel reimbursements, honoraria, research funding, and royalties from Bayer Healthcare, Mahana Therapeutics, Gates, and Merck, among others.

_This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication._

0

Credit  

Lead image: Digital Vision/Getty Images

Medscape Medical News ¬© 2024 WebMD, LLC  
Send comments and news tips to [news@medscape.net](mailto:news@medscape.net).

Cite this: Edited by Javed Choudhury and Lisa Gillespie. COVID-19 Booster Vaccine Shortens Menstrual Cycles in Teens - Medscape \- August 28, 2024.

###### TOP PICKS FOR YOU

Recommendations

What to Read Next on Medscape

[Special Coverage: **COVID-19**](https://www.medscape.com/resource/coronavirus)

*   [Latest](https://www.medscape.com/resource/coronavirus#rc-news)
*   [Perspective](https://www.medscape.com/resource/coronavirus#rc-perspective)
*   [Guidelines](https://www.medscape.com/resource/coronavirus#rc-guidelines)
*   [Drugs & Diseases](https://www.medscape.com/resource/coronavirus#rc-ref)
*   [Global Coverage](https://www.medscape.com/resource/coronavirus#rc-global)
*   [Additional Resources](https://www.medscape.com/resource/coronavirus#rc-additional)

Business of Medicine

*   [Europe Greenlights Two Avian Flu Vaccines](https://www.medscape.com/viewarticle/europe-greenlights-two-avian-flu-vaccines-2024a10003nj)
*   [Congo Authorities Approve Mpox Vaccines to Try to Contain Outbreak](https://www.medscape.com/viewarticle/congo-authorities-approve-mpox-vaccines-try-contain-outbreak-2024a1000bya)
*   [Exclusive-Mpox in Africa Prompts $500 Million Funding From Gavi for Vaccines](https://www.medscape.com/viewarticle/exclusive-mpox-africa-prompts-500-million-funding-gavi-2024a1000f1r)

Recommended Reading

*   [Monkeypox Vaccines: Q&A With the CDC's Agam Rao, MD](https://www.medscape.com/viewarticle/980134)
*   Drugs[influenza virus vaccine quadrivalent](https://reference.medscape.com/drug/fluarix-quadrivalent-fluzone-quadrivalent-influenza-virus-vaccine-quadrivalent-999829)
*   Drugs[influenza virus vaccine quadrivalent, adjuvanted](https://reference.medscape.com/drug/fluad-quadrivalent-influenza-virus-vaccine-quadrivalent-adjuvanted-4000082)
*   Drugs[hepatitis b vaccine/haemophilus influenzae type b vaccine](https://reference.medscape.com/drug/comvax-hepatitis-b-vaccine-haemophilus-influenzae-type-b-vaccine-343220)

Related Conditions & Procedures

*   [COVID-19 Vaccines](https://emedicine.medscape.com/article/2500139-overview)
*   [Vaccinations/Immunizations During Pregnancy](https://emedicine.medscape.com/article/2500098-overview)
*   [Vaccinations - Adult](https://emedicine.medscape.com/article/2172006-overview)
*   [Vaccinations, Travel](https://emedicine.medscape.com/article/2172334-overview)
*   [Vaccinations - Infants and Children](https://emedicine.medscape.com/article/2172012-overview)
*   [Pediatric Vaccines: Global Brands and Country Availability](https://emedicine.medscape.com/article/2500038-overview)

SLIDESHOW

*   [10 Travel Diseases You Need to Know](https://reference.medscape.com/slideshow/travel-diseases-6006331)

Expert Commentary

*   [Newsbeat - MMR Vaccine and Autism: Dispelling the Myth](https://www.medscape.com/pages/editorial/newsbeats/mmr)
*   [New mRNA Vaccines in Development for Cancer and Infections](https://www.medscape.com/viewarticle/promising-mrna-vaccines-new-therapies-infections-cancer-and-2024a10008gs)
*   [Europe Greenlights Two Avian Flu Vaccines](https://www.medscape.com/viewarticle/europe-greenlights-two-avian-flu-vaccines-2024a10003nj)

¬†.

![Image 30](blob:https://www.medscape.com/6742166de2ffdc98a2fc8b83a0aa235b)
"
2024-08-27 09:00:00,2024-08-29 23:24:04,"üåü Exciting Developments in PCOS Management! üåü  
Have you heard about the recent findings on biomarkers that could guide the management of Polycystic Ovary Syndrome (PCOS) in clinical settings? This new research highlights **22 core biomarkers** that can provide valuable insights into the multifaceted impact of PCOS‚Äîa condition that affects many women.  

üîç **Key Takeaways:**  
According to a study published by Hugo Walford et al., these core biomarkers range from hormonal levels like **testosterone** and **prolactin** to metabolic indicators such as **cholesterol** levels and **insulin resistance**. For instance, elevated levels of **anti-Mullerian hormone (AMH)** show promise in refining PCOS diagnosis and treatment strategies. Regular monitoring could lead to more tailored and effective management plans for patients.  

‚öôÔ∏è **Why It Matters:**  
Implementing these biomarkers into clinical practice can enable healthcare providers to evaluate treatment responses better and develop comprehensive strategies that address the systemic nature of PCOS. However, the pathway to adoption requires careful consideration of testing methodologies and validation processes.  

ü§î **Your Thoughts?**  
Given these exciting advancements, how do you think biomarkers will change the landscape of PCOS management in the coming years? Let's discuss!  

üîó Read the full article for more insights: [List of Biomarkers Could Help Inform PCOS Management](https://www.medscape.co.uk/viewarticle/list-biomarkers-could-help-inform-pcos-management-2024a1000fcp)  

#PCOS #Biomarkers #HealthCare #WomenHealth #ClinicalResearch  
![Image](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240205_polycystic_ovary_syndrome_800x450.jpg)",https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240205_polycystic_ovary_syndrome_800x450.jpg,https://www.medscape.co.uk/viewarticle/list-biomarkers-could-help-inform-pcos-management-2024a1000fcp,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Thumbnail image URL: https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240205_polycystic_ovary_syndrome_800x450.jpg 

Title: List of Biomarkers Could Help Inform PCOS Management

URL Source: https://www.medscape.co.uk/viewarticle/list-biomarkers-could-help-inform-pcos-management-2024a1000fcp

Published Time: 2024-08-27T09:00:00-04:00

Markdown Content:
List of Biomarkers Could Help Inform PCOS Management
===============
                                     

This site is intended for UK healthcare professionals

[![Image 1: Medscape UK Univadis Logo](https://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/medscape-uk-logo.4a9c814f.svg)](https://www.medscape.co.uk/)

*   Recent Searches [Clear](https://www.medscape.co.uk/viewarticle/list-biomarkers-could-help-inform-pcos-management-2024a1000fcp#)

Log In Register

[![Image 2: Medscape UK Univadis Logo](https://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/medscape-uk-logo.4a9c814f.svg)](https://www.medscape.co.uk/)

*   Recent Searches [Clear](https://www.medscape.co.uk/viewarticle/list-biomarkers-could-help-inform-pcos-management-2024a1000fcp#)

Log In Register

*   Recent Searches [Clear](https://www.medscape.co.uk/viewarticle/list-biomarkers-could-help-inform-pcos-management-2024a1000fcp#)

*   Menu
*   News
    
*   Guidelines
    
*   Drugs
    
*   Quizzes
    
*   Search

Clinical Summary

List of Biomarkers Could Help Inform PCOS Management
====================================================

Miriam E. Tucker | 27 August 2024

[](https://www.medscape.co.uk/viewarticle/list-biomarkers-could-help-inform-pcos-management-2024a1000fcp#)

TOPLINE:
--------

A total of 22 core biomarkers could help to assess the multisystemic impact of polycystic ovary syndrome (PCOS) and inform its management in everyday clinical practice.

Continue Reading Below

METHODOLOGY:¬†
-------------

*   A review of systematic reviews comparing biomarkers in women with PCOS vs healthy control participants to identify those potentially most useful for clinical management of PCOS.
*   A total of 75 systematic reviews were included, examining 88 biomarkers in 191,792 women.

TAKEAWAY:
---------

*   Among 63 abnormal biomarkers identified in women with PCOS vs healthy control participants, the following 22 were core biomarkers that could help evaluate the multisystemic impact of PCOS and inform patient management and surveillance:
    *   Higher dehydroepiandrosterone: Standardised mean difference (SMD), 1.15 ng/mL; 95% CI, 0.59-1.71.
    *   Higher prolactin: Weighted mean difference (WMD), 1.01 IU/L; 0.04-1.98.
    *   Lower sex hormone‚Äêbinding globulin: SMD, ‚àí0.83 nmol/L; ‚àí1.01 to ‚àí0.64.
    *   Higher total testosterone: SMD, 2.58 nmol/L; 1.82-3.35.
    *   Higher free testosterone: SMD, 1.37 nmol/L; 0.56-2.17.
    *   Higher anti‚ÄêMullerian hormone (AMH): Increased by a mean of 3 units, WMD: 3.05 ng/mL (2.09-4.01). AMH cutoff 4.8 ng/mL showed a good diagnostic accuracy (sensitivity of 0.78 \[0.74-0.81\] and specificity of 0.87 \[0.84-0.90\]).
    *   Higher systolic blood pressure: WMD, 3.23 mmHg; 1.90-4.56.
    *   Higher diastolic blood pressure: WMD, 1.58 mmHg; 0.49-2.68.
    *   Higher C-reactive protein: SMD, 1.26 mg/L; 0.99-1.53.
    *   Higher fibrinogen: Mean difference (MD), 21.51 mg/dL; 3.78-39.25.
    *   Higher values on a 2-hour oral glucose tolerance test: MD, 6.25 mmol/L; 1.02-11.48.
    *   Higher homoeostatic model assessment-insulin resistance index: SMD, 0.76; 0.35-1.17.
    *   Higher fasting insulin: MD, 9.10 mIU/L; 1.83-16.36.
    *   Higher total cholesterol: MD, 7.14 mg/dL, 1.58-12.70.
    *   Higher low-density lipoprotein cholesterol: SMD, 0.29 mmol/L; 0.20-0.39.
    *   Higher triglycerides: SMD, 0.38 mmol/L; 0.29-0.48.
    *   Higher lipoprotein(a): SMD, 1.1 mg/dL; 0.7-1.4.
    *   Lower high-density lipoprotein (HDL) cholesterol: SMD, ‚àí0.21 mmol/L; ‚àí0.35 to ‚àí0.08.
    *   Higher non-HDL-cholesterol: SMD, 0.42 mmol/L; 0.31-0.52.
    *   Lower ferritin: SMD , 0.68 Œºg/L; 0.44-0.91.
    *   Higher iron: MD, 12.98 Œºmol/L; 5.87-20.09.
    *   Lower 25-hydroxy-vitamin D: SMD, ‚àí0.64 nmol/L; ‚àí1.12 to ‚àí0.15).

IN PRACTICE:
------------

""While the diagnosis of PCOS remains clinical based on the Rotterdam criteria, several biomarkers identified in this review could help to refine the diagnosis and specify the relevant PCOS phenotype,"" the authors wrote. ""Regular monitoring of these biomarkers could help to evaluate treatment response and inform a comprehensive treatment strategy that address the multisystemic nature of PCOS,"" they added. ""Their adoption in clinical practice remains limited due to varied tests assays, diagnostic thresholds, and the lack of validation across different phenotypes...Clear implementation pathways are therefore required to maximise the value of these biomarkers in everyday clinical practice.""

SOURCE:¬†
--------

The study was conducted by Hugo Walford, of the Institute of Women's Health, University College London, UK, and colleagues and was [published online](https://onlinelibrary.wiley.com/doi/10.1111/cen.15101) August 18, 2024, in _Clinical Endocrinology_.

Continue Reading Below

Continue Reading Below

LIMITATIONS:
------------

Most studies were observational case-control design, thus cannot demonstrate causality. Most included meta-analyses had high statistical heterogeneity. Incomplete reporting on assays used. Suboptimal pooling methodology across included reviews.

DISCLOSURES:
------------

The authors have no funding to report.

Continue reading with a FREE Medscape UK account

Access the latest UK medical news, UK-specific clinical guideline summaries,  
UK vaccination schedule and more for free.

Register Today

Already a member? Log in

* * *

#### 

References

Walford H, Tyler B, Abbara A, Clarke S, Talaulikar V, Wattar BA. Biomarkers to inform the management of polycystic ovary syndrome: A review of systematic reviews. Clin Endocrinol (Oxf). Published online August 18, 2024. doi:10.1111/cen.15101

* * *

EDITOR'S RECOMMENDATIONS
------------------------

*   ![Image 3: related](https://img.medscapestatic.com/pi/global/1x1.png)
    
    [Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids](https://www.medscape.co.uk/s/viewarticle/breast-cancer-drug-may-slow-aggressive-brain-tumour-kids-2024a1000fra)
    
    Ribociclib, commonly used for breast cancer, has been found to stabilise a subtype of diffuse hemispheric glioma for about 17 months before regrowth begins.
    
*   ![Image 4: related](https://img.medscapestatic.com/pi/global/1x1.png)
    
    [Listeriosis During Pregnancy Can Be Fatal for the Fetus](https://www.medscape.co.uk/s/viewarticle/listeriosis-during-pregnancy-can-be-fatal-fetus-2024a1000frm)
    
    The rate of fetal loss or neonatal death from invasive listeriosis is 29%.
    
*   ![Image 5: related](https://img.medscapestatic.com/pi/global/1x1.png)
    
    [Primary Care Docs Track Average of 57 (!) Quality Measures](https://www.medscape.co.uk/s/viewarticle/primary-care-physicians-track-average-57-quality-measures-2024a1000fqu)
    
    Medicare tracked the most metrics tied to payment, while Medicaid tracked the least, according to a new JAMA Health Forum analysis.
    

YOU MAY ALSO LIKE
-----------------

[![Image 6: Alternate Insomnia Therapy Has Good Showing](https://img.medscapestatic.com/vim/live/professional_assets/dt_240313_insomnia_800x450px.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu ""Alternate Insomnia Therapy Has Good Showing"")

[Alternate Insomnia Therapy Has Good Showing](https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu ""Alternate Insomnia Therapy Has Good Showing"")

The brief nurse-delivered therapy aimed at restricting and standardising time in bed could make treatment more accessible to primary care patients.

*   Medscape News UK
*   7 hours ago

[![Image 7: Prisons Often Waste Ambulance Crew Time](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240829_prison_in_uk_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/prisons-often-waste-ambulance-crew-time-2024a1000fqp ""Prisons Often Waste Ambulance Crew Time"")

[Prisons Often Waste Ambulance Crew Time](https://www.medscape.co.uk/viewarticle/prisons-often-waste-ambulance-crew-time-2024a1000fqp ""Prisons Often Waste Ambulance Crew Time"")

Unnecessary 999 calls are being made by prison staff due to lack of experience and concerns over legal repercussions.

*   Medscape News UK
*   8 hours ago

[![Image 8: Recurrent UTI: Undercultured, Overtreated Despite Resistance](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_230216_urine_analysis_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni ""Recurrent UTI: Undercultured, Overtreated Despite Resistance"")

[Recurrent UTI: Undercultured, Overtreated Despite Resistance](https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni ""Recurrent UTI: Undercultured, Overtreated Despite Resistance"")

Roughly 40% of general practitioners do not culture recurrent UTIs and instead, just treat.

*   Medscape News UK
*   8 hours ago

[![Image 9: High-Dose Psilocybin Shows Promising Results for Depression](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_220215_psilocybin_mushrooms_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/high-dose-psilocybin-shows-promising-results-depression-2024a1000fqw ""High-Dose Psilocybin Shows Promising Results for Depression"")

[High-Dose Psilocybin Shows Promising Results for Depression](https://www.medscape.co.uk/s/viewarticle/high-dose-psilocybin-shows-promising-results-depression-2024a1000fqw ""High-Dose Psilocybin Shows Promising Results for Depression"")

A meta-analysis found that high-dose psilocybin for depressive symptoms showed better responses than placebo or escitalopram in antidepressant trials.

*   Medscape Medical News
*   8 hours ago

[![Image 10: Female Doctors' Suicide Rates Alarmingly Higher vs General Folks](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240329_surgeon_sad_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/female-doctors-suicide-rates-alarmingly-higher-vs-general-2024a1000fqs ""Female Doctors' Suicide Rates Alarmingly Higher vs General Folks"")

[Female Doctors' Suicide Rates Alarmingly Higher vs General Folks](https://www.medscape.co.uk/viewarticle/female-doctors-suicide-rates-alarmingly-higher-vs-general-2024a1000fqs ""Female Doctors' Suicide Rates Alarmingly Higher vs General Folks"")

Male physicians have a similar suicide rate to the general public, but female physicians show a notably higher suicide rate.

*   Medscape News UK
*   11 hours ago

[![Image 11: Men, Women, & Exercise: Metabolism Differs at Starting Line](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/dt_240828_man_woman_exercising_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn ""Men, Women, & Exercise: Metabolism Differs at Starting Line"")

[Men, Women, & Exercise: Metabolism Differs at Starting Line](https://www.medscape.co.uk/s/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn ""Men, Women, & Exercise: Metabolism Differs at Starting Line"")

The muscles of sedentary men and women with overweight and obesity differ in burning sugar and fatty acids at the start of an exercise program but draw even after training, multi-omics data show.

*   Medscape Medical News
*   13 hours ago

[![Image 12: Dental Caries Could Be a Silent Threat to Your Heart](https://img.medscapestatic.com/vim/live/professional_assets/dreamstime_l_57022209-800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/dental-caries-could-be-silent-threat-your-heart-2024a1000fqm ""Dental Caries Could Be a Silent Threat to Your Heart"")

[Dental Caries Could Be a Silent Threat to Your Heart](https://www.medscape.co.uk/viewarticle/dental-caries-could-be-silent-threat-your-heart-2024a1000fqm ""Dental Caries Could Be a Silent Threat to Your Heart"")

Dental caries are tied to a 40% higher stroke risk, underscoring the importance of oral health in preventing cardiovascular events.

*   Medscape News UK
*   13 hours ago

[Domestic Abuse: Recognition and Support](https://www.medscape.co.uk/viewarticle/supporting-people-affected-domestic-abuse-2024a1000dqo ""Domestic Abuse: Recognition and Support"")

Concise summary on recognising domestic abuse in primary care, including key questions to ask patients

*   Guidelines Summary: Primary Care
*   13 hours ago

[![Image 13: Parents' Technology Use May Shape Adolescents' Mental Health](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240828_distracted_parent_smartphone_girl_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/parents-technology-use-may-shape-adolescents-mental-health-2024a1000fqd ""Parents' Technology Use May Shape Adolescents' Mental Health"")

[Parents' Technology Use May Shape Adolescents' Mental Health](https://www.medscape.co.uk/s/viewarticle/parents-technology-use-may-shape-adolescents-mental-health-2024a1000fqd ""Parents' Technology Use May Shape Adolescents' Mental Health"")

Discussing digital technology use and mental health with parents and adolescents can be part of routine care visits, researchers said.

*   Medscape Medical News
*   16 hours ago

[![Image 14: NICE: Give People With Adrenal Insufficiency Emergency Kits](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240117_adrenal_glands_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/emergency-kits-recommended-adrenal-insufficiency-patients-2024a1000fpx ""NICE: Give People With Adrenal Insufficiency Emergency Kits"")

[NICE: Give People With Adrenal Insufficiency Emergency Kits](https://www.medscape.co.uk/viewarticle/emergency-kits-recommended-adrenal-insufficiency-patients-2024a1000fpx ""NICE: Give People With Adrenal Insufficiency Emergency Kits"")

People with adrenal insufficiency should be given emergency kits to help avoid hospital admission, said NICE in its new clinical guideline.

*   Medscape News UK
*   28 Aug 2024

[![Image 15: NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240828_cancer_patient_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/nice-oks-lonsurf-bevacizumab-advanced-bowel-cancer-2024a1000fpu ""NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer"")

[NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer](https://www.medscape.co.uk/viewarticle/nice-oks-lonsurf-bevacizumab-advanced-bowel-cancer-2024a1000fpu ""NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer"")

Around 1300 people in England will be eligible every year for the new combination treatment.

*   Medscape News UK
*   28 Aug 2024

[![Image 16: Kidney Donor Mortality Plummets Over 30 Years](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/dt_240827_donor_kidney_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/kidney-donor-mortality-plummets-over-30-years-2024a1000fop ""Kidney Donor Mortality Plummets Over 30 Years"")

[Kidney Donor Mortality Plummets Over 30 Years](https://www.medscape.co.uk/s/viewarticle/kidney-donor-mortality-plummets-over-30-years-2024a1000fop ""Kidney Donor Mortality Plummets Over 30 Years"")

The risk for perioperative mortality in living kidney donors has significantly reduced in the past decade, a study showed.

*   Medscape Medical News
*   28 Aug 2024

[![Image 17: A New Exercise 'Evolution' for Stroke Survivors: Go Harder](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_240827_senior_stepper_exercise_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/new-exercise-evolution-stroke-survivors-go-harder-2024a1000fp7 ""A New Exercise 'Evolution' for Stroke Survivors: Go Harder"")

[A New Exercise 'Evolution' for Stroke Survivors: Go Harder](https://www.medscape.co.uk/s/viewarticle/new-exercise-evolution-stroke-survivors-go-harder-2024a1000fp7 ""A New Exercise 'Evolution' for Stroke Survivors: Go Harder"")

A recent study has built on emerging evidence that intense training can be safe and beneficial for patients recovering from stroke.

*   Medscape Medical News
*   28 Aug 2024

[![Image 18: Continuous Glucose Monitor Benefits All Ages With Diabetes](https://img.medscapestatic.com/vim/live/professional_assets/ht_181001_freestyle_libre_glucose_monitor_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/continuous-glucose-monitor-benefits-all-ages-diabetes-2024a1000fhy ""Continuous Glucose Monitor Benefits All Ages With Diabetes"")

[Continuous Glucose Monitor Benefits All Ages With Diabetes](https://www.medscape.co.uk/viewarticle/continuous-glucose-monitor-benefits-all-ages-diabetes-2024a1000fhy ""Continuous Glucose Monitor Benefits All Ages With Diabetes"")

Intermittently scanned continuous glucose monitoring improved glycaemic outcomes in those older and younger than 65 years, but the older group may need individualised targets.

*   Medscape News UK
*   28 Aug 2024

[![Image 19: Hot Flashes, Night Sweats Linked to Menopausal Heart Disease](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/is_210928_hot_flashes_menopause_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/viewarticle/hot-flashes-night-sweats-linked-subclinical-heart-disease-2024a1000fl0 ""Hot Flashes, Night Sweats Linked to Menopausal Heart Disease"")

[Hot Flashes, Night Sweats Linked to Menopausal Heart Disease](https://www.medscape.co.uk/viewarticle/hot-flashes-night-sweats-linked-subclinical-heart-disease-2024a1000fl0 ""Hot Flashes, Night Sweats Linked to Menopausal Heart Disease"")

Early onset and long duration were associated with particularly high risk.

*   Medscape News UK
*   28 Aug 2024

[![Image 20: UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/dt_220707_drug_pharmaceutical_clinical_trial_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/uk-set-open-18-new-clinical-trial-hubs-400m-investment-2024a1000fp5 ""UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment"")

[UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment](https://www.medscape.co.uk/s/viewarticle/uk-set-open-18-new-clinical-trial-hubs-400m-investment-2024a1000fp5 ""UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment"")

Wes Streeting called the investment a major boost for the UK, transforming it into a health research hub and supporting a future-ready NHS.

*   Press Association
*   28 Aug 2024

[![Image 21: Measuring Expectations: Real-World Survival With Osimertinib](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_211029_doctor_patient_notes_800x450.jpg?resize=250:*)](https://www.medscape.co.uk/s/viewarticle/measuring-expectations-real-world-survival-osimertinib-2024a1000fok ""Measuring Expectations: Real-World Survival With Osimertinib"")

[Measuring Expectations: Real-World Survival With Osimertinib](https://www.medscape.co.uk/s/viewarticle/measuring-expectations-real-world-survival-osimertinib-2024a1000fok ""Measuring Expectations: Real-World Survival With Osimertinib"")

In a real-world population of patients with EGFR-mutant advanced lung cancer, overall survival was much worse in patients who would not have been eligible for the pivotal FLAURA trial.

*   Medscape Medical News
*   28 Aug 2024

![Image 22](blob:https://www.medscape.co.uk/6742166de2ffdc98a2fc8b83a0aa235b)

[](https://www.medscape.co.uk/)

#### Find Us On

[](https://www.facebook.com/GuidelinesMedscape/)[](https://twitter.com/medscapeuk)[](http://www.linkedin.com/company/24356)[](https://www.youtube.com/user/medscape/)[](https://www.instagram.com/medscape/)

#### About

[About Medscape](https://www.medscape.com/public/about)[Privacy Policy](https://www.medscape.co.uk/public/privacy)[Editorial Policy](https://www.medscape.com/public/editorialpolicies)[Cookies](https://www.medscape.co.uk/public/cookies) [Manage Preferences](javascript:void\(0\);) [Terms of Use](https://www.medscape.com/public/termsofuse)[UK Modern Slavery Statement](https://www.medscape.co.uk/public/antislavery)[Advertising Policy](https://www.medscape.com/public/adpolicy)[Help Center](https://help.medscape.com/hc/en-us)

#### App

[Medscape](https://www.medscape.com/public/medscapeapp?pid=Medscape_footer&c=FooterIcon)

All material on this website is protected by copyright, Copyright ¬© 1994-2024 by WebMD LLC. This website also contains material copyrighted by 3rd parties.

           

![Image 23](https://t.co/i/adsct?bci=3&eci=2&event_id=68715520-0531-4b70-9728-7e86ae0eab18&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=2577dea2-372d-47ee-9bc2-72c8f31eee89&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Flist-biomarkers-could-help-inform-pcos-management-2024a1000fcp&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o5zto&type=javascript&version=2.3.30)![Image 24](https://analytics.twitter.com/i/adsct?bci=3&eci=2&event_id=68715520-0531-4b70-9728-7e86ae0eab18&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=2577dea2-372d-47ee-9bc2-72c8f31eee89&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Flist-biomarkers-could-help-inform-pcos-management-2024a1000fcp&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o5zto&type=javascript&version=2.3.30)![Image 25](https://t.co/i/adsct?bci=3&eci=2&event_id=616212dd-639e-4b2c-bb29-8a31df5877d9&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=2577dea2-372d-47ee-9bc2-72c8f31eee89&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Flist-biomarkers-could-help-inform-pcos-management-2024a1000fcp&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=nvb1e&type=javascript&version=2.3.30)![Image 26](https://analytics.twitter.com/i/adsct?bci=3&eci=2&event_id=616212dd-639e-4b2c-bb29-8a31df5877d9&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=2577dea2-372d-47ee-9bc2-72c8f31eee89&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Flist-biomarkers-could-help-inform-pcos-management-2024a1000fcp&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=nvb1e&type=javascript&version=2.3.30)![Image 27](https://t.co/i/adsct?bci=3&eci=2&event_id=6c3718a8-62f3-4d84-bc5b-b41d4ee7be37&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=2577dea2-372d-47ee-9bc2-72c8f31eee89&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Flist-biomarkers-could-help-inform-pcos-management-2024a1000fcp&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o5ztw&type=javascript&version=2.3.30)![Image 28](https://analytics.twitter.com/i/adsct?bci=3&eci=2&event_id=6c3718a8-62f3-4d84-bc5b-b41d4ee7be37&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=2577dea2-372d-47ee-9bc2-72c8f31eee89&tw_document_href=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Flist-biomarkers-could-help-inform-pcos-management-2024a1000fcp&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o5ztw&type=javascript&version=2.3.30)

![Image 29](https://thrtle.com/insync?vxii_pid=10015&vxii_pdid=)

![Image 30](https://bh-eu.contextweb.com/bh/sr?action=add&token=Q4S7ZMWDWRFR&ch=1&url=https%3A%2F%2Fwww.medscape.co.uk%2Fviewarticle%2Flist-biomarkers-could-help-inform-pcos-management-2024a1000fcp&rr=&us_privacy=&param1=$$event$$&epid=&did=26557868394824328880409949576426147164&pf=0&usp=0&auth_channel=100&ev_id=0&topicid=$$topicid$$&conceptid=$$conceptid$$&ssp=16&gdpr_consent=&val=$$val$$&val=${val})![Image 31](https://bh.contextweb.com/bh/rtset?pid=562507&ev=0&us_privacy=)![Image 32](https://bh.contextweb.com/bh/rtset?pid=561967&ev=1&us_privacy=&gdpr=0&gdpr_consent=&rurl=https%3A%2F%2Fdsum.casalemedia.com%2Frum%3Fcm_dsp_id%3D189%26external_user_id%3D%25%25VGUID%25%25%26expiration%3D[EXPIRATION]%26us_privacy%3D%24%24us_privacy%24%24%26gdpr%3D%24%24gdpr%24%24%26gdpr_consent%3D%24%24gdpr_consent%24%24)![Image 33](https://bh.contextweb.com/bh/rtset?pid=561590&ev=1&us_privacy=&gdpr=0&gdpr_consent=&rurl=https%3A%2F%2Fpixel.rubiconproject.com%2Ftap.php%3Fv%3D390200%26nid%3D5120%26put%3D%25%25VGUID%25%25%26us_privacy%3D%24%24us_privacy%24%24%26gdpr%3D%24%24gdpr%24%24%26gdpr_consent%3D%24%24gdpr_consent%24%24)![Image 34](https://bh.contextweb.com/bh/rtset?pid=558356&ev=1&us_privacy=&gdpr=0&gdpr_consent=&rurl=https%3A%2F%2Feb2.3lift.com%2Fxuid%3Fmid%3D2636%26xuid%3D%25%25VGUID%25%25%26dongle%3D8bee%26us_privacy%3D%24%24us_privacy%24%24%26gdpr%3D%24%24gdpr%24%24%26gdpr_consent%3D%24%24gdpr_consent%24%24)
"
2024-08-27 09:00:00,2024-08-29 23:24:11,"üåü **Exciting Developments in Menopause Management!** üåü 

Have you ever considered how hot flashes and sleep disturbances affect the quality of life for so many individuals navigating menopause? A recent article published explores a groundbreaking advancement with the novel non-hormonal drug, **elinzanetant**.

This drug has shown remarkable efficacy in two phase 3 trials, effectively reducing moderate to severe vasomotor symptoms (VMS) and improving sleep quality. Over 62% of participants achieved at least a 50% reduction in VMS frequency at just 4 weeks! By week 12, this number increased to 71%, compared to significantly lower rates in placebo groups. 

What makes elinzanetant particularly noteworthy is its non-hormonal nature, providing a vital option for those who are sensitive to hormone therapy. This means we can now offer more personalized care tailored to each individual's needs, improving overall quality of life during this transition. 

As healthcare providers, it's essential for us to stay informed about such innovations and consider incorporating them into treatment plans for patients experiencing these common symptoms of menopause. How do you foresee integrating new treatments like elinzanetant into your practice or discussions with patients? 

For those interested in more details, you can read the full article [here](https://www.medscape.co.uk/viewarticle/novel-non-hormonal-drug-effective-menopausal-hot-flashes-2024a1000fhf). 

#Menopause #HotFlashes #WomenHealth #Elinzanetant #HealthcareInnovation",https://img.medscapestatic.com/vim/live/professional_assets/dt_190104_menopause_hot_flash_800x450.jpg,https://www.medscape.co.uk/viewarticle/novel-non-hormonal-drug-effective-menopausal-hot-flashes-2024a1000fhf,"Create a warm and friendly yet professional ready to use post that reflects on a recent article or development in your field. Focus on engaging your audience subtly and providing valuable insights.

    1. Start with a Hook: Begin with a statement or question that grabs attention. Make it relevant to your field.
    2. Summarize Key Points: Briefly outline the article‚Äôs main ideas, focusing on what‚Äôs most relevant to your audience.
    3. Share Insights and Applications: Highlight the key takeaways and discuss how they can be applied in your field. Offer practical examples or scenarios.
    4. Invite Engagement: End with a question or prompt that encourages your audience to share their thoughts. But do it subtly.
    5. Use Hashtags: Include 3-5 relevant hashtags to increase visibility. Ensure they are directly related to the topic and your industry.
    6. Add Source: Include a link to the source at the end.","Thumbnail image URL: https://img.medscapestatic.com/vim/live/professional_assets/dt_190104_menopause_hot_flash_800x450.jpg 

Title: Novel Non-Hormonal Drug Effective for Menopausal Hot Flashes, Sleep Disturbances

URL Source: https://www.medscape.co.uk/viewarticle/novel-non-hormonal-drug-effective-menopausal-hot-flashes-2024a1000fhf

Published Time: 2024-08-27T09:00:00-04:00

Markdown Content:
Novel Drug Effective for Menopausal Hot Flashes, Sleep Disturbances
===============
                                      

This site is intended for UK healthcare professionals

[![Image 1: Medscape UK Univadis Logo](https://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/medscape-uk-logo.4a9c814f.svg)](https://www.medscape.co.uk/)

*   Recent Searches [Clear](https://www.medscape.co.uk/viewarticle/novel-non-hormonal-drug-effective-menopausal-hot-flashes-2024a1000fhf#)

[![Image 2: Medscape UK Univadis Logo](https://img.wbmdstatic.com/medscapeuk_static_vue/medscape-uk-page-article/client/img/medscape-uk-logo.4a9c814f.svg)](https://www.medscape.co.uk/)

*   Recent Searches [Clear](https://www.medscape.co.uk/viewarticle/novel-non-hormonal-drug-effective-menopausal-hot-flashes-2024a1000fhf#)

*   Recent Searches [Clear](https://www.medscape.co.uk/viewarticle/novel-non-hormonal-drug-effective-menopausal-hot-flashes-2024a1000fhf#)

*   Menu
*   News
    
*   Guidelines
    
*   Drugs
    
*   Quizzes
    
*   Search

Clinical Summary

Novel Non-Hormonal Drug Effective for Menopausal Hot Flashes, Sleep Disturbances
================================================================================

Miriam Davis

[](https://www.medscape.co.uk/viewarticle/novel-non-hormonal-drug-effective-menopausal-hot-flashes-2024a1000fhf#)

TOPLINE:
--------

Menopausal vasomotor symptoms (VMS, also known as hot flashes) and sleep disturbance are common and undertreated. Two phase 3 trials of the novel non-hormonal drug elinzanetant show safety and efficacy against moderate to severe VMS and sleep disturbance. The drug targets for inhibition of the hypothalamic neurons expressing the neurokinin-1,3 receptor that mediate VMS.

METHODOLOGY:
------------

*   OASIS 1 (n = 309) and OASIS 2 (n = 324) are two randomised double-blind phase 3 trials of elinzanetant conducted in North America, Europe, and Israel.
*   Both trials administered once daily oral elinzanetant, 120 mg, for 14 weeks.
*   The primary outcomes were the mean change in frequency and severity of moderate to severe VMS from baseline to weeks 4 and 12 using electronic hot flash daily diary.
*   The secondary outcomes were the improvement in patient-reporting sleep disturbance at week 12 using short-form 8b derived from the PROMIS SD questionnaire and quality of life using the Menopause-specific Quality-of-Life questionnaire.

TAKEAWAY:
---------

*   At week 4, 62.8% (Oasis 1) and 62.2% (OASIS 2) of participants receiving elinzanetant realised at least a 50% reduction in VMS frequency vs 29.2% and 32.3% of placebo recipients, respectively. Severity of VMS was also improved relative to placebo.
*   At week 12, 71.4% (Oasis 1) and 74.7% (OASIS 2) of participants receiving elinzanetant realised at least a 50% reduction in VMS frequency vs 42.0% and 48.3% of placebo recipients, respectively. Severity was also improved relative to placebo.
*   Both sleep disturbance and quality of life also showed improvement at week 12.
*   Elinzanetant displayed a favourable safety profile.

IN PRACTICE:
------------

The authors concluded that ""Elinzanetant has the potential to provide a well-tolerated and efficacious non-hormonal treatment option to address the unmet health needs of many menopausal individuals with moderate to severe VMS.""

An [accompanying editorial](https://jamanetwork.com/journals/jama/fullarticle/2822768) observed that ""...\[I\]t seems we have entered a new era in which menopause management can be individualised‚Ä¶With the discovery of non-hormonal treatment options‚Ä¶menopause care should advance on this solid scientific footing to benefit affected individuals.""

SOURCE:
-------

The lead and corresponding author is JoAnn V. Pinkerton, MD, MSCP, of University of Virginia Health, Charlottesville, VA. The study appeared in [_JAMA_](https://jamanetwork.com/journals/jama/fullarticle/2822766)_._

LIMITATIONS:
------------

Limitations included reliance on electronic diary and other patient-reported measures with high placebo response.

DISCLOSURES:
------------

Several authors, including JoAnn V. Pinkerton, reported competing interests. The funding for the study was from Bayer.

Register Today

Already a member? Log in

EDITOR'S RECOMMENDATIONS
------------------------

*   ![Image 3: related](https://img.medscapestatic.com/pi/global/1x1.png)
    
    [Hot Flashes, Night Sweats Linked to Menopausal Heart Disease](https://www.medscape.co.uk/viewarticle/hot-flashes-night-sweats-linked-subclinical-heart-disease-2024a1000fl0)
    
    Early onset and long duration were associated with particularly high risk.
    
*   [Primary Care Aspects of HIV: Dr Toni Hazell's Guidelines Live Session](https://www.medscape.co.uk/viewarticle/primary-care-aspects-hiv-dr-toni-hazells-guidelines-live-2024a1000eyd)
    
    Video | Dr Toni Hazell | 15 August 2024
    
*   ![Image 4: related](https://img.medscapestatic.com/pi/global/1x1.png)
    
    [New Drug Option Approved for Uterine Fibroids](https://www.medscape.co.uk/viewarticle/new-drug-option-approved-uterine-fibroids-2024a1000eyy)
    
    A new once-daily hormone antagonist tablet has been recommended by NICE to treat moderate or severe symptoms of uterine fibroids.
    

YOU MAY ALSO LIKE
-----------------

[](https://www.medscape.co.uk/s/viewarticle/breast-cancer-drug-may-slow-aggressive-brain-tumour-kids-2024a1000fra ""Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids"")

[Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids](https://www.medscape.co.uk/s/viewarticle/breast-cancer-drug-may-slow-aggressive-brain-tumour-kids-2024a1000fra ""Breast Cancer Drug May Slow Aggressive Brain Tumour in Kids"")

Ribociclib, commonly used for breast cancer, has been found to stabilise a subtype of diffuse hemispheric glioma for about 17 months before regrowth begins.

*   Press Association
*   8 hours ago

[](https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu ""Alternate Insomnia Therapy Has Good Showing"")

[Alternate Insomnia Therapy Has Good Showing](https://www.medscape.co.uk/viewarticle/alternate-insomnia-therapy-has-good-showing-2024a1000fnu ""Alternate Insomnia Therapy Has Good Showing"")

The brief nurse-delivered therapy aimed at restricting and standardising time in bed could make treatment more accessible to primary care patients.

*   Medscape News UK
*   9 hours ago

[](https://www.medscape.co.uk/s/viewarticle/listeriosis-during-pregnancy-can-be-fatal-fetus-2024a1000frm ""Listeriosis During Pregnancy Can Be Fatal for the Fetus"")

[Listeriosis During Pregnancy Can Be Fatal for the Fetus](https://www.medscape.co.uk/s/viewarticle/listeriosis-during-pregnancy-can-be-fatal-fetus-2024a1000frm ""Listeriosis During Pregnancy Can Be Fatal for the Fetus"")

The rate of fetal loss or neonatal death from invasive listeriosis is 29%.

*   Medscape Medical News
*   9 hours ago

[](https://www.medscape.co.uk/viewarticle/prisons-often-waste-ambulance-crew-time-2024a1000fqp ""Prisons Often Waste Ambulance Crew Time"")

[Prisons Often Waste Ambulance Crew Time](https://www.medscape.co.uk/viewarticle/prisons-often-waste-ambulance-crew-time-2024a1000fqp ""Prisons Often Waste Ambulance Crew Time"")

Unnecessary 999 calls are being made by prison staff due to lack of experience and concerns over legal repercussions.

*   Medscape News UK
*   10 hours ago

[](https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni ""Recurrent UTI: Undercultured, Overtreated Despite Resistance"")

[Recurrent UTI: Undercultured, Overtreated Despite Resistance](https://www.medscape.co.uk/viewarticle/recurrent-uti-undercultured-overtreated-despite-resistance-2024a1000fni ""Recurrent UTI: Undercultured, Overtreated Despite Resistance"")

Roughly 40% of general practitioners do not culture recurrent UTIs and instead, just treat.

*   Medscape News UK
*   10 hours ago

[](https://www.medscape.co.uk/s/viewarticle/high-dose-psilocybin-shows-promising-results-depression-2024a1000fqw ""High-Dose Psilocybin Shows Promising Results for Depression"")

[High-Dose Psilocybin Shows Promising Results for Depression](https://www.medscape.co.uk/s/viewarticle/high-dose-psilocybin-shows-promising-results-depression-2024a1000fqw ""High-Dose Psilocybin Shows Promising Results for Depression"")

A meta-analysis found that high-dose psilocybin for depressive symptoms showed better responses than placebo or escitalopram in antidepressant trials.

*   Medscape Medical News
*   10 hours ago

[](https://www.medscape.co.uk/s/viewarticle/primary-care-physicians-track-average-57-quality-measures-2024a1000fqu ""Primary Care Docs Track Average of 57 (!) Quality Measures"")

[Primary Care Docs Track Average of 57 (!) Quality Measures](https://www.medscape.co.uk/s/viewarticle/primary-care-physicians-track-average-57-quality-measures-2024a1000fqu ""Primary Care Docs Track Average of 57 (!) Quality Measures"")

Medicare tracked the most metrics tied to payment, while Medicaid tracked the least, according to a new JAMA Health Forum analysis.

*   Medscape Medical News
*   13 hours ago

[](https://www.medscape.co.uk/viewarticle/female-doctors-suicide-rates-alarmingly-higher-vs-general-2024a1000fqs ""Female Doctors' Suicide Rates Alarmingly Higher vs General Folks"")

[Female Doctors' Suicide Rates Alarmingly Higher vs General Folks](https://www.medscape.co.uk/viewarticle/female-doctors-suicide-rates-alarmingly-higher-vs-general-2024a1000fqs ""Female Doctors' Suicide Rates Alarmingly Higher vs General Folks"")

Male physicians have a similar suicide rate to the general public, but female physicians show a notably higher suicide rate.

*   Medscape News UK
*   13 hours ago

[](https://www.medscape.co.uk/s/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn ""Men, Women, & Exercise: Metabolism Differs at Starting Line"")

[Men, Women, & Exercise: Metabolism Differs at Starting Line](https://www.medscape.co.uk/s/viewarticle/men-women-exercise-metabolism-differs-starting-line-2024a1000fqn ""Men, Women, & Exercise: Metabolism Differs at Starting Line"")

The muscles of sedentary men and women with overweight and obesity differ in burning sugar and fatty acids at the start of an exercise program but draw even after training, multi-omics data show.

*   Medscape Medical News
*   14 hours ago

[](https://www.medscape.co.uk/viewarticle/dental-caries-could-be-silent-threat-your-heart-2024a1000fqm ""Dental Caries Could Be a Silent Threat to Your Heart"")

[Dental Caries Could Be a Silent Threat to Your Heart](https://www.medscape.co.uk/viewarticle/dental-caries-could-be-silent-threat-your-heart-2024a1000fqm ""Dental Caries Could Be a Silent Threat to Your Heart"")

Dental caries are tied to a 40% higher stroke risk, underscoring the importance of oral health in preventing cardiovascular events.

*   Medscape News UK
*   15 hours ago

[Domestic Abuse: Recognition and Support](https://www.medscape.co.uk/viewarticle/supporting-people-affected-domestic-abuse-2024a1000dqo ""Domestic Abuse: Recognition and Support"")

Concise summary on recognising domestic abuse in primary care, including key questions to ask patients

*   Guidelines Summary: Primary Care
*   15 hours ago

[](https://www.medscape.co.uk/s/viewarticle/parents-technology-use-may-shape-adolescents-mental-health-2024a1000fqd ""Parents' Technology Use May Shape Adolescents' Mental Health"")

[Parents' Technology Use May Shape Adolescents' Mental Health](https://www.medscape.co.uk/s/viewarticle/parents-technology-use-may-shape-adolescents-mental-health-2024a1000fqd ""Parents' Technology Use May Shape Adolescents' Mental Health"")

Discussing digital technology use and mental health with parents and adolescents can be part of routine care visits, researchers said.

*   Medscape Medical News
*   18 hours ago

[](https://www.medscape.co.uk/viewarticle/emergency-kits-recommended-adrenal-insufficiency-patients-2024a1000fpx ""NICE: Give People With Adrenal Insufficiency Emergency Kits"")

[NICE: Give People With Adrenal Insufficiency Emergency Kits](https://www.medscape.co.uk/viewarticle/emergency-kits-recommended-adrenal-insufficiency-patients-2024a1000fpx ""NICE: Give People With Adrenal Insufficiency Emergency Kits"")

People with adrenal insufficiency should be given emergency kits to help avoid hospital admission, said NICE in its new clinical guideline.

*   Medscape News UK
*   28 Aug 2024

[](https://www.medscape.co.uk/viewarticle/nice-oks-lonsurf-bevacizumab-advanced-bowel-cancer-2024a1000fpu ""NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer"")

[NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer](https://www.medscape.co.uk/viewarticle/nice-oks-lonsurf-bevacizumab-advanced-bowel-cancer-2024a1000fpu ""NICE OKs Lonsurf + Bevacizumab for Advanced Bowel Cancer"")

Around 1300 people in England will be eligible every year for the new combination treatment.

*   Medscape News UK
*   28 Aug 2024

[](https://www.medscape.co.uk/s/viewarticle/kidney-donor-mortality-plummets-over-30-years-2024a1000fop ""Kidney Donor Mortality Plummets Over 30 Years"")

[Kidney Donor Mortality Plummets Over 30 Years](https://www.medscape.co.uk/s/viewarticle/kidney-donor-mortality-plummets-over-30-years-2024a1000fop ""Kidney Donor Mortality Plummets Over 30 Years"")

The risk for perioperative mortality in living kidney donors has significantly reduced in the past decade, a study showed.

*   Medscape Medical News
*   28 Aug 2024

[](https://www.medscape.co.uk/s/viewarticle/new-exercise-evolution-stroke-survivors-go-harder-2024a1000fp7 ""A New Exercise 'Evolution' for Stroke Survivors: Go Harder"")

[A New Exercise 'Evolution' for Stroke Survivors: Go Harder](https://www.medscape.co.uk/s/viewarticle/new-exercise-evolution-stroke-survivors-go-harder-2024a1000fp7 ""A New Exercise 'Evolution' for Stroke Survivors: Go Harder"")

A recent study has built on emerging evidence that intense training can be safe and beneficial for patients recovering from stroke.

*   Medscape Medical News
*   28 Aug 2024

[](https://www.medscape.co.uk/viewarticle/continuous-glucose-monitor-benefits-all-ages-diabetes-2024a1000fhy ""Continuous Glucose Monitor Benefits All Ages With Diabetes"")

[Continuous Glucose Monitor Benefits All Ages With Diabetes](https://www.medscape.co.uk/viewarticle/continuous-glucose-monitor-benefits-all-ages-diabetes-2024a1000fhy ""Continuous Glucose Monitor Benefits All Ages With Diabetes"")

Intermittently scanned continuous glucose monitoring improved glycaemic outcomes in those older and younger than 65 years, but the older group may need individualised targets.

*   Medscape News UK
*   28 Aug 2024

[](https://www.medscape.co.uk/s/viewarticle/uk-set-open-18-new-clinical-trial-hubs-400m-investment-2024a1000fp5 ""UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment"")

[UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment](https://www.medscape.co.uk/s/viewarticle/uk-set-open-18-new-clinical-trial-hubs-400m-investment-2024a1000fp5 ""UK Set to Open 18 New Clinical Trial Hubs With ¬£400M Investment"")

Wes Streeting called the investment a major boost for the UK, transforming it into a health research hub and supporting a future-ready NHS.

*   Press Association
*   28 Aug 2024

[](https://www.medscape.co.uk/s/viewarticle/measuring-expectations-real-world-survival-osimertinib-2024a1000fok ""Measuring Expectations: Real-World Survival With Osimertinib"")

[Measuring Expectations: Real-World Survival With Osimertinib](https://www.medscape.co.uk/s/viewarticle/measuring-expectations-real-world-survival-osimertinib-2024a1000fok ""Measuring Expectations: Real-World Survival With Osimertinib"")

In a real-world population of patients with EGFR-mutant advanced lung cancer, overall survival was much worse in patients who would not have been eligible for the pivotal FLAURA trial.

*   Medscape Medical News
*   28 Aug 2024

![Image 5](blob:https://www.medscape.co.uk/6742166de2ffdc98a2fc8b83a0aa235b)
"
